Details of Disease

General Information of Disease (ID: DISCM4YA)

• Disease Name: Lung cancer
• Synonyms: Nonsmall cell lung cancer; alveolar cell carcinoma; lung cancer, protection against; lung neoplasm; nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation; malignant neoplasm of lung; malignant lung neoplasm; malignant tumor of the lung; malignant lung tumour; lung cancer, resistance to, autosomal dominant, somatic mutation; lung cancer, susceptibility to, autosomal dominant, somatic mutation; lung cancer, somatic; malignant tumor of lung; nonsmall cell lung cancer, susceptibility to, autosomal dominant, somatic mutation; lung cancer; malignant neoplasm of the lung; malignant tumour of lung; cancer of lung; adenocarcinoma of lung, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation; nonsmall cell lung cancer, somatic; lung cancer, protection against, autosomal dominant, somatic mutation; malignant tumour of the lung; malignant lung tumor; adenocarcinoma of lung, somatic
• Disease Class: 2C25: Lung cancer
• Definition: A malignant neoplasm involving the lung.
• Disease Hierarchy:
  DISS63QW: Respiratory system cancer
  DISVARNB: Lung neoplasm
  DIS4GB9P: Thymic cancer
  DISAT1Z9: Advanced cancer
  DISCM4YA: Lung cancer
• ICD Code:
  ICD-11: ICD-11: 2C25.0
  ICD-9: ICD-9: 162
  Expand ICD-11: '2C25.0
  Expand ICD-9: 162
• Disease Identifiers:
  MONDO ID: MONDO_0008903
  MESH ID: D008175
  UMLS CUI: C0242379
  OMIM ID: 211980
  MedGen ID: 66885
  SNOMED CT ID: 363358000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 43 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aldesleukin	DM4YMIS	Approved	NA	[1]
Alectinib	DMP1I6Y	Approved	Small molecular drug	[2]
Aminophylline	DML2NIB	Approved	Small molecular drug	[3]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[4]
Bortezomib	DMNO38U	Approved	Small molecular drug	[5]
Bupropion	DM5PCS7	Approved	Small molecular drug	[6]
Carboplatin	DMG281S	Approved	Small molecular drug	[7]
Celecoxib	DM6LOQU	Approved	Small molecular drug	[8]
Cetuximab	DMLNCE0	Approved	Antibody	[9]
Cisplatin	DMRHGI9	Approved	Small molecular drug	[10]
Citalopram	DM2G9AE	Approved	Small molecular drug	[11]
Dasatinib	DMJV2EK	Approved	Small molecular drug	[12]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[13]
Docetaxel	DMDI269	Approved	Small molecular drug	[14]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[15]
Erlotinib	DMCMBHA	Approved	Small molecular drug	[16]
Etoposide	DMNH3PG	Approved	Small molecular drug	[17]
Everolimus	DM8X2EH	Approved	Small molecular drug	[18]
Fludarabine	DMVRLT7	Approved	Small molecular drug	[19]
Folic Acid	DMEMBJC	Approved	Small molecular drug	[20]
Gefitinib	DM15F0X	Approved	Small molecular drug	[21]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[22]
Hm61713	DMRJQQB	Approved	NA	[23]
Hydroxocobalamin	DMGKV9D	Approved	Small molecular drug	[24]
Imatinib	DM7RJXL	Approved	Small molecular drug	[25]
Mechlorethamine	DM0CVXA	Approved	Small molecular drug	[26]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[27]
Nicotine	DMWX5CO	Approved	Small molecular drug	[28]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[29]
Panobinostat	DM58WKG	Approved	Small molecular drug	[30]
Pemetrexed	DMMX2E6	Approved	Small molecular drug	[31]
Plicamycin	DM7C8YV	Approved	Small molecular drug	[32]
Prinomastat	DM9HOKG	Approved	Small molecular drug	[33]
Sirolimus	DMGW1ID	Approved	Small molecular drug	[34]
Sorafenib	DMS8IFC	Approved	Small molecular drug	[35]
Sunitinib	DMCBJSR	Approved	Small molecular drug	[36]
Temozolomide	DMKECZD	Approved	Small molecular drug	[37]
Theophylline	DMRJFN9	Approved	Small molecular drug	[38]
Topotecan	DMP6G8T	Approved	Small molecular drug	[39]
Trastuzumab	DMZQOUX	Approved	Antibody	[40]
Vidarabine	DM0N85H	Approved	Small molecular drug	[41]
Vindesine	DMVR628	Approved	Small molecular drug	[42]
Vinorelbine	DMVXFYE	Approved	Small molecular drug	[43]

This Disease is Treated as An Indication in 34 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CO-1686	DMWZ2TU	Phase 3	Small molecular drug	[44]
Custirsen	DMIQ31Y	Phase 3	Small molecular drug	[45]
Dimesna	DMU4T9Y	Phase 3	Small molecular drug	[46]
Efaproxyn	DMX7BM4	Phase 3	Small molecular drug	[47]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[46]
Karenitecin	DMCRGY4	Phase 3	Small molecular drug	[48]
Marimastat	DM6V34C	Phase 3	Small molecular drug	[49]
MK-7684	DMN7H5K	Phase 3	NA	[50]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[4]
Coxsackievirus A21	DM2K5VP	Phase 2	NA	[4]
L-DOS47	DMIEZUB	Phase 2	NA	[51]
OGX-427	DMJTU8D	Phase 2	Antisense drug	[52]
Ranpirnase	DMM15RI	Phase 2	NA	[53]
S-488410	DMPHM07	Phase 2	NA	[54]
Salirasib	DMRSU4X	Phase 2	Small molecular drug	[55]
SVV-001	DMKSFD0	Phase 2	Oncolytic virus therapy	[56]
AC vaccine	DM62505	Phase 1/2	NA	[57]
Anti-EGFR V III CAR-T cells	DM8EAGV	Phase 1/2	CAR T Cell Therapy	[58]
Anti-HER2 CAR-T	DMQD6B9	Phase 1/2	CAR T Cell Therapy	[59]
Anti-mesothelin CAR transduced PBL	DMXI03L	Phase 1/2	CAR T Cell Therapy	[60]
Anti-MUC1 CAR T Cells	DM0C1IX	Phase 1/2	CAR T Cell Therapy	[61]
Anti-NY-ESO-1 CAR-T cells	DM26VCZ	Phase 1/2	CAR T Cell Therapy	[58]
CAR-T cells targeting GD2	DMFCPG0	Phase 1/2	CAR T Cell Therapy	[62]
CAR-T cells targeting MAGE-A1	DM1W7LV	Phase 1/2	CAR T Cell Therapy	[62]
CAR-T cells targeting MAGE-A4	DMUBEX4	Phase 1/2	CAR T Cell Therapy	[62]
CAR-T cells targeting Mesothelin	DMMAQJ7	Phase 1/2	CAR T Cell Therapy	[62]
CAR-T cells targeting MucI	DMBPN4K	Phase 1/2	CAR T Cell Therapy	[62]
JNJ-64041757	DMVCJHO	Phase 1/2	NA	[46]
Re-188-P-2045	DM614BA	Phase 1/2	NA	[63]
Anti-CEA-CAR T	DMJA3H1	Phase 1	CAR T Cell Therapy	[64]
Dendritic cell-based exosome vaccine	DMSX3A5	Phase 1	NA	[65]
Hu-CART meso cells	DM9VB4I	Phase 1	CAR T Cell Therapy	[66]
ICasp9M28z T cell	DMY6V5T	Phase 1	CAR T Cell Therapy	[67]
INNO-305	DMG6S8U	Phase 1	NA	[68]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID28460551-Compound-1	DMHV75N	Patented	Small molecular drug	[69]

This Disease is Treated as An Indication in 7 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
INS 316	DMTHMEI	Discontinued in Phase 3	Small molecular drug	[70]
Tanomastat	DMVB9XC	Discontinued in Phase 3	Small molecular drug	[71]
Agatolimod	DM497SK	Discontinued in Phase 2	NA	[72]
Lurtotecan	DMF1RTW	Discontinued in Phase 2	Small molecular drug	[73]
VLTS-587	DMOS6CM	Discontinued in Phase 2	NA	[74]
NY-ESO-1 tumour vaccine	DMB2R3Y	Discontinued in Phase 1	NA	[75]
A-74932	DMNCGOP	Terminated	Small molecular drug	[79]

This Disease is Treated as An Indication in 3 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A-893	DM8XHJG	Preclinical	Small molecular drug	[76]
PT630	DM9SY8E	Preclinical	Peptide	[77]
SLIT TR-03	DMWTS2H	Preclinical	NA	[78]

This Disease is Treated as An Indication in 9 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adv-005	DMNTNGI	Investigative	NA	[80]
Cu64-CNND1-L	DMFTIXU	Investigative	NA	[80]
DWP-451	DMR2VRU	Investigative	NA	[80]
GS-497C	DM804F1	Investigative	NA	[80]
MDX-1110	DM92CGF	Investigative	NA	[80]
Medi-NK	DMXPL0H	Investigative	NA	[80]
Nephesh-1000	DMUO7IW	Investigative	NA	[80]
VG-LC	DMNH00H	Investigative	NA	[80]
WZ-3146	DMBWUR0	Investigative	Small molecular drug	[81]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1035 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC3	TTVLG21	Limited	Altered Expression	[84]
ALDH2	TTFLN4T	Limited	Biomarker	[85]
ANPEP	TTPHMWB	Limited	Altered Expression	[86]
ARAF	TT5TURO	Limited	Biomarker	[87]
ATG7	TTLVB9Z	Limited	Altered Expression	[88]
ATP1A1	TTWK8D0	Limited	Biomarker	[89]
AURKA	TTPS3C0	Limited	Biomarker	[90]
AXL	TTZPY6J	Limited	Altered Expression	[91]
BBC3	TT7JUKC	Limited	Biomarker	[92]
BCL2L2	TTQ79W8	Limited	Biomarker	[93]
BIRC2	TTQ5LRD	Limited	Biomarker	[94]
BIRC5	TTTPU1G	Limited	Biomarker	[95]
BMX	TTN2I9E	Limited	Biomarker	[96]
BPHL	TTTZ3EU	Limited	Biomarker	[97]
C1QBP	TTWTD7F	Limited	Altered Expression	[98]
CAMKK2	TTV298Y	Limited	Biomarker	[99]
CCL20	TT2XAZY	Limited	Biomarker	[100]
CCL21	TTLZK1U	Limited	Biomarker	[101]
CCR2	TTFZYTO	Limited	Altered Expression	[102]
CD38	TTPURFN	Limited	Altered Expression	[103]
CDK12	TTJ21A9	Limited	Biomarker	[104]
CFB	TTA0P7K	Limited	Genetic Variation	[105]
CFH	TTUW6OP	Limited	Altered Expression	[106]
CHRNB4	TTTVAFQ	Limited	Autosomal dominant	[107]
CLDN18	TT6PKBX	Limited	Altered Expression	[108]
CMA1	TT8VUE0	Limited	Genetic Variation	[109]
CRYZ	TTP6UO8	Limited	Genetic Variation	[110]
CTSG	TTQAJF1	Limited	Biomarker	[111]
CYP19A1	TTSZLWK	Limited	Biomarker	[112]
CYP21A2	TTP4GLG	Limited	Genetic Variation	[105]
CYP2B6	TTMH124	Limited	Genetic Variation	[113]
CYP3A5	TTHS0OK	Limited	Genetic Variation	[114]
DAPK3	TTERVQN	Limited	Altered Expression	[115]
DEPDC1	TT8S9CM	Limited	Biomarker	[116]
DLL3	TT1C9K6	Limited	Altered Expression	[117]
DLL4	TTV23LH	Limited	Altered Expression	[118]
EGLN1	TT9ISBX	Limited	Genetic Variation	[119]
EGLN2	TTMHFRY	Limited	Genetic Variation	[120]
EIF2AK3	TT79U1M	Limited	Altered Expression	[121]
ELAVL1	TTPC9D0	Limited	Biomarker	[122]
EPCAM	TTZ8WH4	Limited	Biomarker	[123]
EPHA1	TTLFZVU	Limited	Altered Expression	[124]
EPHA5	TTV9KOD	Limited	Biomarker	[125]
EPHA8	TTHZ2LW	Limited	Altered Expression	[126]
EPOR	TTAUX24	Limited	Biomarker	[127]
ERBB2	TT6EO5L	Limited	Autosomal dominant	[107]
EREG	TTYSB89	Limited	Altered Expression	[128]
FADS2	TTT2VDU	Limited	Genetic Variation	[129]
FASLG	TTO7014	Limited	Genetic Variation	[130]
FGFR2	TTGJVQM	Limited	Genetic Variation	[131]
FGL2	TTYBS89	Limited	Biomarker	[132]
FN1	TTPJ921	Limited	Biomarker	[133]
FOXQ1	TTEJZOL	Limited	Biomarker	[134]
G3BP1	TTG0R8Z	Limited	Altered Expression	[135]
GADD45B	TTMDW9L	Limited	Genetic Variation	[136]
GAST	TT4LRVO	Limited	Biomarker	[137]
GDF2	TTAP4T1	Limited	Biomarker	[138]
GLIPR1	TTEQF1O	Limited	Biomarker	[139]
GPC3	TTJTSX4	Limited	Biomarker	[140]
GRB2	TTEYRJ9	Limited	Biomarker	[141]
GSN	TTUH7OM	Limited	Biomarker	[142]
HAL	TTXQOZW	Limited	Biomarker	[143]
HDAC10	TTYHPU6	Limited	Biomarker	[144]
HNRNPA1	TTPJ9XK	Limited	Biomarker	[145]
HNRNPA2B1	TT8UPW6	Limited	Altered Expression	[146]
HSPA5	TTW26OG	Limited	Biomarker	[147]
ID1	TTBXVDE	Limited	Altered Expression	[148]
IDUA	TT0IUKX	Limited	Genetic Variation	[149]
IFNW1	TTS2TGF	Limited	Genetic Variation	[150]
IL1RL1	TT4GZA4	Limited	Biomarker	[151]
IL22	TTLDX4N	Limited	Biomarker	[152]
IRF8	TTHUBNK	Limited	Biomarker	[153]
ITGA5	TTHIZP9	Limited	Biomarker	[154]
ITGB3	TTJA1ZO	Limited	Altered Expression	[155]
KDM4C	TTV8CRH	Limited	Biomarker	[156]
KHDRBS1	TTAT6C7	Limited	Altered Expression	[157]
LDHA	TTW76JE	Limited	Altered Expression	[158]
MAGEA2	TTOZT28	Limited	Altered Expression	[159]
MALT1	TTCI81G	Limited	Genetic Variation	[160]
MAP3K2	TTIX0ZU	Limited	Biomarker	[161]
MARCKS	TTHRM39	Limited	Biomarker	[162]
MARK2	TTAJ45Y	Limited	Biomarker	[163]
MCM7	TT1RM3F	Limited	Altered Expression	[164]
MMP10	TTXLEG7	Limited	Biomarker	[165]
MMP15	TTNSTO3	Limited	Altered Expression	[166]
MSLN	TT4RXME	Limited	Biomarker	[140]
NCOA3	TT124R0	Limited	Biomarker	[167]
NFKB1	TTUIZKC	Limited	Genetic Variation	[168]
NOTCH4	TTXDIK2	Limited	Genetic Variation	[105]
NPY4R	TTW4N16	Limited	Biomarker	[169]
NTRK3	TTXABCW	Limited	Biomarker	[170]
PARG	TT39J16	Limited	Biomarker	[97]
PBK	TTMY6BZ	Limited	Altered Expression	[171]
PCSK9	TTNIZ2B	Limited	Biomarker	[172]
PDCD1LG2	TTW14O3	Limited	Biomarker	[173]
PDCD2	TTYOVWN	Limited	Biomarker	[174]
PDE10A	TTJW4LU	Limited	Altered Expression	[175]
PDE5A	TTJ0IQB	Limited	Biomarker	[176]
PDPK1	TTYMGWX	Limited	Altered Expression	[177]
PLA2G4A	TTT1JVS	Limited	Altered Expression	[178]
PLCG1	TT6T4JI	Limited	Biomarker	[179]
PLG	TTP86E2	Limited	Biomarker	[180]
PLK1	TTH4IP0	Limited	Biomarker	[181]
PLOD2	TT8MEUD	Limited	Altered Expression	[182]
PPIA	TTL2ADK	Limited	Biomarker	[183]
PPP1CA	TTFLH0E	Limited	Biomarker	[184]
PRTN3	TT5MLC4	Limited	Biomarker	[185]
PTBP1	TTWMX0U	Limited	Biomarker	[186]
PTGES	TTYLQ8V	Limited	Biomarker	[187]
PTPN2	TTY8PUS	Limited	Genetic Variation	[188]
RAB22A	TTAJ746	Limited	Biomarker	[189]
RABL3	TTYGK57	Limited	Biomarker	[190]
RARA	TTW38KT	Limited	Biomarker	[191]
RENBP	TTZCG0Q	Limited	Genetic Variation	[192]
RNASEL	TT7V0K4	Limited	Biomarker	[193]
RRM1	TTWP0NS	Limited	Genetic Variation	[194]
RSF1	TTMP86V	Limited	Altered Expression	[195]
RSPO3	TT7HJTF	Limited	Biomarker	[196]
S100A4	TTPR5SX	Limited	Altered Expression	[197]
SCG3	TTY5R9H	Limited	Biomarker	[198]
SERPINH1	TTPSWQG	Limited	Altered Expression	[199]
SGO1	TTBPKGD	Limited	Genetic Variation	[200]
SIK2	TTCUGZR	Limited	Biomarker	[201]
SLC16A1	TTN1J82	Limited	Genetic Variation	[109]
SLC27A4	TT20AYF	Limited	Biomarker	[202]
SLC38A4	TTJE54U	Limited	Genetic Variation	[194]
SMAD1	TT9GR53	Limited	Altered Expression	[203]
SORT1	TTRX9AV	Limited	Altered Expression	[204]
SOX5	TTXHSZK	Limited	Altered Expression	[205]
SPARC	TTBQFM7	Limited	Biomarker	[206]
SREBF1	TTER0UB	Limited	Biomarker	[207]
STS	TTHM0R1	Limited	Biomarker	[208]
TFRC	TT8MG4S	Limited	Biomarker	[209]
TNFRSF10B	TTW20TU	Limited	Altered Expression	[210]
TNKS	TTVUSO7	Limited	Altered Expression	[211]
TRPM8	TTXDKTO	Limited	Biomarker	[212]
USP10	TT5IH09	Limited	Biomarker	[213]
USP14	TTVSYP9	Limited	Biomarker	[214]
VEGFB	TTPJQHE	Limited	Biomarker	[215]
VEGFC	TT0QUFV	Limited	Altered Expression	[216]
WNT5A	TTKG7F8	Limited	Altered Expression	[217]
ABCC1	TTOI92F	Disputed	Altered Expression	[218]
AQP3	TTLDNMQ	Disputed	Biomarker	[219]
BCL2L1	TTRE6AX	Disputed	Altered Expression	[220]
BLK	TTNDSC3	Disputed	Altered Expression	[221]
BRD9	TTR7L5Y	Disputed	Genetic Variation	[222]
CDK4	TT0PG8F	Disputed	Altered Expression	[223]
CDKN1C	TTBSUAR	Disputed	Altered Expression	[224]
CHUK	TT1F8OQ	Disputed	Biomarker	[225]
DAAM2	TTN0Z6H	Disputed	Genetic Variation	[222]
DKK1	TTE3RAC	Disputed	Biomarker	[226]
DNMT3B	TT6VZ78	Disputed	Biomarker	[227]
ERBB4	TTWALCO	Disputed	Biomarker	[228]
FGF2	TTGKIED	Disputed	Biomarker	[229]
HPGDS	TTCYE56	Disputed	Altered Expression	[230]
KRT19	TT3JF9E	Disputed	Biomarker	[231]
LRRC32	TT0FAYT	Disputed	Altered Expression	[232]
MAPK7	TTU6FSC	Disputed	Biomarker	[233]
MDM4	TT9OUDQ	Disputed	Altered Expression	[218]
RNF34	TTEWDK1	Disputed	Biomarker	[234]
SKP2	TT5B2EO	Disputed	Biomarker	[235]
SLIT2	TTDWK85	Disputed	Altered Expression	[236]
TACSTD2	TTP2HE5	Disputed	Biomarker	[237]
TNFRSF1B	TT63WSF	Disputed	Genetic Variation	[238]
TTR	TTPOYU7	Disputed	Biomarker	[239]
TUSC2	TTJ8O14	Disputed	Biomarker	[240]
UCHL1	TTX9IFP	Disputed	Biomarker	[241]
VDR	TTK59TV	Disputed	Genetic Variation	[242]
XPA	TTGT87E	Disputed	Genetic Variation	[243]
ADAM9	TTTYQNS	moderate	Biomarker	[244]
ADORA3	TTJFY5U	moderate	Biomarker	[245]
AKR1C3	TT5ZWB6	moderate	Biomarker	[246]
ALCAM	TT2AFT6	moderate	Biomarker	[247]
AMOT	TTI48OS	moderate	Altered Expression	[248]
ANGPT2	TTKLQTJ	moderate	Altered Expression	[249]
ANXA1	TTUCK4B	moderate	Altered Expression	[250]
ATR	TT8ZYBQ	moderate	Biomarker	[251]
AURKB	TT9RTBL	moderate	Biomarker	[252]
AVP	TTJ8EWH	moderate	Altered Expression	[253]
BMP4	TTD3BSX	moderate	Altered Expression	[254]
BRSK1	TTV6WMQ	moderate	Biomarker	[255]
BRSK2	TTHZN4X	moderate	Biomarker	[255]
CALCA	TTVSFJW	moderate	Biomarker	[256]
CARM1	TTIZQFJ	moderate	Biomarker	[257]
CASP2	TT12VNG	moderate	Biomarker	[258]
CASP9	TTB6T7O	moderate	Altered Expression	[259]
CBR1	TTVG0SN	moderate	Biomarker	[260]
CCNB1	TT9P6OW	moderate	Altered Expression	[261]
CD276	TT6CQUM	moderate	Altered Expression	[262]
CD33	TTJVYO3	moderate	Biomarker	[263]
CD40LG	TTIJP3Q	moderate	Biomarker	[264]
CD44	TTWFBT7	moderate	Altered Expression	[265]
CD47	TT28S46	moderate	Biomarker	[266]
CDK5	TTL4Q97	moderate	Biomarker	[267]
CFLAR	TTJZQYH	moderate	Biomarker	[268]
CHAT	TTKYFSB	moderate	Altered Expression	[269]
COMT	TTKWFB8	moderate	Genetic Variation	[270]
CR1	TTEA8OW	moderate	Genetic Variation	[271]
CSF1R	TT7MRDV	moderate	Altered Expression	[272]
CTAG1A	TTE5ITK	moderate	Biomarker	[273]
CXCL1	TTLK1RW	moderate	Biomarker	[274]
CXCR2	TT30C9G	moderate	Genetic Variation	[275]
CYP17A1	TTRA5BZ	moderate	Altered Expression	[276]
DCN	TTB3XAN	moderate	Biomarker	[277]
DLK1	TTF4AVB	moderate	Biomarker	[278]
DNM2	TTVRA5G	moderate	Genetic Variation	[279]
DRD1	TTZFYLI	moderate	Genetic Variation	[280]
DYRK1B	TTYGQ8A	moderate	Altered Expression	[281]
E2F3	TTWIJYH	moderate	Altered Expression	[282]
ELK3	TT5OJMV	moderate	Biomarker	[283]
ENTPD1	TTYM8DJ	moderate	Biomarker	[284]
EPAS1	TTWPA54	moderate	Altered Expression	[285]
EPHA3	TTHS2LR	moderate	Biomarker	[286]
EPHB1	TT8MDAC	moderate	Biomarker	[283]
EPHB4	TTI4ZX2	moderate	Biomarker	[287]
ETS1	TTTGPSD	moderate	Altered Expression	[277]
F2R	TTL935N	moderate	Altered Expression	[288]
FAT1	TTGUJYV	moderate	Biomarker	[289]
FDFT1	TTFQEO5	moderate	Altered Expression	[290]
FKBP10	TT4P8O2	moderate	Biomarker	[291]
FOLR2	TTT54CI	moderate	Biomarker	[292]
FOSL1	TTY8LZG	moderate	Altered Expression	[293]
GLB1	TTNGJPH	moderate	Biomarker	[294]
HKDC1	TTVUI8G	moderate	Biomarker	[295]
HLA-DRB1	TTUXSTW	moderate	Biomarker	[296]
HMGB2	TTA78JQ	moderate	Genetic Variation	[297]
HPSE	TTR7GJO	moderate	Biomarker	[298]
HSP90AB1	TTH5YN2	moderate	Biomarker	[299]
HSP90B1	TTFPKXQ	moderate	Biomarker	[300]
IDO1	TTZJYKH	moderate	Altered Expression	[301]
IGFBP1	TTCJTWF	moderate	Altered Expression	[302]
IGFBP5	TTDWEA8	moderate	Altered Expression	[303]
IGFBP7	TTUQ01B	moderate	Biomarker	[304]
IL12A	TTRTK6Y	moderate	Genetic Variation	[305]
IL13RA2	TTMPZ7V	moderate	Biomarker	[306]
IL16	TTW4R0B	moderate	Genetic Variation	[307]
IL7	TT8FRMO	moderate	Biomarker	[308]
IRS1	TTAJSQ0	moderate	Biomarker	[309]
KDM2A	TT8XTY2	moderate	Biomarker	[310]
KLK1	TT5T3P6	moderate	Altered Expression	[311]
KLK4	TT4319X	moderate	Altered Expression	[311]
KLK5	TTULSEW	moderate	Altered Expression	[311]
KLK7	TTE6GTB	moderate	Altered Expression	[311]
LATS2	TTML7FG	moderate	Altered Expression	[312]
LGALS3	TTFPQV7	moderate	Biomarker	[313]
MAGEA1	TT63M7Q	moderate	Biomarker	[314]
MAP3K20	TTTUZ3O	moderate	Genetic Variation	[315]
MAP3K3	TTJZNIG	moderate	Biomarker	[316]
MIA	TT5HNVS	moderate	Biomarker	[317]
MTNR1A	TT0WAIE	moderate	Genetic Variation	[318]
NES	TTHZ752	moderate	Biomarker	[319]
NPR1	TTM9IYA	moderate	Altered Expression	[320]
NRP1	TTIPJCB	moderate	Biomarker	[321]
NRP2	TTRXUVC	moderate	Biomarker	[322]
PAK4	TT7Y3BZ	moderate	Biomarker	[323]
PDE4A	TTZ97H5	moderate	Biomarker	[324]
PDE4D	TTSKMI8	moderate	Altered Expression	[324]
PECAM1	TT4EZB2	moderate	Genetic Variation	[325]
PGF	TT48I1Y	moderate	Biomarker	[326]
PIM1	TTTN5QW	moderate	Biomarker	[327]
PIN1	TTJNTSI	moderate	Altered Expression	[328]
PINX1	TT4FJ3A	moderate	Altered Expression	[329]
PKM	TT4LOT8	moderate	Biomarker	[330]
PLA2G2A	TTO8QRU	moderate	Altered Expression	[331]
PML	TTLH9NY	moderate	Biomarker	[332]
PPIF	TTRFQTB	moderate	Biomarker	[333]
PPME1	TTXQ54R	moderate	Biomarker	[334]
PRKCZ	TTBSN0L	moderate	Biomarker	[335]
PRMT1	TTVOJAI	moderate	Altered Expression	[336]
RPS6KA2	TT0ZW9O	moderate	Biomarker	[337]
RPS6KA3	TTUM2ZR	moderate	Biomarker	[338]
S100A3	TTCDFR1	moderate	Biomarker	[191]
SCGB1A1	TTONPVW	moderate	Biomarker	[339]
SENP1	TTW9HY5	moderate	Biomarker	[340]
SIRT6	TTUXYWF	moderate	Biomarker	[341]
SLC22A16	TTITAVR	moderate	Altered Expression	[342]
SLC6A2	TTAWNKZ	moderate	Biomarker	[283]
SMAD7	TT0J32Z	moderate	Biomarker	[343]
SPHK1	TTOHFIY	moderate	Biomarker	[344]
SPHK2	TTCN0M9	moderate	Biomarker	[345]
SRC	TT6PKBN	moderate	Biomarker	[346]
STMN1	TT7W5OT	moderate	Altered Expression	[347]
TDO2	TTXNCBV	moderate	Altered Expression	[348]
TGFA	TTTLQFR	moderate	Biomarker	[349]
THBD	TTAPV67	moderate	Biomarker	[350]
TLR9	TTSHG0T	moderate	Biomarker	[351]
TOP2A	TTCGY2K	moderate	Biomarker	[352]
TRIM28	TTQ2BKV	moderate	Biomarker	[353]
TXNRD1	TTR7UJ3	moderate	Biomarker	[354]
USP8	TT1J07C	moderate	Biomarker	[355]
ABCA4	TTLB52K	Strong	Altered Expression	[356]
ABCB4	TTJUXV6	Strong	Posttranslational Modification	[357]
ABCC2	TTFLHJV	Strong	Altered Expression	[84]
ABCC4	TTUEAFL	Strong	Altered Expression	[358]
ABCG1	TTMWDGU	Strong	Altered Expression	[359]
ACAT1	TTK3C21	Strong	Biomarker	[360]
ACE2	TTUI5H7	Strong	Genetic Variation	[361]
ACLY	TT0Z6Y2	Strong	Biomarker	[362]
ACR	TTAHE2N	Strong	Biomarker	[363]
ADA	TTLP57V	Strong	Biomarker	[364]
ADAM17	TT6AZXG	Strong	Biomarker	[365]
ADAM8	TTQWYMD	Strong	Altered Expression	[366]
ADAMTS1	TTS2TEI	Strong	Biomarker	[367]
ADAMTS5	TTXSU2Y	Strong	Altered Expression	[368]
ADCY1	TTV1ZSQ	Strong	Genetic Variation	[369]
ADCYAP1	TTW4LYC	Strong	Biomarker	[370]
ADCYAP1R1	TT5OREU	Strong	Biomarker	[370]
ADRA1A	TTNGILX	Strong	Biomarker	[371]
ADRA2B	TTWM4TY	Strong	Biomarker	[371]
AGR2	TT9K86S	Strong	Biomarker	[372]
AGTR2	TTQVOEI	Strong	Biomarker	[373]
AHSG	TTKF4WV	Strong	Genetic Variation	[374]
AICDA	TTKRTP6	Strong	Genetic Variation	[375]
AIMP2	TTXWHGF	Strong	Altered Expression	[376]
AKT3	TTO6SGY	Strong	Biomarker	[377]
ALOX12B	TTQ4QQH	Strong	Genetic Variation	[378]
ALOX15	TTN9T81	Strong	Altered Expression	[379]
ALPI	TTHYMUV	Strong	Biomarker	[380]
AMY2A	TTCGSZ4	Strong	Genetic Variation	[381]
ANGPT1	TTWNQ1T	Strong	Biomarker	[382]
ANGPTL4	TTWALY5	Strong	Biomarker	[383]
ANK1	TTKFPMH	Strong	Posttranslational Modification	[384]
ANO1	TTOJI4S	Strong	Altered Expression	[385]
ANXA10	TT0NL6U	Strong	Biomarker	[386]
ANXA2	TT4YANI	Strong	Altered Expression	[387]
ANXA5	TT2Z83I	Strong	Biomarker	[388]
APCS	TTB7VAT	Strong	Biomarker	[389]
APEH	TTYWEDQ	Strong	Genetic Variation	[390]
APLN	TT87D3J	Strong	Altered Expression	[391]
AQP1	TTSF1KH	Strong	Biomarker	[392]
AREG	TT76B3W	Strong	Biomarker	[293]
ARRB1	TTMVD4A	Strong	Altered Expression	[393]
ASAP3	TTB4ZEN	Strong	Altered Expression	[394]
ASRGL1	TT4WT91	Strong	Biomarker	[226]
ATAD2	TT9A0HI	Strong	Biomarker	[395]
ATAT1	TTWUHQ1	Strong	Altered Expression	[396]
ATF3	TTCE793	Strong	Altered Expression	[397]
ATF4	TTQCKWT	Strong	Biomarker	[398]
ATP2A2	TTE6THL	Strong	Genetic Variation	[399]
ATP4A	TTF1QVM	Strong	Biomarker	[400]
ATP7B	TTOPO51	Strong	Genetic Variation	[401]
ATRAID	TTFLIKM	Strong	Biomarker	[402]
ATXN3	TT6A17J	Strong	Biomarker	[403]
AZGP1	TTUPYLV	Strong	Altered Expression	[404]
BACE1	TTJUNZF	Strong	Biomarker	[405]
BACH1	TT2ME4S	Strong	Biomarker	[406]
BAK1	TTFM7V0	Strong	Altered Expression	[407]
BAP1	TT47RXJ	Strong	Genetic Variation	[408]
BCAT1	TTES57P	Strong	Biomarker	[409]
BCL2A1	TTGT9C7	Strong	Biomarker	[410]
BIRC3	TTAIWZN	Strong	Genetic Variation	[411]
BMI1	TTIPNSR	Strong	Biomarker	[412]
BMP1	TT0L58T	Strong	Altered Expression	[413]
BMP2	TTP3IGX	Strong	Biomarker	[414]
BMP6	TT07RIB	Strong	Biomarker	[415]
BRAF	TT0EOB8	Strong	Genetic Variation	[416]
BRD2	TTDP48B	Strong	Biomarker	[417]
BRDT	TT7CPI5	Strong	Biomarker	[418]
BRS3	TTKYEPM	Strong	Biomarker	[371]
BSG	TT5UJWD	Strong	Altered Expression	[419]
C5AR1	TTHXFA1	Strong	Biomarker	[420]
CA12	TTSYM0R	Strong	Biomarker	[421]
CA2	TTANPDJ	Strong	Altered Expression	[422]
CA9	TT2LVK8	Strong	Altered Expression	[423]
CACNA2D2	TTU8P3M	Strong	Biomarker	[424]
CAD	TT2YT1K	Strong	Biomarker	[425]
CALCR	TTLWS2O	Strong	Biomarker	[426]
CAMKK1	TTGLQWZ	Strong	Genetic Variation	[427]
CAMP	TTULOB6	Strong	Biomarker	[428]
CASP5	TTWR48J	Strong	Genetic Variation	[429]
CASP7	TTM7Y45	Strong	Altered Expression	[430]
CASP8	TT6SZNG	Strong	Biomarker	[431]
CASR	TTBUYHA	Strong	Altered Expression	[432]
CBL	TT7QT13	Strong	Genetic Variation	[433]
CBS	TTVZJ7G	Strong	Genetic Variation	[434]
CBX7	TTBN3HC	Strong	Biomarker	[435]
CCL22	TTBTWI1	Strong	Altered Expression	[436]
CCN1	TTPK79J	Strong	Biomarker	[437]
CCNA2	TTAMQ62	Strong	Genetic Variation	[438]
CCND3	TT1JXNR	Strong	Biomarker	[439]
CCR1	TTC24WT	Strong	Altered Expression	[102]
CCR3	TTD3XFU	Strong	Altered Expression	[102]
CCR4	TT7HQD0	Strong	Biomarker	[440]
CCR6	TTFDB30	Strong	Altered Expression	[441]
CD163	TTTZ9DE	Strong	Biomarker	[442]
CD2	TTJDUNO	Strong	Genetic Variation	[443]
CD200	TT0BE68	Strong	Altered Expression	[103]
CD22	TTM6QSK	Strong	Altered Expression	[444]
CD24	TTCTYNP	Strong	Biomarker	[445]
CD36	TTPJMCU	Strong	Biomarker	[446]
CD55	TT5Z9WY	Strong	Genetic Variation	[447]
CD59	TTBGTEJ	Strong	Altered Expression	[448]
CD69	TTPQE9F	Strong	Altered Expression	[449]
CD70	TTNCIE0	Strong	Biomarker	[450]
CD74	TTCMYP9	Strong	Altered Expression	[451]
CD80	TT89Z17	Strong	Biomarker	[452]
CD86	TT53XHB	Strong	Biomarker	[453]
CD9	TTZEIBV	Strong	Biomarker	[454]
CDC20	TTBKFDV	Strong	Biomarker	[455]
CDC25A	TTLZS4Q	Strong	Biomarker	[456]
CDC25B	TTR0SWN	Strong	Altered Expression	[457]
CDC25C	TTESBNC	Strong	Biomarker	[458]
CDCA8	TT04YCM	Strong	Altered Expression	[459]
CDH11	TTRGWZC	Strong	Altered Expression	[460]
CDH2	TT1WS0T	Strong	Biomarker	[461]
CDH5	TTXLCFO	Strong	Altered Expression	[462]
CDK1	TTH6V3D	Strong	Biomarker	[463]
CDK3	TTMYWL7	Strong	Altered Expression	[464]
CDK5R1	TTBYM6V	Strong	Altered Expression	[465]
CDK7	TTQYF7G	Strong	Biomarker	[466]
CDKN1B	TTLGFVW	Strong	Altered Expression	[467]
CDKN2C	TTBRUGA	Strong	Biomarker	[402]
CEACAM1	TTA9CK4	Strong	Biomarker	[468]
CEACAM6	TTIGH2W	Strong	Biomarker	[469]
CEBPA	TT5LWG1	Strong	Altered Expression	[470]
CES1	TTMF541	Strong	Biomarker	[471]
CFI	TT6ATLX	Strong	Biomarker	[472]
CGA	TTFC29G	Strong	Genetic Variation	[473]
CHEK2	TT9ABMF	Strong	Biomarker	[474]
CHKA	TT10AWB	Strong	Biomarker	[269]
CHM	TTOA18V	Strong	Altered Expression	[475]
CHRNA1	TT54JVQ	Strong	Genetic Variation	[476]
CHRNA2	TTF4E0J	Strong	Biomarker	[477]
CHRNA4	TT4H1MQ	Strong	Genetic Variation	[478]
CHRNA9	TTQACP9	Strong	Genetic Variation	[479]
CHRNB4	TTTVAFQ	Strong	Genetic Variation	[480]
CHST15	TTFK7E1	Strong	Biomarker	[481]
CLDN4	TTMTS9H	Strong	Biomarker	[482]
CNTN1	TTPR8FK	Strong	Altered Expression	[483]
COL6A3	TT5WCAH	Strong	Biomarker	[484]
COPS5	TTSTNJR	Strong	Biomarker	[485]
COX17	TT0F26C	Strong	Biomarker	[486]
CPB2	TTP18AY	Strong	Altered Expression	[487]
CPE	TTXPWO6	Strong	Biomarker	[481]
CRTC1	TT4GO0F	Strong	Altered Expression	[488]
CRTC2	TTFWETR	Strong	Biomarker	[489]
CRY1	TT5MLZR	Strong	Biomarker	[490]
CRY2	TTAO58M	Strong	Biomarker	[490]
CSE1L	TTTRULD	Strong	Genetic Variation	[491]
CSNK1E	TTA8PLI	Strong	Biomarker	[490]
CTCFL	TTY0RZT	Strong	Biomarker	[492]
CTSB	TTF2LRI	Strong	Biomarker	[493]
CTSD	TTPT2QI	Strong	Altered Expression	[494]
CTSK	TTDZN01	Strong	Altered Expression	[495]
CTSL	TT36ETB	Strong	Biomarker	[496]
CTSS	TTUMQVO	Strong	Biomarker	[497]
CUBN	TT9YLCR	Strong	Biomarker	[498]
CX3CL1	TT1OFBQ	Strong	Biomarker	[499]
CX3CR1	TT2T98G	Strong	Altered Expression	[499]
CXCL11	TTWG0RE	Strong	Altered Expression	[500]
CXCL12	TT4UGTF	Strong	Altered Expression	[501]
CXCR1	TTMWT8Z	Strong	Biomarker	[502]
CXCR4	TTBID49	Strong	Biomarker	[503]
CXCR6	TT2BVUA	Strong	Biomarker	[371]
CYBB	TT5T8MR	Strong	Biomarker	[504]
CYP2C19	TTZ58XG	Strong	Genetic Variation	[505]
CYP3A4	TTWP7HQ	Strong	Genetic Variation	[506]
CYSLTR1	TTGKOY9	Strong	Biomarker	[507]
CYTH2	TTOM97J	Strong	Biomarker	[508]
DBH	TTYIP79	Strong	Biomarker	[509]
DCK	TTJOCE4	Strong	Biomarker	[510]
DCLK1	TTOHTCY	Strong	Posttranslational Modification	[511]
DDIT4	TTVEOY6	Strong	Biomarker	[512]
DDX5	TTZKPVC	Strong	Altered Expression	[513]
DEK	TT1NMGV	Strong	Altered Expression	[514]
DHCR24	TTTK0NH	Strong	Biomarker	[515]
DIABLO	TTN74LE	Strong	Biomarker	[516]
DKK2	TTST5KX	Strong	Genetic Variation	[517]
DKK3	TTY2ZV6	Strong	Altered Expression	[518]
DLL1	TT9CFQD	Strong	Altered Expression	[519]
DNAJB1	TTPXAWS	Strong	Altered Expression	[520]
DNASE1	TTYWGOJ	Strong	Genetic Variation	[521]
DNMT3A	TTJUALD	Strong	Biomarker	[522]
DOT1L	TTSZ8T1	Strong	Altered Expression	[523]
DPP4	TTDIGC1	Strong	Biomarker	[524]
DPYSL2	TTZCW3T	Strong	Altered Expression	[525]
DSG3	TTEO4P8	Strong	Biomarker	[526]
DTL	TT8396I	Strong	Biomarker	[527]
DUSP1	TTG8HIM	Strong	Altered Expression	[528]
DUSP5	TTZN92A	Strong	Altered Expression	[529]
DUT	TTH6MBO	Strong	Altered Expression	[530]
DYRK1A	TTSBVFO	Strong	Altered Expression	[531]
E2F2	TT5FYX0	Strong	Altered Expression	[532]
EBI3	TTJF68X	Strong	Biomarker	[533]
EBP	TT4VQZX	Strong	Altered Expression	[534]
ECE1	TTQ9RYT	Strong	Biomarker	[535]
EDNRA	TTKRD0G	Strong	Biomarker	[371]
EDNRB	TT3ZTGU	Strong	Biomarker	[536]
EGR1	TTE8LGD	Strong	Altered Expression	[537]
EHMT2	TTS6RZT	Strong	Biomarker	[538]
EIF5A2	TTH53G9	Strong	Genetic Variation	[539]
ENG	TTB30LE	Strong	Biomarker	[206]
ENOX2	TTUJZRL	Strong	Biomarker	[540]
ENPP1	TTZTIWS	Strong	Biomarker	[541]
EPHA2	TTRJB2G	Strong	Biomarker	[542]
EPHA4	TTG84D3	Strong	Biomarker	[543]
EPHA7	TTAHTVG	Strong	Biomarker	[544]
EPHB6	TTZEMUY	Strong	Biomarker	[545]
EPHX2	TT7WVHI	Strong	Genetic Variation	[546]
ERF	TTGXULC	Strong	Biomarker	[547]
ESRRA	TTPNQAC	Strong	Altered Expression	[548]
ETS2	TT9AH0M	Strong	Altered Expression	[549]
EYA2	TTUY9C6	Strong	Biomarker	[550]
EZH2	TT9MZCQ	Strong	Biomarker	[551]
EZR	TTE47YC	Strong	Biomarker	[552]
F11R	TT3C8EG	Strong	Altered Expression	[553]
F13A1	TTXI2RA	Strong	Altered Expression	[554]
F13B	TTAXGIP	Strong	Altered Expression	[554]
F2RL1	TTQR74A	Strong	Biomarker	[371]
FABP4	TTHWMFZ	Strong	Biomarker	[555]
FAM83B	TT1Q347	Strong	Biomarker	[556]
FASN	TT7AOUD	Strong	Biomarker	[557]
FER	TTRA9G0	Strong	Altered Expression	[558]
FGF1	TTMY81X	Strong	Biomarker	[559]
FGF10	TTNPEFX	Strong	Biomarker	[560]
FGF18	TT6ICRA	Strong	Altered Expression	[561]
FLT4	TTDCBX5	Strong	Biomarker	[562]
FOLH1	TT9G4N0	Strong	Biomarker	[563]
FOLR1	TTVC37M	Strong	Biomarker	[564]
FOSL2	TT689IR	Strong	Biomarker	[481]
FOXC2	TTLBAP1	Strong	Altered Expression	[565]
FOXP3	TT1X3QF	Strong	Biomarker	[566]
FPR2	TTOJ1NF	Strong	Altered Expression	[567]
FSCN1	TTTRS9B	Strong	Biomarker	[568]
FTO	TTFW3BT	Strong	Biomarker	[569]
FUT3	TTUPAD7	Strong	Altered Expression	[570]
FUT4	TTNV1KZ	Strong	Biomarker	[571]
FYN	TT2B9KF	Strong	Biomarker	[392]
GABRA3	TT37EDJ	Strong	Altered Expression	[572]
GABRQ	TTXDUR9	Strong	Genetic Variation	[573]
GALC	TT5IZRB	Strong	Posttranslational Modification	[574]
GAS6	TT69QD2	Strong	Biomarker	[575]
GATA4	TT1VDN2	Strong	Biomarker	[576]
GCK	TTDLNGZ	Strong	Biomarker	[577]
GCLM	TTNFESW	Strong	Altered Expression	[578]
GDF15	TT4MXVG	Strong	Genetic Variation	[579]
GGT1	TTZVT7O	Strong	Biomarker	[580]
GHR	TTHJWYD	Strong	Genetic Variation	[581]
GHRHR	TTG4R8V	Strong	Biomarker	[582]
GHSR	TTWDC17	Strong	Biomarker	[583]
GJB2	TTRGZX3	Strong	Biomarker	[584]
GJB4	TTBRDFI	Strong	Altered Expression	[585]
GLI1	TTJOMH6	Strong	Biomarker	[586]
GPI	TT19JIZ	Strong	Biomarker	[587]
GPRC5D	TTHRAPJ	Strong	Altered Expression	[588]
GRHL2	TTUGH4C	Strong	Altered Expression	[589]
GRIA2	TTWM461	Strong	Biomarker	[590]
GRPR	TTC1MVT	Strong	Biomarker	[591]
GSR	TTEP6RV	Strong	Genetic Variation	[592]
GSS	TTVEWR4	Strong	Genetic Variation	[593]
GSTA1	TT4P8DE	Strong	Biomarker	[594]
GSTA2	TTNLFBE	Strong	Genetic Variation	[595]
GZMB	TTKEPHX	Strong	Altered Expression	[596]
HBEGF	TT15SL0	Strong	Biomarker	[597]
HDAC2	TTSHTOI	Strong	Biomarker	[598]
HDAC3	TT4YWTO	Strong	Posttranslational Modification	[599]
HDAC5	TTUELN5	Strong	Biomarker	[600]
HDAC7	TTMUEK1	Strong	Biomarker	[601]
HDAC9	TT8M4E1	Strong	Altered Expression	[602]
HDGF	TTKGV26	Strong	Altered Expression	[603]
HGFAC	TTD96RW	Strong	Biomarker	[180]
HK2	TTK02H8	Strong	Altered Expression	[604]
HLA-A	TTHONFT	Strong	Genetic Variation	[605]
HMOX1	TTI6V2A	Strong	Altered Expression	[606]
HOXA11	TTEX4ZA	Strong	Biomarker	[607]
HOXA13	TTN26OM	Strong	Altered Expression	[608]
HOXA5	TTXSVQP	Strong	Biomarker	[609]
HPD	TT8DSFC	Strong	Altered Expression	[610]
HSD11B2	TT9H85R	Strong	Genetic Variation	[611]
HSD17B1	TTIWB6L	Strong	Altered Expression	[612]
HSPA12B	TTAI9ZQ	Strong	Altered Expression	[613]
HSPA8	TTMQL3K	Strong	Genetic Variation	[614]
HSPA9	TTMTPG3	Strong	Biomarker	[615]
HSPB3	TTLH8WG	Strong	Biomarker	[512]
HTATIP2	TTC6IX5	Strong	Biomarker	[616]
HTR1B	TTK8CXU	Strong	Altered Expression	[617]
HTRA1	TT8POQR	Strong	Biomarker	[481]
IAPP	TTHN8EM	Strong	Biomarker	[380]
IDS	TTNY2AP	Strong	Biomarker	[481]
IFNB1	TT4TZ8J	Strong	Biomarker	[618]
IGF2	TTE8WGO	Strong	Biomarker	[619]
IGF2R	TTPNE41	Strong	Genetic Variation	[620]
IGFBP2	TTU4QSN	Strong	Altered Expression	[621]
IGFBP6	TTLAYV8	Strong	Biomarker	[622]
IKBKB	TTJ3E9X	Strong	Biomarker	[623]
IL15	TTJFA35	Strong	Genetic Variation	[624]
IL1R2	TT51DEV	Strong	Biomarker	[481]
IL2	TTF89GD	Strong	Biomarker	[625]
IL24	TT1EPXZ	Strong	Biomarker	[586]
IL25	TTVMO5W	Strong	Biomarker	[626]
IL2RB	TT9721Y	Strong	Biomarker	[627]
IL31	TT1RJXK	Strong	Genetic Variation	[628]
IL31RA	TT9HPX0	Strong	Genetic Variation	[629]
IL32	TTD4G7L	Strong	Biomarker	[630]
IL33	TT5MD4P	Strong	Genetic Variation	[627]
IL37	TTQTX98	Strong	Biomarker	[631]
IL4R	TTDWHC3	Strong	Genetic Variation	[632]
IL7R	TTAWI51	Strong	Biomarker	[308]
IL9	TT0JTFD	Strong	Biomarker	[633]
INPP5D	TTTP2Z1	Strong	Biomarker	[634]
IRAK3	TTBPJOK	Strong	Altered Expression	[635]
IRF1	TT4TU3L	Strong	Altered Expression	[636]
IRS2	TTF95B8	Strong	Altered Expression	[637]
ISG15	TTVOH3T	Strong	Altered Expression	[638]
ITCH	TT5SEWD	Strong	Biomarker	[639]
ITGA11	TTANXZ7	Strong	Altered Expression	[640]
ITGA2	TTSJ542	Strong	Biomarker	[641]
ITGAV	TTT1R2L	Strong	Genetic Variation	[642]
ITGB1	TTBVIQC	Strong	Altered Expression	[643]
ITGB6	TTKQSXZ	Strong	Genetic Variation	[642]
ITGB8	TTIF29E	Strong	Biomarker	[644]
JAK1	TT6DM01	Strong	Biomarker	[645]
JAK3	TTT7PJU	Strong	Genetic Variation	[646]
KCNH1	TT9XKUC	Strong	Altered Expression	[647]
KCNJ5	TTEO25X	Strong	Altered Expression	[648]
KCNK3	TTGR91N	Strong	Biomarker	[649]
KDM1A	TTNR0UQ	Strong	Altered Expression	[650]
KDM3A	TTKXS4A	Strong	Altered Expression	[651]
KDM4A	TTZHPB8	Strong	Biomarker	[652]
KDM5B	TTCLI75	Strong	Biomarker	[653]
KIR2DS1	TTVWAGF	Strong	Biomarker	[654]
KIR3DL2	TTQH3N0	Strong	Biomarker	[654]
KLK2	TTJLNAW	Strong	Genetic Variation	[378]
KLK3	TTS78AZ	Strong	Biomarker	[655]
KLK8	TTH5MRS	Strong	Biomarker	[656]
KLKB1	TTN0PCX	Strong	Biomarker	[657]
KLRK1	TTLRN4A	Strong	Altered Expression	[658]
KRT17	TTKV0EC	Strong	Altered Expression	[659]
L1CAM	TTC9D3K	Strong	Altered Expression	[660]
LAMB3	TT2WOUQ	Strong	Biomarker	[661]
LANCL1	TTZW8NS	Strong	Biomarker	[633]
LAPTM4B	TTEJQT0	Strong	Biomarker	[662]
LARP1	TTSN1YP	Strong	Biomarker	[663]
LASP1	TTZJA87	Strong	Biomarker	[664]
LCK	TT860QF	Strong	Biomarker	[665]
LGR4	TTY6C71	Strong	Biomarker	[666]
LIF	TTGZ5WN	Strong	Biomarker	[667]
LILRB1	TTC0QRJ	Strong	Altered Expression	[668]
LIMK1	TTWL9TY	Strong	Biomarker	[669]
LIN28A	TTO50LN	Strong	Biomarker	[670]
LNPEP	TTY2KP7	Strong	Biomarker	[671]
LONP1	TTM1VPZ	Strong	Biomarker	[672]
LOX	TTQHNAM	Strong	Genetic Variation	[673]
LOXL2	TTFSUHX	Strong	Biomarker	[674]
LPAR1	TTQ6S1K	Strong	Biomarker	[675]
LPAR2	TTB7Y8I	Strong	Biomarker	[371]
LSM1	TT2KHSC	Strong	Altered Expression	[676]
LY6K	TT5GKHN	Strong	Biomarker	[677]
LYN	TT1RWNJ	Strong	Altered Expression	[678]
LYVE1	TTG8DNU	Strong	Biomarker	[679]
MAD1L1	TTNE9U7	Strong	Genetic Variation	[680]
MAGEA4	TT9EQUY	Strong	Altered Expression	[681]
MAGEC2	TTKGUEB	Strong	Altered Expression	[682]
MAP2K2	TT8H9GB	Strong	Genetic Variation	[683]
MAP3K1	TTW8TJI	Strong	Altered Expression	[684]
MAP3K5	TTOQCD8	Strong	Biomarker	[685]
MAP3K7	TTJQT60	Strong	Biomarker	[686]
MAP3K8	TTGECUM	Strong	Altered Expression	[687]
MAP4K3	TTI0AHJ	Strong	Biomarker	[577]
MAP4K4	TT6NI13	Strong	Biomarker	[481]
MAPK12	TTYT93M	Strong	Altered Expression	[688]
MAPK8	TT0K6EO	Strong	Biomarker	[689]
MAPKAPK2	TTMUG9D	Strong	Biomarker	[690]
MBL2	TTMQDZ5	Strong	Altered Expression	[691]
MBNL2	TTH9OLG	Strong	Altered Expression	[692]
MCAM	TTHRE05	Strong	Biomarker	[693]
MDK	TTV8UE7	Strong	Biomarker	[694]
MELK	TTBZOTY	Strong	Biomarker	[201]
MERTK	TTO7LKR	Strong	Biomarker	[695]
METAP2	TTZL0OI	Strong	Biomarker	[696]
MGLL	TTZ963I	Strong	Altered Expression	[697]
MLH1	TTISG27	Strong	Posttranslational Modification	[698]
MMP11	TTZW4MV	Strong	Genetic Variation	[699]
MMP12	TTXZ0KQ	Strong	Biomarker	[700]
MMP14	TTJ4QE7	Strong	Biomarker	[701]
MSH2	TTCAWRT	Strong	Altered Expression	[213]
MSI1	TTSM4BA	Strong	Genetic Variation	[702]
MSI2	TTTXQF6	Strong	Altered Expression	[703]
MSMB	TTYH1ZK	Strong	Posttranslational Modification	[704]
MSR1	TT2TDH9	Strong	Biomarker	[705]
MST1R	TTBQ3OC	Strong	Biomarker	[706]
MTA1	TTO4HUS	Strong	Altered Expression	[707]
MTAP	TTDBX7N	Strong	Biomarker	[708]
MTDH	TTH6SA5	Strong	Altered Expression	[709]
MTF1	TTTQDEO	Strong	Altered Expression	[710]
MTR	TTUTO39	Strong	Genetic Variation	[711]
MUC17	TTVO0JU	Strong	Altered Expression	[712]
MUC5AC	TTEL90S	Strong	Biomarker	[713]
MUTYH	TTNB0ZK	Strong	Biomarker	[714]
MYCBP	TTVW4XU	Strong	Genetic Variation	[381]
MYCN	TT9JBY5	Strong	Biomarker	[715]
MYD88	TTB6Q2O	Strong	Biomarker	[716]
MYLK	TT18ETS	Strong	Altered Expression	[717]
NCK1	TTMA3VF	Strong	Genetic Variation	[718]
NCL	TTK1V5Q	Strong	Biomarker	[719]
NECTIN4	TTPO9EG	Strong	Biomarker	[720]
NEDD4	TT1QU6G	Strong	Biomarker	[493]
NEDD8	TTNDC4K	Strong	Altered Expression	[721]
NEDD9	TT1UREA	Strong	Biomarker	[722]
NEK2	TT3VZ24	Strong	Biomarker	[723]
NEK8	TT8AH9I	Strong	Biomarker	[724]
NELL1	TT7H4BF	Strong	Biomarker	[725]
NFE2L2	TTA6ZN2	Strong	Altered Expression	[726]
NFKB2	TTKLNRV	Strong	Altered Expression	[727]
NFKBIA	TTSHAEB	Strong	Biomarker	[728]
NISCH	TT789FN	Strong	Genetic Variation	[729]
NME1	TTDY8JH	Strong	Biomarker	[730]
NOD1	TTYSRXM	Strong	Genetic Variation	[731]
NOD2	TTYPUHA	Strong	Biomarker	[731]
NOP2	TTBLG3H	Strong	Altered Expression	[732]
NOS2	TTF10I9	Strong	Biomarker	[733]
NOTCH2	TT82FVD	Strong	Altered Expression	[734]
NOTCH3	TTVX7IA	Strong	Genetic Variation	[735]
NPEPPS	TT371QC	Strong	Biomarker	[655]
NR0B2	TT25A9Q	Strong	Biomarker	[736]
NR1D1	TTAD1O8	Strong	Biomarker	[490]
NR1H2	TTXA6PH	Strong	Genetic Variation	[737]
NR1I2	TT7LCTF	Strong	Biomarker	[738]
NR1I3	TTRANFM	Strong	Altered Expression	[432]
NR4A1	TTMXE2Q	Strong	Biomarker	[739]
NR4A2	TT9HKN3	Strong	Biomarker	[740]
NR4A3	TTJQB49	Strong	Biomarker	[741]
NR5A2	TTAU3SY	Strong	Altered Expression	[742]
NTN1	TT0AH4L	Strong	Biomarker	[743]
NTRK2	TTKN7QR	Strong	Biomarker	[744]
NTSR1	TTTUMEP	Strong	Biomarker	[745]
NUF2	TTIXBFP	Strong	Biomarker	[677]
OAT	TTTSCQ2	Strong	Altered Expression	[746]
ODC1	TTUMGNO	Strong	Biomarker	[747]
OGFR	TT6IEYX	Strong	Altered Expression	[748]
OPRM1	TTKWM86	Strong	Biomarker	[749]
ORAI1	TTE76YK	Strong	Biomarker	[750]
OXTR	TTSCIUP	Strong	Altered Expression	[751]
P2RX1	TTJW7B3	Strong	Genetic Variation	[752]
P2RX3	TT2THBD	Strong	Genetic Variation	[752]
P2RX4	TT1NLOA	Strong	Genetic Variation	[752]
P2RY1	TTA93TL	Strong	Genetic Variation	[752]
P2RY2	TTOZHQC	Strong	Genetic Variation	[752]
PABPC1	TTHC8EF	Strong	Altered Expression	[753]
PADI4	TTQHAXM	Strong	Biomarker	[754]
PAH	TTGSVH2	Strong	Genetic Variation	[755]
PAK1	TTFN95D	Strong	Altered Expression	[756]
PAM	TTF4ZPC	Strong	Biomarker	[757]
PARP1	TTVDSZ0	Strong	Genetic Variation	[758]
PDE7A	TT1BC3A	Strong	Altered Expression	[336]
PDGFD	TTSN0GA	Strong	Altered Expression	[759]
PDK1	TTCZOF2	Strong	Biomarker	[760]
PDK2	TTJGCKM	Strong	Altered Expression	[761]
PDXP	TT9UYG4	Strong	Biomarker	[762]
PEBP1	TT1BGU8	Strong	Biomarker	[763]
PFKFB3	TTTHMQJ	Strong	Altered Expression	[764]
PGD	TTZ3IFB	Strong	Altered Expression	[765]
PGGT1B	TTX20QP	Strong	Therapeutic	[766]
PGRMC1	TTY3LAZ	Strong	Biomarker	[767]
PHB	TT6U071	Strong	Altered Expression	[768]
PHF8	TT81PFE	Strong	Biomarker	[769]
PHGDH	TT8DRCK	Strong	Biomarker	[770]
PIM2	TT69J2Z	Strong	Altered Expression	[771]
PKD2L1	TTAHD89	Strong	Biomarker	[562]
PLA2G1B	TT9V5JH	Strong	Biomarker	[331]
PLAC1	TTM18HX	Strong	Altered Expression	[772]
PLAUR	TTNOSTX	Strong	Biomarker	[773]
PLK4	TTGPNZQ	Strong	Biomarker	[774]
PMEL	TT8MK59	Strong	Altered Expression	[727]
PMS1	TTX1ISF	Strong	Genetic Variation	[775]
POLB	TTA0XPV	Strong	Genetic Variation	[776]
POR	TTOQ9GZ	Strong	Biomarker	[777]
PORCN	TTNFBTO	Strong	Biomarker	[778]
POSTN	TT8ALTZ	Strong	Altered Expression	[779]
PPARD	TT2JWF6	Strong	Genetic Variation	[780]
PPM1D	TTENJAB	Strong	Genetic Variation	[781]
PRDX5	TTLPJWH	Strong	Biomarker	[782]
PRKCA	TTFJ8Q1	Strong	Biomarker	[783]
PRKCD	TT7A1BO	Strong	Biomarker	[784]
PRKCI	TTWJTHX	Strong	Biomarker	[785]
PRKDC	TTK3PY9	Strong	Altered Expression	[786]
PROM1	TTXMZ81	Strong	Altered Expression	[787]
PSIP1	TTH9LDP	Strong	Biomarker	[352]
PSMB6	TT8EPLT	Strong	Biomarker	[788]
PTGER4	TT79WV3	Strong	Posttranslational Modification	[789]
PTK7	TTXH2ZN	Strong	Biomarker	[790]
PTN	TTA9EJK	Strong	Altered Expression	[791]
PTP4A1	TTA8GFO	Strong	Biomarker	[792]
PTP4A2	TT1MHKD	Strong	Biomarker	[793]
PTP4A3	TT7YM8D	Strong	Biomarker	[794]
PTPN13	TT405FP	Strong	Biomarker	[795]
PTPRB	TT64I9Q	Strong	Biomarker	[796]
PTPRJ	TTWMKXP	Strong	Genetic Variation	[797]
RAC1	TT2M9CG	Strong	Biomarker	[798]
RACK1	TTJ10AL	Strong	Altered Expression	[799]
RAD51	TTC0G1L	Strong	Genetic Variation	[800]
RALBP1	TTVSRUA	Strong	Altered Expression	[801]
RAPGEF3	TTOE7I0	Strong	Biomarker	[802]
RECK	TTRZBW7	Strong	Altered Expression	[803]
REG3A	TTL4H8N	Strong	Biomarker	[804]
REG4	TTVZEHU	Strong	Biomarker	[805]
RICTOR	TT143WL	Strong	Biomarker	[806]
ROBO1	TTND1YP	Strong	Altered Expression	[807]
ROR1	TTDEJAU	Strong	Biomarker	[808]
RORA	TT1TYN7	Strong	Biomarker	[490]
RPS6KA1	TTIXKA4	Strong	Biomarker	[337]
RRM2	TT1S4LJ	Strong	Biomarker	[809]
RSPO1	TTI9HL4	Strong	Biomarker	[810]
RXRA	TT6PEUO	Strong	Biomarker	[811]
S100A6	TT716MY	Strong	Biomarker	[812]
S100A8	TT4AF6N	Strong	Biomarker	[813]
S100A9	TT0TMQG	Strong	Biomarker	[814]
S1PR1	TT9JZCK	Strong	Biomarker	[815]
SAA1	TTY0DN9	Strong	Biomarker	[816]
SATB1	TTLFRIC	Strong	Biomarker	[817]
SCD	TT6RIOV	Strong	Biomarker	[818]
SCGB1D2	TT5D314	Strong	Biomarker	[819]
SCT	TTOBVIN	Strong	Posttranslational Modification	[820]
SDC1	TTYDSVG	Strong	Biomarker	[821]
SDC2	TT5H2F0	Strong	Altered Expression	[822]
SEMA4D	TT5UT28	Strong	Altered Expression	[823]
SENP8	TTMBUHI	Strong	Biomarker	[824]
SERPINB3	TT6QLPX	Strong	Biomarker	[825]
SERPINB5	TT1KW50	Strong	Altered Expression	[826]
SERPING1	TTVQ6R9	Strong	Biomarker	[481]
SETD2	TTPC3H4	Strong	Biomarker	[827]
SETD7	TTJ0FSU	Strong	Biomarker	[828]
SFRP4	TTX8I1Y	Strong	Genetic Variation	[829]
SFTPD	TTGLMU7	Strong	Genetic Variation	[830]
SHCBP1	TTZ9WGL	Strong	Biomarker	[831]
SIK1	TT1H6LC	Strong	Biomarker	[832]
SIK3	TTW6L4V	Strong	Biomarker	[832]
SIRT2	TTLKF5M	Strong	Biomarker	[833]
SIRT5	TTH0IOD	Strong	Biomarker	[834]
SLC14A1	TTWVJU1	Strong	Biomarker	[835]
SLC18A2	TTNZRI3	Strong	Biomarker	[836]
SLC19A1	TT09I7D	Strong	Genetic Variation	[837]
SLC1A5	TTF7WRM	Strong	Biomarker	[838]
SLC1A7	TTK41DM	Strong	Genetic Variation	[839]
SLC25A1	TTTD730	Strong	Altered Expression	[840]
SLC33A1	TTL69WB	Strong	Biomarker	[841]
SLC34A2	TTQPZTM	Strong	Altered Expression	[842]
SLC38A1	TT1YE9Z	Strong	Altered Expression	[843]
SLC3A2	TT5CZSM	Strong	Biomarker	[844]
SLC46A1	TTY8Z2E	Strong	Altered Expression	[336]
SLC52A2	TT6TKEN	Strong	Altered Expression	[845]
SLC5A1	TT2UE56	Strong	Altered Expression	[846]
SLC5A2	TTF8JAT	Strong	Altered Expression	[847]
SLC5A5	TTW7HI9	Strong	Biomarker	[848]
SLC6A8	TTYUHB5	Strong	Biomarker	[426]
SLC7A11	TTBZMIO	Strong	Altered Expression	[849]
SLC7A5	TTPH2JB	Strong	Biomarker	[850]
SLCO1B1	TTFGXEB	Strong	Biomarker	[851]
SLCO2A1	TTKVTQO	Strong	Biomarker	[852]
SMAD6	TTON5JB	Strong	Biomarker	[203]
SMC2	TTS8D17	Strong	Biomarker	[481]
SNCG	TT5TQNZ	Strong	Altered Expression	[853]
SOCS1	TT8COJM	Strong	Biomarker	[854]
SOCS3	TTI0ME6	Strong	Biomarker	[855]
SPAG6	TTDAKTW	Strong	Posttranslational Modification	[856]
SPDEF	TT2ZUPY	Strong	Biomarker	[813]
SPN	TTOZAX0	Strong	Altered Expression	[857]
SQLE	TTE14XG	Strong	Biomarker	[858]
SQSTM1	TTOT2RY	Strong	Altered Expression	[157]
SRGN	TTCHB06	Strong	Biomarker	[859]
SST	TTWF7UG	Strong	Altered Expression	[860]
SSTR1	TTIND6G	Strong	Altered Expression	[861]
SSTR2	TTZ6T9E	Strong	Altered Expression	[862]
SSTR3	TTJX3UE	Strong	Biomarker	[863]
SSTR4	TTAE1BR	Strong	Biomarker	[371]
SSTR5	TT2BC4G	Strong	Biomarker	[863]
ST14	TTPRO7W	Strong	Biomarker	[864]
ST8SIA4	TTDP8YM	Strong	Genetic Variation	[865]
STAT6	TTWOE1T	Strong	Altered Expression	[866]
STC1	TTDLUER	Strong	Biomarker	[867]
STC2	TT4EFTR	Strong	Altered Expression	[868]
STK33	TTP34DQ	Strong	Altered Expression	[869]
STK38	TT27XFN	Strong	Biomarker	[684]
STOML2	TTOI329	Strong	Altered Expression	[870]
STRAP	TT165DP	Strong	Biomarker	[871]
STYK1	TTRMCYJ	Strong	Altered Expression	[872]
SUCNR1	TT4FX9Y	Strong	Altered Expression	[873]
SUV39H1	TTUWQTK	Strong	Altered Expression	[698]
SYK	TT2HUPM	Strong	Biomarker	[874]
TACC3	TTQ4UFD	Strong	Altered Expression	[875]
TAGLN	TTDRZ9H	Strong	Genetic Variation	[876]
TAP1	TT7JZI8	Strong	Altered Expression	[877]
TARDBP	TT9RZ03	Strong	Biomarker	[878]
TBK1	TTMP03S	Strong	Biomarker	[879]
TBL1XR1	TTYXT16	Strong	Biomarker	[880]
TBXA2R	TT2O84V	Strong	Altered Expression	[881]
TDP1	TT64IHJ	Strong	Biomarker	[882]
TDP2	TTYF26D	Strong	Biomarker	[883]
TEK	TT9VGXW	Strong	Biomarker	[249]
TENT4A	TT0XZ4Q	Strong	Altered Expression	[884]
TERF1	TT1Y6J2	Strong	Genetic Variation	[885]
TERF2	TT5XSLT	Strong	Genetic Variation	[886]
TF	TT8WXAV	Strong	Biomarker	[887]
TFAP2A	TTDY4BS	Strong	Altered Expression	[888]
TFPI	TT068JH	Strong	Biomarker	[889]
TGFBR2	TTZE3P7	Strong	Altered Expression	[890]
TGM1	TT7A949	Strong	Altered Expression	[554]
TGM2	TT2F4OL	Strong	Biomarker	[891]
THBS1	TTKI0H1	Strong	Altered Expression	[892]
THPO	TTCG5PE	Strong	Biomarker	[893]
TK1	TTP3QRF	Strong	Biomarker	[894]
TLR5	TTCXP8J	Strong	Altered Expression	[895]
TMEM219	TTY078U	Strong	Biomarker	[896]
TMEM97	TT9NXW4	Strong	Biomarker	[897]
TMSB4X	TTMVAIU	Strong	Altered Expression	[898]
TNC	TTUCPMY	Strong	Altered Expression	[899]
TNFAIP3	TT5W0IO	Strong	Biomarker	[900]
TNFRSF12A	TTKPS7V	Strong	Biomarker	[901]
TNFRSF1A	TTG043C	Strong	Biomarker	[902]
TNFRSF8	TT2GM5R	Strong	Altered Expression	[903]
TNFSF11	TT9E8HR	Strong	Biomarker	[904]
TNFSF13	TTOI1RM	Strong	Biomarker	[905]
TNFSF15	TTEST6I	Strong	Genetic Variation	[906]
TNKS2	TTFQI4H	Strong	Biomarker	[907]
TNS4	TT1K65C	Strong	Altered Expression	[908]
TOP1	TTGTQHC	Strong	Genetic Variation	[909]
TOP2B	TT4NVEM	Strong	Altered Expression	[910]
TPBG	TT70MLA	Strong	Altered Expression	[911]
TPP1	TTOVYPT	Strong	Biomarker	[912]
TPT1	TT3PTB6	Strong	Altered Expression	[913]
TPX2	TT0PHL4	Strong	Altered Expression	[727]
TRAF6	TTCDR6M	Strong	Biomarker	[914]
TREM1	TTHZQP0	Strong	Biomarker	[915]
TRIM27	TTTO3QN	Strong	Altered Expression	[567]
TRIM59	TT613U4	Strong	Altered Expression	[916]
TRPA1	TTELV3W	Strong	Biomarker	[917]
TRPM2	TTEBMN7	Strong	Biomarker	[918]
TRPM7	TTFPVZO	Strong	Biomarker	[919]
TRPV3	TT946IA	Strong	Biomarker	[920]
TSG101	TTHU7JA	Strong	Altered Expression	[921]
TSHR	TT6NYJA	Strong	Biomarker	[922]
TSPO	TTPTXIN	Strong	Altered Expression	[923]
TTK	TTP7EGM	Strong	Altered Expression	[924]
TWIST1	TTX1MY7	Strong	Biomarker	[925]
TXNIP	TTTLDZK	Strong	Biomarker	[926]
TYRP1	TTFRV98	Strong	Biomarker	[468]
UBE2T	TT0A1R8	Strong	Biomarker	[527]
UCP2	TTSC2YM	Strong	Biomarker	[927]
UGT1A1	TT34ZAF	Strong	Genetic Variation	[928]
ULK1	TT4D7MJ	Strong	Genetic Variation	[929]
USP1	TTG9MT5	Strong	Biomarker	[930]
USP13	TTVJIO2	Strong	Altered Expression	[931]
USP33	TT4E85Q	Strong	Biomarker	[932]
USP44	TTJLTNM	Strong	Altered Expression	[933]
USP7	TTXU3EQ	Strong	Altered Expression	[569]
UTRN	TTNO1VA	Strong	Altered Expression	[934]
VDAC1	TTAMKGB	Strong	Altered Expression	[935]
VDAC2	TTM1I7L	Strong	Biomarker	[936]
VEGFD	TTOM5H4	Strong	Biomarker	[937]
VHL	TTEMWSD	Strong	Biomarker	[938]
VIP	TTGTWLF	Strong	Biomarker	[939]
VIPR1	TTCL30I	Strong	Biomarker	[940]
VIPR2	TT4O5P0	Strong	Biomarker	[940]
VTCN1	TTCK85E	Strong	Biomarker	[941]
WDR5	TT7OFWB	Strong	Altered Expression	[942]
WEE1	TTJFOAL	Strong	Biomarker	[943]
WNK1	TTJ9UMX	Strong	Biomarker	[944]
WNT7A	TT8NARC	Strong	Altered Expression	[945]
WWP2	TT6TU05	Strong	Altered Expression	[866]
XPO1	TTCJUR4	Strong	Biomarker	[946]
YES1	TT0SQ8J	Strong	Biomarker	[346]
ZWINT	TTWY768	Strong	Biomarker	[947]
ACKR3	TTRQJTC	Definitive	Biomarker	[371]
AGER	TTMO9HF	Definitive	Biomarker	[948]
AMACR	TTLN1AP	Definitive	Genetic Variation	[949]
APOA1	TT5S8DR	Definitive	Biomarker	[950]
APOC3	TTXOZQ1	Definitive	Biomarker	[951]
CCK	TT90CMU	Definitive	Biomarker	[952]
CCN2	TTIL516	Definitive	Biomarker	[953]
CCND1	TTFCJ7S	Definitive	Altered Expression	[954]
CCR8	TTE836A	Definitive	Altered Expression	[955]
CEACAM3	TTPX7I5	Definitive	Altered Expression	[956]
CEACAM5	TTY6DTE	Definitive	Altered Expression	[956]
CHEK1	TTTU902	Definitive	Altered Expression	[957]
CHRNA7	TTLA931	Definitive	Biomarker	[958]
CLU	TTRL76H	Definitive	Biomarker	[959]
COL18A1	TT63DI9	Definitive	Biomarker	[960]
CSNK2A1	TTER6YH	Definitive	Biomarker	[961]
CSNK2A2	TT7GR5W	Definitive	Genetic Variation	[962]
CYP24A1	TT82UI1	Definitive	Genetic Variation	[963]
DDR2	TTU98HG	Definitive	Genetic Variation	[964]
DRD4	TTE0A2F	Definitive	Genetic Variation	[965]
E2F1	TTASI04	Definitive	Biomarker	[966]
EEF2K	TT1QFLA	Definitive	Biomarker	[967]
EGFR	TTZ04AF	Definitive	Autosomal dominant	[107]
EML4	TT92GY4	Definitive	Genetic Variation	[968]
EPHB2	TTKPV6O	Definitive	Biomarker	[969]
FGFR3	TTST7KB	Definitive	Biomarker	[970]
FOXM1	TTD3KOX	Definitive	Altered Expression	[971]
FOXO1	TTLRVIA	Definitive	Biomarker	[972]
FPR1	TT5Y4EM	Definitive	Altered Expression	[973]
FST	TTDNM9W	Definitive	Altered Expression	[974]
GALNS	TTT9YPO	Definitive	Biomarker	[975]
GJA1	TT4F7SL	Definitive	Biomarker	[584]
GJB1	TTSJIRP	Definitive	Biomarker	[976]
HLA-DQA1	TTU2I3J	Definitive	Genetic Variation	[605]
HSP90AA1	TT78R5H	Definitive	Biomarker	[977]
IGFBP3	TTZHNQA	Definitive	Biomarker	[978]
IL10	TTT0Q1F	Definitive	Genetic Variation	[624]
JAK2	TTRMX3V	Definitive	Biomarker	[979]
KAT2B	TTVK7SB	Definitive	Biomarker	[980]
KEAP1	TT3Z6Y9	Definitive	Genetic Variation	[981]
KLF4	TTTI53X	Definitive	Altered Expression	[982]
LGALS1	TTO3NYT	Definitive	Biomarker	[983]
LTF	TTSZDQU	Definitive	Posttranslational Modification	[984]
MAP2K7	TT6QY3J	Definitive	Genetic Variation	[416]
MAPK1	TT4TQBX	Definitive	Biomarker	[985]
MAPK14	TTQBR95	Definitive	Biomarker	[985]
MAPK3	TT1MG9E	Definitive	Biomarker	[986]
MCL1	TTL53M6	Definitive	Posttranslational Modification	[987]
MET	TTNDSF4	Definitive	Biomarker	[988]
MUC1	TTBHFYQ	Definitive	Altered Expression	[989]
NRG1	TTEH395	Definitive	Biomarker	[990]
NTRK1	TTTDVOJ	Definitive	Biomarker	[991]
PCNA	TTLG1PD	Definitive	Biomarker	[992]
PDCD1	TTNBFWK	Definitive	Biomarker	[993]
PON1	TT9LX82	Definitive	Biomarker	[994]
PPM1A	TTLA7IX	Definitive	Biomarker	[932]
PRDX4	TTPBL9I	Definitive	Altered Expression	[995]
PRMT5	TTR1D7X	Definitive	Biomarker	[996]
RAF1	TTAN5W2	Definitive	Altered Expression	[997]
RORB	TTGB2LZ	Definitive	Biomarker	[490]
RORC	TTGV6LY	Definitive	Genetic Variation	[490]
RUNX3	TTKCVO7	Definitive	Biomarker	[998]
RXFP1	TTMAHD1	Definitive	Altered Expression	[999]
SERPINC1	TT4QPUL	Definitive	Biomarker	[403]
SLCO1B3	TTU86P0	Definitive	Biomarker	[1000]
SMARCA4	TTVQEZS	Definitive	Biomarker	[1001]
SOX2	TTCNOT6	Definitive	Posttranslational Modification	[1002]
SSRP1	TTETDKQ	Definitive	Biomarker	[1003]
SULF2	TTLQTHB	Definitive	Biomarker	[1004]
TCF7L2	TT80QAL	Definitive	Altered Expression	[1005]
TEP1	TTQGAVX	Definitive	Biomarker	[1006]
TRIM24	TT9Q7AE	Definitive	Biomarker	[1007]
TRIM37	TTAMCSL	Definitive	Biomarker	[1008]

This Disease Is Related to 20 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC26A1	DTJ785O	moderate	Altered Expression	[1009]
SLC2A10	DT3BI6S	moderate	Biomarker	[1010]
SLC30A1	DT1BO38	moderate	Altered Expression	[1011]
ABCA3	DT2T6VQ	Strong	Biomarker	[1012]
ABCC10	DTPS120	Strong	Genetic Variation	[1013]
ABCC11	DTWN7FC	Strong	Biomarker	[1014]
ABCC5	DTYVM24	Strong	Biomarker	[1015]
ATP12A	DT5NLZA	Strong	Biomarker	[400]
SLC18A1	DTM953D	Strong	Altered Expression	[836]
SLC25A3	DTCRIWV	Strong	Biomarker	[1016]
SLC25A37	DTLBGTZ	Strong	Biomarker	[1017]
SLC27A2	DTXK9WA	Strong	Biomarker	[1018]
SLC27A3	DTEW95J	Strong	Biomarker	[1019]
SLC28A1	DT0EQPW	Strong	Genetic Variation	[1020]
SLC2A3	DT9SQ3L	Strong	Biomarker	[1021]
SLC31A1	DTP8L4F	Strong	Biomarker	[1022]
SLC39A4	DTEZCUM	Strong	Biomarker	[1023]
SLC44A1	DT3I2SU	Strong	Altered Expression	[1024]
SLC52A1	DT7NOKR	Strong	Biomarker	[1025]
SLC5A8	DTE3TAW	Strong	Biomarker	[1026]

This Disease Is Related to 62 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ALDH1A1	DE2JP1Y	Limited	Biomarker	[1027]
AS3MT	DE9KJP3	Limited	Genetic Variation	[1028]
ASNS	DEXISVQ	Limited	Biomarker	[1029]
FADS1	DE05S8C	Limited	Genetic Variation	[129]
HK1	DEDMAGE	Limited	Biomarker	[1030]
MARS1	DE0K52I	Limited	Altered Expression	[1031]
PARK7	DEPOVCH	Limited	Biomarker	[1032]
PSAT1	DEBS17P	Limited	Biomarker	[655]
UGDH	DE48Q2Z	Limited	Posttranslational Modification	[1033]
NT5C2	DE1DOKJ	Disputed	Biomarker	[1034]
PCYT1A	DEQYXD4	Disputed	Biomarker	[1035]
CYP2A13	DEXZA9U	moderate	Biomarker	[1036]
CYP3A7	DERD86B	moderate	Genetic Variation	[1037]
CYP4F3	DEFCMPI	moderate	Genetic Variation	[1038]
GPT	DER5HFI	moderate	Biomarker	[1039]
SULT1A1	DEYWLRK	moderate	Genetic Variation	[1040]
ABO	DESIA7R	Strong	Altered Expression	[1041]
ACP5	DESITDW	Strong	Biomarker	[1042]
ADH1C	DEM1HNL	Strong	Altered Expression	[253]
ADH5	DEIOH6A	Strong	Biomarker	[1043]
AK2	DEY1FJO	Strong	Biomarker	[1044]
AKR1A1	DED2FW3	Strong	Genetic Variation	[1045]
AKR1C1	DE7P2FB	Strong	Biomarker	[1046]
APRT	DE2MV1R	Strong	Altered Expression	[1047]
CHKB	DEHWR6V	Strong	Altered Expression	[1048]
CPA4	DEXKD7J	Strong	Biomarker	[1049]
CRMP1	DE0EUXB	Strong	Altered Expression	[934]
CYP27A1	DEBS639	Strong	Altered Expression	[1050]
CYP27B1	DE3FYEM	Strong	Genetic Variation	[1050]
CYP2C18	DEZMWRE	Strong	Altered Expression	[1051]
CYP4B1	DEMF740	Strong	Genetic Variation	[1052]
DIO3	DET89OV	Strong	Biomarker	[278]
DTYMK	DEOTVYU	Strong	Biomarker	[1053]
EGLN3	DEMQTKH	Strong	Biomarker	[1054]
FMO3	DEP76YL	Strong	Biomarker	[1055]
FUT10	DEP8X02	Strong	Biomarker	[1056]
FUT11	DERG61P	Strong	Biomarker	[1056]
GGCT	DEKW6PB	Strong	Altered Expression	[1057]
GLDC	DEIN8FB	Strong	Biomarker	[1058]
GLS	DE3E0VT	Strong	Posttranslational Modification	[1059]
GSTA4	DEH7XYP	Strong	Genetic Variation	[1060]
GSTM4	DERQ52Z	Strong	Genetic Variation	[1061]
HPGD	DEHKSC6	Strong	Altered Expression	[1062]
HPRT1	DEVXTP5	Strong	Genetic Variation	[1063]
ME1	DE97WM8	Strong	Biomarker	[1064]
MT1A	DE5ME8A	Strong	Genetic Variation	[318]
MTRR	DE6NIY9	Strong	Genetic Variation	[711]
NAT1	DE7OAB3	Strong	Genetic Variation	[1065]
NAT10	DEZV4AP	Strong	Biomarker	[226]
NDUFS2	DEKX5CD	Strong	Altered Expression	[197]
P4HA2	DE5EGK0	Strong	Posttranslational Modification	[1066]
PTGR1	DE4Q2OE	Strong	Biomarker	[1067]
SAT1	DEMWO83	Strong	Altered Expression	[1009]
SULT1E1	DESTKG6	Strong	Biomarker	[1068]
THOP1	DE95LJC	Strong	Genetic Variation	[490]
UCK2	DETN1O0	Strong	Biomarker	[1069]
UGT1A10	DEL5N6Y	Strong	Altered Expression	[1070]
UGT1A6	DESD26P	Strong	Genetic Variation	[1071]
UGT1A7	DEZO4N3	Strong	Genetic Variation	[1072]
GCLC	DESYL1F	Definitive	Biomarker	[481]
PER1	DE9HF0I	Definitive	Biomarker	[490]
VKORC1L1	DERQV72	Definitive	Genetic Variation	[1073]

This Disease Is Related to 1838 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AATK	OTVHAX5N	Limited	Biomarker	[1074]
ABCB10	OT1C44F9	Limited	Genetic Variation	[1075]
ABCF1	OT6Q079J	Limited	Genetic Variation	[105]
ACAD8	OT3JI5GB	Limited	Genetic Variation	[1076]
ACOT7	OT7C68YV	Limited	Altered Expression	[1077]
ACSL1	OTB06ESI	Limited	Altered Expression	[1078]
ACSL4	OTI71MUJ	Limited	Altered Expression	[1078]
ACSL5	OT3L9XO3	Limited	Altered Expression	[1078]
ACTA2	OTEDLG8E	Limited	Genetic Variation	[1079]
ACYP2	OTRB4S6X	Limited	Genetic Variation	[1080]
ADAR	OTQNOHR8	Limited	Biomarker	[1081]
AGO1	OTD3R434	Limited	Biomarker	[1082]
ALDOA	OTWRFTIB	Limited	Biomarker	[1083]
AP4B1	OTGJUIRA	Limited	Altered Expression	[84]
ARHGAP10	OT84ATF5	Limited	Biomarker	[1084]
ARMC3	OTF6M9MM	Limited	Altered Expression	[1085]
ATG4A	OTDHXAPG	Limited	Genetic Variation	[1086]
ATG4B	OTQ4RNRM	Limited	Altered Expression	[202]
ATL1	OTR2788Y	Limited	Biomarker	[1087]
ATN1	OTNZFLKY	Limited	Biomarker	[1088]
ATP2A3	OTFYDEES	Limited	Altered Expression	[1089]
BAIAP2L1	OTZ71SK9	Limited	Genetic Variation	[1090]
BAZ1B	OTD5KR2J	Limited	Biomarker	[1091]
BEND4	OT7Z1422	Limited	Biomarker	[1092]
BHLHE23	OTLSVD17	Limited	Altered Expression	[84]
CA11	OT8RX3AJ	Limited	Biomarker	[174]
CA8	OT9Y8GA8	Limited	Biomarker	[174]
CADM1	OTRWG9QS	Limited	Altered Expression	[1093]
CALM2	OTNYA92F	Limited	Altered Expression	[1094]
CALU	OTSYQN71	Limited	Biomarker	[1095]
CAP1	OTYM8A2N	Limited	Altered Expression	[1096]
CCDC54	OTW5WCX9	Limited	Biomarker	[1097]
CCNG2	OTII38K2	Limited	Biomarker	[1098]
CCT2	OTW1VV4E	Limited	Altered Expression	[1099]
CCT6A	OTCYWL5F	Limited	Biomarker	[1100]
CD151	OTF3UZS7	Limited	Biomarker	[1101]
CD164	OTZ7FIU8	Limited	Altered Expression	[1102]
CD99	OTPUZ5DE	Limited	Genetic Variation	[1103]
CDC16	OTB914M7	Limited	Biomarker	[1104]
CDH4	OT8LH3HN	Limited	Biomarker	[1105]
CDK20	OTOLNN68	Limited	Biomarker	[1106]
CDKN2B	OTAG24N1	Limited	Biomarker	[1107]
CDX2	OTCG4TSY	Limited	Biomarker	[1108]
CHN1	OTM196M3	Limited	Biomarker	[1109]
CHRNB4	OTIV4MC1	Limited	Autosomal dominant	[107]
CISD2	OTVS7S2H	Limited	Biomarker	[1110]
CITED4	OTR6NHI2	Limited	Biomarker	[1111]
CLDN2	OTRF3D6Y	Limited	Biomarker	[1112]
CLDN5	OTUX60YO	Limited	Biomarker	[1113]
CORO1C	OTXDF9T3	Limited	Biomarker	[1114]
COX5A	OTP0961M	Limited	Genetic Variation	[120]
CPOX	OTIAY121	Limited	Genetic Variation	[120]
CPSF1	OTAU1KOM	Limited	Altered Expression	[1115]
CPSF4	OT53UK5L	Limited	Altered Expression	[1116]
CRISPLD2	OTVSFHTL	Limited	Biomarker	[1117]
CTDP1	OTHHFW17	Limited	Altered Expression	[1118]
CTDSPL	OTZJ0CZK	Limited	Posttranslational Modification	[1119]
CTNND2	OTYKE30Y	Limited	Altered Expression	[1120]
CXCL14	OTM189TA	Limited	Biomarker	[1121]
DCLRE1B	OT2LFW7A	Limited	Genetic Variation	[1122]
DCTN4	OTM7C943	Limited	Altered Expression	[157]
DDA1	OTAZIAIH	Limited	Altered Expression	[1123]
DHX33	OTREUESJ	Limited	Altered Expression	[1124]
DIP2C	OTVNSS2T	Limited	Genetic Variation	[1125]
DLGAP5	OTWCN39U	Limited	Biomarker	[1126]
DLX5	OTEEFBEU	Limited	Altered Expression	[217]
DUOX2	OTU14HCN	Limited	Posttranslational Modification	[1127]
DUOXA1	OTNG3HH4	Limited	Altered Expression	[1127]
DUOXA2	OT7AZBZJ	Limited	Altered Expression	[1127]
DUSP4	OT6WAO12	Limited	Biomarker	[1128]
EBNA1BP2	OTBRVMZH	Limited	Biomarker	[633]
ECH1	OTA0UNHM	Limited	Biomarker	[1129]
EFEMP1	OTZVUOOB	Limited	Biomarker	[1130]
EIF4G2	OTEO98CR	Limited	Biomarker	[1131]
EMP2	OTPS2H0L	Limited	Biomarker	[1132]
EMSY	OTBQ3KQE	Limited	Biomarker	[1133]
ENO1	OTB1KWJS	Limited	Altered Expression	[1134]
EPS8	OTZ6ES6V	Limited	Biomarker	[1135]
ERBB2	OTOAUNCK	Limited	Autosomal dominant	[107]
ERGIC3	OT8RWHN3	Limited	Altered Expression	[1136]
ERP44	OT7ZI7AG	Limited	Biomarker	[1137]
ETHE1	OTP9A2BQ	Limited	Biomarker	[1138]
FAM133A	OTO75ZO4	Limited	Biomarker	[1139]
FBLN5	OTLVNZ8U	Limited	Posttranslational Modification	[1140]
FBXO4	OT6VYX67	Limited	Biomarker	[1141]
FCGBP	OT63T6XQ	Limited	Genetic Variation	[1142]
FGA	OTMIHY80	Limited	Genetic Variation	[1143]
FGF16	OT6BHWZP	Limited	Biomarker	[1144]
FLOT1	OT0JPPJZ	Limited	Genetic Variation	[105]
FMNL2	OT9OVWCV	Limited	Altered Expression	[1145]
FOXA2	OTJOCVOY	Limited	Biomarker	[1146]
FRY	OT74IAG2	Limited	Genetic Variation	[1147]
FTHL17	OTIWALXH	Limited	Altered Expression	[1148]
GABBR1	OTU5A52J	Limited	Genetic Variation	[105]
GALNT13	OT650121	Limited	Altered Expression	[1149]
GAS7	OT0M5TNY	Limited	Biomarker	[1150]
GASK1B	OT2HPHEI	Limited	Altered Expression	[1151]
GATA6	OTO2BC0F	Limited	Genetic Variation	[1152]
GDF10	OTEVXGJ7	Limited	Genetic Variation	[1153]
GEMIN4	OTX7402E	Limited	Genetic Variation	[1154]
GFM1	OTUN4V3N	Limited	Biomarker	[597]
GIT2	OTQ2EQJ1	Limited	Biomarker	[1155]
GOLT1A	OTY8H2OF	Limited	Altered Expression	[1156]
GPR135	OTXOY5NW	Limited	Biomarker	[1092]
GPR180	OT2P0XNK	Limited	Biomarker	[1157]
GPR78	OT8TKE6F	Limited	Biomarker	[1158]
GSTM2	OTG4WT05	Limited	Genetic Variation	[1159]
GTF2H4	OTPD1DIU	Limited	Genetic Variation	[1160]
H3C1	OTGBGOZW	Limited	Altered Expression	[1161]
HAS2	OTTD3PAL	Limited	Altered Expression	[1162]
HAT1	OT307KEN	Limited	Altered Expression	[1163]
HELLS	OTVVV668	Limited	Biomarker	[1164]
HES1	OT8P19W2	Limited	Biomarker	[1165]
HHIP	OT77RQYS	Limited	Biomarker	[1166]
HHLA2	OTYBTVQS	Limited	Biomarker	[1167]
HLA-DOA	OTZE5Q7R	Limited	Biomarker	[1168]
HLA-DQA2	OT1DH0N9	Limited	Genetic Variation	[105]
HOXB9	OTMVHQOU	Limited	Biomarker	[1169]
HOXC10	OT5WF17M	Limited	Biomarker	[1170]
HOXC9	OT60K4M0	Limited	Altered Expression	[1171]
HSF4	OT1UX9SK	Limited	Biomarker	[1172]
HUWE1	OTFH6BJS	Limited	Biomarker	[1173]
HYKK	OTBK1QPN	Limited	Genetic Variation	[1174]
IGBP1	OTTHH4YE	Limited	Biomarker	[1175]
ING5	OTRNNSFM	Limited	Altered Expression	[1176]
INPP4B	OTLROA7G	Limited	Biomarker	[1177]
INVS	OT8KPESR	Limited	Biomarker	[1178]
IPO11	OTG19WN0	Limited	Biomarker	[1179]
IPO7	OTDFMQ00	Limited	Altered Expression	[1180]
IQGAP1	OTZRWTGA	Limited	Biomarker	[577]
IREB2	OT747D24	Limited	Altered Expression	[1181]
IRS4	OTTOL40K	Limited	Altered Expression	[1182]
JARID2	OT14UM8H	Limited	Biomarker	[1183]
KDM6A	OTZM3MJJ	Limited	Altered Expression	[1184]
KLF12	OTVH4KD4	Limited	Altered Expression	[1185]
KLHL25	OTPG0G97	Limited	Altered Expression	[362]
KMT2C	OTC59BCO	Limited	Biomarker	[1186]
KRR1	OTCMJ3K3	Limited	Biomarker	[1187]
LAMTOR3	OTG93MCO	Limited	Biomarker	[1188]
LINGO2	OT3N88Q1	Limited	Genetic Variation	[150]
LMO1	OTB59SKB	Limited	Altered Expression	[924]
LNPK	OTOBNX6G	Limited	Altered Expression	[1189]
LRP1B	OT4YZG2N	Limited	Biomarker	[1190]
MAP3K12	OT5HODDD	Limited	Altered Expression	[115]
MAPK6	OTDDNF3Q	Limited	Altered Expression	[1191]
MARCKSL1	OT13J2FM	Limited	Altered Expression	[1192]
MARK4	OT6Z2TGV	Limited	Altered Expression	[1193]
MCAT	OTH07FIW	Limited	Genetic Variation	[109]
MCCC2	OTQDHSMI	Limited	Biomarker	[1194]
MCTS1	OT7SAOJP	Limited	Genetic Variation	[109]
MEAF6	OTAFDRYT	Limited	Altered Expression	[1195]
MED1	OTOO24C4	Limited	Biomarker	[1196]
MEST	OT8Q4U8Y	Limited	Biomarker	[1197]
MIP	OTEBLU3E	Limited	Biomarker	[767]
MORF4L1	OTEA6FYJ	Limited	Genetic Variation	[105]
MPC1	OT6DYFUO	Limited	Altered Expression	[1198]
MRTFA	OTCVXASM	Limited	Altered Expression	[1199]
MS4A2	OTMCAS2D	Limited	Biomarker	[1200]
MT3	OTVCZ7HI	Limited	Biomarker	[1201]
MTO1	OT7HCZ1D	Limited	Biomarker	[1075]
MUCL3	OTGAD3I0	Limited	Genetic Variation	[105]
MYBL2	OTZ3JX8Q	Limited	Altered Expression	[1202]
MYEOV	OTDC7UHL	Limited	Altered Expression	[1203]
MYRF	OTKF6AEB	Limited	Genetic Variation	[129]
NAA40	OTFLRVQO	Limited	Biomarker	[1204]
NANOG	OTUEY1FM	Limited	Biomarker	[1205]
NANOS2	OTFM2IDJ	Limited	Genetic Variation	[1206]
NAV3	OT97M1TR	Limited	Biomarker	[1207]
NBN	OT73B5MD	Limited	Genetic Variation	[1208]
NCBP2	OTQNZTE4	Limited	Genetic Variation	[1209]
NFATC2	OTK5T6HZ	Limited	Biomarker	[1210]
NFIB	OTX94PD0	Limited	Biomarker	[1211]
NINJ1	OTLRZ1EU	Limited	Biomarker	[1212]
NMI	OTYVG3NM	Limited	Biomarker	[1213]
NSD3	OT3677ZG	Limited	Biomarker	[1214]
NUP62	OTMN63DH	Limited	Altered Expression	[157]
OLA1	OTAPOTTG	Limited	Altered Expression	[1215]
OLIG2	OTMCN6D3	Limited	Biomarker	[1216]
OR12D3	OTQ9XNBB	Limited	Genetic Variation	[105]
OR5V1	OTSYXOD6	Limited	Genetic Variation	[105]
PARD6A	OTWLV3X1	Limited	Biomarker	[1217]
PAX8	OTRPD9MI	Limited	Biomarker	[1108]
PAXIP1	OTRHTKG3	Limited	Biomarker	[1218]
PBX2	OTEBYCAW	Limited	Biomarker	[1219]
PCBP1	OTHN0TD7	Limited	Biomarker	[1220]
PCDHGB6	OT1Y20JS	Limited	Posttranslational Modification	[1221]
PDLIM5	OTLQVV22	Limited	Biomarker	[1222]
PDRG1	OT8ZMFZE	Limited	Biomarker	[1223]
PEAK1	OTVVM637	Limited	Altered Expression	[1224]
PEBP4	OTKDCVC6	Limited	Biomarker	[1225]
PFDN1	OT9837QM	Limited	Biomarker	[1226]
PGBD1	OTSJX9UU	Limited	Genetic Variation	[105]
PHB2	OTCAX3AW	Limited	Altered Expression	[1227]
PHF20	OTCBVH5P	Limited	Biomarker	[1228]
PHF5A	OTS94JFM	Limited	Biomarker	[1229]
PHIP	OTZY806Z	Limited	Biomarker	[1230]
PIGR	OT6GLSUL	Limited	Altered Expression	[1231]
PIWIL4	OTDA9MY0	Limited	Biomarker	[1232]
PKP3	OTPL1HRB	Limited	Biomarker	[1233]
PLPP5	OTHT51D6	Limited	Biomarker	[1234]
PMAIP1	OTXEE550	Limited	Biomarker	[1235]
PODXL	OTPNQXF3	Limited	Altered Expression	[1236]
PPA1	OTHZK1QB	Limited	Biomarker	[169]
PPP1R18	OT0JVGOZ	Limited	Genetic Variation	[105]
PPP1R9B	OTDCTHTT	Limited	Biomarker	[184]
PRDX2	OTLWCY9T	Limited	Biomarker	[1237]
PRDX6	OTS8KC8A	Limited	Biomarker	[1238]
PSORS1C1	OT9HK436	Limited	Genetic Variation	[105]
PVR	OT3N91T7	Limited	Altered Expression	[1239]
PXN	OTVMMUOF	Limited	Altered Expression	[1240]
RAB1A	OTKPHRD0	Limited	Biomarker	[1241]
RAB35	OTRH1E2T	Limited	Altered Expression	[1155]
RAB3D	OTGKRR3C	Limited	Genetic Variation	[929]
RAB5A	OTFR2KM4	Limited	Altered Expression	[1242]
RAD52	OT0OTDHI	Limited	Biomarker	[1243]
RAD9A	OTJ3AJQU	Limited	Altered Expression	[1244]
RANBP9	OTM8COM5	Limited	Biomarker	[1245]
RBFOX1	OTFPKEL7	Limited	Genetic Variation	[1246]
RBFOX3	OTL0F3D6	Limited	Altered Expression	[1247]
RBM10	OTES2MES	Limited	Biomarker	[1248]
RBM47	OT6W67VM	Limited	Altered Expression	[1249]
REEP6	OTY4FPO8	Limited	Biomarker	[502]
RMC1	OT7K8MTJ	Limited	Biomarker	[1250]
RNF39	OTUQA9JT	Limited	Genetic Variation	[105]
RPL14	OTZZW7TK	Limited	Genetic Variation	[1251]
RPL3	OTX6VXLB	Limited	Biomarker	[1252]
RRAS	OTBBF28C	Limited	Biomarker	[1253]
RRN3	OTKGOZ49	Limited	Biomarker	[1254]
RTEL1	OTI3PJCT	Limited	Biomarker	[1243]
RTKN	OTSS8XR6	Limited	Biomarker	[1255]
RUSC2	OT0EKMVR	Limited	Biomarker	[1155]
SAA2	OTYAVJWG	Limited	Biomarker	[1256]
SAV1	OTSAEV92	Limited	Altered Expression	[1257]
SCGB3A2	OTB63PHR	Limited	Biomarker	[1258]
SDCBP	OTS3NCC5	Limited	Altered Expression	[1259]
SDHC	OTC8G2MX	Limited	Genetic Variation	[1260]
SEMA3F	OTQFMS8S	Limited	Altered Expression	[1261]
SETD1A	OTVVWRIC	Limited	Posttranslational Modification	[1262]
SFTA2	OTVRIUIV	Limited	Genetic Variation	[105]
SGSM3	OTIB1P8A	Limited	Genetic Variation	[1263]
SHOX2	OTLCZZJW	Limited	Biomarker	[1264]
SKAP2	OTSF44KP	Limited	Biomarker	[1265]
SKP1	OT5BPAZ4	Limited	Biomarker	[1266]
SMARCA2	OTSGJ8SV	Limited	Biomarker	[1001]
SNRPD3	OTZXBQ45	Limited	Posttranslational Modification	[1267]
SOCS2	OTBPNKJQ	Limited	Biomarker	[1268]
SOX12	OT93P8C9	Limited	Altered Expression	[1269]
SOX7	OTOZOFAG	Limited	Altered Expression	[1270]
SPA17	OT8J7T7U	Limited	Biomarker	[1097]
SPAG5	OTCLJ56M	Limited	Biomarker	[1271]
SPANXA1	OTMK3QIS	Limited	Biomarker	[1272]
SRA1	OTYOGMTG	Limited	Biomarker	[167]
SRSF1	OTF61HOV	Limited	Biomarker	[1273]
SRSF5	OTC5WP98	Limited	Altered Expression	[1274]
STAMBPL1	OTI4CYTF	Limited	Genetic Variation	[1079]
STAT5A	OTBSJGN3	Limited	Biomarker	[1275]
STK19	OTYM6437	Limited	Genetic Variation	[105]
STXBP6	OTUEKTIP	Limited	Posttranslational Modification	[1276]
TAB3	OT1ECMDL	Limited	Biomarker	[1277]
TCF19	OT7NKLF9	Limited	Genetic Variation	[105]
TCHP	OTVDMHSY	Limited	Biomarker	[1278]
TCP1	OT1MGUX9	Limited	Biomarker	[1100]
TFAP2C	OTUDIW05	Limited	Biomarker	[1279]
THBS2	OTXET551	Limited	Biomarker	[1280]
TIMELESS	OTD8DCBJ	Limited	Altered Expression	[1281]
TMEM205	OTGV8KK4	Limited	Biomarker	[1282]
TMEM258	OTXSDU14	Limited	Genetic Variation	[129]
TMEM45B	OTVQCO8N	Limited	Biomarker	[1283]
TMEM8B	OTJZWPS6	Limited	Altered Expression	[552]
TNFAIP8L1	OTVVKOTV	Limited	Biomarker	[1284]
TNKS1BP1	OTBIZECQ	Limited	Altered Expression	[1285]
TNS2	OTP72P0F	Limited	Altered Expression	[1286]
TOPORS	OT1ERFFQ	Limited	Biomarker	[1287]
TRAT1	OTMPUNPD	Limited	Altered Expression	[1288]
TRIM10	OTEO4UCZ	Limited	Genetic Variation	[129]
TRIM11	OTMD6IM2	Limited	Biomarker	[1289]
TRIM25	OT35SG1R	Limited	Biomarker	[1290]
TRIM29	OT2DNESG	Limited	Altered Expression	[1291]
TRIM31	OT7VW6RP	Limited	Genetic Variation	[105]
TRIM62	OT15YO6N	Limited	Altered Expression	[1292]
TRIP13	OTFM3TI9	Limited	Altered Expression	[1293]
TSBP1	OT5GE8IO	Limited	Genetic Variation	[105]
TSC1	OTFF4YZ7	Limited	Biomarker	[1294]
TSC22D1	OTN4GFWD	Limited	Biomarker	[1078]
TSPYL5	OT7QEI2X	Limited	Biomarker	[1295]
TTLL12	OTJQ8RF4	Limited	Biomarker	[1296]
AHNAK	OT6KH1WG	Disputed	Biomarker	[1297]
ANLN	OTXJY54C	Disputed	Biomarker	[1298]
ATG4D	OTSWUO4R	Disputed	Altered Expression	[1299]
BAD	OT63ERYM	Disputed	Biomarker	[1300]
BANP	OT1JMTBD	Disputed	Biomarker	[663]
BNC2	OTU22H9Z	Disputed	Altered Expression	[1301]
CCAR1	OTUXLQZZ	Disputed	Biomarker	[234]
CCAR2	OTLUDG5T	Disputed	Posttranslational Modification	[1302]
CCNY	OTK1KG5W	Disputed	Biomarker	[1303]
CD109	OTDADBM4	Disputed	Biomarker	[1304]
CHPT1	OT4FJ0K3	Disputed	Biomarker	[1305]
CNGB1	OTA5DE38	Disputed	Altered Expression	[232]
CTNND1	OTUMPSHR	Disputed	Altered Expression	[1306]
DHDDS	OTVLYBUS	Disputed	Biomarker	[1305]
DUS2	OTVBE313	Disputed	Biomarker	[1307]
EFEMP2	OT0I2B4J	Disputed	Altered Expression	[1308]
ETV4	OT8C98UZ	Disputed	Biomarker	[1309]
FBN2	OT3KYJQL	Disputed	Posttranslational Modification	[1310]
FOSB	OTW6C05J	Disputed	Biomarker	[481]
GABARAPL1	OT4U7SBG	Disputed	Altered Expression	[1299]
GOLPH3	OTDLGYM3	Disputed	Altered Expression	[1311]
H3-4	OTY6ITYF	Disputed	Biomarker	[1312]
HIVEP1	OT7CAG4A	Disputed	Altered Expression	[1308]
HSD17B6	OTSB55D2	Disputed	Genetic Variation	[1313]
JUNB	OTG2JXV5	Disputed	Biomarker	[481]
JUND	OTNKACJD	Disputed	Biomarker	[481]
LPXN	OTUNV3CK	Disputed	Altered Expression	[1314]
MAP1LC3C	OTM4ECDK	Disputed	Biomarker	[1299]
MSH3	OTD3YPVL	Disputed	Altered Expression	[218]
MYCL	OT1MFQ5U	Disputed	Genetic Variation	[1315]
NABP2	OTQU8081	Disputed	Biomarker	[1316]
NFYA	OTWFFOVH	Disputed	Altered Expression	[1317]
RAMP2	OTGQXLH5	Disputed	Biomarker	[999]
RASSF10	OTGB7EBG	Disputed	Altered Expression	[1318]
RGN	OTD04KB1	Disputed	Altered Expression	[1319]
RLIM	OTEBRNHJ	Disputed	Biomarker	[1320]
SIX3	OTP5E3VU	Disputed	Biomarker	[1321]
SMAD4	OTWQWCKG	Disputed	Biomarker	[1322]
SOX30	OTGT38E3	Disputed	Biomarker	[1323]
SRCIN1	OTQZNQQ5	Disputed	Biomarker	[1324]
SSBP1	OTH2PZWH	Disputed	Biomarker	[1316]
TANK	OTZSGFIK	Disputed	Biomarker	[1325]
TRAIP	OTMPT9Y2	Disputed	Biomarker	[1325]
AADAC	OT8VACT2	moderate	Biomarker	[1326]
ACTN4	OTCNZAJ5	moderate	Altered Expression	[1327]
ADAM11	OTPTVW5W	moderate	Biomarker	[1328]
ADIPOR1	OT65ZFZN	moderate	Altered Expression	[1329]
ALG1	OTVXPA9E	moderate	Genetic Variation	[318]
AP2A1	OTEFZB21	moderate	Altered Expression	[1330]
ARFGEF3	OTGQV0CU	moderate	Biomarker	[1331]
ARHGDIB	OT9PD6CS	moderate	Biomarker	[1332]
ARHGEF5	OTUVGFT9	moderate	Altered Expression	[1281]
ATP2C1	OTQN51T3	moderate	Biomarker	[565]
AXIN1	OTRGZGZ5	moderate	Genetic Variation	[1333]
AXIN2	OTRMGQNU	moderate	Altered Expression	[1334]
BANF1	OTP7Z38L	moderate	Biomarker	[1335]
BPIFB1	OTOZYJMO	moderate	Genetic Variation	[1336]
BTG2	OTZF6K1H	moderate	Biomarker	[1337]
BTG3	OT9ANHVT	moderate	Altered Expression	[1338]
BTRC	OT2EZDGR	moderate	Altered Expression	[1339]
CABYR	OTKYMT99	moderate	Biomarker	[1340]
CANX	OTYP1F6J	moderate	Biomarker	[1341]
CD82	OTH8MC64	moderate	Altered Expression	[1342]
CDC73	OT6JASZ1	moderate	Altered Expression	[1343]
CDCP1	OTD7RRWK	moderate	Genetic Variation	[1344]
CELF1	OT6JQ5RS	moderate	Altered Expression	[1345]
CEMP1	OTUEH5X5	moderate	Altered Expression	[1346]
CETN1	OTGQ8JOZ	moderate	Biomarker	[1347]
CFAP100	OTHHFM2Z	moderate	Biomarker	[1348]
CFL1	OTT6D5MH	moderate	Biomarker	[1349]
CLDN1	OT27KV99	moderate	Altered Expression	[1350]
CLIC4	OT6KTPKD	moderate	Biomarker	[1351]
CLPTM1	OT14QP7N	moderate	Genetic Variation	[192]
CLSPN	OTZZXNDK	moderate	Biomarker	[1352]
COL4A5	OTHG60RE	moderate	Biomarker	[1010]
COX8A	OTU0NR39	moderate	Genetic Variation	[120]
CTAG1B	OTIQGW6U	moderate	Biomarker	[273]
CTCF	OT8ZB70U	moderate	Biomarker	[492]
CXADR	OT9ZP02A	moderate	Altered Expression	[432]
DAB2	OTRMQTMZ	moderate	Biomarker	[1353]
DACH1	OTMKNAGG	moderate	Posttranslational Modification	[1354]
DDX53	OTHK3EGZ	moderate	Biomarker	[1355]
DEF6	OTIRBYVK	moderate	Genetic Variation	[1356]
DENND11	OTC0IJ87	moderate	Genetic Variation	[1357]
DGKH	OTYNPJ4B	moderate	Biomarker	[1358]
DLEU7	OTVKX1YP	moderate	Altered Expression	[1359]
DVL3	OTPRROHJ	moderate	Biomarker	[1360]
EEF1E1	OTRA6XOB	moderate	Biomarker	[1361]
EI24	OTD4NOYS	moderate	Altered Expression	[1362]
ENTPD5	OTFH05B9	moderate	Biomarker	[1363]
EPC1	OT3Q25ND	moderate	Biomarker	[1364]
ERCC4	OTFIOPG1	moderate	Genetic Variation	[1365]
EVA1A	OTCY3Q2M	moderate	Altered Expression	[1366]
FAM168A	OTDXQCS5	moderate	Altered Expression	[1367]
FAM3C	OTBR6U9G	moderate	Biomarker	[1368]
FANCD2	OTVEB5LF	moderate	Biomarker	[1369]
FAT4	OT7QONNV	moderate	Altered Expression	[1370]
FBXO32	OTUE978R	moderate	Biomarker	[1371]
FBXW4	OTEGSZOX	moderate	Biomarker	[1326]
FKBPL	OTR9ND6K	moderate	Genetic Variation	[1336]
FOXD3	OTXYV6GO	moderate	Biomarker	[942]
FOXF1	OT2CJZ5K	moderate	Biomarker	[1372]
FUT8	OTJJCVG1	moderate	Biomarker	[1373]
GCAT	OT6WZPWV	moderate	Genetic Variation	[1374]
GINS1	OTVQZMMQ	moderate	Biomarker	[877]
GKN1	OT7ZYFQ9	moderate	Genetic Variation	[1375]
GLUD1	OTXKOCUH	moderate	Biomarker	[99]
H2AX	OT18UX57	moderate	Genetic Variation	[1376]
HBP1	OTDPGGDV	moderate	Biomarker	[1377]
HMG20B	OTY94WRA	moderate	Genetic Variation	[1378]
HNF4G	OTTSIHJP	moderate	Biomarker	[1379]
HNRNPA0	OTCP792K	moderate	Biomarker	[1380]
HOXD13	OTWSC8TF	moderate	Biomarker	[1381]
HPR	OTXSC9UB	moderate	Biomarker	[1019]
HTRA3	OTXJ0H4X	moderate	Biomarker	[1382]
IGFBP4	OT2HZRBD	moderate	Biomarker	[1383]
IL27	OTIS3OF8	moderate	Biomarker	[1384]
IMMT	OTBDSLE7	moderate	Altered Expression	[1385]
IQGAP3	OT4RZV2M	moderate	Biomarker	[1386]
ISG20	OTCWRJJW	moderate	Biomarker	[1387]
ITGA7	OTTBTAYW	moderate	Genetic Variation	[1388]
KCNH4	OTHJ8WTU	moderate	Altered Expression	[1389]
KCNH8	OT3I5FLB	moderate	Altered Expression	[1389]
KIF2A	OT2WQ6QD	moderate	Altered Expression	[1390]
KIF2C	OTJ8G3NP	moderate	Altered Expression	[1390]
KIF4A	OT3UWL7D	moderate	Biomarker	[1391]
KLF9	OTBFEJRQ	moderate	Biomarker	[1392]
KRT8	OTTM4X11	moderate	Posttranslational Modification	[1132]
LGALS3BP	OT9AGQKH	moderate	Biomarker	[1393]
LRRC42	OTZ02075	moderate	Biomarker	[1394]
LRRFIP1	OTN7XAUD	moderate	Biomarker	[1078]
LSP1	OTSPSIFO	moderate	Genetic Variation	[1395]
LZTS1	OTXXL864	moderate	Biomarker	[1396]
MAD2L1	OTXNGZCG	moderate	Altered Expression	[1397]
MAGED4B	OTO37U7W	moderate	Biomarker	[314]
MAK16	OTD546E5	moderate	Biomarker	[1398]
MAP2K4	OTZPZX11	moderate	Biomarker	[1320]
MARVELD1	OT5CPOJE	moderate	Biomarker	[1399]
MAST1	OTEYFN5O	moderate	Biomarker	[1400]
MDC1	OTEUQH4J	moderate	Genetic Variation	[1401]
MED19	OTT9RT5N	moderate	Biomarker	[1402]
MEN1	OTN6U6V0	moderate	Altered Expression	[1403]
MEOX1	OTJEMT2D	moderate	Biomarker	[1404]
MLXIP	OT30UNI7	moderate	Altered Expression	[1405]
MOAP1	OTVF3LUG	moderate	Biomarker	[1406]
MSN	OTZJ4J6G	moderate	Biomarker	[1407]
MST1	OTOC4UNG	moderate	Genetic Variation	[1408]
MT1B	OTUA4FFH	moderate	Genetic Variation	[318]
MT1E	OTXJKU4Y	moderate	Genetic Variation	[318]
MT1F	OTZVUYG1	moderate	Genetic Variation	[318]
MT1H	OT0MVBM6	moderate	Genetic Variation	[318]
MT1M	OTVT8PLU	moderate	Genetic Variation	[318]
MTFMT	OT1OIVJL	moderate	Biomarker	[1409]
MXI1	OTUQ9E0D	moderate	Altered Expression	[1410]
MYDGF	OT9HRPL6	moderate	Biomarker	[1384]
MYH6	OT3YNCH1	moderate	Biomarker	[1411]
MYLIP	OTL0PFGV	moderate	Altered Expression	[1405]
MYO18B	OTGYY4NK	moderate	Genetic Variation	[1412]
MYO6	OTJQYRC7	moderate	Altered Expression	[1411]
MYO9B	OTQ94R5K	moderate	Biomarker	[1413]
MYOD1	OTV2S79X	moderate	Biomarker	[1414]
MZF1	OTMVZCPW	moderate	Altered Expression	[1389]
NLN	OTFRITPU	moderate	Genetic Variation	[1415]
NLRP2	OTJA81JU	moderate	Genetic Variation	[1208]
NPTX1	OTKVHCV0	moderate	Posttranslational Modification	[1416]
OPCML	OT93PQ6Y	moderate	Genetic Variation	[1417]
OPN1LW	OTFNUZ7O	moderate	Biomarker	[1418]
OPN4	OT1LZ7TS	moderate	Genetic Variation	[1415]
PAEP	OTQA0NV4	moderate	Biomarker	[1419]
PEG10	OTWD2278	moderate	Altered Expression	[1420]
PFKFB4	OTQYEXL2	moderate	Altered Expression	[1421]
PLA2G10	OTRZ2L5A	moderate	Altered Expression	[331]
PLAGL2	OT6AP4V2	moderate	Altered Expression	[1422]
PLCE1	OTJISZOX	moderate	Altered Expression	[1423]
PLEKHO1	OTMVUQ9W	moderate	Altered Expression	[1424]
PMS2	OTNLWTMI	moderate	Genetic Variation	[1425]
POU3F1	OTYARA94	moderate	Altered Expression	[342]
POU3F2	OT30NFOC	moderate	Biomarker	[1426]
POU3F3	OT6BBXPD	moderate	Biomarker	[1426]
POU3F4	OTKF5AF7	moderate	Biomarker	[1426]
POU4F2	OT6SW5H0	moderate	Biomarker	[1426]
POU4F3	OTILD0XS	moderate	Biomarker	[1426]
PRRC2A	OTBX6FM5	moderate	Genetic Variation	[1336]
PSMA4	OTAD2XXI	moderate	Biomarker	[1427]
PTBP2	OTF4S7NE	moderate	Biomarker	[1428]
PTPRK	OTAP5AT3	moderate	Genetic Variation	[1429]
PTTG1	OTIMYS4W	moderate	Biomarker	[1430]
RAB37	OTRL8IUO	moderate	Biomarker	[1431]
RAB40B	OTCA9ZF5	moderate	Biomarker	[1432]
RAN	OT2TER5M	moderate	Altered Expression	[1433]
RAP2B	OTD2NDQP	moderate	Altered Expression	[1434]
RASD2	OTETA815	moderate	Altered Expression	[1435]
RBM4	OT5SFQA3	moderate	Biomarker	[1436]
RBM6	OTI99KAZ	moderate	Genetic Variation	[1437]
RGS5	OTUY0Q2I	moderate	Altered Expression	[1438]
RND3	OTXMXPIH	moderate	Biomarker	[1439]
RPA1	OT76POLP	moderate	Altered Expression	[1440]
RPL39	OTL8TZHQ	moderate	Biomarker	[1441]
RPS15A	OT0BUA12	moderate	Altered Expression	[1442]
SALL4	OTC08PR5	moderate	Biomarker	[1443]
SCIN	OT6U09OL	moderate	Biomarker	[1444]
SCN7A	OTK05PXY	moderate	Biomarker	[1445]
SCRIB	OTW4N3FV	moderate	Biomarker	[1446]
SDF4	OTQ7WFYW	moderate	Biomarker	[1347]
SEL1L	OTC0FB7T	moderate	Altered Expression	[1447]
SEMA3B	OTCZCPMS	moderate	Genetic Variation	[1448]
SEMA6A	OTDQ7QAW	moderate	Biomarker	[1449]
SEPTIN9	OT1VMRFQ	moderate	Posttranslational Modification	[1450]
SESN2	OT889IXY	moderate	Biomarker	[1451]
SOX15	OTTB37I1	moderate	Biomarker	[1452]
SPRY4	OT2VK9N0	moderate	Biomarker	[926]
SRRM2	OTSIMMC9	moderate	Biomarker	[1398]
TAS2R38	OTX5MM36	moderate	Altered Expression	[1399]
TBX1	OTQLBPRA	moderate	Genetic Variation	[473]
TCIM	OTARUXQF	moderate	Biomarker	[1453]
TET1	OTZDHT1D	moderate	Biomarker	[1454]
THOC1	OTVABJ4Z	moderate	Biomarker	[1455]
TIMP2	OT8S1RRP	moderate	Altered Expression	[1456]
TIMP3	OTDGQAD1	moderate	Biomarker	[1457]
TJP1	OTBDCUPK	moderate	Altered Expression	[1458]
TOPBP1	OT6UPZPD	moderate	Biomarker	[1352]
TOX4	OTSOXQFN	moderate	Altered Expression	[1459]
TPST1	OTDPQKEA	moderate	Biomarker	[1460]
TSGA13	OT81V4LS	moderate	Altered Expression	[1461]
TSPAN2	OTTDPQF1	moderate	Biomarker	[1462]
A2M	OTFTX90K	Strong	Biomarker	[951]
AAMP	OTZXBSS4	Strong	Biomarker	[1463]
AATF	OT1QOKLD	Strong	Biomarker	[1464]
ABI2	OT8GIIS5	Strong	Genetic Variation	[411]
ABI3	OTQTDSHP	Strong	Biomarker	[1465]
ACACA	OT5CQPZY	Strong	Posttranslational Modification	[1466]
ACP1	OTJ9CKLU	Strong	Biomarker	[796]
ACSBG1	OTM040MW	Strong	Altered Expression	[1467]
ACSL3	OT3MWER1	Strong	Biomarker	[1468]
ACSM1	OT1TS9M9	Strong	Biomarker	[471]
ACTR3	OT05LJSH	Strong	Biomarker	[352]
ACTRT1	OTHFKSIZ	Strong	Genetic Variation	[411]
ADAM28	OT3GBVHL	Strong	Biomarker	[1469]
ADAMTS18	OTRMFI04	Strong	Biomarker	[1470]
ADAMTS8	OT2KFY1S	Strong	Altered Expression	[1471]
ADARB1	OTGKSZEV	Strong	Biomarker	[1472]
ADD1	OTTF68DC	Strong	Biomarker	[1473]
ADGRE2	OTUYJVYG	Strong	Altered Expression	[532]
ADSS1	OTF6FE38	Strong	Genetic Variation	[1474]
AFAP1	OTR473H8	Strong	Altered Expression	[1475]
AGO2	OT4JY32Q	Strong	Biomarker	[1476]
AIFM1	OTKPWB7Q	Strong	Biomarker	[936]
AIMP1	OTTA5C3U	Strong	Biomarker	[1477]
AK4	OTA0T02Q	Strong	Altered Expression	[1478]
AKAP12	OTCVRDDX	Strong	Posttranslational Modification	[1479]
AKAP3	OT42QOFG	Strong	Altered Expression	[1480]
AKAP8	OTK3EQAI	Strong	Altered Expression	[802]
AKT1S1	OT4JHN4Y	Strong	Biomarker	[1481]
ALDH1A3	OT1C9NKQ	Strong	Biomarker	[1482]
ALDH1L1	OT15HOJX	Strong	Altered Expression	[1483]
ALDH3A1	OTAYZZE6	Strong	Biomarker	[1484]
ALKBH1	OTADGU5D	Strong	Altered Expression	[1041]
ALKBH3	OTS1CD9Z	Strong	Biomarker	[1485]
ALOX15B	OTWQQ08W	Strong	Altered Expression	[1486]
ALPK1	OTBW6SGD	Strong	Altered Expression	[1487]
ALPP	OTZU4G9W	Strong	Biomarker	[226]
ALX4	OTNS9A29	Strong	Biomarker	[1488]
AMFR	OTQRX7LC	Strong	Altered Expression	[1489]
AMMECR1	OTWMQ67T	Strong	Biomarker	[1490]
AMPD1	OTU17BCI	Strong	Genetic Variation	[1491]
AMPH	OTWPGWZX	Strong	Biomarker	[1492]
AMY1A	OT6G4B8O	Strong	Genetic Variation	[381]
AMY2B	OTG93YV0	Strong	Genetic Variation	[381]
ANGPTL1	OTXIN6V5	Strong	Biomarker	[1493]
ANK3	OTJ3IRBP	Strong	Biomarker	[481]
ANKRD36B	OT3MW415	Strong	Altered Expression	[1494]
ANTXR1	OT5W1GPC	Strong	Altered Expression	[1495]
ANXA3	OTDD8OI7	Strong	Biomarker	[1496]
ANXA4	OTUCRYXL	Strong	Biomarker	[1497]
APAF1	OTJWIVY0	Strong	Altered Expression	[1498]
APOBEC3A	OTYO6F5P	Strong	Genetic Variation	[1499]
APOBEC3B	OTHLNI51	Strong	Biomarker	[1500]
APOBEC3H	OTXIH4X4	Strong	Genetic Variation	[1501]
APOM	OTI3FQQC	Strong	Biomarker	[815]
APPBP2	OTLNFV4J	Strong	Biomarker	[1502]
AQP5	OT77GBY8	Strong	Biomarker	[1503]
AQP8	OT99JKME	Strong	Altered Expression	[1504]
ARF6	OTVV7KJO	Strong	Altered Expression	[394]
ARHGAP1	OT0H2ZBZ	Strong	Altered Expression	[1505]
ARHGAP15	OT9CKHDC	Strong	Biomarker	[1506]
ARHGAP25	OTYW7ED8	Strong	Altered Expression	[1507]
ARHGAP5	OTOQELUN	Strong	Biomarker	[1508]
ARHGAP6	OTNVXXFX	Strong	Biomarker	[1505]
ARHGEF11	OTDOMEH6	Strong	Genetic Variation	[1509]
ARHGEF19	OTKD9XY9	Strong	Altered Expression	[1510]
ARHGEF2	OTBQTFRT	Strong	Biomarker	[633]
ARHGEF28	OT3F32IU	Strong	Genetic Variation	[1509]
ARHGEF7	OT9BPJCL	Strong	Biomarker	[1511]
ARID2	OTIRJXWM	Strong	Genetic Variation	[1512]
ARL11	OTF6UDDB	Strong	Altered Expression	[1513]
ARL4C	OTQ3QNNU	Strong	Altered Expression	[1514]
ARL6IP1	OT536XAV	Strong	Genetic Variation	[411]
ARMC8	OTNAXGM7	Strong	Altered Expression	[1515]
ARMCX3	OTMG7RWW	Strong	Altered Expression	[1516]
ARMH1	OTTJC0D6	Strong	Biomarker	[633]
ARPP21	OTWXZN5I	Strong	Altered Expression	[1517]
ARR3	OTRZ00CH	Strong	Altered Expression	[432]
ARTN	OTWIWGL6	Strong	Biomarker	[1518]
ASAH1	OT1DNGXL	Strong	Biomarker	[1519]
ASCC2	OT3B204T	Strong	Altered Expression	[727]
ASH1L	OTUT5NLJ	Strong	Biomarker	[465]
ASL	OTI2NGQR	Strong	Biomarker	[1520]
ASS1	OT4ZMG0Q	Strong	Biomarker	[1521]
ASXL1	OTX931AW	Strong	Genetic Variation	[1522]
ATF1	OT251CI0	Strong	Posttranslational Modification	[1523]
ATF2	OTNIZPEA	Strong	Altered Expression	[1524]
ATG10	OTVRPC5X	Strong	Altered Expression	[1525]
ATG101	OTG8QUXY	Strong	Biomarker	[481]
ATG16L1	OTEOYC5D	Strong	Genetic Variation	[1526]
ATG3	OT28VBVK	Strong	Biomarker	[1527]
ATOX1	OT05LF59	Strong	Biomarker	[486]
ATP6AP2	OT0IABVV	Strong	Biomarker	[1528]
ATP6V1E1	OT76J5R9	Strong	Biomarker	[1529]
ATRNL1	OTY5JUX2	Strong	Biomarker	[226]
AVPI1	OTXSBR60	Strong	Biomarker	[481]
AZIN1	OTX5W77I	Strong	Biomarker	[1530]
B3GAT1	OTXFP98E	Strong	Altered Expression	[1531]
B4GALT1	OTBCXEK7	Strong	Biomarker	[1532]
BAG1	OTRQNIA4	Strong	Altered Expression	[1533]
BAG6	OT4Z0S2U	Strong	Genetic Variation	[1174]
BAIAP2L2	OTQDY90J	Strong	Biomarker	[1534]
BAMBI	OTCEJ8W5	Strong	Altered Expression	[1535]
BATF2	OT4XBZC9	Strong	Biomarker	[1536]
BCAR1	OTKT2C2N	Strong	Biomarker	[1537]
BCL11B	OT8KKCVJ	Strong	Biomarker	[1538]
BCL2L10	OTYXQJ3I	Strong	Altered Expression	[1539]
BCL2L12	OTS6IFZY	Strong	Altered Expression	[1025]
BCL9	OTRBIPR4	Strong	Biomarker	[1540]
BHLHE40	OTITX14U	Strong	Altered Expression	[1541]
BIRC6	OTCQJAB0	Strong	Altered Expression	[1542]
BMS1	OTEGQ8ZO	Strong	Biomarker	[1543]
BNIP3	OT4SO7J4	Strong	Altered Expression	[1544]
BPIFA1	OTQFD2J5	Strong	Altered Expression	[1545]
BPTF	OTD1RZAD	Strong	Biomarker	[1546]
BRD8	OTIKS3PC	Strong	Altered Expression	[732]
BRF2	OT2C6TH2	Strong	Biomarker	[1547]
BRINP1	OTEUVSCP	Strong	Biomarker	[1548]
BRK1	OTTUB5KS	Strong	Biomarker	[1549]
BRMS1	OTV5A6LL	Strong	Biomarker	[1550]
BST1	OTAV5SE7	Strong	Biomarker	[1551]
BTBD7	OTNUV6MQ	Strong	Biomarker	[1552]
BUB1B	OT8KME51	Strong	Altered Expression	[1553]
BUB3	OTU91HAU	Strong	Biomarker	[1491]
BZW1	OT4GUFIG	Strong	Altered Expression	[1554]
C12orf42	OTRQP2SW	Strong	Altered Expression	[1555]
C2	OTHMF4YM	Strong	Biomarker	[1556]
C4orf3	OT6TFN1O	Strong	Biomarker	[509]
C5AR2	OTP1Q82J	Strong	Biomarker	[1557]
CABLES1	OTMN4XSX	Strong	Altered Expression	[1558]
CACUL1	OT6P1ZVP	Strong	Biomarker	[1559]
CALB2	OTSNMCG9	Strong	Biomarker	[1560]
CALML3	OTM8DNQU	Strong	Biomarker	[481]
CAND1	OTGB6NU0	Strong	Biomarker	[1561]
CAPNS1	OT95EBBD	Strong	Altered Expression	[1562]
CAPRIN2	OTDYKD95	Strong	Genetic Variation	[1563]
CARD10	OT2RPM4I	Strong	Altered Expression	[1564]
CARD9	OTJ81AWD	Strong	Biomarker	[1565]
CARTPT	OTTE4V9S	Strong	Genetic Variation	[1566]
CASS4	OTGPIPUS	Strong	Biomarker	[1537]
CASTOR1	OTYIH7WK	Strong	Biomarker	[1567]
CASZ1	OTWJ2OR8	Strong	Biomarker	[1568]
CAVIN2	OTFHHDRU	Strong	Altered Expression	[1569]
CAVIN3	OTOLBK79	Strong	Altered Expression	[1570]
CBFA2T2	OTNOIB23	Strong	Biomarker	[1511]
CBLIF	OTNE20WU	Strong	Altered Expression	[1571]
CBLL2	OTB4AD3V	Strong	Altered Expression	[1572]
CBX4	OT4XVRRF	Strong	Biomarker	[412]
CBX5	OT8VYY84	Strong	Biomarker	[1573]
CCDC106	OTWUTA1W	Strong	Biomarker	[1574]
CCDC116	OTYMNP3C	Strong	Biomarker	[1360]
CCDC6	OTXRQDYG	Strong	Genetic Variation	[1575]
CCDC8	OTO295IH	Strong	Biomarker	[1576]
CCDC85B	OTKEQLNK	Strong	Biomarker	[1577]
CCDC88A	OT3SSYYC	Strong	Biomarker	[1578]
CCL13	OTNX0JD0	Strong	Genetic Variation	[624]
CCL18	OT7JYSK9	Strong	Biomarker	[1579]
CCL19	OTQ2UJMH	Strong	Biomarker	[1580]
CCL25	OTLWJ8CJ	Strong	Biomarker	[1581]
CCL27	OTUZYC61	Strong	Biomarker	[226]
CCL4	OT6B8P25	Strong	Altered Expression	[1582]
CCL4L2	OTDBSXOU	Strong	Altered Expression	[1582]
CCL7	OTDIS99H	Strong	Altered Expression	[102]
CCN4	OT69BER9	Strong	Biomarker	[1583]
CCNA1	OTX4HD45	Strong	Biomarker	[1584]
CCP110	OTNOVXA2	Strong	Biomarker	[1585]
CCRL2	OT5PX0RX	Strong	Biomarker	[1586]
CD1D	OT3ROU4J	Strong	Altered Expression	[1587]
CD2AP	OTC76KQM	Strong	Genetic Variation	[1588]
CD68	OTOYEY3J	Strong	Biomarker	[503]
CD79A	OTOJC8DV	Strong	Altered Expression	[1589]
CDC34	OTNBK390	Strong	Altered Expression	[1590]
CDC42	OT5QBC5M	Strong	Biomarker	[1591]
CDC42EP3	OTUZ3U9Z	Strong	Biomarker	[1592]
CDC45	OT6NNLOD	Strong	Biomarker	[1593]
CDC6	OTX93FE7	Strong	Biomarker	[1594]
CDCA5	OTZLCQ5U	Strong	Altered Expression	[465]
CDK16	OTUBXIIT	Strong	Altered Expression	[1595]
CDK2AP2	OTR99SJ8	Strong	Posttranslational Modification	[1596]
CDKN2D	OT2TTZPZ	Strong	Posttranslational Modification	[1597]
CDKN3	OTBE3H07	Strong	Biomarker	[353]
CENPW	OTZL05QN	Strong	Biomarker	[1598]
CEP55	OTGSG2PA	Strong	Biomarker	[1500]
CERS6	OTOP4GV1	Strong	Biomarker	[1599]
CFHR1	OT72R16T	Strong	Biomarker	[1600]
CHCHD5	OTVESFOA	Strong	Altered Expression	[1601]
CHD5	OTS5EVHH	Strong	Altered Expression	[1602]
CHL1	OT6E6E8P	Strong	Biomarker	[1603]
CHMP4C	OT5X8A3O	Strong	Biomarker	[1604]
CHODL	OTVCNOUQ	Strong	Altered Expression	[1605]
CHRNA3	OTCZQY1U	Strong	Genetic Variation	[478]
CHRNA6	OTT6W86V	Strong	Genetic Variation	[1606]
CHRNB3	OTE5XENW	Strong	Genetic Variation	[1607]
CHST7	OT9HCUST	Strong	Biomarker	[1608]
CIB1	OT4BVCRU	Strong	Altered Expression	[1609]
CIB2	OT9ZJX1I	Strong	Altered Expression	[224]
CILK1	OTWOYEYP	Strong	Altered Expression	[1610]
CIR1	OTKP5JKH	Strong	Genetic Variation	[194]
CIZ1	OT3UKHPI	Strong	Biomarker	[1611]
CKS1B	OTNUPLUJ	Strong	Altered Expression	[1612]
CLDN12	OTO55YZI	Strong	Altered Expression	[1613]
CLDN16	OTTHAIKR	Strong	Genetic Variation	[1614]
CLDN3	OT71MN9S	Strong	Biomarker	[1615]
CLEC10A	OTD8HQT6	Strong	Altered Expression	[1616]
CLEC2D	OTVRLKPM	Strong	Altered Expression	[1617]
CLTB	OTPW9VRE	Strong	Biomarker	[481]
CLYBL	OTXZLTST	Strong	Altered Expression	[1618]
CNN1	OTVPG39Z	Strong	Genetic Variation	[876]
CNOT2	OT98OJ42	Strong	Biomarker	[1619]
CNOT3	OT4D5Z9L	Strong	Biomarker	[1620]
COG8	OTDEA7YO	Strong	Altered Expression	[1621]
COL11A2	OT3BQUBH	Strong	Genetic Variation	[758]
COL12A1	OTHLTV53	Strong	Genetic Variation	[1622]
COL4A2	OTJK1LKN	Strong	Biomarker	[1623]
COL6A1	OTYKSCOB	Strong	Biomarker	[1624]
COPE	OTBKHBT7	Strong	Genetic Variation	[1625]
COPS3	OTZWPJ24	Strong	Altered Expression	[1626]
COX7A1	OTHV25GG	Strong	Biomarker	[1627]
CPD	OT2CS64Y	Strong	Altered Expression	[1628]
CPNE1	OTH5YKSL	Strong	Biomarker	[1629]
CPNE3	OTCR3WG2	Strong	Biomarker	[1630]
CPQ	OTTNZNLD	Strong	Posttranslational Modification	[1631]
CRABP2	OTY01V9G	Strong	Altered Expression	[1632]
CRISP2	OT8HLTV5	Strong	Biomarker	[1633]
CRKL	OTOYSD1R	Strong	Genetic Variation	[1634]
CRLS1	OT7XNL0K	Strong	Altered Expression	[1635]
CRTAP	OT53H5U6	Strong	Genetic Variation	[429]
CRYGD	OTW29JC4	Strong	Genetic Variation	[1415]
CSH1	OT33HTRR	Strong	Genetic Variation	[1636]
CSH2	OTW8JVAN	Strong	Biomarker	[1637]
CSMD3	OTAT75SW	Strong	Genetic Variation	[1638]
CSNK2B	OT2WW7R1	Strong	Genetic Variation	[315]
CSTA	OT1K68KE	Strong	Altered Expression	[1639]
CSTB	OT3U0JF8	Strong	Altered Expression	[1640]
CSTF2	OTR6G4II	Strong	Altered Expression	[1641]
CT45A1	OT80VTZO	Strong	Altered Expression	[1642]
CT47A11	OTQHGP0S	Strong	Altered Expression	[1643]
CT83	OTQEGHAB	Strong	Altered Expression	[1644]
CTNNBIP1	OTX9SBJG	Strong	Altered Expression	[1645]
CTTN	OTJRG4ES	Strong	Biomarker	[1646]
CUL4A	OTTBV70J	Strong	Biomarker	[386]
CUL4B	OT2QX4DO	Strong	Biomarker	[1647]
CUL5	OTMTZD47	Strong	Biomarker	[1648]
CUX1	OTU1LCNJ	Strong	Altered Expression	[727]
CWH43	OTT3DPRH	Strong	Biomarker	[481]
CXCL16	OTD49T9R	Strong	Biomarker	[1649]
CXCL17	OTRCEVIZ	Strong	Altered Expression	[1650]
CXCL6	OTFTCQ4O	Strong	Biomarker	[1651]
CXXC1	OTO10D1N	Strong	Genetic Variation	[1652]
CYGB	OTX153DQ	Strong	Biomarker	[1653]
CYLD	OT37FKH0	Strong	Altered Expression	[1201]
CYP20A1	OTIUZ6CF	Strong	Genetic Variation	[1654]
CYP2D7	OTYJTL3S	Strong	Genetic Variation	[1655]
CYTIP	OTRJ3ZC5	Strong	Genetic Variation	[429]
DAAM1	OT0VHIYZ	Strong	Altered Expression	[1656]
DAB2IP	OTF456VC	Strong	Biomarker	[1657]
DACT2	OTNLCC0K	Strong	Posttranslational Modification	[1658]
DAND5	OTWNWQDJ	Strong	Genetic Variation	[1659]
DAP	OT5YLL7E	Strong	Biomarker	[1660]
DAPK1	OTNCNUCO	Strong	Biomarker	[1661]
DAPK2	OTWODUQG	Strong	Altered Expression	[934]
DAXX	OTX6O7PL	Strong	Biomarker	[1662]
DCAF12	OT24XM7T	Strong	Biomarker	[1663]
DCAF4	OTQU0EUO	Strong	Genetic Variation	[629]
DCBLD1	OTA702JK	Strong	Genetic Variation	[1664]
DCBLD2	OTB71I02	Strong	Altered Expression	[1665]
DCD	OTV5PBGJ	Strong	Biomarker	[814]
DCDC2	OTSUFH1H	Strong	Altered Expression	[1666]
DCTN6	OTI8PIN9	Strong	Altered Expression	[920]
DDB2	OTO8HVVB	Strong	Genetic Variation	[1667]
DDIAS	OTTGG2PM	Strong	Biomarker	[1668]
DDIT3	OTI8YKKE	Strong	Biomarker	[1669]
DDOST	OT39PDMS	Strong	Biomarker	[1670]
DDX3X	OTDO4TRX	Strong	Altered Expression	[1671]
DDX43	OTK1RYSK	Strong	Altered Expression	[1672]
DDX59	OTHJANS0	Strong	Biomarker	[1673]
DECR1	OTCDIR6X	Strong	Altered Expression	[1674]
DENND2D	OTXEFJWM	Strong	Altered Expression	[1675]
DENR	OTXP9HOY	Strong	Altered Expression	[934]
DERL1	OTJUS74N	Strong	Altered Expression	[1676]
DERL2	OTI3TUUZ	Strong	Biomarker	[1677]
DESI2	OTHUOKOC	Strong	Genetic Variation	[1678]
DHX9	OT5AAOQI	Strong	Altered Expression	[1679]
DIAPH3	OTPOT23F	Strong	Biomarker	[684]
DIRAS3	OT3XHLQA	Strong	Altered Expression	[1680]
DIXDC1	OT87DXEG	Strong	Altered Expression	[1681]
DKC1	OTX7DJR6	Strong	Altered Expression	[1682]
DKK4	OTWCCVF6	Strong	Genetic Variation	[1683]
DLC1	OTP8LMCR	Strong	Biomarker	[1684]
DLD	OT378CU9	Strong	Biomarker	[1685]
DLEC1	OTMKKBUW	Strong	Biomarker	[1686]
DMP1	OTBWBWW7	Strong	Biomarker	[1687]
DNAJB4	OTUD01BK	Strong	Altered Expression	[1688]
DNASE1L3	OTEUIMC2	Strong	Therapeutic	[1689]
DNTTIP1	OTAP29SS	Strong	Altered Expression	[1690]
DOCK8	OTNQLL21	Strong	Altered Expression	[1691]
DOK1	OTGVRLW6	Strong	Biomarker	[1692]
DOK3	OT842U3C	Strong	Biomarker	[1692]
DOK7	OTR2V7HO	Strong	Altered Expression	[1693]
DPYSL3	OTINJV20	Strong	Altered Expression	[1694]
DRG1	OTIFYMI3	Strong	Biomarker	[1695]
DROSHA	OTCE68KZ	Strong	Biomarker	[1696]
DSC2	OTODVH8K	Strong	Biomarker	[1697]
DSC3	OTYG47F8	Strong	Altered Expression	[1698]
DSPP	OT1TYNDN	Strong	Biomarker	[1699]
DSTN	OTMXO4YB	Strong	Biomarker	[142]
DTX1	OTYX91DX	Strong	Biomarker	[1700]
DUOX1	OTQ2AEW0	Strong	Biomarker	[1674]
DUSP2	OTH54FMR	Strong	Posttranslational Modification	[1701]
DUSP22	OTEZ3U85	Strong	Biomarker	[97]
DUSP6	OT4H6RKW	Strong	Genetic Variation	[1702]
DVL1	OTD67RF1	Strong	Altered Expression	[1703]
DYNLRB1	OTWVKOFB	Strong	Altered Expression	[1704]
E2F8	OTQKZGFP	Strong	Altered Expression	[1705]
EAF2	OTSOET5L	Strong	Biomarker	[1706]
EBAG9	OTTQLQCP	Strong	Altered Expression	[1707]
EDIL3	OTDVVNS0	Strong	Genetic Variation	[1708]
EEF1A1	OT00THXS	Strong	Altered Expression	[1709]
EEF1A2	OT9Z23K5	Strong	Genetic Variation	[1361]
EEF1B2	OTW64NPU	Strong	Biomarker	[1361]
EEF1G	OTW7DH2F	Strong	Biomarker	[1361]
EEF2	OTZ7SZ39	Strong	Biomarker	[1361]
EFNA1	OTU2NUA2	Strong	Biomarker	[1710]
EFNA3	OTJGOUMZ	Strong	Altered Expression	[1711]
EFNB2	OT0DCUOM	Strong	Biomarker	[481]
EHD1	OTDMEKLV	Strong	Altered Expression	[1712]
EIF2B5	OTV3R4RB	Strong	Biomarker	[1713]
EIF3A	OTFABY9G	Strong	Biomarker	[1714]
EIF3E	OTI0WG98	Strong	Altered Expression	[1715]
EIF3J	OTJ4TAWK	Strong	Genetic Variation	[1716]
EIF4A2	OT08H03R	Strong	Biomarker	[1717]
EIF4G1	OT2CF1E6	Strong	Biomarker	[1717]
EIF6	OTEXMUED	Strong	Biomarker	[1718]
ELF3	OTUTLEQO	Strong	Biomarker	[1719]
ELK1	OTH9MXD6	Strong	Altered Expression	[1389]
ELMO3	OTQHO9VM	Strong	Altered Expression	[1720]
ELOVL6	OTB26UJJ	Strong	Altered Expression	[1721]
ELP1	OTYEWBF7	Strong	Genetic Variation	[238]
EMP1	OTSZHUHQ	Strong	Biomarker	[1722]
EMP3	OTODMJ1D	Strong	Altered Expression	[1723]
EMX2	OT0V8OYK	Strong	Biomarker	[1724]
ENO3	OT3HYKYI	Strong	Biomarker	[1725]
EPB41L4B	OT2K30P7	Strong	Altered Expression	[1726]
ERAS	OT528IZO	Strong	Biomarker	[1727]
ERCC3	OTVAW3P1	Strong	Biomarker	[1728]
ERCC6	OT2QZKSF	Strong	Genetic Variation	[1636]
ERLEC1	OTQO3Z0R	Strong	Altered Expression	[1729]
ERRFI1	OT7VZ2IZ	Strong	Biomarker	[1730]
ERVW-1	OTWV8DXJ	Strong	Biomarker	[1731]
ESRP1	OTNCS4SL	Strong	Altered Expression	[1732]
ETFA	OTXX61VZ	Strong	Biomarker	[1733]
ETV5	OTE2OBM4	Strong	Biomarker	[1734]
EXO1	OTI87RS5	Strong	Genetic Variation	[1735]
EXOC1	OTX1CC39	Strong	Biomarker	[1736]
FAIM2	OT6QINVO	Strong	Biomarker	[1737]
FAM107A	OTBG61YZ	Strong	Altered Expression	[1738]
FAM111B	OT9IQ9NV	Strong	Altered Expression	[1739]
FAM13A	OTZ6GN0Q	Strong	Altered Expression	[1740]
FAM98A	OTBLMZXO	Strong	Biomarker	[1741]
FBLN2	OTEHR7N7	Strong	Biomarker	[1742]
FBRS	OTUVH446	Strong	Biomarker	[1743]
FBXO17	OTDSRA7P	Strong	Altered Expression	[1744]
FBXO22	OTEJ5MO0	Strong	Altered Expression	[1745]
FBXO6	OT58MKP3	Strong	Altered Expression	[1746]
FBXO8	OTZNGJGW	Strong	Biomarker	[1743]
FBXW2	OTCHPUCP	Strong	Biomarker	[1747]
FCN2	OTTHJBKZ	Strong	Altered Expression	[465]
FERMT1	OT626PBA	Strong	Altered Expression	[1748]
FEV	OTYEC4IR	Strong	Genetic Variation	[1749]
FEZ1	OTWCXPRE	Strong	Biomarker	[1750]
FGF13	OTHNNVSG	Strong	Altered Expression	[1751]
FLNB	OTPCOYL6	Strong	Biomarker	[1752]
FLOT2	OTZ0QR5L	Strong	Altered Expression	[1753]
FNDC3A	OTUX3S2I	Strong	Biomarker	[1754]
FOXA1	OTEBY0TD	Strong	Biomarker	[1146]
FOXA3	OTRGT2OT	Strong	Biomarker	[1146]
FOXD1	OT80PRHS	Strong	Biomarker	[1755]
FOXD4L5	OTROMIG7	Strong	Biomarker	[1412]
FOXE1	OT5IR5IT	Strong	Biomarker	[1756]
FOXK1	OTLZGS7J	Strong	Altered Expression	[1757]
FOXN2	OTBPLTCM	Strong	Biomarker	[338]
FRAT1	OT1PS84E	Strong	Biomarker	[1758]
FRK	OTEKV1SC	Strong	Biomarker	[1759]
FRMD5	OTC73XJK	Strong	Biomarker	[1760]
FRMPD1	OTCC9A0E	Strong	Altered Expression	[1761]
FSD1	OT8P6PT3	Strong	Biomarker	[1762]
FSD1L	OTBQ48RF	Strong	Biomarker	[1762]
FSIP1	OTYLL6GM	Strong	Biomarker	[1763]
FUT1	OTODG57A	Strong	Biomarker	[1764]
FUT2	OTLXM6WI	Strong	Biomarker	[1765]
FUT5	OTOPGL9M	Strong	Biomarker	[1056]
FUT7	OTJF6BSN	Strong	Altered Expression	[1056]
FUT9	OTLIJBQY	Strong	Biomarker	[1056]
FXYD3	OT9PPRHE	Strong	Altered Expression	[1766]
FXYD5	OT81DIOD	Strong	Biomarker	[1767]
FZD1	OTZATHVS	Strong	Altered Expression	[1768]
FZD8	OTZ9IRFL	Strong	Altered Expression	[1769]
G0S2	OT8FL49L	Strong	Biomarker	[1770]
GAB1	OTQKE6V4	Strong	Genetic Variation	[1771]
GAB2	OTBFN705	Strong	Altered Expression	[1772]
GABPA	OT9YB2SA	Strong	Altered Expression	[726]
GADD45A	OTDRV63V	Strong	Altered Expression	[1773]
GADD45G	OT8V1J4M	Strong	Biomarker	[1774]
GAGE1	OT53E50E	Strong	Altered Expression	[1775]
GAGE2A	OTRAJ80C	Strong	Altered Expression	[1775]
GAGE4	OTPB5C0O	Strong	Altered Expression	[1775]
GAGE5	OTFI6OVS	Strong	Altered Expression	[1775]
GATA2	OTBP2QQ2	Strong	Posttranslational Modification	[1776]
GATA5	OTO81B63	Strong	Biomarker	[1777]
GATAD2B	OTJL128N	Strong	Altered Expression	[1778]
GBE1	OTK2N05B	Strong	Biomarker	[827]
GCHFR	OTEOT8GI	Strong	Altered Expression	[465]
GCNT1	OTF6OC66	Strong	Altered Expression	[1779]
GDE1	OTU6FSBF	Strong	Biomarker	[1780]
GDF1	OTZ1VRBH	Strong	Genetic Variation	[1781]
GDI2	OTGLY3I7	Strong	Altered Expression	[1782]
GFI1	OT9HB9H8	Strong	Biomarker	[1783]
GHRH	OT94U6MO	Strong	Genetic Variation	[1784]
GINS4	OTCVOO3S	Strong	Biomarker	[1164]
GIPC1	OTXLVCPJ	Strong	Altered Expression	[1785]
GK5	OT65U8L1	Strong	Biomarker	[1786]
GLCE	OTPRSHX5	Strong	Altered Expression	[1787]
GLRX3	OTUPAU1N	Strong	Altered Expression	[1788]
GNAI2	OTTLGRGH	Strong	Altered Expression	[1789]
GNL3	OTILGYO4	Strong	Altered Expression	[1790]
GOLGA2	OT5S9KYM	Strong	Altered Expression	[1791]
GOLM1	OTOZSV6O	Strong	Biomarker	[1792]
GOPC	OTRBGH71	Strong	Genetic Variation	[1793]
GORASP1	OTQS91S7	Strong	Altered Expression	[166]
GPC5	OT8NR7GC	Strong	Biomarker	[1794]
GPR19	OTR7MUS5	Strong	Altered Expression	[588]
GPR4	OTIBF32I	Strong	Altered Expression	[588]
GPR42	OTEB0ROY	Strong	Biomarker	[371]
GPRC5C	OT45AJT3	Strong	Altered Expression	[588]
GPX2	OTXI2NTI	Strong	Biomarker	[246]
GPX3	OT6PK94R	Strong	Biomarker	[1795]
GPX4	OTRAFFX2	Strong	Altered Expression	[872]
GRB7	OTF8Y9XY	Strong	Biomarker	[468]
GREB1	OTU6ZA26	Strong	Biomarker	[1796]
GSDME	OT1ZWY32	Strong	Altered Expression	[1797]
GSPT1	OT18H1B0	Strong	Biomarker	[1566]
GTF2H1	OTCRXC6B	Strong	Altered Expression	[157]
GTF2IRD1	OTEG9KU1	Strong	Biomarker	[1798]
GYPA	OTABU4YV	Strong	Biomarker	[1799]
GYPB	OTESHUIX	Strong	Biomarker	[1799]
GYPE	OTBHAG6A	Strong	Biomarker	[1799]
GZMA	OT43R33L	Strong	Altered Expression	[1800]
H2AZ1	OT3KJJNQ	Strong	Posttranslational Modification	[1801]
H4C1	OTB71W46	Strong	Biomarker	[1204]
HADHA	OTO557N2	Strong	Biomarker	[1802]
HAP1	OT6SG0JQ	Strong	Genetic Variation	[1803]
HAPLN1	OTXWR9TJ	Strong	Altered Expression	[1804]
HAVCR1	OT184CRZ	Strong	Altered Expression	[1281]
HDGFL3	OTNN7WYH	Strong	Biomarker	[1805]
HERC4	OTU4DSDE	Strong	Biomarker	[1806]
HERC5	OTZ5PR39	Strong	Biomarker	[1807]
HES3	OTJ1J42N	Strong	Biomarker	[1808]
HIC1	OTI9TWY4	Strong	Biomarker	[1809]
HILPDA	OTEID3ZM	Strong	Biomarker	[481]
HJURP	OTWMV16B	Strong	Altered Expression	[1471]
HLA-DRB4	OTNXIHQU	Strong	Genetic Variation	[1810]
HLTF	OTRX2OSF	Strong	Altered Expression	[1811]
HM13	OTGEO1LP	Strong	Altered Expression	[1812]
HMGB3	OTCJ2EZY	Strong	Biomarker	[700]
HMGN5	OTUUAHVQ	Strong	Altered Expression	[1813]
HNRNPK	OTNPRM8U	Strong	Biomarker	[1814]
HNRNPU	OTLQN1E2	Strong	Altered Expression	[732]
HOOK1	OTTTKV7V	Strong	Altered Expression	[1815]
HOPX	OTBSR6C9	Strong	Biomarker	[1816]
HORMAD2	OTL2ENWI	Strong	Genetic Variation	[1817]
HOXA1	OTMSOJ7D	Strong	Biomarker	[1818]
HOXA4	OTNVTQDT	Strong	Altered Expression	[1819]
HOXA9	OTKNK5H0	Strong	Biomarker	[1820]
HOXB7	OTC7WYU8	Strong	Altered Expression	[1821]
HOXC8	OTJUYU8J	Strong	Altered Expression	[1822]
HOXD3	OTBUZ35T	Strong	Biomarker	[1332]
HRG	OTPLUFOG	Strong	Biomarker	[1823]
HS3ST2	OTWFA0GJ	Strong	Altered Expression	[1824]
HSD11B1L	OTZ6KH9M	Strong	Altered Expression	[1825]
HSPA1A	OTKGIE76	Strong	Altered Expression	[520]
HSPA1L	OTC2V1K6	Strong	Genetic Variation	[1826]
HSPA2	OTSDET7B	Strong	Biomarker	[1827]
HSPA4	OT5HR0AR	Strong	Altered Expression	[376]
HSPB2	OTS01646	Strong	Biomarker	[512]
HYAL2	OTTVINXW	Strong	Biomarker	[1828]
ICAM2	OT3E070F	Strong	Biomarker	[103]
ICAM3	OTTZ5A5D	Strong	Biomarker	[1829]
ID3	OTUULW5Z	Strong	Biomarker	[468]
ID4	OTPMJ39I	Strong	Biomarker	[1830]
IER2	OT5OY8BO	Strong	Biomarker	[481]
IFI27	OTI2XGIT	Strong	Altered Expression	[920]
IFIT2	OTI4EOAR	Strong	Biomarker	[1831]
IFITM1	OTECO1G8	Strong	Biomarker	[1832]
IFNA1	OTPMKY0L	Strong	Biomarker	[1833]
IFNA8	OTW0PCKU	Strong	Biomarker	[1834]
IFNLR1	OTWWWK45	Strong	Altered Expression	[1835]
IFRD1	OT4SQMLQ	Strong	Biomarker	[1836]
IGF2BP1	OT9G360P	Strong	Altered Expression	[1837]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[1838]
IGSF1	OT3XD6U2	Strong	Altered Expression	[732]
IGSF10	OTB9QOGO	Strong	Altered Expression	[1839]
IKBKG	OTNWJWSD	Strong	Biomarker	[471]
IKZF1	OTCW1FKL	Strong	Posttranslational Modification	[1840]
IL17B	OTS86H50	Strong	Biomarker	[1841]
IL17C	OTKXIVNQ	Strong	Biomarker	[1841]
IL17RB	OT0KDNSF	Strong	Altered Expression	[1842]
IL18R1	OT83XMPQ	Strong	Biomarker	[533]
IL1F10	OTJAASGC	Strong	Biomarker	[1843]
IL34	OTZ15VVK	Strong	Altered Expression	[1844]
IL6R	OTCQL07Z	Strong	Biomarker	[1845]
IL6ST	OT1N9C70	Strong	Biomarker	[463]
ILF3	OTKMZ5K5	Strong	Biomarker	[1846]
ILRUN	OTE8FHQD	Strong	Altered Expression	[1847]
IMMP1L	OTA6LOLR	Strong	Altered Expression	[1812]
IMPA1	OTBUVW1Z	Strong	Altered Expression	[1848]
ING1	OTEZBRKW	Strong	Biomarker	[1849]
ING2	OT6H0EWF	Strong	Altered Expression	[1850]
ING4	OT0VVG4V	Strong	Biomarker	[1851]
INO80B	OTSHV8JF	Strong	Biomarker	[1852]
INS-IGF2	OTZR74BO	Strong	Biomarker	[619]
INSL4	OTK9F0LX	Strong	Biomarker	[1853]
INSM1	OTG8RV8E	Strong	Biomarker	[1854]
INSRR	OT3F75WA	Strong	Genetic Variation	[1855]
INTS1	OT7TY1M1	Strong	Biomarker	[1856]
IPO8	OTBHGNKT	Strong	Biomarker	[1857]
IQSEC1	OTK1PBFD	Strong	Biomarker	[481]
IRF2	OTAZRUW3	Strong	Biomarker	[1858]
IRF5	OT8SIIAP	Strong	Biomarker	[966]
IRF6	OTKJ44EV	Strong	Altered Expression	[1859]
IRF7	OTC1A2PQ	Strong	Biomarker	[1860]
IST1	OTSFEZ2O	Strong	Altered Expression	[1861]
ISYNA1	OT49ONSE	Strong	Biomarker	[1862]
ITGA9	OTHN1IKA	Strong	Altered Expression	[1863]
ITGAX	OTOGIMHE	Strong	Biomarker	[1864]
ITGB4	OT28UK84	Strong	Altered Expression	[1865]
ITIH1	OTSXJGQF	Strong	Genetic Variation	[1866]
ITIH5	OTP46PZM	Strong	Posttranslational Modification	[1867]
ITPKA	OTX5ERUD	Strong	Biomarker	[1868]
ITSN1	OT8YF3S5	Strong	Biomarker	[1135]
JAG1	OT3LGT6K	Strong	Genetic Variation	[1869]
JTB	OT314JB6	Strong	Biomarker	[1870]
KARS1	OT0EU4SV	Strong	Genetic Variation	[1871]
KAT5	OTL7257A	Strong	Biomarker	[356]
KAT8	OT5LPQTR	Strong	Biomarker	[1872]
KCTD11	OT64DFBU	Strong	Biomarker	[1873]
KDM4B	OT5P1UPY	Strong	Biomarker	[1874]
KHSRP	OTDHZARB	Strong	Biomarker	[1833]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[1875]
KIF13A	OTSSZGBQ	Strong	Genetic Variation	[1876]
KIF14	OTXHT4JM	Strong	Altered Expression	[1877]
KIF20A	OTXOQHE0	Strong	Biomarker	[689]
KIF22	OTY6X6BL	Strong	Biomarker	[1878]
KIF23	OTY850JC	Strong	Biomarker	[1879]
KIF3A	OTMUBSSK	Strong	Biomarker	[1880]
KL	OTD4VWU6	Strong	Biomarker	[1881]
KLC4	OTACUFB2	Strong	Biomarker	[1882]
KLF11	OTKVQDJD	Strong	Altered Expression	[1883]
KLF17	OT5NWVP7	Strong	Biomarker	[1884]
KLF2	OTIP1UFX	Strong	Biomarker	[1885]
KLF3	OTIIAC18	Strong	Biomarker	[1886]
KLF5	OT1ABI9N	Strong	Altered Expression	[1887]
KLF6	OTQY9S7F	Strong	Altered Expression	[1888]
KLF8	OTUC5CDB	Strong	Biomarker	[1889]
KLHL1	OTAX6SAD	Strong	Altered Expression	[84]
KLK11	OT5PKX7Y	Strong	Altered Expression	[1890]
KLK12	OTNYK59J	Strong	Biomarker	[1891]
KLK13	OT8LOD2U	Strong	Biomarker	[1892]
KLRB1	OTQ2959Y	Strong	Altered Expression	[1617]
KNL1	OT4Q3LHV	Strong	Biomarker	[1893]
KPNA2	OTU7FOE6	Strong	Altered Expression	[1894]
KPNA4	OTP0EX18	Strong	Altered Expression	[1895]
KRT14	OTUVZ1DW	Strong	Biomarker	[1896]
KRT18	OTVLQFIP	Strong	Altered Expression	[1897]
KRT5	OTVGI9HT	Strong	Biomarker	[633]
KRT7	OTLT3JFN	Strong	Biomarker	[633]
L1TD1	OTB2W20Y	Strong	Posttranslational Modification	[856]
LAMTOR1	OTIBJBW9	Strong	Biomarker	[402]
LAMTOR2	OTHEDISB	Strong	Posttranslational Modification	[1596]
LARP6	OTUQ9QS9	Strong	Biomarker	[1898]
LARS1	OT4557NF	Strong	Altered Expression	[1899]
LATS1	OTOOCG4R	Strong	Biomarker	[1900]
LDHB	OT9B1CT3	Strong	Altered Expression	[1901]
LDOC1	OTWZH4O9	Strong	Biomarker	[1902]
LECT2	OTSFZ9JD	Strong	Biomarker	[1088]
LEF1	OTWS5I5H	Strong	Biomarker	[1903]
LETM1	OT8N4MRU	Strong	Altered Expression	[1904]
LGALS8	OT71LJ8T	Strong	Biomarker	[1905]
LGI3	OT0CZ85H	Strong	Altered Expression	[1906]
LGSN	OTQG5Z82	Strong	Genetic Variation	[1907]
LHX6	OT47UQZ5	Strong	Altered Expression	[1222]
LIMCH1	OTYPC4XA	Strong	Biomarker	[1908]
LIMD1	OTN1CG6R	Strong	Biomarker	[1909]
LIN28B	OTVWP0FN	Strong	Biomarker	[1449]
LMLN	OTQF0JPY	Strong	Posttranslational Modification	[704]
LMNB1	OT100T3P	Strong	Biomarker	[1910]
LMNTD1	OT2TKBVM	Strong	Biomarker	[1911]
LMO7	OTDLY6TC	Strong	Biomarker	[1912]
LNX1	OTZWFMAZ	Strong	Biomarker	[1902]
LOXL4	OT6XY2JL	Strong	Biomarker	[1913]
LPCAT1	OTCV7AGV	Strong	Genetic Variation	[1914]
LPIN1	OTQ75KF2	Strong	Biomarker	[1915]
LPP	OT6TU8SE	Strong	Genetic Variation	[1916]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[1917]
LRPPRC	OTXSK5LP	Strong	Biomarker	[463]
LUM	OTSRC874	Strong	Biomarker	[1918]
LYNX1	OTK4103B	Strong	Biomarker	[1919]
LYPD4	OTYNO8BS	Strong	Biomarker	[1920]
LZTS2	OTQFSQEE	Strong	Biomarker	[1921]
MACC1	OTV3DLX0	Strong	Altered Expression	[1922]
MACROH2A2	OTAKSVYV	Strong	Biomarker	[1923]
MAD2L2	OT24ZO59	Strong	Biomarker	[1924]
MAFG	OTBQFUZH	Strong	Genetic Variation	[1925]
MAFK	OTZJUE4P	Strong	Biomarker	[402]
MAGED1	OT6EOLFC	Strong	Biomarker	[1926]
MAGI1	OTMV4ASV	Strong	Genetic Variation	[408]
MAGI2	OTXDDKZS	Strong	Genetic Variation	[411]
MAGT1	OTQSAV5C	Strong	Biomarker	[380]
MAP1B	OTVXW089	Strong	Biomarker	[1814]
MAP2K3	OTI2OREX	Strong	Biomarker	[1927]
MAP2K6	OTK13JKC	Strong	Altered Expression	[1928]
MAPK15	OT8SW0L7	Strong	Biomarker	[1929]
MAPK1IP1L	OTG5B19W	Strong	Biomarker	[1930]
MAPRE1	OTCVQD60	Strong	Biomarker	[1931]
MARCHF8	OTH7PNN2	Strong	Biomarker	[1932]
MARVELD3	OTFTPOJ4	Strong	Biomarker	[1933]
MATK	OTVOJJLJ	Strong	Genetic Variation	[1934]
MAX	OTKZ0YKM	Strong	Biomarker	[1935]
MB	OTYWYL2D	Strong	Altered Expression	[1936]
MBD1	OTD19VO6	Strong	Genetic Variation	[1937]
MBD2	OTUQPP0R	Strong	Biomarker	[1938]
MBD3	OTRL76H5	Strong	Biomarker	[1394]
MBD4	OTWR9YXE	Strong	Genetic Variation	[1939]
MCM10	OTV0O3JN	Strong	Biomarker	[1940]
MCM2	OTGGORIQ	Strong	Altered Expression	[1941]
MCM5	OTAHLB62	Strong	Biomarker	[1942]
MCRS1	OT8K2X8P	Strong	Altered Expression	[1943]
MED12	OTQZ4D2X	Strong	Biomarker	[1944]
MED23	OTKZQT0R	Strong	Altered Expression	[1945]
MED8	OTSIZ1I7	Strong	Altered Expression	[1944]
MEF2D	OT7CEIG0	Strong	Altered Expression	[1946]
MEIOB	OTTX5TF0	Strong	Altered Expression	[1947]
MEOX2	OTKZCJCB	Strong	Biomarker	[1948]
MESP1	OTY5QDBN	Strong	Biomarker	[1949]
METTL3	OTSXP1M3	Strong	Altered Expression	[1950]
MFAP1	OTZN4FT3	Strong	Altered Expression	[1047]
MFSD2A	OTVG1VG0	Strong	Genetic Variation	[1951]
MICA	OTPEIEAR	Strong	Biomarker	[1952]
MID1	OTWN1PGU	Strong	Biomarker	[1953]
MIEF1	OTFSP3FS	Strong	Biomarker	[259]
MINDY4	OTBZ2SZB	Strong	Biomarker	[1954]
MIPEP	OTB2IHCT	Strong	Genetic Variation	[129]
MKS1	OT83W5PB	Strong	Biomarker	[1064]
MLKL	OTDSLC81	Strong	Biomarker	[1955]
MMD	OTB5I4OC	Strong	Biomarker	[1956]
MMP19	OTLSTT2B	Strong	Altered Expression	[1957]
MMRN1	OT7ZNYHT	Strong	Biomarker	[1958]
MMUT	OTBBBV70	Strong	Biomarker	[1959]
MNAT1	OTXLOYCB	Strong	Altered Expression	[465]
MNT	OTPC4ANL	Strong	Biomarker	[1960]
MOB1A	OTSPBZ4Z	Strong	Biomarker	[1961]
MOGS	OT99MBGB	Strong	Biomarker	[578]
MOK	OTQK7M9V	Strong	Genetic Variation	[1962]
MOS	OTNMQPFJ	Strong	Biomarker	[1963]
MPG	OTAHW80B	Strong	Biomarker	[1964]
MPP1	OTA2ENZQ	Strong	Biomarker	[468]
MPP2	OTPH8CZY	Strong	Altered Expression	[1965]
MPRIP	OT5FV5NS	Strong	Biomarker	[1966]
MRE11	OTGU8TZM	Strong	Genetic Variation	[1939]
MRGPRD	OTTMOJ8U	Strong	Altered Expression	[1967]
MRPL17	OTBPCPVW	Strong	Biomarker	[1968]
MRPL58	OTPTWLZY	Strong	Biomarker	[1969]
MSC	OTBRPZL5	Strong	Biomarker	[1970]
MT1G	OTAV1OCR	Strong	Genetic Variation	[318]
MT1X	OT9AKFVS	Strong	Biomarker	[1971]
MTA2	OTCCYIQJ	Strong	Genetic Variation	[1972]
MTG1	OTC9U1LI	Strong	Altered Expression	[394]
MTHFD1	OTMKHVWC	Strong	Altered Expression	[1973]
MTMR3	OTBIT23O	Strong	Genetic Variation	[129]
MTURN	OTEBJNVG	Strong	Altered Expression	[1935]
MTUS1	OTBPALMU	Strong	Altered Expression	[1974]
MUC3A	OTI4XUDY	Strong	Altered Expression	[712]
MUC4	OTLT11V1	Strong	Biomarker	[1975]
MUC6	OTPVL723	Strong	Altered Expression	[713]
MUL1	OT2JC9YR	Strong	Altered Expression	[1572]
MXD1	OTS5CTHX	Strong	Genetic Variation	[1491]
MXRA5	OTXZBWCU	Strong	Biomarker	[1976]
MYH9	OT94Z706	Strong	Biomarker	[1630]
MYL12B	OTXMLQOT	Strong	Altered Expression	[1863]
MYL9	OT6B22JB	Strong	Altered Expression	[717]
MYO7A	OTBZSPEL	Strong	Biomarker	[1977]
MZB1	OT071TET	Strong	Biomarker	[370]
NAA10	OTYB9R6I	Strong	Biomarker	[1978]
NAA25	OTS3QVF1	Strong	Altered Expression	[732]
NAB2	OTG4BDF3	Strong	Posttranslational Modification	[1979]
NAIF1	OT0B3H72	Strong	Biomarker	[1980]
NANOS3	OTGX9IQU	Strong	Altered Expression	[1981]
NAPSA	OT6F8IAL	Strong	Biomarker	[633]
NCBP1	OTYBR927	Strong	Biomarker	[1982]
NCOA6	OTOMIGTV	Strong	Altered Expression	[1983]
NDC1	OTF2GQC1	Strong	Biomarker	[897]
NDC80	OTS7D306	Strong	Biomarker	[1189]
NDUFA4L2	OTK0PG7R	Strong	Biomarker	[1984]
NDUFS1	OTTIZDFR	Strong	Biomarker	[1985]
NDUFS8	OTMEAWKO	Strong	Biomarker	[1985]
NECTIN1	OTTE5ZR6	Strong	Biomarker	[720]
NECTIN2	OTIE0W6O	Strong	Biomarker	[720]
NEDD4L	OT1B19RU	Strong	Altered Expression	[1986]
NEIL2	OTV6JEON	Strong	Altered Expression	[1987]
NEK4	OTOB8366	Strong	Biomarker	[1988]
NEMF	OT9DK06P	Strong	Altered Expression	[1989]
NEU1	OTH9BY8Y	Strong	Genetic Variation	[1990]
NEURL1	OT2C4P70	Strong	Genetic Variation	[1990]
NFASC	OTBDUXZT	Strong	Biomarker	[1991]
NFATC1	OT4TMERS	Strong	Biomarker	[1992]
NFIL3	OTQH9HM3	Strong	Biomarker	[1993]
NFYB	OTXSE7KW	Strong	Biomarker	[1994]
NHLH1	OTXN5B9R	Strong	Biomarker	[1995]
NIBAN2	OTVDQSPI	Strong	Biomarker	[1996]
NID2	OTHC33FF	Strong	Posttranslational Modification	[1997]
NINL	OTWIK6HT	Strong	Biomarker	[1998]
NIPBL	OTF6OOLU	Strong	Biomarker	[1999]
NIT1	OT1KHPKJ	Strong	Biomarker	[2000]
NKD1	OTY3MO97	Strong	Altered Expression	[2001]
NKX2-8	OT6Q3DJ0	Strong	Biomarker	[2002]
NLK	OT2LETFS	Strong	Altered Expression	[2003]
NLRP6	OTEREN4W	Strong	Biomarker	[2004]
NLRP7	OTE9BI32	Strong	Biomarker	[724]
NMB	OT4NLN6H	Strong	Biomarker	[2005]
NMBR	OTBJEGPN	Strong	Altered Expression	[2006]
NME2	OTCYGLHV	Strong	Altered Expression	[2007]
NMU	OTW9X7BQ	Strong	Biomarker	[2008]
NOCT	OTVSYP2D	Strong	Genetic Variation	[2009]
NOG	OTGRHHPG	Strong	Biomarker	[2010]
NOL10	OTC4R5O7	Strong	Altered Expression	[1732]
NOXO1	OTW29FB4	Strong	Biomarker	[2011]
NPAS2	OTMRT2TS	Strong	Biomarker	[490]
NPC1	OTRIPICX	Strong	Biomarker	[2012]
NPRL2	OTOB10MO	Strong	Genetic Variation	[1119]
NPTN	OTAQKSAU	Strong	Biomarker	[813]
NR1D2	OT9CVF41	Strong	Biomarker	[490]
NR2C2	OTDZWVOJ	Strong	Biomarker	[686]
NR2F2	OTJFS67N	Strong	Genetic Variation	[2013]
NSD2	OTQ6SW4R	Strong	Altered Expression	[2014]
NSG1	OTRIMA50	Strong	Genetic Variation	[2015]
NSUN5	OTBN7RS8	Strong	Altered Expression	[732]
NTHL1	OTPQXPT1	Strong	Genetic Variation	[2016]
NTMT1	OTLRH78U	Strong	Genetic Variation	[2017]
NTS	OTPGDNQS	Strong	Biomarker	[2018]
NUCB2	OTHO6JWN	Strong	Altered Expression	[2019]
NUDCD1	OT8DS3CX	Strong	Biomarker	[2020]
NUDT1	OTZSES3W	Strong	Altered Expression	[2021]
NUMB	OTMB586Q	Strong	Biomarker	[1437]
NUP205	OTJKHCY6	Strong	Biomarker	[2022]
NUP58	OTMLLWJW	Strong	Genetic Variation	[2023]
NUP98	OTNT12G2	Strong	Altered Expression	[2024]
NUSAP1	OT85HIJ5	Strong	Biomarker	[700]
NUTM1	OTONYC08	Strong	Biomarker	[2025]
NXF1	OTEFHXG6	Strong	Biomarker	[1752]
OAS3	OT6E5FYS	Strong	Altered Expression	[727]
OASL	OTZ05YRP	Strong	Biomarker	[2026]
OBP2A	OTBIJ5TI	Strong	Biomarker	[1878]
OCLN	OTSUTVWL	Strong	Biomarker	[2027]
OIP5	OTI5C2DE	Strong	Altered Expression	[2028]
ONECUT1	OTK1QUQT	Strong	Biomarker	[2029]
OPRPN	OT6K1ZD6	Strong	Biomarker	[792]
OR2AG1	OTEITRP4	Strong	Genetic Variation	[2030]
ORM1	OTZKSBRE	Strong	Biomarker	[2031]
OSR1	OTB19LEQ	Strong	Altered Expression	[2032]
OTUD3	OTHUWQHP	Strong	Biomarker	[2033]
OTUD7B	OTMVM8R7	Strong	Altered Expression	[2034]
OVCA2	OT5LSKCS	Strong	Altered Expression	[2035]
OXA1L	OTS0BFRD	Strong	Biomarker	[2036]
P2RX2	OT0LF34A	Strong	Genetic Variation	[752]
P2RX5	OTLBR20R	Strong	Genetic Variation	[752]
P2RX6	OT1FNTXA	Strong	Genetic Variation	[752]
P3H3	OTRC8QCM	Strong	Altered Expression	[2037]
PADI2	OTT40K94	Strong	Biomarker	[2038]
PAF1	OTDDGUBQ	Strong	Biomarker	[2039]
PAFAH1B1	OT9T2TCJ	Strong	Genetic Variation	[2040]
PAG1	OTFOJUIQ	Strong	Biomarker	[1418]
PAK5	OT32WQGL	Strong	Biomarker	[2041]
PAPLN	OTCJD85N	Strong	Biomarker	[778]
PAPPA	OTTTG9PG	Strong	Biomarker	[2042]
PAQR7	OTIWX5AM	Strong	Biomarker	[2043]
PC	OT6O0V51	Strong	Biomarker	[2044]
PCDH10	OT2GIT0E	Strong	Altered Expression	[2045]
PCDH7	OTP091X8	Strong	Biomarker	[2046]
PCK2	OTJ8LX4N	Strong	Biomarker	[2047]
PCLAF	OTMVIOUU	Strong	Biomarker	[2048]
PDCD5	OT6T2DDL	Strong	Biomarker	[2049]
PDCD6	OT2YA5M8	Strong	Genetic Variation	[2050]
PDCD6IP	OTS8T6A7	Strong	Genetic Variation	[411]
PDIK1L	OTISF4KG	Strong	Biomarker	[2051]
PDK4	OTCMHMBZ	Strong	Altered Expression	[2052]
PDLIM2	OTEURRPD	Strong	Altered Expression	[2053]
PDLIM3	OTVXQC81	Strong	Biomarker	[226]
PDLIM4	OT23LZYY	Strong	Biomarker	[481]
PDPN	OTBUV19I	Strong	Altered Expression	[2054]
PDSS2	OTEOQBMX	Strong	Altered Expression	[2055]
PDZK1IP1	OTWA6M5K	Strong	Biomarker	[2056]
PEA15	OTKCKTSX	Strong	Altered Expression	[2057]
PELI1	OTMLBCLC	Strong	Biomarker	[2058]
PELP1	OTVXQNOT	Strong	Altered Expression	[2059]
PER2	OTU2B1DJ	Strong	Biomarker	[490]
PERP	OTP0YL53	Strong	Biomarker	[2060]
PFN2	OT5SSSA7	Strong	Biomarker	[2061]
PGAM1	OTZ5DB06	Strong	Biomarker	[2062]
PGK1	OT6V1ICH	Strong	Biomarker	[2063]
PGP	OT6QQ7OR	Strong	Altered Expression	[2064]
PHF14	OTZT3GV1	Strong	Biomarker	[2065]
PHLDA3	OTXFUDO2	Strong	Genetic Variation	[2066]
PHLPP1	OTIFXW8D	Strong	Altered Expression	[2067]
PHPT1	OTFYWNFX	Strong	Biomarker	[2068]
PIAS3	OT3TWH9R	Strong	Biomarker	[2069]
PIAS4	OTB7SVMZ	Strong	Biomarker	[2070]
PIK3R1	OT5BZ1J9	Strong	Biomarker	[2071]
PIK3R2	OTZSUQK5	Strong	Biomarker	[1511]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[2072]
PINK1	OT50NR57	Strong	Biomarker	[2073]
PITX1	OTA0UN4C	Strong	Altered Expression	[2074]
PIWIL1	OT7CRGZ3	Strong	Biomarker	[1232]
PKD1	OT5ALRZ5	Strong	Biomarker	[212]
PKP1	OT9HSQ8F	Strong	Altered Expression	[2075]
PLA2G6	OT5FL0WU	Strong	Biomarker	[2076]
PLAA	OTZ7NJGA	Strong	Biomarker	[671]
PLAAT4	OTI66SAJ	Strong	Altered Expression	[2077]
PLAG1	OTT9AJQY	Strong	Biomarker	[655]
PLB1	OTZ6TTYV	Strong	Biomarker	[331]
PLCD1	OT6WFVXZ	Strong	Genetic Variation	[2078]
PLEC	OTU4XDEG	Strong	Biomarker	[2079]
PLEK	OTB73XXA	Strong	Genetic Variation	[2080]
PLK3	OT19CT2Z	Strong	Altered Expression	[2081]
PLOD3	OTT00T7Q	Strong	Biomarker	[2082]
PLRG1	OTIVZ5LL	Strong	Biomarker	[792]
PMEPA1	OTY8Z9UF	Strong	Biomarker	[2083]
PNO1	OT010GIS	Strong	Biomarker	[2084]
PNPLA2	OTR3ERMR	Strong	Biomarker	[892]
POLA2	OTTWQ73N	Strong	Biomarker	[2085]
POLD1	OTWO4UCJ	Strong	Genetic Variation	[2086]
POLE	OTFM3MMU	Strong	Genetic Variation	[2086]
POLI	OTBA4DCE	Strong	Biomarker	[2087]
POLK	OTKZ38JH	Strong	Altered Expression	[884]
POLL	OTZ24QGM	Strong	Altered Expression	[884]
POLM	OT0SRIP4	Strong	Biomarker	[2087]
POLQ	OTBHK0E6	Strong	Altered Expression	[2088]
POLR3B	OT3FS9MB	Strong	Biomarker	[2089]
POT1	OTNBXJCQ	Strong	Genetic Variation	[1122]
POTEF	OTV3WXYE	Strong	Altered Expression	[2090]
PPBP	OT1FHGQS	Strong	Biomarker	[2091]
PPP1R11	OTSHYPPW	Strong	Altered Expression	[685]
PPP1R12C	OT9Q86JO	Strong	Biomarker	[1511]
PPP1R13B	OTC88VQO	Strong	Biomarker	[1511]
PPP1R1A	OTGTAGCV	Strong	Genetic Variation	[2092]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[2093]
PPP2R1B	OTFIHQGD	Strong	Biomarker	[2094]
PPP2R2B	OTSFVC82	Strong	Genetic Variation	[2095]
PPP2R2C	OTXK0SDM	Strong	Genetic Variation	[2096]
PPP2R5C	OTF7CGO2	Strong	Genetic Variation	[2097]
PPP2R5E	OT8GPFT5	Strong	Biomarker	[2098]
PRAP1	OT48QD82	Strong	Biomarker	[2099]
PRB2	OTAD4JZ0	Strong	Genetic Variation	[2100]
PRCC	OTJ0KRYX	Strong	Altered Expression	[2101]
PRDM14	OTWZKY4L	Strong	Biomarker	[2102]
PRDM16	OT0BGA27	Strong	Altered Expression	[2103]
PRDM2	OT8L7CGX	Strong	Genetic Variation	[2104]
PRDM5	OTU1GB68	Strong	Biomarker	[2105]
PRDX1	OTZ3BEC4	Strong	Biomarker	[2106]
PRDX3	OTLB2WEU	Strong	Altered Expression	[2107]
PRG2	OT0BCPQG	Strong	Biomarker	[2108]
PRIMA1	OT9ITT3P	Strong	Biomarker	[2109]
PRKAA1	OT7TNF0L	Strong	Altered Expression	[2110]
PRKAA2	OTU1KZPV	Strong	Altered Expression	[2110]
PRKAB1	OT1OG4QZ	Strong	Altered Expression	[2110]
PRKN	OTJBN41W	Strong	Biomarker	[2111]
PRMT6	OT5V3XIN	Strong	Biomarker	[2112]
PROCR	OTRHED17	Strong	Biomarker	[2113]
PROS1	OTXQWNOI	Strong	Biomarker	[655]
PRPF31	OTSJ0Z1Y	Strong	Genetic Variation	[1360]
PRR11	OT2JJ08Z	Strong	Biomarker	[2114]
PRR14	OTZMIMOK	Strong	Altered Expression	[2115]
PRSS55	OTXXWI5Y	Strong	Biomarker	[1633]
PSD	OTUZIXUZ	Strong	Biomarker	[2116]
PSMA6	OTJ6RPX5	Strong	Biomarker	[2117]
PSMD2	OT6HZHN7	Strong	Biomarker	[2118]
PSMD7	OT7PZZ4K	Strong	Biomarker	[633]
PSMD8	OTY6X27P	Strong	Biomarker	[1529]
PSMD9	OT6Y5CC3	Strong	Altered Expression	[920]
PSME3	OTSTC4YY	Strong	Biomarker	[343]
PSMG1	OTZ5I6UM	Strong	Altered Expression	[2119]
PSPH	OTV1PVAX	Strong	Biomarker	[2120]
PTGFRN	OTBG4SA2	Strong	Altered Expression	[2121]
PTPA	OTRGFOI7	Strong	Biomarker	[2122]
PTPMT1	OT9WVC6N	Strong	Biomarker	[2123]
PTPN3	OTSLZBVY	Strong	Biomarker	[1656]
PTPRD	OTZPJ3GX	Strong	Biomarker	[2124]
PTPRH	OTDUHQGF	Strong	Altered Expression	[2125]
PTPRT	OTV5TXNN	Strong	Genetic Variation	[2126]
PTPRU	OTHDO0QG	Strong	Biomarker	[1016]
PYCR1	OTQHB52T	Strong	Biomarker	[2127]
QKI	OTTAUGLB	Strong	Biomarker	[2128]
QRSL1	OTJDU2UG	Strong	Genetic Variation	[2129]
QTRT1	OTC33MCV	Strong	Biomarker	[2130]
RAB15	OTU0GGR3	Strong	Biomarker	[1930]
RAB23	OTBAKFBR	Strong	Altered Expression	[2131]
RAB25	OTW0W6NP	Strong	Biomarker	[2132]
RAB26	OTHMPRJK	Strong	Biomarker	[2133]
RABEP2	OTO61X27	Strong	Biomarker	[2134]
RABEPK	OTCZSREH	Strong	Biomarker	[633]
RAC2	OTAOHFNH	Strong	Biomarker	[2135]
RACGAP1	OTQE8IEH	Strong	Biomarker	[2136]
RAD17	OT1I93DT	Strong	Biomarker	[2137]
RAD23A	OTBPAWHX	Strong	Biomarker	[925]
RAD23B	OT0PGOG3	Strong	Genetic Variation	[2138]
RAD50	OTYMU9G1	Strong	Biomarker	[698]
RAD51AP1	OTXM7UTD	Strong	Altered Expression	[1622]
RALGPS2	OTOYS0SD	Strong	Biomarker	[2139]
RAP1A	OT5RH6TI	Strong	Biomarker	[2140]
RAPGEF1	OTZ0TBN1	Strong	Altered Expression	[2141]
RASA2	OTL06RG2	Strong	Biomarker	[2142]
RASEF	OTGSAM2E	Strong	Biomarker	[2143]
RASSF2	OT2JHDO4	Strong	Biomarker	[2144]
RASSF4	OT7YLOFH	Strong	Altered Expression	[2145]
RASSF5	OT6Q41I2	Strong	Altered Expression	[2146]
RASSF7	OT0V4EIZ	Strong	Altered Expression	[2147]
RASSF8	OTXKGIB3	Strong	Biomarker	[2148]
RBBP6	OTTVG4HU	Strong	Genetic Variation	[2149]
RBFOX2	OTXY1WVH	Strong	Altered Expression	[2150]
RBL1	OTDEBFYC	Strong	Altered Expression	[2151]
RBM3	OTAJ7R31	Strong	Biomarker	[2152]
RBM39	OTCMPTF9	Strong	Biomarker	[2153]
RBMS3	OTFSC9MR	Strong	Biomarker	[1398]
RCC2	OTUJVTLS	Strong	Altered Expression	[2154]
RCCD1	OT60N06L	Strong	Biomarker	[2155]
RCHY1	OTAE7504	Strong	Biomarker	[2156]
RDM1	OTBSJEAG	Strong	Altered Expression	[2157]
RECQL	OTPCH3JH	Strong	Biomarker	[2158]
RECQL4	OT59LSW7	Strong	Biomarker	[2159]
REEP5	OTZU4TJI	Strong	Biomarker	[502]
REG1A	OTMHUH1D	Strong	Altered Expression	[804]
REG1B	OTSC2133	Strong	Biomarker	[804]
REG3G	OTLIUY8Z	Strong	Altered Expression	[804]
REST	OTLL92LQ	Strong	Biomarker	[2160]
RETN	OTW5Z1NH	Strong	Biomarker	[2161]
RETREG2	OT5CJTMK	Strong	Biomarker	[2162]
REV1	OTHIKICX	Strong	Biomarker	[2163]
REV3L	OT0OP8EJ	Strong	Biomarker	[2164]
RGCC	OTYJMLWM	Strong	Biomarker	[2165]
RGL1	OTY6ZHVA	Strong	Biomarker	[2166]
RGS11	OTIAZ36F	Strong	Altered Expression	[2167]
RGS17	OT5RVUDS	Strong	Biomarker	[2168]
RHOBTB2	OT2DATFX	Strong	Genetic Variation	[2169]
RHOV	OTW4N3QN	Strong	Altered Expression	[2170]
RHOXF2	OTKQWLKZ	Strong	Altered Expression	[2171]
RING1	OTCWTAX0	Strong	Altered Expression	[2172]
RIOK1	OT1OS3H3	Strong	Biomarker	[2173]
RIOX1	OTN41QXP	Strong	Altered Expression	[2174]
RIOX2	OT2YFPI2	Strong	Biomarker	[2175]
RIPK3	OTL1D484	Strong	Biomarker	[1966]
RNASE1	OTKZ7CO9	Strong	Biomarker	[2176]
RNASE3	OTVE2XD1	Strong	Biomarker	[2177]
RNASET2	OTWY64L7	Strong	Biomarker	[477]
RNF146	OTE4CO7E	Strong	Altered Expression	[2178]
RNF2	OTFPLOIN	Strong	Genetic Variation	[408]
RNF38	OTRLV4WZ	Strong	Biomarker	[2179]
RNH1	OT6EC79B	Strong	Genetic Variation	[1781]
ROM1	OTE7H0YV	Strong	Biomarker	[2180]
ROMO1	OTIEYVBW	Strong	Altered Expression	[2181]
RPL17	OTTYMPS6	Strong	Biomarker	[2182]
RPL22	OTVCN8K0	Strong	Altered Expression	[2183]
RPL29	OTUFIBJL	Strong	Altered Expression	[2184]
RPL36A	OT1LYV85	Strong	Biomarker	[1730]
RPN2	OTJ1SKOA	Strong	Biomarker	[2185]
RPP14	OT4OYFSK	Strong	Posttranslational Modification	[1596]
RPRM	OTNNBAS1	Strong	Altered Expression	[2186]
RRAD	OTW2O4GD	Strong	Altered Expression	[2187]
RSL1D1	OT3CL4R3	Strong	Biomarker	[2188]
RSPO2	OT3HHXU0	Strong	Biomarker	[810]
RTRAF	OTJ6NVMW	Strong	Biomarker	[1713]
RUFY3	OTMA4YA4	Strong	Altered Expression	[2189]
RUVBL1	OTWV19L7	Strong	Biomarker	[2190]
RYBP	OTZZ4P2Z	Strong	Altered Expression	[2191]
S100A11	OTI57KDN	Strong	Altered Expression	[2192]
S100A13	OT582SUS	Strong	Altered Expression	[2193]
S100A2	OTTGHJ1H	Strong	Altered Expression	[2194]
S100A7	OTJFVJRF	Strong	Biomarker	[2195]
SAGE1	OT4H6FFA	Strong	Altered Expression	[1672]
SAMHD1	OTBCIBC7	Strong	Altered Expression	[2196]
SAMSN1	OT7N88T1	Strong	Genetic Variation	[2197]
SARDH	OTQ49Q27	Strong	Biomarker	[738]
SARNP	OTE0OVK5	Strong	Biomarker	[2153]
SARS1	OTFKXQ1O	Strong	Biomarker	[1871]
SARS2	OTU4T99W	Strong	Biomarker	[1871]
SART3	OTC1AM7S	Strong	Altered Expression	[727]
SASH1	OTQA8BD4	Strong	Biomarker	[2198]
SATB2	OT2W80XC	Strong	Biomarker	[2199]
SBSN	OT89RKJH	Strong	Altered Expression	[2200]
SCAF1	OT16TM3N	Strong	Biomarker	[2201]
SCAI	OTAK3TMO	Strong	Altered Expression	[2202]
SCARA3	OT46I38Y	Strong	Genetic Variation	[2203]
SCG5	OTXSJMT1	Strong	Genetic Variation	[2204]
SCML1	OT7V5DAR	Strong	Altered Expression	[1732]
SCNN1A	OTE2KVZV	Strong	Altered Expression	[2205]
SCRT1	OTWTE24S	Strong	Altered Expression	[2206]
SCTR	OTC80IMR	Strong	Altered Expression	[2207]
SDHAF2	OT0UG9H5	Strong	Altered Expression	[2208]
SEC14L3	OTGQ8GWM	Strong	Altered Expression	[2209]
SECISBP2L	OTMSOLZU	Strong	Biomarker	[477]
SELENBP1	OT3NZNTR	Strong	Biomarker	[2210]
SELENOF	OT2JFB3S	Strong	Genetic Variation	[2211]
SEMA4B	OT1Y3YZD	Strong	Biomarker	[2212]
SEMA4G	OT7BCPU7	Strong	Genetic Variation	[2213]
SEMA5A	OTUOIOJV	Strong	Biomarker	[2214]
SERPINA4	OTBK0GG7	Strong	Biomarker	[2215]
SERPINB4	OT88LHZ8	Strong	Biomarker	[825]
SESN3	OTJRY1Y5	Strong	Biomarker	[2216]
SET	OTGYYQJO	Strong	Biomarker	[2217]
SETD4	OTBMCZQA	Strong	Biomarker	[2218]
SETDB1	OTWVUA1B	Strong	Biomarker	[2219]
SEZ6L	OT5Z9CUA	Strong	Genetic Variation	[2220]
SEZ6L2	OTUIKN2I	Strong	Biomarker	[2221]
SF3B6	OTPRKS6S	Strong	Posttranslational Modification	[1596]
SFN	OTLJCZ1U	Strong	Posttranslational Modification	[2222]
SFRP1	OT0U9G41	Strong	Altered Expression	[2223]
SFTPA2	OT6SFOMU	Strong	Genetic Variation	[2224]
SFTPC	OTIZJD09	Strong	Altered Expression	[2225]
SH2B1	OTJZO2CI	Strong	Biomarker	[2226]
SH3RF1	OT7MYGYO	Strong	Genetic Variation	[2227]
SHARPIN	OTU1J2KH	Strong	Biomarker	[2228]
SHC1	OT1J5IRN	Strong	Altered Expression	[2229]
SHC3	OT305NPA	Strong	Genetic Variation	[1781]
SHISA3	OTE8TPCP	Strong	Biomarker	[2230]
SHMT1	OTIINA3J	Strong	Biomarker	[2231]
SHMT2	OT5NCAZN	Strong	Genetic Variation	[2232]
SHOC2	OTUNQ2CT	Strong	Genetic Variation	[2233]
SIAH2	OTKED2XN	Strong	Biomarker	[2234]
SIDT2	OTU2L002	Strong	Biomarker	[481]
SINHCAF	OTHMZZ0A	Strong	Altered Expression	[2235]
SIPA1	OTXY5RXC	Strong	Genetic Variation	[2236]
SIRT4	OT5S0J23	Strong	Biomarker	[2237]
SIX1	OT70YYWM	Strong	Altered Expression	[2238]
SIX2	OTYOVGSC	Strong	Altered Expression	[2239]
SKA2	OTVYF4XT	Strong	Biomarker	[2114]
SLAMF1	OTBTT3ZQ	Strong	Altered Expression	[2240]
SLC2A4RG	OTW3LX8D	Strong	Biomarker	[2241]
SLFN5	OTT1AESL	Strong	Altered Expression	[2242]
SLIT3	OTU8MKEU	Strong	Posttranslational Modification	[2243]
SLPI	OTUNFUU8	Strong	Biomarker	[226]
SMAGP	OT57BZII	Strong	Altered Expression	[2244]
SMARCA1	OT0Y6PTU	Strong	Genetic Variation	[2245]
SMARCC1	OTUOMBE7	Strong	Biomarker	[468]
SMARCD1	OTHFFT6G	Strong	Biomarker	[2246]
SMARCE1	OTAX4ITH	Strong	Altered Expression	[2247]
SMR3B	OTL5HNM8	Strong	Biomarker	[2248]
SMUG1	OT2YIOCQ	Strong	Biomarker	[2249]
SMURF1	OT5UIZR8	Strong	Biomarker	[2250]
SMURF2	OT3TRVL7	Strong	Biomarker	[2251]
SNAI2	OT7Y8EJ2	Strong	Altered Expression	[2070]
SNIP1	OTL3RA91	Strong	Biomarker	[2252]
SNU13	OTH56TIH	Strong	Biomarker	[2253]
SNX1	OTXQSJ1J	Strong	Posttranslational Modification	[2254]
SNX2	OT889MQA	Strong	Biomarker	[2255]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[618]
SOS2	OTV3XRE5	Strong	Biomarker	[2256]
SOSTDC1	OTAKDNSM	Strong	Genetic Variation	[2108]
SOX1	OTVI1RAR	Strong	Posttranslational Modification	[2257]
SOX17	OT9H4WWE	Strong	Altered Expression	[2258]
SOX18	OTPUMHWA	Strong	Altered Expression	[2259]
SOX4	OTSS40SS	Strong	Biomarker	[2260]
SOX6	OTT0W0LE	Strong	Biomarker	[2261]
SOX9	OTVDJFGN	Strong	Altered Expression	[2262]
SPAAR	OTWXG2R8	Strong	Biomarker	[2263]
SPAG9	OT45AHMB	Strong	Altered Expression	[2264]
SPATA2	OTOA45GL	Strong	Biomarker	[2182]
SPATC1L	OTED6WB8	Strong	Genetic Variation	[1614]
SPC24	OT1HVYV4	Strong	Altered Expression	[2265]
SPC25	OTCAS0OH	Strong	Altered Expression	[2266]
SPG7	OT8OY9ST	Strong	Altered Expression	[432]
SPINK7	OTK3VOI3	Strong	Biomarker	[2267]
SPINT2	OTQV7BKQ	Strong	Altered Expression	[180]
SPNS2	OTPODAPU	Strong	Biomarker	[2268]
SPOP	OTP0107S	Strong	Altered Expression	[2269]
SPRR1A	OTJMI34A	Strong	Biomarker	[1622]
SPRY2	OTH0CRCZ	Strong	Biomarker	[2270]
SPZ1	OTQH8HJ5	Strong	Biomarker	[1633]
SRF	OTW18FQN	Strong	Altered Expression	[1837]
SRL	OT7IEBWZ	Strong	Biomarker	[738]
SRRM4	OTALUISN	Strong	Biomarker	[2271]
SRSF7	OTRS4W4S	Strong	Biomarker	[2272]
SRY	OT516T6D	Strong	Altered Expression	[1209]
SSX4	OT0E4H2D	Strong	Altered Expression	[2273]
ST13	OTNML6UP	Strong	Biomarker	[2274]
ST6GAL1	OT7US3NO	Strong	Genetic Variation	[2275]
ST8SIA1	OTGND2YZ	Strong	Biomarker	[2276]
STAG2	OTR6X1Q7	Strong	Genetic Variation	[2277]
STAT2	OTO9G2RZ	Strong	Altered Expression	[398]
STAT5B	OTZVPEBT	Strong	Biomarker	[1275]
STATH	OTQHBHM9	Strong	Altered Expression	[2278]
STIM1	OT8CLQ1W	Strong	Biomarker	[2279]
STIP1	OT7TXLOX	Strong	Biomarker	[2280]
STK11	OT1YZSP3	Strong	Genetic Variation	[2281]
STN1	OT8UWRA3	Strong	Biomarker	[477]
STPG4	OT5K4UFL	Strong	Genetic Variation	[2282]
STUB1	OTSUYI9A	Strong	Biomarker	[2274]
SUB1	OTK71JYU	Strong	Posttranslational Modification	[1596]
SUGP1	OT7W0EB8	Strong	Biomarker	[2283]
SULF1	OTJCNCO0	Strong	Altered Expression	[2284]
SUMO1	OTJFD4P5	Strong	Biomarker	[2285]
SUN2	OT2IQJUC	Strong	Biomarker	[255]
SUSD2	OTSJTAZP	Strong	Biomarker	[2286]
SUV39H2	OTU0F4LL	Strong	Altered Expression	[2287]
SYCE1L	OTXU44F3	Strong	Altered Expression	[84]
SYCP3	OTKOF54H	Strong	Altered Expression	[2288]
SYNE1	OTSBSLUH	Strong	Biomarker	[2166]
SYNM	OTOI8TRJ	Strong	Biomarker	[2289]
SYT1	OTVTPOI6	Strong	Altered Expression	[166]
SYT7	OTBWAOWY	Strong	Biomarker	[2290]
SYTL2	OTUIOWKL	Strong	Altered Expression	[870]
TAP2	OTWSYFI7	Strong	Altered Expression	[2209]
TARBP2	OT1QQ8H3	Strong	Biomarker	[2291]
TBKBP1	OTXTU37H	Strong	Biomarker	[2292]
TC2N	OT6482WN	Strong	Altered Expression	[2293]
TCEAL1	OTAPG2L5	Strong	Genetic Variation	[2015]
TCF21	OT393IMA	Strong	Posttranslational Modification	[2294]
TCF4	OTB9ASTK	Strong	Altered Expression	[166]
TCF7	OT1ID822	Strong	Posttranslational Modification	[1801]
TCN1	OTW6A49Y	Strong	Biomarker	[2295]
TENM1	OTSKSU4V	Strong	Biomarker	[2296]
TES	OTL8PP6V	Strong	Biomarker	[2297]
TESC	OTI8C76M	Strong	Biomarker	[2298]
TESMIN	OTZ5UILU	Strong	Biomarker	[2299]
TFAM	OTXXV5V7	Strong	Altered Expression	[2300]
TFAP2B	OTR1T8E9	Strong	Biomarker	[2301]
TFDP1	OT6RZ7VT	Strong	Biomarker	[2302]
TFDP3	OTI4K6MN	Strong	Altered Expression	[2303]
TFF2	OTRXB19X	Strong	Altered Expression	[2304]
TFF3	OTJJDRTU	Strong	Altered Expression	[2304]
TFPI2	OTZCRWOR	Strong	Altered Expression	[2305]
TGFBI	OTR443C5	Strong	Altered Expression	[566]
TGFBR3	OTQOOUC4	Strong	Biomarker	[2306]
THEM4	OTSIZU8Y	Strong	Biomarker	[2307]
THY1	OTVONVTB	Strong	Biomarker	[2308]
TIAM2	OTPYIPT6	Strong	Biomarker	[2309]
TICAM2	OTK7GIJ5	Strong	Altered Expression	[920]
TIGAR	OTR7NMRJ	Strong	Altered Expression	[2310]
TIMD4	OTGGC20G	Strong	Biomarker	[2311]
TLCD3A	OTVZUR1Z	Strong	Altered Expression	[2312]
TLE1	OT50MRZ1	Strong	Altered Expression	[602]
TM4SF1	OTY0ECQN	Strong	Altered Expression	[2313]
TM7SF2	OTILU5S7	Strong	Biomarker	[1594]
TMED6	OTLYX1ZZ	Strong	Altered Expression	[1621]
TMED7	OTONO8E6	Strong	Altered Expression	[920]
TMEFF2	OT1WZ2QO	Strong	Biomarker	[2314]
TMEM100	OTRJ6OHY	Strong	Biomarker	[2315]
TMEM106B	OTUWA6NW	Strong	Biomarker	[2316]
TMEM125	OTWF8MC1	Strong	Biomarker	[103]
TMEM17	OTEU00OH	Strong	Altered Expression	[2317]
TMEM196	OTPFLB1R	Strong	Posttranslational Modification	[2318]
TMEM209	OTH9U9U1	Strong	Altered Expression	[2022]
TMEM45A	OT54KJG6	Strong	Biomarker	[481]
TMEM74	OT3IZBM0	Strong	Biomarker	[2319]
TMEM88	OTA96YEL	Strong	Biomarker	[2320]
TMPRSS13	OTMAOAP3	Strong	Posttranslational Modification	[704]
TMPRSS4	OTCCGY2K	Strong	Biomarker	[2321]
TNFAIP8	OT1G9297	Strong	Biomarker	[1900]
TNFAIP8L2	OTII0RM0	Strong	Biomarker	[2322]
TNFAIP8L3	OTHSBS1B	Strong	Biomarker	[2323]
TNFRSF19	OTTVT4MB	Strong	Biomarker	[2324]
TNFSF8	OTDYGDJ3	Strong	Genetic Variation	[2325]
TNFSF9	OTV9L89D	Strong	Altered Expression	[2326]
TOB1	OTNW949D	Strong	Altered Expression	[2327]
TOMM34	OTH6MITE	Strong	Altered Expression	[2038]
TOP3B	OTNFEUOO	Strong	Altered Expression	[2328]
TOX	OTE8BL5Z	Strong	Altered Expression	[2329]
TOX3	OTC9NR4W	Strong	Altered Expression	[2329]
TP53AIP1	OT1XVNDP	Strong	Altered Expression	[2330]
TP53BP2	OTOWJ2Y4	Strong	Biomarker	[2331]
TPI1	OT14KP4B	Strong	Biomarker	[2332]
TPM3	OT5RU5G6	Strong	Biomarker	[2333]
TPM4	OTN4YLYR	Strong	Biomarker	[2334]
TPPP2	OTI3WA6X	Strong	Biomarker	[402]
TRAF1	OTTLM5RU	Strong	Biomarker	[2335]
TRAF2	OT1MEZZN	Strong	Biomarker	[813]
TRAF4	OTJLRVMC	Strong	Biomarker	[2336]
TRAP1	OTNG0L8J	Strong	Biomarker	[2337]
TRARG1	OTQ1R3JD	Strong	Altered Expression	[2338]
TREH	OTJE0NOY	Strong	Altered Expression	[2339]
TRIB2	OTHSX3MX	Strong	Altered Expression	[2340]
TRIB3	OTG5OS7X	Strong	Biomarker	[2341]
TRIM13	OTQIUACB	Strong	Altered Expression	[432]
TRIM15	OTNYAKP6	Strong	Biomarker	[2342]
TRIM21	OTA4UJCF	Strong	Biomarker	[2343]
TRIM32	OTJOV0PG	Strong	Biomarker	[979]
TRIM45	OTFDQT4E	Strong	Altered Expression	[2344]
TRIM52	OTKTKCT1	Strong	Biomarker	[2345]
TRIM58	OT7OIIRH	Strong	Posttranslational Modification	[2346]
TRIM65	OTSQTK3A	Strong	Biomarker	[2347]
TRIT1	OTCU9FS5	Strong	Biomarker	[2348]
TRO	OTRZQMU8	Strong	Altered Expression	[2349]
TROAP	OTC8CE0R	Strong	Altered Expression	[2350]
TRPS1	OT7XPPEL	Strong	Altered Expression	[2351]
TSPAN33	OTH6C0WU	Strong	Biomarker	[2352]
TSPAN8	OT1F68WQ	Strong	Biomarker	[2353]
TSPYL2	OTGGW2EF	Strong	Biomarker	[2354]
TTF1	OT4K90WD	Strong	Biomarker	[1108]
ABCE1	OTH19LOA	Definitive	Altered Expression	[356]
ACTB	OT1MCP2F	Definitive	Biomarker	[1656]
ADA2	OTGCV24S	Definitive	Genetic Variation	[2355]
AHRR	OTSJ12W6	Definitive	Biomarker	[2356]
AHSA1	OTC7AFHT	Definitive	Biomarker	[985]
ANAPC11	OTK2SJXR	Definitive	Altered Expression	[2357]
ANKRD1	OTHJ7JV9	Definitive	Genetic Variation	[2358]
ANKRD18A	OTHLBM3Z	Definitive	Biomarker	[2359]
APC	OTKV0TIK	Definitive	Genetic Variation	[2360]
ARHGEF17	OTUGS4FL	Definitive	Biomarker	[1333]
B3GNTL1	OTYWGHF1	Definitive	Genetic Variation	[2361]
BHLHE41	OTY9GJ1Y	Definitive	Biomarker	[481]
BICRA	OTDTPGW0	Definitive	Genetic Variation	[2362]
C2CD5	OTI495RD	Definitive	Biomarker	[2363]
CCBE1	OTO4UIDB	Definitive	Biomarker	[679]
CCND2	OTDULQF9	Definitive	Posttranslational Modification	[2364]
CCNG1	OT17IA9L	Definitive	Biomarker	[2365]
CDH13	OTD2CYM5	Definitive	Altered Expression	[2366]
CDK5R2	OTNUTLPU	Definitive	Biomarker	[2367]
CEACAM7	OTKFDTZY	Definitive	Altered Expression	[956]
CENPU	OTQ4TZRS	Definitive	Biomarker	[2368]
CHFR	OTRAD2TT	Definitive	Altered Expression	[2369]
CHI3L1	OT2Z7VJH	Definitive	Biomarker	[2370]
CIP2A	OTVS2GXA	Definitive	Altered Expression	[2371]
CLCA2	OTF191LZ	Definitive	Biomarker	[481]
CMTR2	OT82FBWS	Definitive	Genetic Variation	[2372]
CRYBG3	OTHXQCX7	Definitive	Altered Expression	[2373]
CSNK2A3	OTZP4KZK	Definitive	Genetic Variation	[962]
CTNNBL1	OT6KLHPA	Definitive	Altered Expression	[2374]
CYB561D2	OT1ZXC66	Definitive	Biomarker	[2375]
DCSTAMP	OTFKRP2H	Definitive	Altered Expression	[2376]
DDX49	OT13VWB7	Definitive	Biomarker	[2377]
DOK2	OTIJ38UF	Definitive	Biomarker	[1692]
DOK4	OTUEWLG8	Definitive	Altered Expression	[2378]
DSP	OTB2MOP8	Definitive	Biomarker	[2379]
EGFR	OTAPLO1S	Definitive	Autosomal dominant	[107]
ENO2	OTRODL0T	Definitive	Biomarker	[2380]
EPB41L3	OTS6CHG2	Definitive	Altered Expression	[2381]
ESPL1	OTMGEVOK	Definitive	Biomarker	[2382]
EXTL3	OT2BRUBN	Definitive	Biomarker	[2383]
FGF9	OT2SKDGM	Definitive	Altered Expression	[2384]
FOXO3	OTHXQG4P	Definitive	Altered Expression	[2385]
FRMD3	OT0CD2GG	Definitive	Biomarker	[2386]
FSTL1	OT6KEZUD	Definitive	Altered Expression	[2387]
GAGE7	OTF8BTR9	Definitive	Biomarker	[2388]
GC	OTWS63BY	Definitive	Altered Expression	[950]
GFER	OTVK43OK	Definitive	Biomarker	[2389]
GPRC5A	OTPOCWR7	Definitive	Altered Expression	[217]
GRAP2	OTS5NIZ3	Definitive	Biomarker	[985]
HCFC1R1	OTGDPS5C	Definitive	Altered Expression	[2390]
HEBP2	OTVDIMLM	Definitive	Altered Expression	[2391]
HEY1	OTJQL0I3	Definitive	Altered Expression	[2392]
HIPK3	OT4WYQM2	Definitive	Biomarker	[2393]
HOXB2	OTTD6HMV	Definitive	Genetic Variation	[2394]
ICMT	OT8CNKBO	Definitive	Biomarker	[2395]
ITPKB	OTSVVPAV	Definitive	Biomarker	[1868]
KCTD12	OTPYKT4Z	Definitive	Altered Expression	[2396]
KIF15	OTJRJEXL	Definitive	Biomarker	[2397]
KIF5B	OTT34MT8	Definitive	Altered Expression	[2398]
KIFBP	OT1XADKG	Definitive	Genetic Variation	[2399]
LCP1	OTK61F2A	Definitive	Biomarker	[2400]
LIPH	OTRGYLKL	Definitive	Altered Expression	[2401]
LZTFL1	OTIEIOEW	Definitive	Biomarker	[2402]
MCPH1	OTYT3TT5	Definitive	Biomarker	[2403]
MOB4	OTOQRMAS	Definitive	Altered Expression	[2404]
MORC2	OT52A8BJ	Definitive	Biomarker	[2405]
MTHFS	OTZ39JNR	Definitive	Genetic Variation	[2406]
NPPA	OTMQNTNX	Definitive	Genetic Variation	[2407]
NUDT21	OTZHKWAR	Definitive	Biomarker	[2408]
OGN	OTKP5S4L	Definitive	Biomarker	[2409]
PBXIP1	OTEAAUBY	Definitive	Altered Expression	[2390]
PCDH20	OTFSNRXK	Definitive	Posttranslational Modification	[2410]
PDCD4	OTZ6NXUX	Definitive	Biomarker	[2411]
PDSS1	OTXGVHAB	Definitive	Biomarker	[2412]
PER3	OTVKYVJA	Definitive	Biomarker	[490]
PHLDA2	OTMV9DPP	Definitive	Biomarker	[2413]
PLAC8	OT3SYRUJ	Definitive	Biomarker	[2414]
PLCH1	OT6Z1L2E	Definitive	Genetic Variation	[2415]
POFUT1	OTOBJZIT	Definitive	Biomarker	[1373]
POLDIP2	OT8SZSJ6	Definitive	Biomarker	[985]
POU5F1	OTDHHN7O	Definitive	Biomarker	[2416]
PPP1R13L	OTNCPLWE	Definitive	Posttranslational Modification	[2417]
PRDM1	OTQLSVBS	Definitive	Biomarker	[2418]
PRRG4	OT2SZQI7	Definitive	Biomarker	[2419]
PSG2	OT2EIXAI	Definitive	Altered Expression	[956]
PYCARD	OT67RON3	Definitive	Biomarker	[2420]
QSOX1	OT4ZPK4P	Definitive	Biomarker	[2421]
RAD21	OTQS84ZF	Definitive	Altered Expression	[2303]
RASGRF2	OT67DAGF	Definitive	Altered Expression	[2422]
RBM5	OTCBWHHV	Definitive	Biomarker	[2423]
RFC5	OTAD79RT	Definitive	Biomarker	[2424]
RHOJ	OTWI65OA	Definitive	Biomarker	[2425]
RIN2	OTCY73U9	Definitive	Biomarker	[162]
RNF19A	OTKWCV80	Definitive	Biomarker	[985]
RPL19	OT33LM66	Definitive	Altered Expression	[2426]
S100A14	OTVFJJ91	Definitive	Posttranslational Modification	[2427]
S100A7A	OTNM8DCP	Definitive	Posttranslational Modification	[2427]
SELENOP	OT02B8IR	Definitive	Biomarker	[2428]
SEPHS1	OTZ19I59	Definitive	Biomarker	[2412]
SERINC2	OTZ039U0	Definitive	Altered Expression	[2429]
SFTPA1	OT87XL1U	Definitive	Biomarker	[2430]
SFTPB	OTOHS07E	Definitive	Biomarker	[448]
SGMS1	OTZQE7PW	Definitive	Altered Expression	[2404]
SMC3	OTWGFRHD	Definitive	Biomarker	[2431]
SMS	OT8JYKNH	Definitive	Biomarker	[2412]
SMYD5	OTE5VET6	Definitive	Biomarker	[2432]
SNAI1	OTDPYAMC	Definitive	Biomarker	[2433]
SND1	OTT734JN	Definitive	Altered Expression	[727]
SPAG4	OTVXS2SM	Definitive	Biomarker	[2434]
STK11IP	OTLQ6P8R	Definitive	Biomarker	[1333]
SYNPO2	OTC3U0YH	Definitive	Altered Expression	[888]
TBC1D7	OT1ALJ63	Definitive	Biomarker	[1294]
TBX2	OTTOT7A9	Definitive	Biomarker	[2435]
TBX4	OTW58FG4	Definitive	Biomarker	[2412]
TEAD1	OTK6971C	Definitive	Genetic Variation	[2436]
TIMP1	OTOXC51H	Definitive	Biomarker	[2437]
TLE4	OT4QEH6T	Definitive	Biomarker	[2438]
TMPRSS11B	OT2852G1	Definitive	Biomarker	[2439]
TPRG1L	OTU7GPKK	Definitive	Biomarker	[2440]
TRAM1	OT3I0H8E	Definitive	Biomarker	[167]
TRDMT1	OTAYQ8ZF	Definitive	Genetic Variation	[2406]
TRIM44	OT0B1T2B	Definitive	Altered Expression	[2441]
TRIM66	OT0VJCP6	Definitive	Biomarker	[2442]
TRMT9B	OTU3UPEE	Definitive	Altered Expression	[461]

References

• [1] Targeting interleukin-1 and inflammation in lung cancer. Biomark Res. 2022 Jan 27;10(1):5.
• [2] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29-39.
• [3] Aminophylline FDA Label
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Bortezomib FDA Label
• [6] Bupropion FDA Label
• [7] Carboplatin FDA Label
• [8] Celecoxib FDA Label
• [9] Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther. 2018 Apr;18(4):483-493.
• [10] Cisplatin FDA Label
• [11] Citalopram FDA Label
• [12] Dasatinib FDA Label
• [13] Dexamethasone FDA Label
• [14] Docetaxel FDA Label
• [15] Doxorubicin FDA Label
• [16] Erlotinib FDA Label
• [17] Etoposide FDA Label
• [18] Everolimus FDA Label
• [19] Fludarabine FDA Label
• [20] Folic acid FDA Label
• [21] Gefitinib FDA Label
• [22] Gemcitabine FDA Label
• [23] Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7.
• [24] Hydroxocobalamin FDA Label
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
• [26] Mechlorethamine FDA Label
• [27] Methotrexate FDA Label
• [28] Nicotine FDA Label
• [29] Paclitaxel FDA Label
• [30] Panobinostat FDA Label
• [31] Pemetrexed FDA Label
• [32] The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy.Ann Am Thorac Soc. 2018 Apr;15(Supplement_2):S124.
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505).
• [34] Sirolimus FDA Label
• [35] Sorafenib FDA Label
• [36] Sunitinib FDA Label
• [37] Temozolomide FDA Label
• [38] Theophylline FDA Label
• [39] Topotecan FDA Label
• [40] Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251.
• [41] Vidarabine FDA Label
• [42] Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010 Aug 10;28(23):3739-45.
• [43] Vinorelbine FDA Label
• [44] ClinicalTrials.gov (NCT02322281) TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
• [45] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016680)
• [46] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [47] ClinicalTrials.gov (NCT00083304) Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer. U.S. National Institutes of Health.
• [48] ClinicalTrials.gov (NCT00477282) Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer. U.S. National Institutes of Health.
• [49] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220).
• [50] ClinicalTrials.gov (NCT04738487) Vibostolimab (MK-7684) With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003). U.S. National Institutes of Health.
• [51] ClinicalTrials.gov (NCT02340208) A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47. U.S. National Institutes of Health.
• [52] ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
• [53] ClinicalTrials.gov (NCT01184287) A Study Of Ranpirnase(Onconase) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [54] ClinicalTrials.gov (NCT01592617) Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [55] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6281).
• [56] ClinicalTrials.gov (NCT01017601) Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer. U.S. National Institutes of Health.
• [57] Clinical pipeline report, company report or official report of AVAX Technologies.
• [58] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [59] ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
• [60] ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
• [61] ClinicalTrials.gov (NCT03525782) Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
• [62] ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
• [63] The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
• [64] ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
• [65] Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005 Mar 2;3(1):10.
• [66] ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers
• [67] ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
• [68] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
• [69] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [70] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008257)
• [71] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468).
• [72] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011959)
• [73] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010410)
• [74] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008879)
• [75] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020776)
• [76] Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Med Chem Lett. 2015 Apr 29;6(6):695-700.
• [77] Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25.
• [78] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021320)
• [79] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003878)
• [80] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [81] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [82] Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
• [83] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [84] New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.Biomed Pharmacother. 2017 Dec;96:659-666. doi: 10.1016/j.biopha.2017.10.041. Epub 2017 Nov 6.
• [85] ALDH2 Repression Promotes Lung Tumor Progression via Accumulated Acetaldehyde and DNA Damage.Neoplasia. 2019 Jun;21(6):602-614. doi: 10.1016/j.neo.2019.03.008. Epub 2019 May 6.
• [86] Potential therapeutic impact of CD13 expression in non-small cell lung cancer.PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017.
• [87] Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. doi: 10.1073/pnas.1610456113. Epub 2016 Nov 9.
• [88] The effect and mechanism of miR-210 in down-regulating the autophagy of lung cancer cells.Pathol Res Pract. 2019 Mar;215(3):453-458. doi: 10.1016/j.prp.2018.12.018. Epub 2018 Dec 12.
• [89] Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.Sci Rep. 2016 Jul 19;6:29721. doi: 10.1038/srep29721.
• [90] Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.Nat Med. 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26.
• [91] Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.Mol Cancer. 2019 Feb 11;18(1):24. doi: 10.1186/s12943-019-0953-y.
• [92] Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells.Oncol Lett. 2018 Apr;15(4):5473-5480. doi: 10.3892/ol.2018.8036. Epub 2018 Feb 13.
• [93] MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.Biochem Biophys Res Commun. 2009 Oct 23;388(3):483-9. doi: 10.1016/j.bbrc.2009.07.143. Epub 2009 Aug 3.
• [94] Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.Cancers (Basel). 2019 Nov 21;11(12):1835. doi: 10.3390/cancers11121835.
• [95] The miR-195 Axis Regulates Chemoresistance through TUBB and Lung Cancer Progression through BIRC5.Mol Ther Oncolytics. 2019 Aug 6;14:288-298. doi: 10.1016/j.omto.2019.07.004. eCollection 2019 Sep 27.
• [96] A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma.Oncotarget. 2017 May 16;8(20):33405-33415. doi: 10.18632/oncotarget.16796.
• [97] Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells.Cancer Res. 2019 Aug 1;79(15):3851-3861. doi: 10.1158/0008-5472.CAN-18-1037. Epub 2019 May 29.
• [98] Quantitative proteomics analysis of mitochondrial proteins in lung adenocarcinomas and normal lung tissue using iTRAQ and tandem mass spectrometry.Am J Transl Res. 2017 Sep 15;9(9):3918-3934. eCollection 2017.
• [99] The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer.Mol Cell. 2018 Jan 4;69(1):87-99.e7. doi: 10.1016/j.molcel.2017.11.025. Epub 2017 Dec 14.
• [100] lncRNAu50535 promotes the progression of lung cancer by activating CCL20/ERK signaling.Oncol Rep. 2019 Nov;42(5):1946-1956. doi: 10.3892/or.2019.7302. Epub 2019 Sep 5.
• [101] A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.PLoS One. 2018 Apr 4;13(4):e0193461. doi: 10.1371/journal.pone.0193461. eCollection 2018.
• [102] High CCL7 expression is associated with migration, invasion and bone metastasis of non-small cell lung cancer cells.Am J Transl Res. 2019 Jan 15;11(1):442-452. eCollection 2019.
• [103] Integrative Analysis of CD133 mRNA in Human Cancers Based on Data Mining.Stem Cell Rev Rep. 2019 Feb;15(1):23-34. doi: 10.1007/s12015-018-9865-2.
• [104] Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer.J Cancer Res Ther. 2016 Dec;12(Supplement):C186-C190. doi: 10.4103/0973-1482.200597.
• [105] Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls.Hum Mol Genet. 2012 Nov 15;21(22):4980-95. doi: 10.1093/hmg/dds334. Epub 2012 Aug 16.
• [106] Upregulation of Complement Factor H by SOCS-1/3STAT4 in Lung Cancer.Cancers (Basel). 2019 Apr 3;11(4):471. doi: 10.3390/cancers11040471.
• [107] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [108] Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells.Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1170-8. doi: 10.1016/j.bbamcr.2016.02.015. Epub 2016 Feb 24.
• [109] Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells.Front Pharmacol. 2019 Mar 22;10:260. doi: 10.3389/fphar.2019.00260. eCollection 2019.
• [110] Interactive effect of smoking and NQO1 haplotypes on lung cancer risk.J Korean Med Sci. 2015 Mar;30(3):221-6. doi: 10.3346/jkms.2015.30.3.221. Epub 2015 Feb 16.
• [111] Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin.Oncotarget. 2017 Nov 20;8(63):106672-106684. doi: 10.18632/oncotarget.22508. eCollection 2017 Dec 5.
• [112] Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.J Thorac Oncol. 2018 Mar;13(3):399-412. doi: 10.1016/j.jtho.2017.11.126. Epub 2017 Dec 9.
• [113] Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.Chem Res Toxicol. 2017 Jan 17;30(1):53-60. doi: 10.1021/acs.chemrestox.6b00286. Epub 2016 Oct 26.
• [114] Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.Tumour Biol. 2014 Feb;35(2):1671-8. doi: 10.1007/s13277-013-1230-0. Epub 2013 Oct 2.
• [115] Relationship between DLK1 gene promoter region DNA methylation and non-small cell lung cancer biological behavior.Oncol Lett. 2017 Jun;13(6):4123-4126. doi: 10.3892/ol.2017.6019. Epub 2017 Apr 10.
• [116] Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-B signaling pathway.Onco Targets Ther. 2017 Sep 11;10:4443-4454. doi: 10.2147/OTT.S142244. eCollection 2017.
• [117] Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.Oncotarget. 2017 Sep 1;8(43):73419-73432. doi: 10.18632/oncotarget.20621. eCollection 2017 Sep 26.
• [118] Downregulation of DLL4 predicts poor survival in nonsmall cell lung cancer patients due to promotion of lymph node metastasis.Oncol Rep. 2018 Nov;40(5):2988-2996. doi: 10.3892/or.2018.6679. Epub 2018 Aug 31.
• [119] Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer.Oncotarget. 2017 Feb 14;8(7):11739-11747. doi: 10.18632/oncotarget.14340.
• [120] Correlations of an Insertion/Deletion Polymorphism (rs10680577) in the RERT-lncRNA with the Susceptibility, Clinicopathological Features, and Prognosis of Lung Cancer.Biochem Genet. 2019 Feb;57(1):147-158. doi: 10.1007/s10528-018-9883-4. Epub 2018 Aug 2.
• [121] Quantitative proteomics reveals a novel role of karyopherin alpha 2 in cell migration through the regulation of vimentin-pErk protein complex levels in lung cancer.J Proteome Res. 2015 Apr 3;14(4):1739-51. doi: 10.1021/pr501097a. Epub 2015 Mar 13.
• [122] Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR.Mol Cancer Ther. 2017 Aug;16(8):1470-1486. doi: 10.1158/1535-7163.MCT-17-0134. Epub 2017 Jun 1.
• [123] EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale.Crit Rev Oncol Hematol. 2018 Jun;126:52-63. doi: 10.1016/j.critrevonc.2018.03.006. Epub 2018 Mar 21.
• [124] EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.Tumour Biol. 2016 Sep;37(9):11959-11971. doi: 10.1007/s13277-016-5048-4. Epub 2016 Apr 21.
• [125] Reduced expression of EphA5 is associated with lymph node metastasis, advanced TNM stage, and poor prognosis in colorectal carcinoma.Histol Histopathol. 2017 May;32(5):491-497. doi: 10.14670/HH-11-815. Epub 2016 Sep 21.
• [126] ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.Pharmacol Res. 2017 Jul;121:202-212. doi: 10.1016/j.phrs.2017.04.022. Epub 2017 Apr 30.
• [127] Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells.PLoS Comput Biol. 2016 Aug 5;12(8):e1005049. doi: 10.1371/journal.pcbi.1005049. eCollection 2016 Aug.
• [128] Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.Carcinogenesis. 2017 Jun 1;38(6):604-614. doi: 10.1093/carcin/bgx039.
• [129] A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese.Nat Genet. 2011 Jul 3;43(8):792-6. doi: 10.1038/ng.875.
• [130] Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.Carcinogenesis. 2008 Nov;29(11):2147-52. doi: 10.1093/carcin/bgn205. Epub 2008 Aug 29.
• [131] Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.PLoS One. 2018 Feb 8;13(2):e0192194. doi: 10.1371/journal.pone.0192194. eCollection 2018.
• [132] Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer.Int J Biol Sci. 2017 Jun 1;13(6):804-814. doi: 10.7150/ijbs.19398. eCollection 2017.
• [133] Pterostilbene prevents AKT-ERK axis-mediated polymerization of surface fibronectin on suspended lung cancer cells independently of apoptosis and suppresses metastasis.J Hematol Oncol. 2017 Mar 21;10(1):72. doi: 10.1186/s13045-017-0441-z.
• [134] Expression of microRNA-133 inhibits epithelial-mesenchymal transition in lung cancer cells by directly targeting FOXQ1.Arch Bronconeumol. 2016 Oct;52(10):505-11. doi: 10.1016/j.arbres.2015.10.016. Epub 2016 Feb 5.
• [135] The roles and mechanisms of G3BP1 in tumour promotion. J Drug Target. 2019 Mar;27(3):300-305.
• [136] 19p13.3-GADD45B common variants and 19q13.3-PPP1R13L and 19q13.3-CD3EAP in lung cancer risk among Chinese.Chem Biol Interact. 2017 Nov 1;277:74-78. doi: 10.1016/j.cbi.2017.08.018. Epub 2017 Sep 1.
• [137] Glycine-extended gastrin promotes the growth of lung cancer.Cancer Res. 2004 Jan 1;64(1):196-201. doi: 10.1158/0008-5472.can-03-2112.
• [138] BMP9 inhibits the growth and migration of lung adenocarcinoma A549 cells in a bone marrow stromal cellderived microenvironment through the MAPK/ERK and NF-B pathways.Oncol Rep. 2016 Jul;36(1):410-8. doi: 10.3892/or.2016.4796. Epub 2016 May 9.
• [139] GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer.Mol Cancer. 2016 Mar 18;15:25. doi: 10.1186/s12943-016-0508-4.
• [140] DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells.Oncoimmunology. 2018 Nov 2;8(1):e1509173. doi: 10.1080/2162402X.2018.1509173. eCollection 2019.
• [141] MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.Clin Cancer Res. 2017 Nov 15;23(22):7084-7096. doi: 10.1158/1078-0432.CCR-16-3006. Epub 2017 Aug 29.
• [142] WDR1 Promotes Cell Growth and Migration and Contributes to Malignant Phenotypes of Non-small Cell Lung Cancer through ADF/cofilin-mediated Actin Dynamics.Int J Biol Sci. 2018 Jun 8;14(9):1067-1080. doi: 10.7150/ijbs.23845. eCollection 2018.
• [143] A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer: HAL.Am J Respir Crit Care Med. 2017 Jun 15;195(12):1651-1660. doi: 10.1164/rccm.201607-1397OC.
• [144] HDAC10 promotes lung cancer proliferation via AKT phosphorylation.Oncotarget. 2016 Sep 13;7(37):59388-59401. doi: 10.18632/oncotarget.10673.
• [145] Knockdown of HNRNPA1 inhibits lung adenocarcinoma cell proliferation through cell cycle arrest at G0/G1 phase.Gene. 2016 Feb 1;576(2 Pt 2):791-7. doi: 10.1016/j.gene.2015.11.009. Epub 2015 Nov 12.
• [146] Nm23-H1-stabilized hnRNPA2/B1 promotes internal ribosomal entry site (IRES)-mediated translation of Sp1 in the lung cancer progression.Sci Rep. 2017 Aug 22;7(1):9166. doi: 10.1038/s41598-017-09558-7.
• [147] Glucose-Regulated Protein 78 Signaling Regulates Hypoxia-Induced Epithelial-Mesenchymal Transition in A549 Cells.Front Oncol. 2019 Mar 12;9:137. doi: 10.3389/fonc.2019.00137. eCollection 2019.
• [148] Baicalein Inhibits Orthotopic Human Non-Small Cell Lung Cancer Xenografts via Src/Id1 Pathway.Evid Based Complement Alternat Med. 2019 Mar 4;2019:9806062. doi: 10.1155/2019/9806062. eCollection 2019.
• [149] Imaging of Integrin (v)(3) Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer (99m)Tc-IDA-D-[c(RGDfK)](2).Cancer Biother Radiopharm. 2017 Oct;32(8):288-296. doi: 10.1089/cbr.2017.2233.
• [150] Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers.Carcinogenesis. 2014 Dec;35(12):2698-705. doi: 10.1093/carcin/bgu203. Epub 2014 Sep 19.
• [151] Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer.Cell Death Dis. 2016 Jan 21;7(1):e2057. doi: 10.1038/cddis.2015.418.
• [152] Interleukin-22 secreted by cancer-associated fibroblasts regulates the proliferation and metastasis of lung cancer cells via the PI3K-Akt-mTOR signaling pathway.Am J Transl Res. 2019 Jul 15;11(7):4077-4088. eCollection 2019.
• [153] IFN regulatory factor-8 expression in macrophages governs an antimetastatic program.JCI Insight. 2019 Feb 7;4(3):e124267. doi: 10.1172/jci.insight.124267.
• [154] Integrin v promotes proliferation by activating ERK 1/2 in the human lung cancer cell line A549.Mol Med Rep. 2015 Feb;11(2):1266-71. doi: 10.3892/mmr.2014.2860. Epub 2014 Nov 4.
• [155] Acquired Resistance to EGFR TKIs Mediated by TGF1/Integrin 3 Signaling in EGFR-Mutant Lung Cancer.Mol Cancer Ther. 2019 Dec;18(12):2357-2367. doi: 10.1158/1535-7163.MCT-19-0181. Epub 2019 Sep 9.
• [156] Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.Biomed Pharmacother. 2017 May;89:305-315. doi: 10.1016/j.biopha.2017.02.014. Epub 2017 Feb 24.
• [157] p62 functions as an oncogene in colorectal cancer through inhibiting apoptosis and promoting cell proliferation by interacting with the vitamin D receptor.Cell Prolif. 2019 May;52(3):e12585. doi: 10.1111/cpr.12585. Epub 2019 Feb 22.
• [158] miR-449a Suppresses LDHA-Mediated Glycolysis to Enhance the Sensitivity of Non-Small Cell Lung Cancer Cells to Ionizing Radiation.Oncol Res. 2018 May 7;26(4):547-556. doi: 10.3727/096504017X15016337254605. Epub 2017 Aug 11.
• [159] Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer. Int J Oncol. 2017 Jun;50(6):2154-2170.
• [160] MALT1 is required for EGFR-induced NF-B activation and contributes to EGFR-driven lung cancer progression.Oncogene. 2016 Feb 18;35(7):919-28. doi: 10.1038/onc.2015.146. Epub 2015 May 18.
• [161] MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer.Int J Oncol. 2016 Oct;49(4):1437-44. doi: 10.3892/ijo.2016.3637. Epub 2016 Jul 29.
• [162] Construction of High Sensitive CD133 Immune PLGA Magnetic Spheres Platform for Lung Cancer Stem Cells Isolation and Its Property Evaluation.J Biomed Nanotechnol. 2018 Jun 1;14(6):1066-1074. doi: 10.1166/jbn.2018.2562.
• [163] Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt.Int J Oncol. 2017 Jan;50(1):93-100. doi: 10.3892/ijo.2016.3768. Epub 2016 Nov 15.
• [164] MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.Carcinogenesis. 2017 Jan;38(1):64-75. doi: 10.1093/carcin/bgw110. Epub 2016 Oct 17.
• [165] Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential.PLoS One. 2012;7(4):e35040. doi: 10.1371/journal.pone.0035040. Epub 2012 Apr 24.
• [166] T cell factor-4 functions as a co-activator to promote NF-B-dependent MMP-15 expression in lung carcinoma cells.Sci Rep. 2016 Apr 5;6:24025. doi: 10.1038/srep24025.
• [167] SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.Cancer Lett. 2019 Feb 1;442:310-319. doi: 10.1016/j.canlet.2018.11.012. Epub 2018 Nov 10.
• [168] Association and interaction of NFKB1 rs28362491 insertion/deletion ATTG polymorphism and PPP1R13L and CD3EAP related to lung cancer risk in a Chinese population.Tumour Biol. 2016 Apr;37(4):5467-73. doi: 10.1007/s13277-015-4373-3. Epub 2015 Nov 13.
• [169] Genetic alterations and expression of the protein phosphatase 1 genes in human cancers.Int J Oncol. 2001 Apr;18(4):817-24. doi: 10.3892/ijo.18.4.817.
• [170] New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.Lab Invest. 2017 Nov;97(11):1268-1270. doi: 10.1038/labinvest.2017.91.
• [171] Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase.Front Pharmacol. 2019 Oct 22;10:1248. doi: 10.3389/fphar.2019.01248. eCollection 2019.
• [172] PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.Exp Ther Med. 2017 May;13(5):1993-1999. doi: 10.3892/etm.2017.4218. Epub 2017 Mar 10.
• [173] Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.Int J Gynecol Pathol. 2019 Sep;38(5):404-413. doi: 10.1097/PGP.0000000000000543.
• [174] Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.Virchows Arch. 2006 Jun;448(6):830-7. doi: 10.1007/s00428-006-0199-0. Epub 2006 Apr 12.
• [175] Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking -catenin and MAPK signaling.Oncotarget. 2017 Aug 27;8(41):69264-69280. doi: 10.18632/oncotarget.20566. eCollection 2017 Sep 19.
• [176] Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk.Sci Transl Med. 2017 Nov 15;9(416):eaai9048. doi: 10.1126/scitranslmed.aai9048.
• [177] Novel reciprocal interaction of lncRNA HOTAIR and miR-214-3p contribute to the solamargine-inhibited PDPK1 gene expression in human lung cancer.J Cell Mol Med. 2019 Nov;23(11):7749-7761. doi: 10.1111/jcmm.14649. Epub 2019 Sep 1.
• [178] Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.Med Sci Monit. 2019 Jul 26;25:5543-5551. doi: 10.12659/MSM.915314.
• [179] Identification of gene markers in the development of smoking-induced lung cancer.Gene. 2016 Jan 15;576(1 Pt 3):451-7. doi: 10.1016/j.gene.2015.10.060. Epub 2015 Oct 27.
• [180] HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.Br J Cancer. 2019 Mar;120(5):499-511. doi: 10.1038/s41416-019-0400-2. Epub 2019 Feb 15.
• [181] pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.Int J Nanomedicine. 2018 Oct 26;13:6885-6902. doi: 10.2147/IJN.S180119. eCollection 2018.
• [182] Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space.J Biol Chem. 2016 Dec 9;291(50):25799-25808. doi: 10.1074/jbc.M116.759803. Epub 2016 Nov 1.
• [183] Cyclophilin A promotes non-small cell lung cancer metastasis via p38 MAPK.Thorac Cancer. 2018 Jan;9(1):120-128. doi: 10.1111/1759-7714.12548. Epub 2017 Nov 7.
• [184] Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer.Oncotarget. 2017 Oct 26;8(62):105196-105210. doi: 10.18632/oncotarget.22111. eCollection 2017 Dec 1.
• [185] Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.Cancer Immunol Res. 2017 Apr;5(4):319-329. doi: 10.1158/2326-6066.CIR-16-0141. Epub 2017 Mar 2.
• [186] NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in cancer cells.Oncogene. 2019 Apr;38(16):2937-2952. doi: 10.1038/s41388-018-0639-8. Epub 2018 Dec 19.
• [187] mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.Prostaglandins Other Lipid Mediat. 2019 Aug;143:106344. doi: 10.1016/j.prostaglandins.2019.106344. Epub 2019 Jun 15.
• [188] Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium.Sci Rep. 2017 Apr 11;7(1):825. doi: 10.1038/s41598-017-00850-0.
• [189] Rab22a enhances CD147 recycling and is required for lung cancer cell migration and invasion.Exp Cell Res. 2017 Aug 1;357(1):9-16. doi: 10.1016/j.yexcr.2017.04.020. Epub 2017 Apr 19.
• [190] High Expression of Rab-like 3 (Rabl3) is Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer via Repression of MAPK8/9/10-Mediated Autophagy.Med Sci Monit. 2016 May 10;22:1582-8. doi: 10.12659/msm.898632.
• [191] S100A3 a partner protein regulating the stability/activity of RAR and PML-RAR in cellular models of breast/lung cancer and acute myeloid leukemia.Oncogene. 2019 Apr;38(14):2482-2500. doi: 10.1038/s41388-018-0599-z. Epub 2018 Dec 7.
• [192] Genetic polymorphisms in the TERT-CLPTM1L region and lung cancer susceptibility in Chinese males.Oncol Lett. 2017 Aug;14(2):1588-1594. doi: 10.3892/ol.2017.6289. Epub 2017 Jun 1.
• [193] IFN- restores the impaired function of RNase L and induces mitochondria-mediated apoptosis in lung cancer.Cell Death Dis. 2019 Sep 9;10(9):642. doi: 10.1038/s41419-019-1902-9.
• [194] Polymorphisms in cancer-related pathway genes and lung cancer.Eur Respir J. 2016 Oct;48(4):1184-1191. doi: 10.1183/13993003.02040-2015. Epub 2016 Sep 1.
• [195] Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer.Virchows Arch. 2017 May;470(5):553-560. doi: 10.1007/s00428-017-2102-6. Epub 2017 Mar 13.
• [196] RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer.J Transl Med. 2019 Apr 15;17(1):125. doi: 10.1186/s12967-019-1878-3.
• [197] S100A4 alters metabolism and promotes invasion of lung cancer cells by up-regulating mitochondrial complex I protein NDUFS2.J Biol Chem. 2019 May 3;294(18):7516-7527. doi: 10.1074/jbc.RA118.004365. Epub 2019 Mar 18.
• [198] Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma.J Proteome Res. 2017 Dec 1;16(12):4495-4505. doi: 10.1021/acs.jproteome.7b00484. Epub 2017 Oct 12.
• [199] Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis.J Hum Genet. 2016 Dec;61(12):985-993. doi: 10.1038/jhg.2016.99. Epub 2016 Aug 4.
• [200] SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers. Sci Rep. 2013 Oct 22;3:3012.
• [201] The target landscape of clinical kinase drugs.Science. 2017 Dec 1;358(6367):eaan4368. doi: 10.1126/science.aan4368.
• [202] SLC27A4 regulate ATG4B activity and control reactions to chemotherapeutics-induced autophagy in human lung cancer cells.Tumour Biol. 2016 May;37(5):6943-52. doi: 10.1007/s13277-015-4587-4. Epub 2015 Dec 11.
• [203] Inhibition of miR-32 activity promoted EMT induced by PM2.5 exposure through the modulation of the Smad1-mediated signaling pathways in lung cancer cells.Chemosphere. 2017 Oct;184:289-298. doi: 10.1016/j.chemosphere.2017.05.152. Epub 2017 May 30.
• [204] Could lung cancer exosomes induce apoptosis of natural killer cells through the p75NTR-proNGF-sortilin axis?.Med Hypotheses. 2017 Oct;108:151-153. doi: 10.1016/j.mehy.2017.09.003. Epub 2017 Sep 6.
• [205] SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition.Oncotarget. 2017 Nov 6;9(13):10891-10904. doi: 10.18632/oncotarget.22443. eCollection 2018 Feb 16.
• [206] Correlation between SPARC, TGF1, Endoglin and angiogenesis mechanism in lung cancer.J Biol Regul Homeost Agents. 2018 Nov-Dec;32(6):1525-1531.
• [207] B7-H3 regulates lipid metabolism of lung cancer through SREBP1-mediated expression of FASN.Biochem Biophys Res Commun. 2017 Jan 22;482(4):1246-1251. doi: 10.1016/j.bbrc.2016.12.021. Epub 2016 Dec 7.
• [208] A Prolonged Air Leak Score for Lung Cancer Resection: An Analysis of The Society of Thoracic Surgeons General Thoracic Surgery Database.Ann Thorac Surg. 2019 Nov;108(5):1478-1483. doi: 10.1016/j.athoracsur.2019.05.069. Epub 2019 Jul 16.
• [209] MRI reporter gene MagA suppresses transferrin receptor and maps Fe(2+) dependent lung cancer.Nanomedicine. 2019 Oct;21:102064. doi: 10.1016/j.nano.2019.102064. Epub 2019 Jul 18.
• [210] Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.Int J Biochem Cell Biol. 2018 Sep;102:20-30. doi: 10.1016/j.biocel.2018.06.006. Epub 2018 Jun 19.
• [211] XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.Oncol Lett. 2018 Jun;15(6):8973-8982. doi: 10.3892/ol.2018.8491. Epub 2018 Apr 13.
• [212] Data-driven Analysis of TRP Channels in Cancer: Linking Variation in Gene Expression to Clinical Significance.Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):83-90.
• [213] Association and clinical implication of the USP10 and MSH2 proteins in non-small cell lung cancer.Oncol Lett. 2019 Jan;17(1):1128-1138. doi: 10.3892/ol.2018.9702. Epub 2018 Nov 15.
• [214] USP14 Inhibition Regulates Tumorigenesis by Inducing Autophagy in Lung Cancer In Vitro.Int J Mol Sci. 2019 Oct 24;20(21):5300. doi: 10.3390/ijms20215300.
• [215] Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study.J Hematol Oncol. 2017 Mar 23;10(1):74. doi: 10.1186/s13045-017-0440-0.
• [216] Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor-C in a mouse model of lung cancer.Cancer Sci. 2018 Aug;109(8):2469-2478. doi: 10.1111/cas.13665. Epub 2018 Jul 20.
• [217] Gprc5a depletion enhances the risk of smoking-induced lung tumorigenesis and mortality.Biomed Pharmacother. 2019 Jun;114:108791. doi: 10.1016/j.biopha.2019.108791. Epub 2019 Mar 19.
• [218] MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.Biochem Pharmacol. 2019 Oct;168:237-248. doi: 10.1016/j.bcp.2019.07.009. Epub 2019 Jul 11.
• [219] RNA interference influenced the proliferation and invasion of XWLC-05 lung cancer cells through inhibiting aquaporin 3.Biochem Biophys Res Commun. 2017 Apr 8;485(3):627-634. doi: 10.1016/j.bbrc.2017.02.013. Epub 2017 Feb 9.
• [220] Exogenous Let-7a-5p Induces A549 Lung Cancer Cell Death Through BCL2L1-Mediated PI3K Signaling Pathway.Front Oncol. 2019 Aug 23;9:808. doi: 10.3389/fonc.2019.00808. eCollection 2019.
• [221] A novel BLK-induced tumor model.Tumour Biol. 2017 Jul;39(7):1010428317714196. doi: 10.1177/1010428317714196.
• [222] Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.J Thorac Oncol. 2018 Oct;13(10):1483-1495. doi: 10.1016/j.jtho.2018.06.016. Epub 2018 Jul 4.
• [223] RB constrains lineage fidelity and multiple stages of tumour progression and metastasis.Nature. 2019 May;569(7756):423-427. doi: 10.1038/s41586-019-1172-9. Epub 2019 May 1.
• [224] Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients.Int J Biol Markers. 2011 Jan-Mar;26(1):9-21. doi: 10.5301/jbm.2011.6372.
• [225] IKK Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization.Comput Struct Biotechnol J. 2019 Feb 7;17:251-262. doi: 10.1016/j.csbj.2019.02.003. eCollection 2019.
• [226] Bone turnover markers and novel biomarkers in lung cancer bone metastases.Biomarkers. 2018 Sep;23(6):518-526. doi: 10.1080/1354750X.2018.1463566. Epub 2018 Apr 23.
• [227] The inhibitory activity of gallic acid against DNA methylation: application of gallic acid on epigenetic therapy of human cancers.Oncotarget. 2017 Dec 7;9(1):361-374. doi: 10.18632/oncotarget.23015. eCollection 2018 Jan 2.
• [228] Study of lung cancer regulatory network that involves erbB4 and tumor marker gene.Saudi J Biol Sci. 2017 Mar;24(3):649-657. doi: 10.1016/j.sjbs.2017.01.038. Epub 2017 Jan 27.
• [229] Basic fibroblast growth factor blockade enhances lung cancer cell invasion by activating the AKT/MMP-2/VEGF pathway.Basic Clin Pharmacol Toxicol. 2020 Jan;126(1):43-50. doi: 10.1111/bcpt.13290. Epub 2019 Aug 8.
• [230] Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O(2)-(2,4-dinitrophenyl) diazeniumdiolate for intervention of drug-resistant lung cancer.Eur J Med Chem. 2018 Apr 10;149:269-280. doi: 10.1016/j.ejmech.2018.02.062. Epub 2018 Feb 23.
• [231] Recent advances in biosensor for detection of lung cancer biomarkers.Biosens Bioelectron. 2019 Sep 15;141:111416. doi: 10.1016/j.bios.2019.111416. Epub 2019 Jun 6.
• [232] Expression of GARP Is Increased in Tumor-Infiltrating Regulatory T Cells and Is Correlated to Clinicopathology of Lung Cancer Patients.Front Immunol. 2017 Feb 14;8:138. doi: 10.3389/fimmu.2017.00138. eCollection 2017.
• [233] Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response.Exp Mol Med. 2019 Feb 21;51(2):1-20. doi: 10.1038/s12276-019-0209-3.
• [234] A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.Oncotarget. 2018 Jul 3;9(51):29680-29697. doi: 10.18632/oncotarget.25671. eCollection 2018 Jul 3.
• [235] MiR-339 depresses cell proliferation via directly targeting S-phase kinase-associated protein? mRNA in lung cancer.Thorac Cancer. 2018 Mar;9(3):408-414. doi: 10.1111/1759-7714.12597. Epub 2018 Jan 29.
• [236] Lung Tumorigenesis Alters the Expression of Slit2-exon15 Splicing Variants in Tumor Microenvironment.Cancers (Basel). 2019 Feb 1;11(2):166. doi: 10.3390/cancers11020166.
• [237] Variation of Trop2 on non-small-cell lung cancer and normal cell membranes revealed by super-resolution fluorescence imaging.Talanta. 2020 Jan 15;207:120312. doi: 10.1016/j.talanta.2019.120312. Epub 2019 Sep 3.
• [238] Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial.Mol Carcinog. 2019 Jul;58(7):1094-1104. doi: 10.1002/mc.23017. Epub 2019 Apr 15.
• [239] Transthyretin Stimulates Tumor Growth through Regulation of Tumor, Immune, and Endothelial Cells.J Immunol. 2019 Feb 1;202(3):991-1002. doi: 10.4049/jimmunol.1800736. Epub 2018 Dec 19.
• [240] TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.Cancer Immunol Res. 2018 Feb;6(2):163-177. doi: 10.1158/2326-6066.CIR-17-0273. Epub 2018 Jan 16.
• [241] Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.Cancer Sci. 2020 Feb;111(2):610-620. doi: 10.1111/cas.14284. Epub 2020 Jan 19.
• [242] Association between Polymorphisms of Vitamin D Receptor and Lung Cancer Susceptibility: Evidence from an Updated Meta-analysis.J Cancer. 2019 Jun 9;10(16):3639-3649. doi: 10.7150/jca.33431. eCollection 2019.
• [243] Association between XPA gene rs1800975 polymorphism and susceptibility to lung cancer: a meta-analysis.Clin Respir J. 2018 Feb;12(2):448-458. doi: 10.1111/crj.12535. Epub 2016 Aug 21.
• [244] ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT.Sci Rep. 2017 Nov 8;7(1):15108. doi: 10.1038/s41598-017-15159-1.
• [245] Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.BMC Genomics. 2014;15 Suppl 3(Suppl 3):S1. doi: 10.1186/1471-2164-15-S3-S1. Epub 2014 May 6.
• [246] Finding genes discriminating smokers from non-smokers by applying a growing self-organizing clustering method to large airway epithelium cell microarray data.Asian Pac J Cancer Prev. 2013;14(1):111-6. doi: 10.7314/apjcp.2013.14.1.111.
• [247] Hypoxia-induced cell stemness leads to drug resistance and poor prognosis in lung adenocarcinoma.Lung Cancer. 2015 Feb;87(2):98-106. doi: 10.1016/j.lungcan.2014.11.017. Epub 2014 Dec 3.
• [248] Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.Oncogene. 2015 Jul 30;34(31):4056-68. doi: 10.1038/onc.2014.333. Epub 2014 Nov 10.
• [249] Correlations between angiopoietin-2 gene polymorphisms and lung cancer progression in a Chinese Han population.J Cancer. 2019 Jun 2;10(13):2935-2941. doi: 10.7150/jca.31134. eCollection 2019.
• [250] MicroRNA-26a regulates ANXA1, rather than DAL-1, in the development of lung cancer.Oncol Lett. 2018 Apr;15(4):5893-5902. doi: 10.3892/ol.2018.8048. Epub 2018 Feb 14.
• [251] RAD-ADAPT: Software for modelling clonogenic assay data in radiation biology.DNA Repair (Amst). 2017 Apr;52:24-30. doi: 10.1016/j.dnarep.2017.02.004. Epub 2017 Feb 20.
• [252] High expression of Aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancer.Int J Biol Markers. 2018 May;33(2):215-221. doi: 10.1177/1724600817753098. Epub 2018 Apr 30.
• [253] ADH IB expression, but not ADH III, is decreased in human lung cancer.PLoS One. 2012;7(12):e52995. doi: 10.1371/journal.pone.0052995. Epub 2012 Dec 28.
• [254] Association between BMP4 expression and pathology, CT characteristics and prognosis of non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5787-5794. doi: 10.26355/eurrev_201907_18317.
• [255] SUN2: A potential therapeutic target in cancer.Oncol Lett. 2019 Feb;17(2):1401-1408. doi: 10.3892/ol.2018.9764. Epub 2018 Nov 27.
• [256] Differential regulation of the parathyroid hormone-related protein gene P1 and P3 promoters by cAMP.Mol Cell Endocrinol. 1998 Mar 16;138(1-2):173-84. doi: 10.1016/s0303-7207(97)00239-6.
• [257] CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.Biochimie. 2014 Feb;97:210-8. doi: 10.1016/j.biochi.2013.10.021. Epub 2013 Nov 6.
• [258] Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo.Cell Death Differ. 2015 May;22(5):719-30. doi: 10.1038/cdd.2014.159. Epub 2014 Oct 10.
• [259] Yap-Hippo promotes A549 lung cancer cell death via modulating MIEF1-related mitochondrial stress and activating JNK pathway.Biomed Pharmacother. 2019 May;113:108754. doi: 10.1016/j.biopha.2019.108754. Epub 2019 Mar 12.
• [260] A CBR framework with gradient boosting based feature selection for lung cancer subtype classification.Comput Biol Med. 2017 Jul 1;86:98-106. doi: 10.1016/j.compbiomed.2017.05.010. Epub 2017 May 13.
• [261] The LncRNA EPEL Promotes Lung Cancer Cell Proliferation Through E2F Target Activation.Cell Physiol Biochem. 2018;45(3):1270-1283. doi: 10.1159/000487460. Epub 2018 Feb 9.
• [262] Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.Lung Cancer. 2018 Sep;123:87-90. doi: 10.1016/j.lungcan.2018.06.028. Epub 2018 Jun 26.
• [263] The influence of myeloid-derived suppressor cells on angiogenesis and tumor growth after cancer surgery.Int J Cancer. 2016 Jun 1;138(11):2688-99. doi: 10.1002/ijc.29998. Epub 2016 Jan 25.
• [264] DNA damage induced by human CD40 ligand mutant promotes senescence and induces demethylation of GATA4 in lung cancer.Oncol Rep. 2018 May;39(5):2071-2080. doi: 10.3892/or.2018.6310. Epub 2018 Mar 13.
• [265] CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.Cancer Res. 2020 Feb 1;80(3):444-457. doi: 10.1158/0008-5472.CAN-19-1108. Epub 2019 Nov 13.
• [266] A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a "Glutamine Trap" To Inhibit Lung Cancer Cell Growth.Mol Pharm. 2018 Aug 6;15(8):3032-3045. doi: 10.1021/acs.molpharmaceut.8b00076. Epub 2018 Jul 6.
• [267] Mechanistic insight of cyclin-dependent kinase 5 in modulating lung cancer growth.Chin J Physiol. 2019 Nov-Dec;62(6):231-240. doi: 10.4103/CJP.CJP_67_19.
• [268] Anti-Tumorigenic Effects of Resveratrol in Lung Cancer Cells Through Modulation of c-FLIP.Curr Cancer Drug Targets. 2017;17(7):669-680. doi: 10.2174/1568009617666170315162932.
• [269] Use of C-Choline positron emission tomography/computed tomography to investigate the mechanism of choline metabolism in lung cancer.Mol Med Rep. 2015 May;11(5):3285-90. doi: 10.3892/mmr.2015.3200. Epub 2015 Jan 14.
• [270] Genetic polymorphism of catechol-O-methyltransferase modulates the association of green tea consumption and lung cancer.Eur J Cancer Prev. 2019 Jul;28(4):316-322. doi: 10.1097/CEJ.0000000000000464.
• [271] Tag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancer.Mol Cancer. 2014 Mar 12;13:56. doi: 10.1186/1476-4598-13-56.
• [272] CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining.Cancers (Basel). 2018 Jul 31;10(8):252. doi: 10.3390/cancers10080252.
• [273] Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.J Thorac Oncol. 2017 Feb;12(2):249-257. doi: 10.1016/j.jtho.2016.09.136. Epub 2016 Oct 25.
• [274] Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis.Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8948-E8957. doi: 10.1073/pnas.1806219115. Epub 2018 Aug 29.
• [275] Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer.Cancer Res. 2015 Feb 1;75(3):566-75. doi: 10.1158/0008-5472.CAN-14-2101. Epub 2014 Dec 5.
• [276] Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma.Cancer Prev Res (Phila). 2016 Sep;9(9):739-49. doi: 10.1158/1940-6207.CAPR-16-0023. Epub 2016 Jun 23.
• [277] Mechanism of decorin protein inhibiting invasion and metastasis of non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1520-1527. doi: 10.26355/eurrev_201902_17110.
• [278] Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.Oncotarget. 2016 Jul 15;9(4):4395-4410. doi: 10.18632/oncotarget.10611. eCollection 2018 Jan 12.
• [279] Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer.Oncol Lett. 2019 Jul;18(1):219-226. doi: 10.3892/ol.2019.10310. Epub 2019 May 3.
• [280] A DRD1 polymorphism predisposes to lung cancer among those exposed to secondhand smoke during childhood.Cancer Prev Res (Phila). 2014 Dec;7(12):1210-8. doi: 10.1158/1940-6207.CAPR-14-0158. Epub 2014 Oct 3.
• [281] Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.Cancer Biol Ther. 2009 Sep;8(17):1671-9. doi: 10.4161/cbt.8.17.9322. Epub 2009 Sep 20.
• [282] Long non-coding RNA FLVCR1-AS1 contributes to the proliferation and invasion of lung cancer by sponging miR-573 to upregulate the expression of E2F transcription factor 3.Biochem Biophys Res Commun. 2018 Nov 2;505(3):931-938. doi: 10.1016/j.bbrc.2018.09.057. Epub 2018 Oct 9.
• [283] Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors.Haematologica. 2020 Jan;105(1):218-225. doi: 10.3324/haematol.2019.217083. Epub 2019 May 2.
• [284] Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer.Lung Cancer. 2015 Dec;90(3):516-21. doi: 10.1016/j.lungcan.2015.10.005. Epub 2015 Oct 9.
• [285] EGFR-AS1/HIF2A regulates the expression of FOXP3 to impact the cancer stemness of smoking-related non-small cell lung cancer.Ther Adv Med Oncol. 2019 Jun 13;11:1758835919855228. doi: 10.1177/1758835919855228. eCollection 2019.
• [286] Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.Appl Microbiol Biotechnol. 2018 Nov;102(22):9585-9594. doi: 10.1007/s00253-018-9291-z. Epub 2018 Aug 24.
• [287] EphB4: A promising target for upper aerodigestive malignancies.Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):128-137. doi: 10.1016/j.bbcan.2018.01.003. Epub 2018 Jan 31.
• [288] TGF upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.Oncotarget. 2016 Oct 4;7(40):65471-65484. doi: 10.18632/oncotarget.11472.
• [289] Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition.Biomed Res Int. 2015;2015:239764. doi: 10.1155/2015/239764. Epub 2015 Aug 3.
• [290] Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis.Am J Respir Crit Care Med. 2014 Sep 15;190(6):675-87. doi: 10.1164/rccm.201404-0714OC.
• [291] Diet-induced unresolved ER stress hinders KRAS-driven lung tumorigenesis.Cell Metab. 2015 Jan 6;21(1):117-25. doi: 10.1016/j.cmet.2014.11.020. Epub 2014 Dec 18.
• [292] High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.Mol Cancer Ther. 2016 Aug;15(8):1998-2008. doi: 10.1158/1535-7163.MCT-15-0950. Epub 2016 Jun 2.
• [293] FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.Am J Respir Cell Mol Biol. 2018 May;58(5):625-635. doi: 10.1165/rcmb.2017-0164OC.
• [294] Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis.Cancer Gene Ther. 2010 Jan;17(1):20-7. doi: 10.1038/cgt.2009.45.
• [295] Inferring therapeutic targets from heterogeneous data: HKDC1 is a novel potential therapeutic target for cancer.Bioinformatics. 2014 Mar 15;30(6):748-52. doi: 10.1093/bioinformatics/btt606. Epub 2013 Oct 24.
• [296] Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction.Clin Chem. 2020 Jan 1;66(1):178-187. doi: 10.1373/clinchem.2019.308833.
• [297] Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response.Clin Exp Pharmacol Physiol. 2014 Jun;41(6):408-15. doi: 10.1111/1440-1681.12232.
• [298] Patient derived xenografts (PDX) predict an effective heparanase-based therapy for lung cancer.Oncotarget. 2018 Apr 10;9(27):19294-19306. doi: 10.18632/oncotarget.25022. eCollection 2018 Apr 10.
• [299] Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review.Anticancer Agents Med Chem. 2018;18(7):964-984. doi: 10.2174/1871520618666171229185926.
• [300] HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.Int J Hyperthermia. 2017 May;33(3):303-317. doi: 10.1080/02656736.2016.1256503. Epub 2016 Dec 20.
• [301] Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.Mol Cancer Res. 2020 Jan;18(1):105-117. doi: 10.1158/1541-7786.MCR-19-0239. Epub 2019 Oct 18.
• [302] Inactivation of Stat3 and crosstalk of miRNA155-5p and FOXO3a contribute to the induction of IGFBP1 expression by beta-elemene in human lung cancer.Exp Mol Med. 2018 Sep 12;50(9):1-14. doi: 10.1038/s12276-018-0146-6.
• [303] Evidence that RASSF1C stimulation of lung cancer cell proliferation depends on IGFBP-5 and PIWIL1 expression levels.PLoS One. 2014 Jul 9;9(7):e101679. doi: 10.1371/journal.pone.0101679. eCollection 2014.
• [304] IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer.Cancers (Basel). 2019 Jan 2;11(1):36. doi: 10.3390/cancers11010036.
• [305] The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer.Anticancer Res. 2018 Nov;38(11):6321-6327. doi: 10.21873/anticanres.12989.
• [306] IL-13 receptor 2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.Oncotarget. 2015 Oct 20;6(32):32902-13. doi: 10.18632/oncotarget.5361.
• [307] Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients.Mol Carcinog. 2015 Jun;54 Suppl 1(0 1):E172-84. doi: 10.1002/mc.22275. Epub 2015 Jan 18.
• [308] Interleukin 7 receptor activates PI3K/Akt/mTOR signaling pathway via downregulation of Beclin-1 in lung cancer.Mol Carcinog. 2019 Mar;58(3):358-365. doi: 10.1002/mc.22933. Epub 2018 Dec 5.
• [309] Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer.Genet Mol Biol. 2019 Feb 25;42(1):15-25. doi: 10.1590/1678-4685-gmb-2017-0307. Print 2019 Jan-Mar.
• [310] Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.Tumour Biol. 2015 Jan;36(1):271-8. doi: 10.1007/s13277-014-2630-5. Epub 2014 Sep 23.
• [311] KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer.Biochem Biophys Res Commun. 2005 Apr 22;329(4):1260-6. doi: 10.1016/j.bbrc.2005.02.100.
• [312] LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway.Biomed Pharmacother. 2019 Jan;109:679-689. doi: 10.1016/j.biopha.2018.10.097. Epub 2018 Nov 5.
• [313] Galectin-3 activates TLR4/NF-B signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.BMC Cancer. 2018 May 22;18(1):580. doi: 10.1186/s12885-018-4461-z.
• [314] A new strategy for the diagnosis of MAGE-expressing cancers.J Immunol Methods. 2002 Aug 1;266(1-2):79-86. doi: 10.1016/s0022-1759(02)00105-9.
• [315] Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer.Mol Carcinog. 2018 Feb;57(2):216-224. doi: 10.1002/mc.22748. Epub 2017 Oct 31.
• [316] MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.Sci Rep. 2015 Jun 19;5:11471. doi: 10.1038/srep11471.
• [317] Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma.Ann Thorac Surg. 2018 Dec;106(6):1682-1690. doi: 10.1016/j.athoracsur.2018.06.058. Epub 2018 Aug 8.
• [318] Impact of metallothionein gene polymorphisms on the risk of lung cancer in a Japanese population.Mol Carcinog. 2015 Jun;54 Suppl 1:E122-8. doi: 10.1002/mc.22198. Epub 2014 Aug 30.
• [319] Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.Nat Commun. 2019 Nov 6;10(1):5043. doi: 10.1038/s41467-019-12925-9.
• [320] Natriuretic peptide receptor A as a novel target for cancer.World J Surg Oncol. 2014 Jun 3;12:174. doi: 10.1186/1477-7819-12-174.
• [321] The Role of the Tumor Microenvironment in Neuropilin 1-Induced Radiation Resistance in Lung Cancer Cells.J Cancer. 2019 Jul 8;10(17):4017-4030. doi: 10.7150/jca.28163. eCollection 2019.
• [322] The neuropilin 2 isoform NRP2b uniquely supports TGF-mediated progression in lung cancer.Sci Signal. 2017 Jan 17;10(462):eaag0528. doi: 10.1126/scisignal.aag0528.
• [323] PAK4 Phosphorylates Fumarase and Blocks TGF-Induced Cell Growth Arrest in Lung Cancer Cells.Cancer Res. 2019 Apr 1;79(7):1383-1397. doi: 10.1158/0008-5472.CAN-18-2575. Epub 2019 Jan 25.
• [324] Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D.Mol Cancer Ther. 2014 Oct;13(10):2463-73. doi: 10.1158/1535-7163.MCT-14-0297. Epub 2014 Aug 13.
• [325] Expression and Prognostic Impact of VEGF, CD31 and SMA in Resected Primary Lung Cancers.Anticancer Res. 2018 Jul;38(7):4057-4063. doi: 10.21873/anticanres.12695.
• [326] Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.Mol Cell Biochem. 2018 Feb;439(1-2):163-169. doi: 10.1007/s11010-017-3145-3. Epub 2017 Aug 31.
• [327] An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine.Sci Rep. 2016 Feb 26;6:22120. doi: 10.1038/srep22120.
• [328] Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.Lab Invest. 2016 Apr;96(4):391-8. doi: 10.1038/labinvest.2015.155. Epub 2016 Jan 11.
• [329] Comparison between effects of free curcumin and curcumin loaded NIPAAm-MAA nanoparticles on telomerase and PinX1 gene expression in lung cancer cells.Asian Pac J Cancer Prev. 2014;15(20):8931-6. doi: 10.7314/apjcp.2014.15.20.8931.
• [330] Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity.Sci Transl Med. 2019 Feb 6;11(478):eaau8866. doi: 10.1126/scitranslmed.aau8866.
• [331] Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.Int J Oncol. 2014 Sep;45(3):978-84. doi: 10.3892/ijo.2014.2486. Epub 2014 Jun 10.
• [332] PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.Cell Cycle. 2014;13(19):3132-42. doi: 10.4161/15384101.2014.949212.
• [333] Pre-clinical evaluation of cinobufotalin as a potential anti-lung cancer agent.Biochem Biophys Res Commun. 2014 Sep 26;452(3):768-74. doi: 10.1016/j.bbrc.2014.08.147. Epub 2014 Sep 6.
• [334] Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target.Cancer Biol Ther. 2014 Jan;15(1):128-34. doi: 10.4161/cbt.27146. Epub 2013 Nov 19.
• [335] HOIL-1L functions as the PKC ubiquitin ligase to promote lung tumor growth.Am J Respir Crit Care Med. 2014 Sep 15;190(6):688-98. doi: 10.1164/rccm.201403-0463OC.
• [336] Discovery of novel HSP90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells.Eur J Med Chem. 2018 Feb 10;145:551-558. doi: 10.1016/j.ejmech.2018.01.024. Epub 2018 Jan 10.
• [337] Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.Nat Commun. 2015 Jul 9;6:7679. doi: 10.1038/ncomms8679.
• [338] -Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer.Cell Death Differ. 2018 Aug;25(8):1473-1485. doi: 10.1038/s41418-017-0055-6. Epub 2018 Feb 2.
• [339] Development of a Novel AOP for Cyp2F2-Mediated Lung Cancer in Mice.Toxicol Sci. 2019 Nov 1;172(1):1-10. doi: 10.1093/toxsci/kfz185.
• [340] Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells.Tumour Biol. 2014 Jul;35(7):6557-65. doi: 10.1007/s13277-014-1879-z. Epub 2014 Apr 2.
• [341] MicroRNA-186 suppresses lung cancer progression by targeting SIRT6.Cancer Biomark. 2018 Feb 6;21(2):415-423. doi: 10.3233/CBM-170650.
• [342] Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer.Cancer Chemother Pharmacol. 2015 May;75(5):985-91. doi: 10.1007/s00280-015-2723-x. Epub 2015 Mar 14.
• [343] Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis.Cell Death Differ. 2020 Jun;27(6):1795-1806. doi: 10.1038/s41418-019-0459-6. Epub 2019 Nov 26.
• [344] Increased SPK1 expression promotes cell growth by activating the ERK1/2 signaling in non-small-cell lung cancer.Anticancer Drugs. 2019 Jun;30(5):458-465. doi: 10.1097/CAD.0000000000000733.
• [345] Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.Sci Signal. 2015 Jun 16;8(381):ra58. doi: 10.1126/scisignal.aaa4998.
• [346] YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC.
• [347] Increased stathmin correlates with advanced stage and poor survival of non-small cell lung cancer.Cancer Biomark. 2017;19(1):35-43. doi: 10.3233/CBM-160239.
• [348] Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis.Oncotarget. 2016 May 10;7(19):27584-98. doi: 10.18632/oncotarget.8488.
• [349] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.Oncogene. 2018 Jul;37(28):3894-3908. doi: 10.1038/s41388-018-0240-1. Epub 2018 Apr 17.
• [350] Risk factors for disseminated intravascular coagulation in patients with lung cancer.Thorac Cancer. 2018 Aug;9(8):931-938. doi: 10.1111/1759-7714.12766. Epub 2018 May 31.
• [351] MitochondrialDNAassociated TLR9 signalling is a potential serological biomarker for nonsmall cell lung cancer.Oncol Rep. 2019 Feb;41(2):999-1006. doi: 10.3892/or.2018.6855. Epub 2018 Nov 9.
• [352] Discovering novel lung cancer associated antigens and the utilization of their autoantibodies in detection of lung cancer.Immunobiology. 2020 Mar;225(2):151891. doi: 10.1016/j.imbio.2019.11.026. Epub 2019 Nov 27.
• [353] KAP1 inhibits the Raf-MEK-ERK pathway to promote tumorigenesis in A549 lung cancer cells.Mol Carcinog. 2018 Oct;57(10):1396-1407. doi: 10.1002/mc.22853. Epub 2018 Jun 22.
• [354] MicroRNA-124 regulates the radiosensitivity of non-small cell lung cancer cells by targeting TXNRD1.Oncol Lett. 2017 Apr;13(4):2071-2078. doi: 10.3892/ol.2017.5701. Epub 2017 Feb 8.
• [355] High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma.Med Sci Monit. 2018 Jul 16;24:4934-4943. doi: 10.12659/MSM.909235.
• [356] Tip60-siRNA regulates ABCE1 acetylation to suppress lung cancer growth via activation of the apoptotic signaling pathway.Exp Ther Med. 2019 Apr;17(4):3195-3202. doi: 10.3892/etm.2019.7302. Epub 2019 Feb 22.
• [357] ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. Sci Rep. 2014 Nov 4;4:6899.
• [358] Upregulation of COX-2 in the lung cancer promotes overexpression of multidrug resistance protein 4 (MRP4) via PGE2-dependent pathway.Eur J Pharm Sci. 2014 Oct 1;62:189-96. doi: 10.1016/j.ejps.2014.05.023. Epub 2014 Jun 5.
• [359] ABCG1 as a potential oncogene in lung cancer. Exp Ther Med. 2017 Jun;13(6):3189-3194.
• [360] Effect of inhibiting ACAT-1 expression on the growth and metastasis of Lewis lung carcinoma.Oncol Lett. 2019 Aug;18(2):1548-1556. doi: 10.3892/ol.2019.10427. Epub 2019 May 31.
• [361] Interaction of tobacco smoking and chewing with Angiotensin converting enzyme (insertion/deletion) gene polymorphisms and risk of lung cancer in a high risk area from northeast India.Asian Pac J Cancer Prev. 2014;15(24):10691-5. doi: 10.7314/apjcp.2014.15.24.10691.
• [362] Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression.Genes Dev. 2016 Sep 1;30(17):1956-70. doi: 10.1101/gad.283283.116.
• [363] Lung Cancer Screening in the National Cancer Institute Community Oncology Research Program: Availability and Service Organization.J Am Coll Radiol. 2019 Apr;16(4 Pt A):427-434. doi: 10.1016/j.jacr.2018.12.016. Epub 2019 Feb 26.
• [364] Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.Lung Cancer. 2019 Jul;133:4-9. doi: 10.1016/j.lungcan.2019.04.022. Epub 2019 Apr 27.
• [365] ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.EMBO Mol Med. 2019 Apr;11(4):e9976. doi: 10.15252/emmm.201809976.
• [366] Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer.Oncogene. 2010 Jul 1;29(26):3758-69. doi: 10.1038/onc.2010.130. Epub 2010 May 10.
• [367] Complement Activation via a C3a Receptor Pathway Alters CD4(+) T Lymphocytes and Mediates Lung Cancer Progression.Cancer Res. 2018 Jan 1;78(1):143-156. doi: 10.1158/0008-5472.CAN-17-0240. Epub 2017 Nov 8.
• [368] Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer.Tumour Biol. 2016 Jul;37(7):8681-9. doi: 10.1007/s13277-015-4573-x. Epub 2016 Jan 6.
• [369] A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer.J Cancer. 2019 Nov 1;10(27):6848-6857. doi: 10.7150/jca.36614. eCollection 2019.
• [370] VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: a study in biopsy specimens.Peptides. 2003 Mar;24(3):429-36. doi: 10.1016/s0196-9781(03)00058-5.
• [371] Protease-activated receptor 2 induces migration and promotes Slug-mediated epithelial-mesenchymal transition in lung adenocarcinoma cells.Biochim Biophys Acta Mol Cell Res. 2019 Mar;1866(3):486-503. doi: 10.1016/j.bbamcr.2018.10.011. Epub 2018 Oct 13.
• [372] Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study.Cancer Lett. 2019 May 1;449:125-134. doi: 10.1016/j.canlet.2019.01.025. Epub 2019 Jan 25.
• [373] Combined Local Pulmonary and Systemic Delivery of AT2R Gene by Modified TAT Peptide Nanoparticles Attenuates Both Murine and Human Lung Carcinoma Xenografts in Mice.J Pharm Sci. 2017 Jan;106(1):385-394. doi: 10.1016/j.xphs.2016.08.023. Epub 2016 Oct 18.
• [374] Lower rates of cancer and all-cause mortality in an Adventist cohort compared with a US Census population.Cancer. 2020 Mar 1;126(5):1102-1111. doi: 10.1002/cncr.32571. Epub 2019 Nov 25.
• [375] The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer.Cancer Res. 2018 Dec 15;78(24):6728-6735. doi: 10.1158/0008-5472.CAN-17-3370. Epub 2018 Oct 17.
• [376] Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development.Nat Chem Biol. 2020 Jan;16(1):31-41. doi: 10.1038/s41589-019-0415-2. Epub 2019 Dec 2.
• [377] Establishment of a Strong Link Between Smoking and Cancer Pathogenesis through DNA Methylation Analysis.Sci Rep. 2017 May 12;7(1):1811. doi: 10.1038/s41598-017-01856-4.
• [378] Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China.Environ Mol Mutagen. 2009 May;50(4):285-90. doi: 10.1002/em.20452.
• [379] Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion.Cancer Prev Res (Phila). 2011 Dec;4(12):1961-72. doi: 10.1158/1940-6207.CAPR-10-0280. Epub 2011 Aug 31.
• [380] Association of cooking oil fumes exposure with lung cancer: involvement of inhibitor of apoptosis proteins in cell survival and proliferation in vitro.Mutat Res. 2007 Apr 2;628(2):107-16. doi: 10.1016/j.mrgentox.2006.12.005. Epub 2006 Dec 22.
• [381] Amylase mRNA transcripts in normal tissues and neoplasms: the implication of different expressions of amylase isogenes.J Cancer Res Clin Oncol. 1994;120(4):213-20. doi: 10.1007/BF01372559.
• [382] Sex-specific SNP-SNP interaction analyses within topologically associated domains reveals ANGPT1 as a novel tumor suppressor gene for lung cancer.Genes Chromosomes Cancer. 2020 Jan;59(1):13-22. doi: 10.1002/gcc.22793. Epub 2019 Aug 10.
• [383] ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway.Lung. 2016 Aug;194(4):637-46. doi: 10.1007/s00408-016-9895-y. Epub 2016 May 11.
• [384] ANK1 Methylation regulates expression of MicroRNA-486-5p and discriminates lung tumors by histology and smoking status.Cancer Lett. 2017 Dec 1;410:191-200. doi: 10.1016/j.canlet.2017.09.038. Epub 2017 Sep 29.
• [385] TMEM16A as a Potential Biomarker in the Diagnosis and Prognosis of Lung Cancer.Arch Iran Med. 2019 Jan 1;22(1):32-38.
• [386] Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10.Cancers (Basel). 2019 May 2;11(5):618. doi: 10.3390/cancers11050618.
• [387] Modulation of Vascular Endothelial Growth Factor and Annexin A2 in Response to 4-(Methylnitrosamino)-1-(3-pyridyl)-1-Butanone -Induced Inflammation via Swimming Training.Iran J Allergy Asthma Immunol. 2018 Oct 7;17(5):418-427.
• [388] Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest.Respir Res. 2018 May 21;19(1):96. doi: 10.1186/s12931-018-0804-1.
• [389] Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients.Biochim Biophys Acta. 2012 Apr;1824(4):692-700. doi: 10.1016/j.bbapap.2012.01.016. Epub 2012 Feb 2.
• [390] Expression in lung cancer of a transcribed sequence at the DNF15S2 locus at chromosome 3P21.Anticancer Res. 1990 Jan-Feb;10(1):23-7.
• [391] MicroRNA-195 suppresses the progression of lung adenocarcinoma by directly targeting apelin.Thorac Cancer. 2019 Jun;10(6):1419-1430. doi: 10.1111/1759-7714.13087. Epub 2019 May 9.
• [392] Protective potential of miR-146a-5p and its underlying molecular mechanism in diverse cancers: a comprehensive meta-analysis and bioinformatics analysis.Cancer Cell Int. 2019 Jun 24;19:167. doi: 10.1186/s12935-019-0886-y. eCollection 2019.
• [393] Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.Br J Cancer. 2018 Aug;119(5):580-590. doi: 10.1038/s41416-018-0200-0. Epub 2018 Aug 6.
• [394] DDEFL1 correlated with Rho GTPases activity in breast cancer.Oncotarget. 2017 Oct 26;8(68):112487-112497. doi: 10.18632/oncotarget.22095. eCollection 2017 Dec 22.
• [395] Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers.Oncogene. 2010 Sep 16;29(37):5171-81. doi: 10.1038/onc.2010.259. Epub 2010 Jun 28.
• [396] Alpha-tubulin acetyltransferase/MEC-17 regulates cancer cell migration and invasion through epithelial-mesenchymal transition suppression and cell ... Sci Rep. 2018 Nov 30;8(1):17477.
• [397] NDRG1 Downregulates ATF3 and Inhibits Cisplatin-Induced Cytotoxicity in Lung Cancer A549 Cells.Int J Med Sci. 2018 Oct 20;15(13):1502-1507. doi: 10.7150/ijms.28055. eCollection 2018.
• [398] The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung Cancer.Dis Markers. 2018 Sep 16;2018:5068701. doi: 10.1155/2018/5068701. eCollection 2018.
• [399] Alterations in the ATP2A2 gene in correlation with colon and lung cancer.Cancer Genet Cytogenet. 2006 Dec;171(2):105-11. doi: 10.1016/j.cancergencyto.2006.06.016.
• [400] Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study.Cancer Manag Res. 2019 Sep 19;11:8539-8546. doi: 10.2147/CMAR.S222278. eCollection 2019.
• [401] The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour Biol. 2014 Aug;35(8):8259-65.
• [402] Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers.Int J Cancer. 1996 Mar 15;65(6):734-9. doi: 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#.
• [403] Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.PLoS One. 2018 Aug 16;13(8):e0202360. doi: 10.1371/journal.pone.0202360. eCollection 2018.
• [404] AZGP1 mRNA levels in normal human lung tissue correlate with lung cancer disease status.Oncogene. 2008 Mar 6;27(11):1650-6. doi: 10.1038/sj.onc.1210775. Epub 2007 Aug 27.
• [405] The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.Thorac Cancer. 2019 Sep;10(9):1770-1778. doi: 10.1111/1759-7714.13139. Epub 2019 Jul 18.
• [406] BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis.Cell. 2019 Jul 11;178(2):330-345.e22. doi: 10.1016/j.cell.2019.06.005. Epub 2019 Jun 27.
• [407] Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells.Clin Cancer Res. 2000 Mar;6(3):887-90.
• [408] Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.Virchows Arch. 2019 Jan;474(1):29-37. doi: 10.1007/s00428-018-2478-y. Epub 2018 Oct 30.
• [409] Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors.Cell Rep. 2019 Jul 9;28(2):512-525.e6. doi: 10.1016/j.celrep.2019.06.026.
• [410] Mendelian randomization study of telomere length and lung cancer risk in East Asian population.Cancer Med. 2019 Dec;8(17):7469-7476. doi: 10.1002/cam4.2590. Epub 2019 Oct 11.
• [411] A common genetic variant (97906C>A) of DAB2IP/AIP1 is associated with an increased risk and early onset of lung cancer in Chinese males.PLoS One. 2011;6(10):e26944. doi: 10.1371/journal.pone.0026944. Epub 2011 Oct 26.
• [412] CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer.J Cell Mol Med. 2020 Jan;24(1):618-631. doi: 10.1111/jcmm.14771. Epub 2019 Nov 13.
• [413] Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function.Am J Respir Crit Care Med. 2019 Aug 1;200(3):348-358. doi: 10.1164/rccm.201801-0080OC.
• [414] Silencing BMP-2 expression inhibits A549 and H460 cell proliferation and migration.Diagn Pathol. 2014 Jun 19;9:123. doi: 10.1186/1746-1596-9-123.
• [415] Expression of bone morphogenetic protein 6 in non-small cell lung cancer and its significance.Oncol Lett. 2019 Feb;17(2):1946-1952. doi: 10.3892/ol.2018.9781. Epub 2018 Nov 30.
• [416] ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.Mol Cancer Ther. 2020 Feb;19(2):325-336. doi: 10.1158/1535-7163.MCT-19-0183. Epub 2019 Nov 19.
• [417] Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.RNA. 2008 May;14(5):844-52. doi: 10.1261/rna.939908. Epub 2008 Mar 28.
• [418] The Role of Bromodomain Testis-Specific Factor, BRDT, in Cancer: A Biomarker and A Possible Therapeutic Target.Cell J. 2017 Spring;19(Suppl 1):1-8. doi: 10.22074/cellj.2017.5060. Epub 2017 May 17.
• [419] Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma.Pathol Int. 2018 Apr;68(4):232-240. doi: 10.1111/pin.12646. Epub 2018 Feb 12.
• [420] Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176. doi: 10.1164/rccm.201703-0660OC.
• [421] Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.Molecules. 2019 Sep 19;24(18):3409. doi: 10.3390/molecules24183409.
• [422] Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.Clin Cancer Res. 2005 Nov 15;11(22):8201-7. doi: 10.1158/1078-0432.CCR-05-0816.
• [423] JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.Gastroenterology. 2018 Apr;154(5):1480-1493. doi: 10.1053/j.gastro.2017.12.004. Epub 2017 Dec 14.
• [424] Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas.Oncogene. 2004 Jul 29;23(34):5719-28. doi: 10.1038/sj.onc.1207760.
• [425] Correction to: Toward clinically usable CAD for lung cancer screening with computed tomography.Eur Radiol. 2020 Mar;30(3):1822. doi: 10.1007/s00330-019-06512-1.
• [426] Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease : Effects of modern radiotherapy techniques.Strahlenther Onkol. 2018 Mar;194(3):196-205. doi: 10.1007/s00066-017-1213-y. Epub 2017 Sep 15.
• [427] Association of calcium/calmodulin-dependent protein kinase kinase1 rs7214723 polymorphism with lung cancer risk in a Chinese population.Biosci Rep. 2017 Aug 31;37(4):BSR20170762. doi: 10.1042/BSR20170762. Epub 2017 Jul 24.
• [428] Comparative Molecular Immunological Activity of Physiological Metal Oxide Nanoparticle and its Anticancer Peptide and RNA Complexes.Nanomaterials (Basel). 2019 Nov 22;9(12):1670. doi: 10.3390/nano9121670.
• [429] A literature-based systematic HuGE review and meta-analysis show that CASP gene family polymorphisms are associated with risk of lung cancer.Genet Mol Res. 2013 Jan 4;12(3):3057-69. doi: 10.4238/2013.January.4.22.
• [430] MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7.Oncotarget. 2015 Sep 8;6(26):21802-15. doi: 10.18632/oncotarget.5224.
• [431] Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.Immunology. 2014 Feb;141(2):242-55. doi: 10.1111/imm.12190.
• [432] Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma.Int J Mol Sci. 2019 Mar 5;20(5):1125. doi: 10.3390/ijms20051125.
• [433] CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.PLoS One. 2010 Jan 29;5(1):e8972. doi: 10.1371/journal.pone.0008972.
• [434] Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina.Toxicol Appl Pharmacol. 2010 Sep 1;247(2):138-45. doi: 10.1016/j.taap.2010.06.006. Epub 2010 Jun 17.
• [435] miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression.Onco Targets Ther. 2018 Dec 7;11:8865-8874. doi: 10.2147/OTT.S181433. eCollection 2018.
• [436] Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion.Cancer Lett. 2019 Jun 28;452:244-253. doi: 10.1016/j.canlet.2019.03.040. Epub 2019 Mar 27.
• [437] Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer.Exp Ther Med. 2018 Aug;16(2):730-738. doi: 10.3892/etm.2018.6274. Epub 2018 Jun 8.
• [438] A functional single nucleotide polymorphism at the promoter region of cyclin A2 is associated with increased risk of colon, liver, and lung cancers.Cancer. 2011 Sep 1;117(17):4080-91. doi: 10.1002/cncr.25930. Epub 2011 Feb 24.
• [439] High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.Lung Cancer. 2011 Dec;74(3):384-91. doi: 10.1016/j.lungcan.2011.04.004. Epub 2011 May 8.
• [440] CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF- pathway in human non-small cell lung cancer.Biochem Biophys Res Commun. 2017 Jun 17;488(1):196-203. doi: 10.1016/j.bbrc.2017.05.034. Epub 2017 May 6.
• [441] Expression of the chemokine receptor CCR6 correlates with a favorable prognosis in patients with adenocarcinoma of the lung.Tumour Biol. 2011 Feb;32(1):197-202. doi: 10.1007/s13277-010-0113-x. Epub 2010 Sep 25.
• [442] [Corrigendum] Neutrophils in cancer development and progression: Roles, mechanisms, and implications (Review).Int J Oncol. 2017 Feb;50(2):745. doi: 10.3892/ijo.2016.3764. Epub 2016 Nov 9.
• [443] Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.Cancer Res. 2001 Nov 1;61(21):7943-9.
• [444] A reevaluation of CD22 expression in human lung cancer.Cancer Res. 2014 Jan 1;74(1):263-71. doi: 10.1158/0008-5472.CAN-13-1436.
• [445] Downregulation of CD24 suppresses bone metastasis of lung cancer.Cancer Sci. 2018 Jan;109(1):112-120. doi: 10.1111/cas.13435. Epub 2017 Nov 29.
• [446] Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors.J Clin Med. 2019 Nov 14;8(11):1980. doi: 10.3390/jcm8111980.
• [447] A common CD55 rs2564978 variant is associated with the susceptibility of non-small cell lung cancer.Oncotarget. 2017 Jan 24;8(4):6216-6221. doi: 10.18632/oncotarget.14053.
• [448] Inhibition of human lung adenocarcinoma growth and metastasis by JC polyomavirus-like particles packaged with an SP-B promoter-driven CD59-specific shRNA.Clin Sci (Lond). 2019 Nov 15;133(21):2159-2169. doi: 10.1042/CS20190395.
• [449] Unfavorable clinical implications of peripheral blood CD44+ and CD54+ lymphocytes in patients with lung cancer undergoing chemotherapy.Int J Biol Markers. 2018 May;33(2):208-214. doi: 10.5301/ijbm.5000309. Epub 2017 Nov 15.
• [450] Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26.
• [451] Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.Cancer Res. 2016 Feb 15;76(4):974-83. doi: 10.1158/0008-5472.CAN-15-2135. Epub 2016 Feb 2.
• [452] Replication-deficient adenovirus-mediated transfer of B7-1 (CD80) cDNA induces anti-tumour immunity in isolated human lung cancer.Respirology. 2001 Jun;6(2):135-44. doi: 10.1046/j.1440-1843.2001.00322.x.
• [453] A cycle involving HMGB1, IFN- and dendritic cells plays a putative role in anti-tumor immunity.Cell Immunol. 2019 Sep;343:103850. doi: 10.1016/j.cellimm.2018.08.011. Epub 2018 Aug 20.
• [454] Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model.Cancer Res. 2007 Feb 15;67(4):1744-9. doi: 10.1158/0008-5472.CAN-06-3090.
• [455] A genome-wide comprehensive analysis of alterations in driver genes in non-small-cell lung cancer.Anticancer Drugs. 2018 Jan;29(1):10-18. doi: 10.1097/CAD.0000000000000571.
• [456] YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.Oncotarget. 2016 Dec 13;7(50):82139-82157. doi: 10.18632/oncotarget.10080.
• [457] The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells.Cancer Res. 2003 Feb 15;63(4):771-5.
• [458] Involvement of cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation.Asian Pac J Cancer Prev. 2013;14(10):5725-30. doi: 10.7314/apjcp.2013.14.10.5725.
• [459] Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis.Cancer Res. 2007 May 1;67(9):4113-22. doi: 10.1158/0008-5472.CAN-06-4705.
• [460] Adducins inhibit lung cancer cell migration through mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression.Biochim Biophys Acta Mol Cell Res. 2019 Mar;1866(3):395-408. doi: 10.1016/j.bbamcr.2018.10.001. Epub 2018 Oct 2.
• [461] Expression of KIAA1456 in lung cancer tissue and its effects on proliferation, migration and invasion of lung cancer cells.Oncol Lett. 2018 Sep;16(3):3791-3795. doi: 10.3892/ol.2018.9119. Epub 2018 Jul 10.
• [462] Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells.PLoS One. 2016 Jun 30;11(6):e0158395. doi: 10.1371/journal.pone.0158395. eCollection 2016.
• [463] Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway.Cell Death Dis. 2019 Apr 1;10(4):297. doi: 10.1038/s41419-019-1528-y.
• [464] HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis.Biotechnol Lett. 2018 Apr;40(4):623-631. doi: 10.1007/s10529-018-2512-9. Epub 2018 Jan 17.
• [465] Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway.Mol Biol Cell. 2012 Aug;23(15):2856-66. doi: 10.1091/mbc.E10-12-1010. Epub 2012 Jun 13.
• [466] ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors.Cancer Res. 2018 Feb 15;78(4):1044-1057. doi: 10.1158/0008-5472.CAN-17-1904. Epub 2017 Dec 19.
• [467] Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells.Oncotarget. 2017 Mar 21;8(12):19172-19191. doi: 10.18632/oncotarget.13432.
• [468] Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysis.Int J Biol Sci. 2011 Apr 28;7(5):551-66. doi: 10.7150/ijbs.7.551.
• [469] Therapeutic Effect of pHLIP-mediated CEACAM6 Gene Silencing in Lung Adenocarcinoma.Sci Rep. 2019 Sep 2;9(1):11607. doi: 10.1038/s41598-019-48104-5.
• [470] Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP expression.Sci Transl Med. 2016 Aug 3;8(350):350ra104. doi: 10.1126/scitranslmed.aad6066.
• [471] A comparison of transcriptomic and metabonomic technologies for identifying biomarkers predictive of two-year rodent cancer bioassays.Toxicol Sci. 2007 Mar;96(1):40-6. doi: 10.1093/toxsci/kfl171. Epub 2006 Nov 17.
• [472] Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.Mol Cancer Ther. 2019 Oct;18(10):1775-1786. doi: 10.1158/1535-7163.MCT-18-0864. Epub 2019 Jul 29.
• [473] Single nucleotide polymorphisms, haplotype association and tumour expression of the vascular endothelial growth factor (VEGF) gene with lung carcinoma.Gene. 2017 Apr 15;608:95-102. doi: 10.1016/j.gene.2017.01.007. Epub 2017 Jan 23.
• [474] Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma.J Thorac Oncol. 2017 Nov;12(11):1673-1678. doi: 10.1016/j.jtho.2017.08.011. Epub 2017 Aug 24.
• [475] Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway.Cell Death Dis. 2017 Feb 23;8(2):e2621. doi: 10.1038/cddis.2017.50.
• [476] Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans.Oncotarget. 2012 Nov;3(11):1428-38. doi: 10.18632/oncotarget.746.
• [477] Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.Nat Genet. 2017 Jul;49(7):1126-1132. doi: 10.1038/ng.3892. Epub 2017 Jun 12.
• [478] Association Between Nicotine-dependent Gene Polymorphism and Smoking Cessation in Patients With Lung Cancer.Clin Lung Cancer. 2020 Mar;21(2):171-176. doi: 10.1016/j.cllc.2019.07.002. Epub 2019 Jul 17.
• [479] Naturally occurring variants of human 9 nicotinic receptor differentially affect bronchial cell proliferation and transformation.PLoS One. 2011;6(11):e27978. doi: 10.1371/journal.pone.0027978. Epub 2011 Nov 18.
• [480] Study on polymorphisms in CHRNA5/CHRNA3/CHRNB4 gene cluster and the associated with the risk of non-small cell lung cancer.Oncotarget. 2017 Dec 20;9(2):2435-2444. doi: 10.18632/oncotarget.23459. eCollection 2018 Jan 5.
• [481] Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.Oncotarget. 2017 Mar 21;8(12):18885-18900. doi: 10.18632/oncotarget.13806.
• [482] Role of TGF--induced Claudin-4 expression through c-Jun signaling in non-small cell lung cancer.Cell Signal. 2016 Oct;28(10):1537-44. doi: 10.1016/j.cellsig.2016.07.006. Epub 2016 Jul 15.
• [483] 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) enhances invasiveness of lung cancer cells by up-regulating contactin-1 via the alpha7 nicotinic acetylcholine receptor/ERK signaling pathway. Chem Biol Interact. 2009 May 15;179(2-3):154-9. doi: 10.1016/j.cbi.2008.10.042. Epub 2008 Nov 5.
• [484] COL6A3 polymorphisms were associated with lung cancer risk in a Chinese population.Respir Res. 2019 Jul 8;20(1):143. doi: 10.1186/s12931-019-1114-y.
• [485] COP9 signalosome subunit CSN5, but not CSN6, is upregulated in lung adenocarcinoma and predicts poor prognosis.J Thorac Dis. 2018 Mar;10(3):1596-1606. doi: 10.21037/jtd.2018.02.09.
• [486] Knockdown of copper chaperone antioxidant-1 by RNA interference inhibits copper-stimulated proliferation of non-small cell lung carcinoma cells.Oncol Rep. 2013 Jul;30(1):269-75. doi: 10.3892/or.2013.2436. Epub 2013 Apr 29.
• [487] Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.Am J Hematol. 2004 Jul;76(3):214-9. doi: 10.1002/ajh.20079.
• [488] Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.J Natl Cancer Inst. 2014 Dec 1;107(1):358. doi: 10.1093/jnci/dju358. Print 2015 Jan.
• [489] CRTC2 promotes non-small cell lung cancer A549 migration and invasion in vitro.Thorac Cancer. 2018 Jan;9(1):136-141. doi: 10.1111/1759-7714.12550. Epub 2017 Nov 3.
• [490] Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies.BMC Med. 2018 Feb 19;16(1):20. doi: 10.1186/s12916-018-1010-1.
• [491] A rule-based expert system for the automatic classification of DNA "ploidy" histograms measured by the CAS 200 image analysis system.Cytometry. 1997 Feb 15;30(1):39-46. doi: 10.1002/(sici)1097-0320(19970215)30:1<39::aid-cyto6>3.0.co;2-a.
• [492] Tomorrow's genome medicine in lung cancer.Semin Cancer Biol. 2017 Feb;42:39-43. doi: 10.1016/j.semcancer.2016.11.003. Epub 2016 Nov 10.
• [493] The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.Mol Cancer. 2018 Feb 19;17(1):24. doi: 10.1186/s12943-018-0784-2.
• [494] Cathepsin D messenger RNA is downregulated in human lung cancer.Biomarkers. 2010 Nov;15(7):608-13. doi: 10.3109/1354750X.2010.504310. Epub 2010 Aug 19.
• [495] Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer.Cancer Res. 2006 Aug 15;66(16):7968-75. doi: 10.1158/0008-5472.CAN-05-4279.
• [496] Cathepsin L-mediated resistance of paclitaxel and cisplatin is mediated by distinct regulatory mechanisms. J Exp Clin Cancer Res. 2019 Aug 1;38(1):333. doi: 10.1186/s13046-019-1299-4.
• [497] Cathepsin-S degraded decorin are elevated in fibrotic lung disorders - development and biological validation of a new serum biomarker.BMC Pulm Med. 2017 Aug 9;17(1):110. doi: 10.1186/s12890-017-0455-x.
• [498] A water soluble vitamin B12-ReI fluorescent conjugate for cell uptake screens: use in the confirmation of cubilin in the lung cancer line A549.Chem Commun (Camb). 2011 Sep 21;47(35):9792-4. doi: 10.1039/c1cc13615a. Epub 2011 Aug 5.
• [499] CX3CL1 promotes lung cancer cell migration and invasion via the Src/focal adhesion kinase signaling pathway.Oncol Rep. 2019 Mar;41(3):1911-1917. doi: 10.3892/or.2019.6957. Epub 2019 Jan 9.
• [500] Cancer-cell-secreted CXCL11 promoted CD8(+) T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC.J Immunother Cancer. 2019 Feb 11;7(1):42. doi: 10.1186/s40425-019-0511-6.
• [501] Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.Cancer Sci. 2018 Jan;109(1):154-165. doi: 10.1111/cas.13422. Epub 2017 Nov 9.
• [502] The accessory proteins REEP5 and REEP6 refine CXCR1-mediated cellular responses and lung cancer progression.Sci Rep. 2016 Dec 14;6:39041. doi: 10.1038/srep39041.
• [503] The expression and significance of tumor associated macrophages and CXCR4 in non-small cell lung cancer.J BUON. 2018 Mar-Apr;23(2):398-402.
• [504] Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer.Mol Cancer Ther. 2017 Oct;16(10):2144-2156. doi: 10.1158/1535-7163.MCT-16-0915. Epub 2017 May 23.
• [505] Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population.Tumour Biol. 2014 Jun;35(6):5295-8. doi: 10.1007/s13277-014-1689-3. Epub 2014 Feb 9.
• [506] Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.Cancer Res. 2016 Mar 15;76(6):1485-1493. doi: 10.1158/0008-5472.CAN-15-1410.
• [507] Exosomes and cells from lung cancer pleural exudates transform LTC4 to LTD4, promoting cell migration and survival via CysLT1.Cancer Lett. 2019 Mar 1;444:1-8. doi: 10.1016/j.canlet.2018.11.033. Epub 2018 Dec 1.
• [508] Cytohesin-2 as a novel prognostic marker for hepatocellular carcinoma.Oncol Rep. 2013 Jun;29(6):2211-8. doi: 10.3892/or.2013.2366. Epub 2013 Mar 26.
• [509] Bone metastasis target redox-responsive micell for the treatment of lung cancer bone metastasis and anti-bone resorption.Artif Cells Nanomed Biotechnol. 2018;46(sup1):380-391. doi: 10.1080/21691401.2018.1426007. Epub 2018 Jan 16.
• [510] Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):237-44. doi: 10.1016/s0360-3016(02)02891-2.
• [511] Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.Clin Transl Oncol. 2016 Apr;18(4):398-404. doi: 10.1007/s12094-015-1382-z. Epub 2015 Aug 27.
• [512] Induction of HSP27 and HSP70 by constitutive overexpression of Redd1 confers resistance of lung cancer cells to ionizing radiation.Oncol Rep. 2019 May;41(5):3119-3126. doi: 10.3892/or.2019.7036. Epub 2019 Feb 28.
• [513] MiR-431 suppresses proliferation and metastasis of lung cancer via down-regulating DDX5.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):699-707. doi: 10.26355/eurrev_201901_16883.
• [514] Oncogene DEK is highly expressed in lung cancerous tissues and positively regulates cell proliferation as well as invasion.Oncol Lett. 2018 Jun;15(6):8573-8581. doi: 10.3892/ol.2018.8436. Epub 2018 Apr 5.
• [515] Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI.PLoS One. 2011 Jan 20;6(1):e16062. doi: 10.1371/journal.pone.0016062.
• [516] Knockdown of second mitochondria-derived activator of caspase expression by RNAi enhances growth and cisplatin resistance of human lung cancer cells.Cancer Biother Radiopharm. 2010 Dec;25(6):705-12. doi: 10.1089/cbr.2010.0786.
• [517] Association of polymorphisms in Dickopff (DKK) gene towards modulating risk for lung cancer in north Indians.Future Oncol. 2017 Feb;13(3):213-232. doi: 10.2217/fon-2016-0117. Epub 2016 Sep 19.
• [518] DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.Oncol Res. 2018 Jan 19;26(1):45-58. doi: 10.3727/096504017X14926874596386. Epub 2017 May 4.
• [519] Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.BMC Cancer. 2018 Jul 13;18(1):739. doi: 10.1186/s12885-018-4659-0.
• [520] Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation.Oncotarget. 2017 Jun 30;8(47):82123-82143. doi: 10.18632/oncotarget.18899. eCollection 2017 Oct 10.
• [521] Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci.Carcinogenesis. 2019 May 14;40(3):432-440. doi: 10.1093/carcin/bgy187.
• [522] MicroRNA-30a-3p inhibits the progression of lung cancer via the PI3K/AKT by targeting DNA methyltransferase 3a.Onco Targets Ther. 2019 Aug 28;12:7015-7024. doi: 10.2147/OTT.S213583. eCollection 2019.
• [523] Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation.J Biol Chem. 2012 Feb 17;287(8):5588-99. doi: 10.1074/jbc.M111.328138. Epub 2011 Dec 21.
• [524] The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.Carcinogenesis. 2019 Apr 29;40(2):324-334. doi: 10.1093/carcin/bgz009.
• [525] Collapsin response mediator protein 2 is involved in regulating breast cancer progression.Breast Cancer. 2014 Nov;21(6):715-23. doi: 10.1007/s12282-013-0447-5. Epub 2013 Feb 5.
• [526] The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung.Am J Pathol. 2009 May;174(5):1629-37. doi: 10.2353/ajpath.2009.080778. Epub 2009 Mar 26.
• [527] Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.Sci Rep. 2017 Dec 13;7(1):17530. doi: 10.1038/s41598-017-17836-7.
• [528] DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.Clin Cancer Res. 2015 Jan 15;21(2):428-38. doi: 10.1158/1078-0432.CCR-14-1150.
• [529] Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.Biochem Biophys Res Commun. 2009 Dec 18;390(3):849-54. doi: 10.1016/j.bbrc.2009.10.061. Epub 2009 Oct 20.
• [530] A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity.Biochim Biophys Acta. 2008 Jan;1782(1):41-50. doi: 10.1016/j.bbadis.2007.11.004. Epub 2007 Nov 22.
• [531] DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.J Cell Mol Med. 2019 Nov;23(11):7427-7437. doi: 10.1111/jcmm.14609. Epub 2019 Aug 27.
• [532] miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer.Cell Death Dis. 2017 Oct 26;8(10):e3141. doi: 10.1038/cddis.2017.544.
• [533] Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.Cancer Immunol Res. 2015 Aug;3(8):855-63. doi: 10.1158/2326-6066.CIR-15-0024. Epub 2015 May 26.
• [534] A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer.Cancer Res. 2004 Jun 15;64(12):4137-47. doi: 10.1158/0008-5472.CAN-03-4052.
• [535] Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium.Am J Respir Cell Mol Biol. 2000 Apr;22(4):422-31. doi: 10.1165/ajrcmb.22.4.3795.
• [536] Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancer.Int J Oncol. 2009 Feb;34(2):465-71.
• [537] Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer.BMC Cancer. 2019 Aug 9;19(1):791. doi: 10.1186/s12885-019-6014-5.
• [538] H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.Cancer Res. 2010 Oct 15;70(20):7830-40. doi: 10.1158/0008-5472.CAN-10-0833. Epub 2010 Oct 12.
• [539] EIF5A2 is a novel chemoresistance gene in breast cancer.Breast Cancer. 2015 Nov;22(6):602-7. doi: 10.1007/s12282-014-0526-2. Epub 2014 Mar 18.
• [540] Immune response evoked by tumor-associated NADH oxidase (tNOX) confers potential inhibitory effect on lung carcinoma in a mouse model.Am J Cancer Res. 2019 Apr 1;9(4):740-751. eCollection 2019.
• [541] Dysregulated ENPP1 increases the malignancy of human lung cancer by inducing epithelial-mesenchymal transition phenotypes and stem cell features.Am J Cancer Res. 2019 Jan 1;9(1):134-144. eCollection 2019.
• [542] Coagulation factor IV is an indicator of symptomatic pulmonary embolism in patients with primary lung cancer.Clin Respir J. 2020 Feb;14(2):124-131. doi: 10.1111/crj.13109. Epub 2019 Dec 9.
• [543] Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.Mol Cancer Ther. 2012 Sep;11(9):2021-32. doi: 10.1158/1535-7163.MCT-12-0030. Epub 2012 Jul 17.
• [544] Functional genomics lead to new therapies in follicular lymphoma.Ann N Y Acad Sci. 2013 Jul;1293:18-24. doi: 10.1111/nyas.12120. Epub 2013 May 15.
• [545] The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.Clin Cancer Res. 2010 Apr 15;16(8):2275-83. doi: 10.1158/1078-0432.CCR-09-2000. Epub 2010 Apr 6.
• [546] Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls.Hum Genet. 2013 May;132(5):579-89. doi: 10.1007/s00439-013-1270-y. Epub 2013 Feb 1.
• [547] EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.Cancer Res. 2010 Nov 1;70(21):8822-31. doi: 10.1158/0008-5472.CAN-10-0638. Epub 2010 Oct 26.
• [548] ERR is an aggressive factor in lung adenocarcinoma indicating poor prognostic outcomes.Cancer Manag Res. 2019 Sep 2;11:8111-8123. doi: 10.2147/CMAR.S204732. eCollection 2019.
• [549] Epidermal growth factor activates telomerase activity by direct binding of Ets-2 to hTERT promoter in lung cancer cells.Tumour Biol. 2015 Jul;36(7):5389-98. doi: 10.1007/s13277-015-3204-x. Epub 2015 Feb 14.
• [550] Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.Mol Cancer Ther. 2019 Sep;18(9):1484-1496. doi: 10.1158/1535-7163.MCT-18-1239. Epub 2019 Jul 8.
• [551] A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.
• [552] Expression and purification of a rapidly degraded protein, TMEM8B-a, in mammalian cell line.Protein Expr Purif. 2018 Nov;151:38-45. doi: 10.1016/j.pep.2018.06.002. Epub 2018 Jun 8.
• [553] Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth.Cancer Lett. 2019 Jan;440-441:23-34. doi: 10.1016/j.canlet.2018.09.032. Epub 2018 Oct 9.
• [554] In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer.Am J Respir Cell Mol Biol. 2003 Apr;28(4):428-35. doi: 10.1165/rcmb.2002-0114OC.
• [555] Inhibition of oncogenic Src induces FABP4-mediated lipolysis via PPAR activation exerting cancer growth suppression.EBioMedicine. 2019 Mar;41:134-145. doi: 10.1016/j.ebiom.2019.02.015. Epub 2019 Feb 10.
• [556] FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.Int J Oncol. 2015 Mar;46(3):999-1006. doi: 10.3892/ijo.2015.2817. Epub 2015 Jan 7.
• [557] FASN-TGF-1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells.Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Mar;1863(3):313-322. doi: 10.1016/j.bbalip.2017.12.012. Epub 2018 Jan 3.
• [558] MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.Gastroenterology. 2017 Oct;153(4):1120-1132.e15. doi: 10.1053/j.gastro.2016.12.036. Epub 2017 Feb 27.
• [559] Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening.Hum Gene Ther Methods. 2018 Feb;29(1):30-43. doi: 10.1089/hgtb.2017.104. Epub 2018 Jan 26.
• [560] Wavelet-based identification of DNA focal genomic aberrations from single nucleotide polymorphism arrays.BMC Bioinformatics. 2011 May 11;12:146. doi: 10.1186/1471-2105-12-146.
• [561] Fibroblast growth factor 18 promotes proliferation and migration of H460 cells via the ERK and p38 signaling pathways.Oncol Rep. 2017 Feb;37(2):1235-1242. doi: 10.3892/or.2016.5301. Epub 2016 Dec 7.
• [562] A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers.Drug Deliv Transl Res. 2019 Feb;9(1):37-52. doi: 10.1007/s13346-018-0575-8.
• [563] 68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake.Clin Nucl Med. 2018 Feb;43(2):117-119. doi: 10.1097/RLU.0000000000001935.
• [564] Folate Receptor -Targeted (89)Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.Mol Pharm. 2019 Sep 3;16(9):3996-4006. doi: 10.1021/acs.molpharmaceut.9b00653. Epub 2019 Aug 16.
• [565] Mechanism of LncRNA FOXC2-AC1 promoting lung cancer metastasis by regulating miR-107.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):690-698. doi: 10.26355/eurrev_201901_16882.
• [566] High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors.Ann Surg Oncol. 2020 Mar;27(3):933-942. doi: 10.1245/s10434-019-07878-8. Epub 2019 Sep 30.
• [567] RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations.Pathol Int. 2012 May;62(5):324-30. doi: 10.1111/j.1440-1827.2012.02797.x. Epub 2012 Mar 27.
• [568] Fascin Controls Metastatic Colonization and Mitochondrial Oxidative Phosphorylation by Remodeling Mitochondrial Actin Filaments.Cell Rep. 2019 Sep 10;28(11):2824-2836.e8. doi: 10.1016/j.celrep.2019.08.011.
• [569] The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA.Biochem Biophys Res Commun. 2019 May 7;512(3):479-485. doi: 10.1016/j.bbrc.2019.03.093. Epub 2019 Mar 21.
• [570] Neutrophil interactions with sialyl Lewis X on human nonsmall cell lung carcinoma cells regulate invasive behavior.Cancer. 2011 Oct 1;117(19):4493-505. doi: 10.1002/cncr.26059. Epub 2011 Mar 22.
• [571] Fucosyltransferase 4 and 7 mediates adhesion of non-small cell lung cancer cells to brain-derived endothelial cells and results in modification of the blood-brain-barrier: in vitro investigation of CD15 and CD15s in lung-to-brain metastasis.J Neurooncol. 2019 Jul;143(3):405-415. doi: 10.1007/s11060-019-03188-x. Epub 2019 May 18.
• [572] GABRA3 promotes lymphatic metastasis in lung adenocarcinoma by mediating upregulation of matrix metalloproteinases.Oncotarget. 2016 May 31;7(22):32341-50. doi: 10.18632/oncotarget.8700.
• [573] Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States).Cancer Causes Control. 1997 Jul;8(4):554-9. doi: 10.1023/a:1018434027502.
• [574] DNA promoter hypermethylation contributes to down-regulation of galactocerebrosidase gene in lung and head and neck cancers.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11042-50. eCollection 2015.
• [575] Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.Sci Rep. 2017 Mar 8;7:43908. doi: 10.1038/srep43908.
• [576] Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition.Nat Commun. 2019 Apr 10;10(1):1665. doi: 10.1038/s41467-019-09295-7.
• [577] MAP4K3/GLK Promotes Lung Cancer Metastasis by Phosphorylating and Activating IQGAP1.Cancer Res. 2019 Oct 1;79(19):4978-4993. doi: 10.1158/0008-5472.CAN-19-1402. Epub 2019 Aug 20.
• [578] Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients.Anticancer Res. 2001 Nov-Dec;21(6A):3933-6.
• [579] The role of GDF15 in bone metastasis of lung adenocarcinoma cells.Oncol Rep. 2019 Apr;41(4):2379-2388. doi: 10.3892/or.2019.7024. Epub 2019 Feb 21.
• [580] Pulmonary epithelial cancer cells and their exosomes metabolize myeloid cell-derived leukotriene C4 to leukotriene D4.J Lipid Res. 2016 Sep;57(9):1659-69. doi: 10.1194/jlr.M066910. Epub 2016 Jul 19.
• [581] A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation.Oncogene. 2018 Jan 25;37(4):489-501. doi: 10.1038/onc.2017.352. Epub 2017 Oct 2.
• [582] The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17424-9. doi: 10.1073/pnas.0506844102. Epub 2005 Nov 18.
• [583] Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.Hum Cell. 2019 Jul;32(3):360-366. doi: 10.1007/s13577-019-00245-5. Epub 2019 Apr 24.
• [584] Insight into the Role and Regulation of Gap Junction Genes in Lung Cancer and Identification of Nuclear Cx43 as a Putative Biomarker of Poor Prognosis.Cancers (Basel). 2019 Mar 6;11(3):320. doi: 10.3390/cancers11030320.
• [585] Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation.Oncogene. 2019 Feb;38(6):822-837. doi: 10.1038/s41388-018-0471-1. Epub 2018 Sep 3.
• [586] IL-24 Inhibits Lung Cancer Growth by Suppressing GLI1 and Inducing DNA Damage.Cancers (Basel). 2019 Nov 27;11(12):1879. doi: 10.3390/cancers11121879.
• [587] Autocrine motility factor receptor gene expression and cell motility in lung cancer cell lines.Oncol Rep. 2002 Jan-Feb;9(1):125-8.
• [588] Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression.Mol Cancer Res. 2012 Oct;10(10):1343-58. doi: 10.1158/1541-7786.MCR-12-0139. Epub 2012 Aug 21.
• [589] A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):E943-51. doi: 10.1073/pnas.1100132108. Epub 2011 Sep 26.
• [590] Knockdown of GluA2 induces apoptosis in non-small-cell lung cancer A549 cells through the p53 signaling pathway.Oncol Lett. 2017 Jul;14(1):1005-1010. doi: 10.3892/ol.2017.6234. Epub 2017 May 24.
• [591] Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.Nucl Med Biol. 2017 Sep;52:57-62. doi: 10.1016/j.nucmedbio.2017.06.001. Epub 2017 Jun 10.
• [592] Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization.Am J Cancer Res. 2019 Jun 1;9(6):1201-1211. eCollection 2019.
• [593] Conjugation of carcinogens by theta class glutathione s-transferases: mechanisms and relevance to variations in human risk.Pharmacogenetics. 1995;5 Spec No:S103-7. doi: 10.1097/00008571-199512001-00010.
• [594] Glutathione S-transferase A1 mediates nicotine-induced lung cancer cell metastasis by promoting epithelial-mesenchymal transition.Exp Ther Med. 2017 Aug;14(2):1783-1788. doi: 10.3892/etm.2017.4663. Epub 2017 Jun 23.
• [595] Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes.Carcinogenesis. 2007 Jun;28(6):1287-93. doi: 10.1093/carcin/bgm021. Epub 2007 Jan 27.
• [596] Autoimmune response in lung cancer patients with neurological paraneoplastic syndromes.Neurol Neurochir Pol. 2019;53(3):217-226. doi: 10.5603/PJNNS.a2019.0025. Epub 2019 Jun 12.
• [597] HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFR(T790M).Anticancer Res. 2017 Jul;37(7):3825-3831. doi: 10.21873/anticanres.11761.
• [598] Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.FEBS Open Bio. 2019 Jan 30;9(3):478-489. doi: 10.1002/2211-5463.12585. eCollection 2019 Mar.
• [599] Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression.Cell Death Differ. 2019 Jul;26(7):1283-1298. doi: 10.1038/s41418-018-0204-6. Epub 2018 Sep 26.
• [600] MiR-2861 Behaves as a Biomarker of Lung Cancer Stem Cells and Regulates the HDAC5-ERK System Genes.Cell Reprogram. 2018 Apr;20(2):99-106. doi: 10.1089/cell.2017.0045. Epub 2018 Mar 13.
• [601] Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.Int J Oncol. 2019 Mar;54(3):1112-1122. doi: 10.3892/ijo.2019.4682. Epub 2019 Jan 9.
• [602] Trichostatin A suppresses lung adenocarcinoma development in Grg1 overexpressing transgenic mice.Biochem Biophys Res Commun. 2015 Aug 7;463(4):1230-6. doi: 10.1016/j.bbrc.2015.06.090. Epub 2015 Jun 15.
• [603] p53 negatively regulates the hepatoma growth factor HDGF.Cancer Res. 2011 Nov 15;71(22):7038-47. doi: 10.1158/0008-5472.CAN-11-1053. Epub 2011 Oct 17.
• [604] Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells.Oncotarget. 2017 Nov 6;8(62):105536-105552. doi: 10.18632/oncotarget.22317. eCollection 2017 Dec 1.
• [605] Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer.Lung Cancer. 2017 Oct;112:169-175. doi: 10.1016/j.lungcan.2017.08.016. Epub 2017 Aug 31.
• [606] Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019 Aug 15;79(16):4072-4085. doi: 10.1158/0008-5472.CAN-18-3503. Epub 2019 Jun 21.
• [607] An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma.Epigenetics. 2019 Oct;14(10):949-960. doi: 10.1080/15592294.2019.1625673. Epub 2019 Jun 3.
• [608] The expression of HOXA13 in lung adenocarcinoma and its clinical significance: A study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction.Oncol Lett. 2018 Jun;15(6):8556-8572. doi: 10.3892/ol.2018.8381. Epub 2018 Mar 29.
• [609] HOXA5 and p53 cooperate to suppress lung cancer cell invasion and serve as good prognostic factors in non-small cell lung cancer.J Cancer. 2017 Apr 9;8(6):1071-1081. doi: 10.7150/jca.17295. eCollection 2017.
• [610] 4-hydroxyphenylpyruvate dioxygenase promotes lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-AMPK/HDAC10/G6PD axis.Cell Death Dis. 2019 Jul 8;10(7):525. doi: 10.1038/s41419-019-1756-1.
• [611] 2016 Annual report from the Italian VATS Group.Future Oncol. 2018 Mar;14(6s):23-28. doi: 10.2217/fon-2017-0423.
• [612] Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer.Lung Cancer. 2015 Feb;87(2):107-16. doi: 10.1016/j.lungcan.2014.12.012. Epub 2014 Dec 25.
• [613] uc.454 Inhibited Growth by Targeting Heat Shock Protein Family A Member 12B in Non-Small-Cell Lung Cancer.Mol Ther Nucleic Acids. 2018 Sep 7;12:174-183. doi: 10.1016/j.omtn.2018.05.004. Epub 2018 May 29.
• [614] Intronic polymorphism (1541-1542delGT) of the constitutive heat shock protein 70 gene has functional significance and shows evidence of association with lung cancer risk.Mol Carcinog. 2004 Mar;39(3):155-63. doi: 10.1002/mc.20009.
• [615] Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer.Tumour Biol. 2017 Mar;39(3):1010428317695918. doi: 10.1177/1010428317695918.
• [616] Human immunodeficiency virus Tat-TIP30 interaction promotes metastasis by enhancing the nuclear translocation of Snail in lung cancer cell lines.Cancer Sci. 2018 Oct;109(10):3105-3114. doi: 10.1111/cas.13768. Epub 2018 Sep 3.
• [617] Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis.Oncogene. 2001 Nov 8;20(51):7505-13. doi: 10.1038/sj.onc.1204940.
• [618] JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.Cancer Gene Ther. 2019 Nov;26(11-12):411-418. doi: 10.1038/s41417-018-0074-6. Epub 2019 Jan 9.
• [619] lncINS-IGF2 Promotes Cell Proliferation and Migration by Promoting G1/S Transition in Lung Cancer.Technol Cancer Res Treat. 2019 Jan 1;18:1533033818823029. doi: 10.1177/1533033818823029.
• [620] M6P/IGF2R is mutated in squamous cell carcinoma of the lung.Oncogene. 2000 Mar 16;19(12):1572-8. doi: 10.1038/sj.onc.1203437.
• [621] Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy.Sci Rep. 2018 Mar 2;8(1):3917. doi: 10.1038/s41598-018-22257-1.
• [622] Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22.
• [623] IKK targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.Lung Cancer. 2019 Apr;130:169-178. doi: 10.1016/j.lungcan.2019.02.027. Epub 2019 Feb 25.
• [624] Circulating Inflammation Proteins Associated With Lung Cancer in African Americans.J Thorac Oncol. 2019 Jul;14(7):1192-1203. doi: 10.1016/j.jtho.2019.03.014. Epub 2019 Apr 3.
• [625] Role of natural killer cells in lung cancer.J Cancer Res Clin Oncol. 2018 Jun;144(6):997-1003. doi: 10.1007/s00432-018-2635-3. Epub 2018 Apr 3.
• [626] IL-25 promotes cisplatin resistance of lung cancer cells by activating NF-B signaling pathway to increase of major vault protein.Cancer Med. 2019 Jul;8(7):3491-3501. doi: 10.1002/cam4.2213. Epub 2019 May 1.
• [627] Association between ADRB2, IL33, and IL2RB gene polymorphisms and lung cancer risk in a Chinese Han population.Int Immunopharmacol. 2019 Dec;77:105930. doi: 10.1016/j.intimp.2019.105930. Epub 2019 Nov 2.
• [628] The Role of Interleukin-31 Polymorphisms in Non-Small Cell Lung Cancer Genetic Susceptibility and Clinical Outcome.Genet Test Mol Biomarkers. 2018 May;22(5):314-319. doi: 10.1089/gtmb.2017.0256.
• [629] Functional variants in DCAF4 associated with lung cancer risk in European populations.Carcinogenesis. 2017 May 1;38(5):541-551. doi: 10.1093/carcin/bgx033.
• [630] IL-32 suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway.Cell Death Dis. 2019 Jul 1;10(7):506. doi: 10.1038/s41419-019-1737-4.
• [631] Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer.J Exp Clin Cancer Res. 2016 Jan 20;35:13. doi: 10.1186/s13046-016-0293-3.
• [632] Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.J Thorac Oncol. 2018 May;13(5):649-659. doi: 10.1016/j.jtho.2018.01.022. Epub 2018 Mar 23.
• [633] Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer.Sci Rep. 2019 Feb 4;9(1):1319. doi: 10.1038/s41598-018-37722-0.
• [634] SHIP1 inhibits cell growth, migration, and invasion in nonsmall cell lung cancer through the PI3K/AKT pathway.Oncol Rep. 2019 Apr;41(4):2337-2350. doi: 10.3892/or.2019.6990. Epub 2019 Jan 30.
• [635] TGF--induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth.Oncogene. 2011 May 26;30(21):2475-84. doi: 10.1038/onc.2010.619. Epub 2011 Jan 31.
• [636] The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.EBioMedicine. 2018 Nov;37:188-204. doi: 10.1016/j.ebiom.2018.10.044. Epub 2018 Oct 30.
• [637] Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.Tumour Biol. 2015 Aug;36(8):6507-13. doi: 10.1007/s13277-015-3341-2. Epub 2015 Mar 29.
• [638] Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase activity and inhibits lung cancer cell growth in response to type I interferon.Cell Death Dis. 2018 Jan 24;9(2):97. doi: 10.1038/s41419-017-0138-9.
• [639] Inhibition of ITCH Suppresses Proliferation and Induces Apoptosis of Lung Cancer Cells.Cell Physiol Biochem. 2018;48(4):1703-1709. doi: 10.1159/000492295. Epub 2018 Aug 3.
• [640] Integrin 11 in non-small cell lung cancer is associated with tumor progression and postoperative recurrence.Cancer Sci. 2020 Jan;111(1):200-208. doi: 10.1111/cas.14257. Epub 2019 Dec 18.
• [641] Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.Biochem J. 2013 Sep 15;454(3):501-13. doi: 10.1042/BJ20121750.
• [642] Genetic variants in the ITGB6 gene is associated with the risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy.Tumour Biol. 2016 Mar;37(3):3469-77. doi: 10.1007/s13277-015-4171-y. Epub 2015 Oct 8.
• [643] Chinese Herbal Medicine Wenxia Changfu Formula Reverses Cell Adhesion-Mediated Drug Resistance via the Integrin 1-PI3K-AKT Pathway in Lung Cancer.J Cancer. 2019 Jan 1;10(2):293-304. doi: 10.7150/jca.25163. eCollection 2019.
• [644] Alteration in metastasis potential and gene expression in human lung cancer cell lines by ITGB8 silencing.Anat Rec (Hoboken). 2012 Sep;295(9):1446-54. doi: 10.1002/ar.22521. Epub 2012 Jul 2.
• [645] MicroRNA-214 inhibits the proliferation and invasion of lung carcinoma cells by targeting JAK1.Am J Transl Res. 2018 Apr 15;10(4):1164-1171. eCollection 2018.
• [646] Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.Genome Med. 2017 Oct 30;9(1):89. doi: 10.1186/s13073-017-0478-1.
• [647] The combination astemizole-gefitinib as a potential therapy for human lung cancer.Onco Targets Ther. 2017 Dec 6;10:5795-5803. doi: 10.2147/OTT.S144506. eCollection 2017.
• [648] Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.Cancer Immunol Immunother. 2002 Dec;51(11-12):614-20. doi: 10.1007/s00262-002-0328-9. Epub 2002 Oct 18.
• [649] TASK-1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial-mesenchymal transition in lung cancer.Exp Ther Med. 2018 Jan;15(1):365-370. doi: 10.3892/etm.2017.5426. Epub 2017 Nov 1.
• [650] ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect.Front Pharmacol. 2018 Dec 4;9:1411. doi: 10.3389/fphar.2018.01411. eCollection 2018.
• [651] The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene.Int J Cancer. 2012 Aug 1;131(3):E179-89. doi: 10.1002/ijc.26501. Epub 2011 Dec 21.
• [652] Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.Oncol Rep. 2016 Jan;35(1):352-8. doi: 10.3892/or.2015.4349. Epub 2015 Oct 26.
• [653] JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.Tumour Biol. 2015 Sep;36(9):7133-42. doi: 10.1007/s13277-015-3418-y. Epub 2015 Apr 16.
• [654] A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14.
• [655] Multiplex measurement of twelve tumor markers using a GMR multi-biomarker immunoassay biosensor.Biosens Bioelectron. 2019 Jan 1;123:204-210. doi: 10.1016/j.bios.2018.08.060. Epub 2018 Aug 25.
• [656] Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer.Clin Chem. 2010 Jun;56(6):987-97. doi: 10.1373/clinchem.2009.138917. Epub 2010 Apr 1.
• [657] Biomarkers for the lung cancer diagnosis and their advances in proteomics.BMB Rep. 2008 Sep 30;41(9):615-25. doi: 10.5483/bmbrep.2008.41.9.615.
• [658] MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells.Mol Med Rep. 2019 Jan;19(1):213-220. doi: 10.3892/mmr.2018.9676. Epub 2018 Nov 20.
• [659] Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis.Cancer Manag Res. 2019 Aug 7;11:7485-7497. doi: 10.2147/CMAR.S218926. eCollection 2019.
• [660] L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer.Clin Cancer Res. 2012 Apr 1;18(7):1914-24. doi: 10.1158/1078-0432.CCR-11-2893. Epub 2012 Feb 3.
• [661] miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.Cancer Res. 2016 Oct 1;76(19):5777-5787. doi: 10.1158/0008-5472.CAN-15-2936.
• [662] LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells.Sci Rep. 2015 Sep 7;5:13846. doi: 10.1038/srep13846.
• [663] CircRNA circ-BANP-mediated miR-503/LARP1 signaling contributes to lung cancer progression.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2429-2435. doi: 10.1016/j.bbrc.2018.06.172. Epub 2018 Jul 6.
• [664] Role of LASP-1, a novel SOX9 transcriptional target, in the progression of lung cancer.Int J Oncol. 2018 Jan;52(1):179-188. doi: 10.3892/ijo.2017.4201. Epub 2017 Nov 10.
• [665] Reconstructing targetable pathways in lung cancer by integrating diverse omics data.Nat Commun. 2013;4:2617. doi: 10.1038/ncomms3617.
• [666] Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.Cancer Res. 2018 Sep 1;78(17):4929-4942. doi: 10.1158/0008-5472.CAN-18-0152. Epub 2018 Jul 2.
• [667] The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.Adv Exp Med Biol. 2016;890:57-74. doi: 10.1007/978-3-319-24932-2_4.
• [668] Hypermethylation of Anti-oncogenic MicroRNA 7 is Increased in Emphysema Patients.Arch Bronconeumol (Engl Ed). 2020 Aug;56(8):506-513. doi: 10.1016/j.arbres.2019.10.017. Epub 2019 Nov 25.
• [669] Downregulation of LIMK1 level inhibits migration of lung cancer cells and enhances sensitivity to chemotherapy drugs.Oncol Res. 2013;20(11):491-8. doi: 10.3727/096504013X13657689382699.
• [670] Long non-coding RNA Linc00662 promotes cell invasion and contributes to cancer stem cell-like phenotypes in lung cancer cells.J Biochem. 2018 Dec 1;164(6):461-469. doi: 10.1093/jb/mvy078.
• [671] Clinical and biological significance of an isozyme tumor marker--PLAP.Clin Biochem. 1987 Dec;20(6):387-92. doi: 10.1016/0009-9120(87)90003-8.
• [672] Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.Mol Cancer. 2014 Oct 24;13:240. doi: 10.1186/1476-4598-13-240.
• [673] Lysyl Oxidase Gene G473A Polymorphism and Cigarette Smoking in Association with a High Risk of Lung and Colorectal Cancers in a North Chinese Population.Int J Environ Res Public Health. 2016 Jun 28;13(7):635. doi: 10.3390/ijerph13070635.
• [674] ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.Oncogene. 2017 Apr 6;36(14):1925-1938. doi: 10.1038/onc.2016.358. Epub 2016 Oct 3.
• [675] Expression of sphingosine-1-phosphate receptors and lysophosphatidic acid receptors on cultured and xenografted human colon, breast, melanoma, and lung tumor cells.Tumour Biol. 2010 Aug;31(4):341-9. doi: 10.1007/s13277-010-0043-7. Epub 2010 May 18.
• [676] CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes.Am J Respir Cell Mol Biol. 2008 Jun;38(6):671-8. doi: 10.1165/rcmb.2007-0205OC. Epub 2008 Jan 24.
• [677] Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination.Cancer Immunol Immunother. 2018 Jun;67(6):949-964. doi: 10.1007/s00262-018-2152-x. Epub 2018 Mar 22.
• [678] Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.Oncotarget. 2018 Jun 8;9(44):27346-27362. doi: 10.18632/oncotarget.25213. eCollection 2018 Jun 8.
• [679] Clinical significance of CCBE1 expression in lung cancer.Mol Med Rep. 2018 Feb;17(2):2107-2112. doi: 10.3892/mmr.2017.8187. Epub 2017 Nov 29.
• [680] Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer.J Med Genet. 2010 Sep;47(9):616-22. doi: 10.1136/jmg.2009.074252. Epub 2010 Jun 1.
• [681] Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status.Int J Oncol. 2018 Aug;53(2):713-724. doi: 10.3892/ijo.2018.4425. Epub 2018 May 31.
• [682] HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma.Lab Invest. 2003 Aug;83(8):1185-92. doi: 10.1097/01.lab.0000080605.73839.96.
• [683] Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines.Oncogene. 1997 Mar 13;14(10):1231-4. doi: 10.1038/sj.onc.1200947.
• [684] DIAPH3 promotes the tumorigenesis of lung adenocarcinoma.Exp Cell Res. 2019 Dec 1;385(1):111662. doi: 10.1016/j.yexcr.2019.111662. Epub 2019 Oct 3.
• [685] Ecliptasaponin A induces apoptosis through the activation of ASK1/JNK pathway and autophagy in human lung cancer cells.Ann Transl Med. 2019 Oct;7(20):539. doi: 10.21037/atm.2019.10.07.
• [686] Molecular cloning of human TAK1 and its mutational analysis in human lung cancer.Int J Cancer. 1998 Feb 9;75(4):559-63. doi: 10.1002/(sici)1097-0215(19980209)75:4<559::aid-ijc11>3.0.co;2-4.
• [687] TPL2 kinase is a suppressor of lung carcinogenesis.Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1470-9. doi: 10.1073/pnas.1215938110. Epub 2013 Mar 26.
• [688] Activation loop phosphorylation of ERK3 is important for its kinase activity and ability to promote lung cancer cell invasiveness.J Biol Chem. 2018 Oct 19;293(42):16193-16205. doi: 10.1074/jbc.RA118.003699. Epub 2018 Aug 30.
• [689] KIF20A silence inhibits the migration, invasion and proliferation of non-small cell lung cancer and regulates the JNK pathway.Clin Exp Pharmacol Physiol. 2020 Jan;47(1):135-142. doi: 10.1111/1440-1681.13183. Epub 2019 Oct 22.
• [690] A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.Am J Hum Genet. 2012 Aug 10;91(2):384-90. doi: 10.1016/j.ajhg.2012.07.003.
• [691] Biological role of mannose binding lectin: From newborns to centenarians.Clin Chim Acta. 2015 Dec 7;451(Pt A):78-81. doi: 10.1016/j.cca.2015.03.007. Epub 2015 Mar 14.
• [692] The natural compound neobractatin inhibits tumor metastasis by upregulating the RNA-binding-protein MBNL2.Cell Death Dis. 2019 Jul 18;10(8):554. doi: 10.1038/s41419-019-1789-5.
• [693] CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer.Clin Respir J. 2019 Jan;13(1):23-33. doi: 10.1111/crj.12976.
• [694] Inhibition of the growth factor MDK/midkine by a novel small molecule compound to treat non-small cell lung cancer.PLoS One. 2013 Aug 16;8(8):e71093. doi: 10.1371/journal.pone.0071093. eCollection 2013.
• [695] MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.Clin Cancer Res. 2018 Dec 15;24(24):6523-6535. doi: 10.1158/1078-0432.CCR-18-0040. Epub 2018 Sep 7.
• [696] Methionine Aminopeptidase 2 as a Potential Therapeutic Target for Human Non-Small-Cell Lung Cancers.Adv Clin Exp Med. 2016 Jan-Feb;25(1):117-28. doi: 10.17219/acem/60715.
• [697] Monoglyceride lipase gene knockout in mice leads to increased incidence of lung adenocarcinoma.Cell Death Dis. 2018 Jan 18;9(2):36. doi: 10.1038/s41419-017-0188-z.
• [698] Chromate exposure induces DNA hypermethylation of the mismatch repair gene MLH1 in lung cancer.Mol Carcinog. 2020 Jan;59(1):24-31. doi: 10.1002/mc.23125. Epub 2019 Oct 3.
• [699] The Association of MMP-11 Promoter Polymorphisms With Susceptibility to Lung Cancer in Taiwan.Anticancer Res. 2019 Oct;39(10):5375-5380. doi: 10.21873/anticanres.13731.
• [700] Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.Clin Immunol. 2020 Jan;210:108262. doi: 10.1016/j.clim.2019.108262. Epub 2019 Oct 17.
• [701] Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor.Neoplasia. 2017 Feb;19(2):55-64. doi: 10.1016/j.neo.2016.11.005. Epub 2016 Dec 23.
• [702] Functional Polymorphism in the MSI1 Gene Promoter Confers a Decreased Risk of Lung Cancer in Chinese by Reducing MSI1 Expression.Curr Genomics. 2018 Aug;19(5):375-383. doi: 10.2174/1389202919666171128151544.
• [703] Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy.J Exp Clin Cancer Res. 2013 May 17;32(1):28. doi: 10.1186/1756-9966-32-28.
• [704] Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer.Tumour Biol. 2013 Apr;34(2):749-57. doi: 10.1007/s13277-012-0604-z. Epub 2012 Nov 29.
• [705] Function of macrophage scavenger receptor 1 gene polymorphisms in chronic obstructive pulmonary disease with and without lung cancer in China.Oncol Lett. 2018 May;15(5):8046-8052. doi: 10.3892/ol.2018.8311. Epub 2018 Mar 21.
• [706] Brain Metastases from Lung Cancer: Is MET an Actionable Target?.Cancers (Basel). 2019 Feb 26;11(3):271. doi: 10.3390/cancers11030271.
• [707] MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer.J Exp Clin Cancer Res. 2015 Dec 23;34:157. doi: 10.1186/s13046-015-0263-1.
• [708] Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.J Biol Chem. 2011 Feb 11;286(6):4902-11. doi: 10.1074/jbc.M110.198374. Epub 2010 Dec 6.
• [709] Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression.Oncotarget. 2017 Jun 28;8(37):61901-61916. doi: 10.18632/oncotarget.18717. eCollection 2017 Sep 22.
• [710] Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues.World J Surg Oncol. 2013 Aug 16;11:199. doi: 10.1186/1477-7819-11-199.
• [711] Association of Three Single Nucleotide Polymorphisms in MTR and MTRR Genes with Lung Cancer in a Turkish Population.Genet Test Mol Biomarkers. 2017 Jul;21(7):428-432. doi: 10.1089/gtmb.2017.0062. Epub 2017 May 24.
• [712] Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer.Tumour Biol. 1996;17(3):176-92. doi: 10.1159/000217980.
• [713] Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer.Pathol Res Pract. 2019 Mar;215(3):459-465. doi: 10.1016/j.prp.2018.12.011. Epub 2018 Dec 10.
• [714] Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.Pathol Oncol Res. 2019 Oct;25(4):1327-1340. doi: 10.1007/s12253-017-0372-6. Epub 2017 Dec 5.
• [715] The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.BMC Cancer. 2018 Feb 21;18(1):217. doi: 10.1186/s12885-018-4129-8.
• [716] Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.Tumour Biol. 2016 May;37(5):6017-25. doi: 10.1007/s13277-015-4436-5. Epub 2015 Nov 23.
• [717] MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.Tumour Biol. 2014 Dec;35(12):12189-200. doi: 10.1007/s13277-014-2527-3. Epub 2014 Sep 2.
• [718] Protective effect of transferrin C3 in lung cancer?.Oncology. 1999;56(4):328-31. doi: 10.1159/000011987.
• [719] Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.PLoS One. 2017 May 22;12(5):e0178286. doi: 10.1371/journal.pone.0178286. eCollection 2017.
• [720] Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?.Wien Klin Wochenschr. 2019 Sep;131(17-18):419-426. doi: 10.1007/s00508-019-01537-4. Epub 2019 Aug 22.
• [721] Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.EBioMedicine. 2019 Jul;45:81-91. doi: 10.1016/j.ebiom.2019.06.005. Epub 2019 Jun 14.
• [722] NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition.Int J Cancer. 2014 May 15;134(10):2294-304. doi: 10.1002/ijc.28568. Epub 2013 Nov 15.
• [723] NIMA-related kinase 2 overexpression is associated with poor survival in cancer patients: a systematic review and meta-analysis.Cancer Manag Res. 2019 Jan 3;11:455-465. doi: 10.2147/CMAR.S188347. eCollection 2019.
• [724] Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy.Anticancer Res. 2004 Sep-Oct;24(5A):2665-73.
• [725] Effect of NELL1 on lung cancer stemlike cell differentiation.Oncol Rep. 2019 Mar;41(3):1817-1826. doi: 10.3892/or.2019.6954. Epub 2019 Jan 3.
• [726] Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.Cancer Sci. 2020 Feb;111(2):667-678. doi: 10.1111/cas.14278. Epub 2020 Jan 15.
• [727] p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA-320a in lung cancer.Thorac Cancer. 2018 Jan;9(1):152-158. doi: 10.1111/1759-7714.12564. Epub 2017 Nov 21.
• [728] Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell.J Exp Clin Cancer Res. 2003 Mar;22(1):69-75.
• [729] Cigarette smoke induces methylation of the tumor suppressor gene NISCH.Epigenetics. 2013 Apr;8(4):383-8. doi: 10.4161/epi.24195. Epub 2013 Mar 15.
• [730] Nm23-H1 inhibits hypoxia induced epithelial-mesenchymal transition and stemness in non-small cell lung cancer cells.Biol Chem. 2019 May 27;400(6):765-776. doi: 10.1515/hsz-2018-0351.
• [731] Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.J Med Chem. 2017 Jun 22;60(12):5162-5192. doi: 10.1021/acs.jmedchem.7b00608. Epub 2017 Jun 12.
• [732] Expression of nucleolar protein p120 in human lung cancer: difference in histological types as a marker for proliferation.Clin Cancer Res. 1997 Oct;3(10):1873-7.
• [733] MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells.Mol Biotechnol. 2015 Jan;57(1):1-11. doi: 10.1007/s12033-014-9796-3.
• [734] Pathobiology of Notch2 in lung cancer.Pathology. 2017 Aug;49(5):486-493. doi: 10.1016/j.pathol.2017.05.005. Epub 2017 Jun 27.
• [735] Common Variants rs3815188 and rs1043994 on Notch3 Gene Confer Susceptibility to Lung Cancer: A Hospital-Based Case-Control Study.J Environ Pathol Toxicol Oncol. 2019;38(1):61-68. doi: 10.1615/JEnvironPatholToxicolOncol.2018028403.
• [736] Stability and utility of the unique human small cell carcinoma line SHP-77.Cancer Res. 1985 Jun;45(6):2725-31.
• [737] The multi-faceted high order polymorphic synergistic interactions among nucleotide excision repair genes increase the risk of lung cancer in North Indians.Mutat Res. 2019 Nov;816-818:111673. doi: 10.1016/j.mrfmmm.2019.111673. Epub 2019 Jun 8.
• [738] Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure.Bioorg Med Chem. 2020 Jan 1;28(1):115186. doi: 10.1016/j.bmc.2019.115186. Epub 2019 Nov 11.
• [739] Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells.Oncotarget. 2018 May 25;9(40):26072-26085. doi: 10.18632/oncotarget.25437. eCollection 2018 May 25.
• [740] Activation of thromboxane A(2) receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells.Carcinogenesis. 2009 Sep;30(9):1606-13. doi: 10.1093/carcin/bgp161. Epub 2009 Jul 1.
• [741] Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.Oncogene. 2019 Mar;38(12):2108-2122. doi: 10.1038/s41388-018-0566-8. Epub 2018 Nov 19.
• [742] Nr5a2 promotes cancer stem cell properties and tumorigenesis in nonsmall cell lung cancer by regulating Nanog.Cancer Med. 2019 Mar;8(3):1232-1245. doi: 10.1002/cam4.1992. Epub 2019 Feb 10.
• [743] Netrin? interference potentiates epithelialtomesenchymal transition through the PI3K/AKT pathway under the hypoxic microenvironment conditions of nonsmall cell lung cancer.Int J Oncol. 2019 Apr;54(4):1457-1465. doi: 10.3892/ijo.2019.4716. Epub 2019 Feb 15.
• [744] A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma.PeerJ. 2019 Jun 17;7:e7125. doi: 10.7717/peerj.7125. eCollection 2019.
• [745] Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.Oncotarget. 2014 Sep 30;5(18):8252-69. doi: 10.18632/oncotarget.1633.
• [746] Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21.J Cell Physiol. 2019 Aug;234(8):12828-12838. doi: 10.1002/jcp.27939. Epub 2018 Dec 13.
• [747] Adenovirus-mediated expression of both antisense ornithine decarboxylase and S-adenosylmethionine decarboxylase inhibits lung cancer cell growth.Acta Biochim Biophys Sin (Shanghai). 2007 Jun;39(6):423-30. doi: 10.1111/j.1745-7270.2007.00294.x.
• [748] Morphine Suppresses Lung Cancer Cell Proliferation Through the Interaction with Opioid Growth Factor Receptor: An In Vitro and Human Lung Tissue Study.Anesth Analg. 2016 Dec;123(6):1429-1436. doi: 10.1213/ANE.0000000000001293.
• [749] The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.PLoS One. 2014 Mar 24;9(3):e91577. doi: 10.1371/journal.pone.0091577. eCollection 2014.
• [750] Over-expression of Orai1 mediates cell proliferation and associates with poor prognosis in human non-small cell lung carcinoma.Int J Clin Exp Pathol. 2015 May 1;8(5):5080-8. eCollection 2015.
• [751] Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung.Lung Cancer. 2005 Nov;50(2):177-88. doi: 10.1016/j.lungcan.2005.05.027. Epub 2005 Jul 25.
• [752] Correlation of P2RX7 gene rs1718125 polymorphism with postoperative fentanyl analgesia in patients with lung cancer.Medicine (Baltimore). 2019 Feb;98(7):e14445. doi: 10.1097/MD.0000000000014445.
• [753] Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung.Int J Cancer. 2007 Jun 15;120(12):2538-44. doi: 10.1002/ijc.22585.
• [754] PADI4mediated epithelialmesenchymal transition in lung cancer cells.Mol Med Rep. 2019 Apr;19(4):3087-3094. doi: 10.3892/mmr.2019.9968. Epub 2019 Feb 19.
• [755] Aromatic adducts and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Spanish cohort.Carcinogenesis. 2014 Sep;35(9):2047-54. doi: 10.1093/carcin/bgu098. Epub 2014 Apr 29.
• [756] Knockdown of PAK1 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells Through the ERK Pathway.Appl Immunohistochem Mol Morphol. 2020 Sep;28(8):602-610. doi: 10.1097/PAI.0000000000000803.
• [757] Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors.Lung Cancer. 1999 Mar;23(3):209-22. doi: 10.1016/s0169-5002(99)00015-x.
• [758] Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.Biochem Biophys Res Commun. 2020 Jan 29;522(1):121-126. doi: 10.1016/j.bbrc.2019.11.050. Epub 2019 Nov 18.
• [759] Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.Cancer Res. 2002 May 1;62(9):2468-73.
• [760] PDK-1 mediated Hippo-YAP-IRS2 signaling pathway and involved in the apoptosis of non-small cell lung cancer cells.Biosci Rep. 2019 May 14;39(5):BSR20182099. doi: 10.1042/BSR20182099. Print 2019 May 31.
• [761] PDK2 induces cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3.J Drug Target. 2019 Apr;27(4):460-465. doi: 10.1080/1061186X.2018.1550648. Epub 2018 Dec 4.
• [762] Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.Am J Pathol. 2001 Oct;159(4):1345-52. doi: 10.1016/S0002-9440(10)62521-7.
• [763] Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling.Cells. 2019 May 10;8(5):442. doi: 10.3390/cells8050442.
• [764] Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.J Biol Chem. 2019 Jul 5;294(27):10530-10543. doi: 10.1074/jbc.RA119.007784. Epub 2019 May 24.
• [765] YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.Carcinogenesis. 2020 Jul 10;41(5):541-550. doi: 10.1093/carcin/bgz152.
• [766] Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I.PLoS One. 2011;6(10):e26135. doi: 10.1371/journal.pone.0026135. Epub 2011 Oct 18.
• [767] Characteristic analysis of pulmonary ground-glass lesions with the help of 64-slice CT technology.Eur Rev Med Pharmacol Sci. 2017 Jul;21(14):3212-3217.
• [768] Differential expression and subcellular localization of Prohibitin 1 are related to tumorigenesis and progression of non-small cell lung cancer.Int J Clin Exp Pathol. 2013 Sep 15;6(10):2092-101. eCollection 2013.
• [769] The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.Biochem Biophys Res Commun. 2014 Aug 15;451(1):119-25. doi: 10.1016/j.bbrc.2014.07.076. Epub 2014 Jul 24.
• [770] Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.Theranostics. 2018 Feb 12;8(7):1808-1823. doi: 10.7150/thno.23177. eCollection 2018.
• [771] Downregulation of Pim-2 induces cell cycle arrest in the G(0)/G(1) phase via the p53-non-dependent p21 signaling pathway.Oncol Lett. 2018 Apr;15(4):4079-4086. doi: 10.3892/ol.2018.7865. Epub 2018 Jan 26.
• [772] Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer.Oncol Rep. 2018 Jan;39(1):53-60. doi: 10.3892/or.2017.6086. Epub 2017 Nov 9.
• [773] Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.Lung Cancer. 2009 Aug;65(2):237-41. doi: 10.1016/j.lungcan.2008.11.012. Epub 2008 Dec 31.
• [774] Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1913-1918. doi: 10.1073/pnas.1719760115. Epub 2018 Feb 6.
• [775] Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype.Cancer Genet. 2015 Apr;208(4):152-5. doi: 10.1016/j.cancergen.2015.02.004. Epub 2015 Feb 20.
• [776] DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy.Mol Cancer Res. 2017 Mar;15(3):269-280. doi: 10.1158/1541-7786.MCR-16-0227-T. Epub 2017 Jan 10.
• [777] A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.Cancer Gene Ther. 2005 May;12(5):497-508. doi: 10.1038/sj.cgt.7700817.
• [778] Suppression of PPN/MG61 attenuates Wnt/beta-catenin signaling pathway and induces apoptosis in human lung cancer.Oncogene. 2008 May 29;27(24):3483-8. doi: 10.1038/sj.onc.1211006. Epub 2008 Jan 14.
• [779] Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer.Oncotarget. 2017 Jul 15;8(37):62248-62260. doi: 10.18632/oncotarget.19273. eCollection 2017 Sep 22.
• [780] Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers.Lung Cancer. 2014 Sep;85(3):449-56. doi: 10.1016/j.lungcan.2014.06.014. Epub 2014 Jun 27.
• [781] Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.Br J Cancer. 2015 Mar 17;112(6):1114-20. doi: 10.1038/bjc.2015.79.
• [782] Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.Cancer Res. 2019 Jan 1;79(1):125-132. doi: 10.1158/0008-5472.CAN-18-1938. Epub 2018 Nov 6.
• [783] Zinc suppresses stem cell properties of lung cancer cells through protein kinase C-mediated -catenin degradation.Am J Physiol Cell Physiol. 2017 Apr 1;312(4):C487-C499. doi: 10.1152/ajpcell.00173.2016. Epub 2017 Jan 25.
• [784] Co-dependency of PKC and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.Oncogene. 2017 Jul 27;36(30):4370-4378. doi: 10.1038/onc.2017.27. Epub 2017 Apr 3.
• [785] PKC maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis.Mol Cancer Res. 2013 Dec;11(12):1624-35. doi: 10.1158/1541-7786.MCR-13-0371-T. Epub 2013 Oct 30.
• [786] DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.DNA Repair (Amst). 2019 Jul;79:1-9. doi: 10.1016/j.dnarep.2019.04.006. Epub 2019 Apr 27.
• [787] Melatonin reduces lung cancer stemness through inhibiting of PLC, ERK, p38, -catenin, and Twist pathways. Environ Toxicol. 2019 Feb;34(2):203-209. doi: 10.1002/tox.22674. Epub 2018 Nov 12.
• [788] T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer.Immunology. 1994 Feb;81(2):234-9.
• [789] Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.J Thorac Oncol. 2017 Jan;12(1):77-84. doi: 10.1016/j.jtho.2016.08.123. Epub 2016 Aug 18.
• [790] Protein tyrosine kinase 7 plays a tumor suppressor role by inhibiting ERK and AKT phosphorylation in lung cancer.Oncol Rep. 2014 Jun;31(6):2708-12. doi: 10.3892/or.2014.3164. Epub 2014 Apr 30.
• [791] Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis.PLoS One. 2017 May 31;12(5):e0177964. doi: 10.1371/journal.pone.0177964. eCollection 2017.
• [792] miR-339-5p Increases Radiosensitivity of Lung Cancer Cells by Targeting Phosphatases of Regenerating Liver-1 (PRL-1).Med Sci Monit. 2018 Nov 21;24:8408-8416. doi: 10.12659/MSM.910808.
• [793] Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.Oncol Rep. 2012 Feb;27(2):535-40. doi: 10.3892/or.2011.1495. Epub 2011 Oct 6.
• [794] Effect of protein-tyrosine phosphatase 4A3 by small interfering RNA on the proliferation of lung cancer.Gene. 2012 Dec 15;511(2):169-76. doi: 10.1016/j.gene.2012.09.079. Epub 2012 Oct 2.
• [795] Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting IB.Onco Targets Ther. 2018 Oct 30;11:7603-7612. doi: 10.2147/OTT.S167106. eCollection 2018.
• [796] Implication of a protein-tyrosine-phosphatase in human lung cancer.Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):677-85.
• [797] Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.J Cell Biochem. 2017 Oct;118(10):3391-3400. doi: 10.1002/jcb.25995. Epub 2017 May 3.
• [798] Different signaling and functionality of Rac1 and Rac1b in the progression of lung adenocarcinoma.Biol Chem. 2020 Mar 26;401(4):517-531. doi: 10.1515/hsz-2019-0329.
• [799] RACK1 forms a complex with FGFR1 and PKM2, and stimulates the growth and migration of squamous lung cancer cells.Mol Carcinog. 2017 Nov;56(11):2391-2399. doi: 10.1002/mc.22663. Epub 2017 Sep 15.
• [800] Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy.Mol Cancer Ther. 2019 Mar;18(3):656-666. doi: 10.1158/1535-7163.MCT-18-0067. Epub 2018 Nov 26.
• [801] Anticancer activity of 2'-hydroxyflavanone towards lung cancer.Oncotarget. 2018 Nov 16;9(90):36202-36219. doi: 10.18632/oncotarget.26329. eCollection 2018 Nov 16.
• [802] Epac1 is involved in cell cycle progression in lung cancer through PKC and Cx43 regulation.Folia Histochem Cytobiol. 2018;56(1):21-26. doi: 10.5603/FHC.a2018.0004. Epub 2018 Mar 12.
• [803] Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci. 2007 Feb;98(2):169-73. doi: 10.1111/j.1349-7006.2006.00367.x.
• [804] REG I gene expression is linked with the poor prognosis of lung adenocarcinoma and squamous cell carcinoma patients via discrete mechanisms.Oncol Rep. 2013 Dec;30(6):2625-31. doi: 10.3892/or.2013.2739. Epub 2013 Sep 19.
• [805] REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.J Cancer Res Clin Oncol. 2019 Sep;145(9):2273-2283. doi: 10.1007/s00432-019-02988-y. Epub 2019 Aug 19.
• [806] Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.
• [807] ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).Anticancer Res. 2019 Mar;39(3):1267-1273. doi: 10.21873/anticanres.13237.
• [808] Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.Cancer Treat Rev. 2019 Jul;77:11-19. doi: 10.1016/j.ctrv.2019.05.006. Epub 2019 May 29.
• [809] RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.Clin Cancer Res. 2013 Jul 1;19(13):3416-28. doi: 10.1158/1078-0432.CCR-13-0073. Epub 2013 May 29.
• [810] R-spondin family members as novel biomarkers and prognostic factors in lung cancer.Oncol Lett. 2019 Oct;18(4):4008-4015. doi: 10.3892/ol.2019.10778. Epub 2019 Aug 22.
• [811] Distinct Molecular Mechanisms Analysis of Three Lung Cancer Subtypes Based on Gene Expression Profiles.J Comput Biol. 2019 Oct;26(10):1140-1155. doi: 10.1089/cmb.2019.0046. Epub 2019 Jul 15.
• [812] S100A6/miR193a regulates the proliferation, invasion, migration and angiogenesis of lung cancer cells through the P53 acetylation.Am J Transl Res. 2019 Aug 15;11(8):4634-4649. eCollection 2019.
• [813] Neuroplastin- mediates S100A8/A9-induced lung cancer disseminative progression.Mol Carcinog. 2019 Jun;58(6):980-995. doi: 10.1002/mc.22987. Epub 2019 Feb 27.
• [814] Mass Spectrometry Analysis of the Exhaled Breath Condensate and Proposal of Dermcidin and S100A9 as Possible Markers for Lung Cancer Prognosis.Lung. 2019 Aug;197(4):523-531. doi: 10.1007/s00408-019-00238-z. Epub 2019 May 21.
• [815] Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways.Biochem Biophys Res Commun. 2018 Jun 22;501(2):520-526. doi: 10.1016/j.bbrc.2018.05.029.
• [816] Soluble sPD-L1 and Serum Amyloid A1 as Potential Biomarkers for Lung Cancer.J Med Biochem. 2019 May 11;38(3):332-341. doi: 10.2478/jomb-2018-0036. eCollection 2019 Jul.
• [817] Elevated expression of SATB1 is involved in pancreatic tumorigenesis and is associated with poor patient survival.Mol Med Rep. 2017 Dec;16(6):8842-8848. doi: 10.3892/mmr.2017.7683. Epub 2017 Oct 2.
• [818] SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals.Cancer Cell Int. 2019 Apr 18;19:103. doi: 10.1186/s12935-019-0809-y. eCollection 2019.
• [819] Serum antibodies to lipophilin B detected in late stage breast cancer patients. Clin Cancer Res. 2003 Feb;9(2):749-54.
• [820] Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.J Thorac Oncol. 2016 Mar;11(3):346-360. doi: 10.1016/j.jtho.2015.11.004. Epub 2015 Dec 25.
• [821] Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes.Am J Pathol. 2018 Apr;188(4):1094-1103. doi: 10.1016/j.ajpath.2017.12.009. Epub 2018 Jan 31.
• [822] Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.Am J Respir Cell Mol Biol. 2019 Jun;60(6):659-666. doi: 10.1165/rcmb.2018-0118OC.
• [823] Sema4D expression and secretion are increased by HIF-1 and inhibit osteogenesis in bone metastases of lung cancer.Clin Exp Metastasis. 2019 Feb;36(1):39-56. doi: 10.1007/s10585-018-9951-5. Epub 2019 Jan 7.
• [824] Dengue viruses can infect human primary lung epithelia as well as lung carcinoma cells, and can also induce the secretion of IL-6 and RANTES.Virus Res. 2007 Jun;126(1-2):216-25. doi: 10.1016/j.virusres.2007.03.003. Epub 2007 Apr 9.
• [825] Squamous cell carcinoma antigen 1 promotes caspase-8-mediated apoptosis in response to endoplasmic reticulum stress while inhibiting necrosis induced by lysosomal injury.Mol Cell Biol. 2011 Jul;31(14):2902-19. doi: 10.1128/MCB.05452-11. Epub 2011 May 16.
• [826] Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression.Cancer Res. 2004 Oct 1;64(19):6900-5. doi: 10.1158/0008-5472.CAN-04-1657.
• [827] Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.Mol Cancer. 2019 Jun 20;18(1):108. doi: 10.1186/s12943-019-1027-x.
• [828] Opposite Effects of SET7/9 on Apoptosis of Human Acute Myeloid Leukemia Cells and Lung Cancer Cells.J Cancer. 2017 Jul 5;8(11):2069-2078. doi: 10.7150/jca.19143. eCollection 2017.
• [829] High-order gene interactions between the genetic polymorphisms in Wnt and AhR pathway in modulating lung cancer susceptibility.Per Med. 2017 Nov;14(6):487-502. doi: 10.2217/pme-2017-0018. Epub 2017 Nov 28.
• [830] Genetic variants of SP-D confer susceptibility to radiation pneumonitis in lung cancer patients undergoing thoracic radiation therapy.Cancer Med. 2019 May;8(5):2599-2611. doi: 10.1002/cam4.2088. Epub 2019 Mar 21.
• [831] SHCBP1 regulates apoptosis in lung cancer cells through phosphatase and tensin homolog.Oncol Lett. 2019 Aug;18(2):1888-1894. doi: 10.3892/ol.2019.10520. Epub 2019 Jun 24.
• [832] The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.Cancer Discov. 2019 Nov;9(11):1606-1627. doi: 10.1158/2159-8290.CD-18-1261. Epub 2019 Jul 26.
• [833] miR?50 promotes the proliferation and migration of nonsmall cell lung cancer cells by regulating the SIRT2/JMJD2A signaling pathway.Oncol Rep. 2018 Aug;40(2):943-951. doi: 10.3892/or.2018.6487. Epub 2018 Jun 12.
• [834] SUN2 exerts tumor suppressor functions by suppressing the Warburg effect in lung cancer.Sci Rep. 2015 Dec 10;5:17940. doi: 10.1038/srep17940.
• [835] UTE-SENCEFUL: first results for 3D high-resolution lung ventilation imaging.Magn Reson Med. 2019 Apr;81(4):2464-2473. doi: 10.1002/mrm.27576. Epub 2018 Nov 4.
• [836] Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer.Cancer Genomics Proteomics. 2018 Sep-Oct;15(5):387-393. doi: 10.21873/cgp.20097.
• [837] Folate/homocysteine metabolism and lung cancer risk among smokers.PLoS One. 2019 Apr 2;14(4):e0214462. doi: 10.1371/journal.pone.0214462. eCollection 2019.
• [838] Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.Mol Imaging Biol. 2016 Feb;18(1):18-23. doi: 10.1007/s11307-015-0862-4.
• [839] Susceptibility loci in lung cancer and COPD: association of IREB2 and FAM13A with pulmonary diseases.Sci Rep. 2015 Aug 27;5:13502. doi: 10.1038/srep13502.
• [840] The Mitochondrial Citrate Carrier (SLC25A1) Sustains Redox Homeostasis and Mitochondrial Metabolism Supporting Radioresistance of Cancer Cells With Tolerance to Cycling Severe Hypoxia.Front Oncol. 2018 May 25;8:170. doi: 10.3389/fonc.2018.00170. eCollection 2018.
• [841] The synergistic induction of cyclooxygenase-2 in lung fibroblasts by angiotensin II and pro-inflammatory cytokines.Mol Cell Biochem. 2009 Jan;320(1-2):163-71. doi: 10.1007/s11010-008-9918-y. Epub 2008 Oct 1.
• [842] MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):14569-85. doi: 10.18632/oncotarget.7538.
• [843] TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers.PLoS One. 2016 Jun 13;11(6):e0157453. doi: 10.1371/journal.pone.0157453. eCollection 2016.
• [844] Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.Mol Cancer Ther. 2018 Sep;17(9):2024-2033. doi: 10.1158/1535-7163.MCT-17-1178. Epub 2018 Jun 29.
• [845] Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer.Am J Pathol. 2011 Jul;179(1):513-23. doi: 10.1016/j.ajpath.2011.03.025. Epub 2011 May 7.
• [846] SGLT gene expression in primary lung cancers and their metastatic lesions.Jpn J Cancer Res. 2001 Aug;92(8):874-9. doi: 10.1111/j.1349-7006.2001.tb01175.x.
• [847] MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer.Int J Oncol. 2019 Jan;54(1):199-208. doi: 10.3892/ijo.2018.4599. Epub 2018 Oct 19.
• [848] Sodium/iodide symporter gene transfection increases radionuclide uptake in human cisplatin-resistant lung cancer cells.Clin Transl Oncol. 2015 Oct;17(10):795-802. doi: 10.1007/s12094-015-1307-x. Epub 2015 Jun 27.
• [849] QSurface: fast identification of surface expression markers in cancers.BMC Syst Biol. 2018 Mar 19;12(Suppl 2):17. doi: 10.1186/s12918-018-0541-6.
• [850] Up-regulation of long noncoding RNA MINCR promotes non-small cell of lung cancer growth by negatively regulating miR-126/SLC7A5 axis.Biochem Biophys Res Commun. 2019 Jan 15;508(3):780-784. doi: 10.1016/j.bbrc.2018.11.162. Epub 2018 Dec 6.
• [851] Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis.Pharmacogenomics. 2016 Jul;17(10):1189-1205. doi: 10.2217/pgs-2015-0005. Epub 2016 Jul 6.
• [852] Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway.Int J Clin Exp Pathol. 2015 Aug 1;8(8):9175-81. eCollection 2015.
• [853] Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by downregulation of DNMT3B.Oncogene. 2007 Aug 30;26(40):5900-10. doi: 10.1038/sj.onc.1210400. Epub 2007 Mar 19.
• [854] Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.Cancer Sci. 2013 Nov;104(11):1483-91. doi: 10.1111/cas.12266. Epub 2013 Sep 19.
• [855] Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.JCI Insight. 2019 Oct 17;4(20):e131340. doi: 10.1172/jci.insight.131340.
• [856] SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.
• [857] CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target.Int J Cancer. 2013 Apr 15;132(8):1761-70. doi: 10.1002/ijc.27873. Epub 2012 Oct 29.
• [858] Squalene epoxidase promotes the proliferation and metastasis of lung squamous cell carcinoma cells though extracellular signal-regulated kinase signaling.Thorac Cancer. 2019 Mar;10(3):428-436. doi: 10.1111/1759-7714.12944. Epub 2019 Feb 7.
• [859] Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.Oncogene. 2017 Apr 27;36(17):2457-2471. doi: 10.1038/onc.2016.404. Epub 2016 Nov 7.
• [860] Multimodality imaging of naturally active melanin nanoparticles targeting somatostatin receptor subtype 2 in human small-cell lung cancer.Nanoscale. 2019 Aug 1;11(30):14400-14409. doi: 10.1039/c9nr04371c.
• [861] Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines.Life Sci. 1994;55(23):1797-806. doi: 10.1016/0024-3205(94)90090-6.
• [862] Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer.Int J Cancer. 2019 Mar 1;144(5):1104-1114. doi: 10.1002/ijc.31771. Epub 2018 Oct 9.
• [863] Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.Cell Oncol (Dordr). 2011 Oct;34(5):435-41. doi: 10.1007/s13402-011-0025-9. Epub 2011 Apr 19.
• [864] ZEB1-responsive genes in non-small cell lung cancer.Cancer Lett. 2011 Jan 1;300(1):66-78. doi: 10.1016/j.canlet.2010.09.007. Epub 2010 Oct 25.
• [865] CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians.Lung Cancer. 2010 Jul;69(1):19-25. doi: 10.1016/j.lungcan.2009.09.001. Epub 2009 Sep 30.
• [866] ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer via a STAT6-WWP2-p27 axis.Carcinogenesis. 2020 Jul 10;41(5):711-721. doi: 10.1093/carcin/bgz144.
• [867] Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1.Mol Ther. 2012 Feb;20(2):417-23. doi: 10.1038/mt.2011.259. Epub 2011 Dec 6.
• [868] Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.Int J Cancer. 2019 Sep 15;145(6):1609-1624. doi: 10.1002/ijc.32487. Epub 2019 Jun 25.
• [869] Withdrawal Notice: STK33-Dependent Transcriptional Regulation of SFTA3 Induces Cisplatin-Resistance in Lung Adenocarcinoma.Anticancer Agents Med Chem. 2019 May 6. doi: 10.2174/1871520619666190507100912. Online ahead of print.
• [870] SLP-2 overexpression is associated with tumour distant metastasis and poor prognosis in pulmonary squamous cell carcinoma.Biomarkers. 2010 Mar;15(2):104-10. doi: 10.3109/13547500903311910.
• [871] Structure, molecular dynamics simulation, and docking studies of Dictyostelium discoideum and human STRAPs.J Cell Biochem. 2018 Sep;119(9):7177-7191. doi: 10.1002/jcb.26840. Epub 2018 May 24.
• [872] STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.Biochem Biophys Res Commun. 2019 Nov 19;519(4):659-666. doi: 10.1016/j.bbrc.2019.09.032. Epub 2019 Sep 18.
• [873] Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor.Mol Cell. 2020 Jan 16;77(2):213-227.e5. doi: 10.1016/j.molcel.2019.10.023. Epub 2019 Nov 14.
• [874] Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells.FEBS J. 2018 Nov;285(22):4229-4245. doi: 10.1111/febs.14665. Epub 2018 Oct 8.
• [875] The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer.Oncol Rep. 2016 Jan;35(1):436-46. doi: 10.3892/or.2015.4373. Epub 2015 Nov 2.
• [876] An investigation of the relationship between SULT1A1 Arg(213)His polymorphism and lung cancer susceptibility in a Turkish population.Cell Biochem Funct. 2009 Jun;27(4):211-5. doi: 10.1002/cbf.1558.
• [877] Knockdown of PSF1 expression inhibits cell proliferation in lung cancer cells in vitro.Tumour Biol. 2015 Mar;36(3):2163-8. doi: 10.1007/s13277-014-2826-8. Epub 2014 Nov 15.
• [878] TDP-43 regulates cancer-associated microRNAs.Protein Cell. 2018 Oct;9(10):848-866. doi: 10.1007/s13238-017-0480-9. Epub 2017 Sep 26.
• [879] TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.Cancer Res. 2017 Sep 15;77(18):5077-5094. doi: 10.1158/0008-5472.CAN-17-0829. Epub 2017 Jul 17.
• [880] TBL1XR1 is involved in c-Met-mediated tumorigenesis of human nonsmall cell lung cancer.Cancer Gene Ther. 2020 Apr;27(3-4):136-146. doi: 10.1038/s41417-019-0111-0. Epub 2019 Jun 27.
• [881] Thromboxane A2 receptor-mediated release of matrix metalloproteinase-1 (MMP-1) induces expression of monocyte chemoattractant protein-1 (MCP-1) by activation of protease-activated receptor 2 (PAR2) in A549 human lung adenocarcinoma cells.Mol Carcinog. 2014 Aug;53(8):659-66. doi: 10.1002/mc.22020. Epub 2013 Mar 8.
• [882] Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1).SLAS Discov. 2017 Oct;22(9):1093-1105. doi: 10.1177/2472555217717200. Epub 2017 Jul 11.
• [883] ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.Oncotarget. 2016 Feb 9;7(6):6665-75. doi: 10.18632/oncotarget.6682.
• [884] Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis.Cancer Res. 2005 Jan 1;65(1):325-30.
• [885] Multiple cancer pathways regulate telomereprotection.EMBO Mol Med. 2019 Jul;11(7):e10292. doi: 10.15252/emmm.201910292. Epub 2019 Jun 13.
• [886] Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility.Lung Cancer. 2009 Nov;66(2):157-61. doi: 10.1016/j.lungcan.2009.02.005. Epub 2009 Mar 13.
• [887] Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.Int J Nanomedicine. 2019 Apr 24;14:2879-2902. doi: 10.2147/IJN.S192219. eCollection 2019.
• [888] Molecular Changes of Lung Malignancy in HIV Infection.Sci Rep. 2018 Sep 3;8(1):13128. doi: 10.1038/s41598-018-31572-6.
• [889] Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer.Biomed Res Int. 2017;2017:8983763. doi: 10.1155/2017/8983763. Epub 2017 Jan 26.
• [890] An epigenetic auto-feedback loop regulates TGF- type II receptor expression and function in NSCLC.Oncotarget. 2015 Oct 20;6(32):33237-52. doi: 10.18632/oncotarget.4893.
• [891] Transglutaminase 2 Promotes Migration and Invasion of Lung Cancer Cells.Oncol Res. 2018 Sep 14;26(8):1175-1182. doi: 10.3727/096504018X15149761920868. Epub 2018 Jan 4.
• [892] Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1.Cancer Lett. 2019 Feb 1;442:287-298. doi: 10.1016/j.canlet.2018.10.031. Epub 2018 Nov 12.
• [893] Plasma Fibrinogen and sP-Selectin are Associated with the Risk of Lung Cancer in a Prospective Study.Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1221-1227. doi: 10.1158/1055-9965.EPI-18-1285. Epub 2019 Apr 23.
• [894] Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression.PLoS Genet. 2019 Oct 7;15(10):e1008439. doi: 10.1371/journal.pgen.1008439. eCollection 2019 Oct.
• [895] Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner.Asian Pac J Cancer Prev. 2012;13(6):2807-12. doi: 10.7314/apjcp.2012.13.6.2807.
• [896] Tobacco specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone suppresses a newly identified anti-tumor IGFBP-3/IGFBP-3R system in lung cancer cells.Lung Cancer. 2013 Jun;80(3):270-7. doi: 10.1016/j.lungcan.2013.02.016. Epub 2013 Mar 14.
• [897] TMEM Proteins in Cancer: A Review.Front Pharmacol. 2018 Dec 6;9:1345. doi: 10.3389/fphar.2018.01345. eCollection 2018.
• [898] Thymosin beta 4 silencing suppresses proliferation and invasion of non-small cell lung cancer cells by repressing Notch1 activation.Acta Biochim Biophys Sin (Shanghai). 2016 Sep;48(9):788-94. doi: 10.1093/abbs/gmw070. Epub 2016 Aug 12.
• [899] Correlation of Expression of Tenascin C and Blood Vessel Density in Non-small Cell Lung Cancers.Anticancer Res. 2018 Apr;38(4):1987-1991. doi: 10.21873/anticanres.12436.
• [900] miR-605-5p promotes invasion and proliferation by targeting TNFAIP3 in non-small-cell lung cancer.J Cell Biochem. 2020 Jan;121(1):779-787. doi: 10.1002/jcb.29323. Epub 2019 Aug 26.
• [901] Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.Mol Cancer Res. 2014 Apr;12(4):550-9. doi: 10.1158/1541-7786.MCR-13-0458. Epub 2014 Jan 27.
• [902] The clinical significance of serum adipocytokines level in patients with lung cancer.J Thorac Dis. 2019 Aug;11(8):3547-3555. doi: 10.21037/jtd.2019.07.66.
• [903] Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.Mol Pharm. 2018 Apr 2;15(4):1627-1634. doi: 10.1021/acs.molpharmaceut.7b01168. Epub 2018 Mar 20.
• [904] Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.Clin Transl Immunology. 2019 Sep 27;8(10):e01081. doi: 10.1002/cti2.1081. eCollection 2019.
• [905] A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer.Exp Lung Res. 2009 Aug;35(6):486-500. doi: 10.1080/01902140902759274.
• [906] TNFSF15 promoter polymorphisms increase the susceptibility to small cell lung cancer: a case-control study.BMC Med Genet. 2019 Feb 8;20(1):29. doi: 10.1186/s12881-019-0762-6.
• [907] Evidence for tankyrases as antineoplastic targets in lung cancer.BMC Cancer. 2013 Apr 28;13:211. doi: 10.1186/1471-2407-13-211.
• [908] C-terminal tensin-like protein mediates invasion of human lung cancer cells and is regulated by signal transducer and activator oftranscription 3.J Thorac Cardiovasc Surg. 2015 Jan;149(1):369-75. doi: 10.1016/j.jtcvs.2014.08.087. Epub 2014 Sep 18.
• [909] Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.Lung Cancer. 2002 Mar;35(3):299-304. doi: 10.1016/s0169-5002(01)00425-1.
• [910] Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes.Br J Cancer. 1993 Oct;68(4):793-800. doi: 10.1038/bjc.1993.430.
• [911] Combining data from TCGA and GEO databases and reverse transcription quantitative PCR validation to identify gene prognostic markers in lung cancer.Onco Targets Ther. 2019 Jan 21;12:709-720. doi: 10.2147/OTT.S183944. eCollection 2019.
• [912] TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells.J Cancer Res Clin Oncol. 2019 Jun;145(6):1509-1519. doi: 10.1007/s00432-019-02921-3. Epub 2019 Apr 23.
• [913] TCTP promotes epithelial-mesenchymal transition in lung adenocarcinoma.Onco Targets Ther. 2019 Feb 27;12:1641-1653. doi: 10.2147/OTT.S184555. eCollection 2019.
• [914] Sodium butyrate-activated TRAF6-TXNIP pathway affects A549 cells proliferation and migration.Cancer Med. 2020 May;9(10):3477-3488. doi: 10.1002/cam4.2564. Epub 2019 Oct 2.
• [915] Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer.Sci Rep. 2018 Jul 17;8(1):10766. doi: 10.1038/s41598-018-28971-0.
• [916] An TRIM59-CDK6 axis regulates growth and metastasis of lung cancer.J Cell Mol Med. 2019 Feb;23(2):1458-1469. doi: 10.1111/jcmm.14052. Epub 2018 Dec 4.
• [917] Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance.Cancer Cell. 2018 Jun 11;33(6):985-1003.e7. doi: 10.1016/j.ccell.2018.05.001. Epub 2018 May 24.
• [918] TRPM2 Silencing Causes G2/M Arrest and Apoptosis in Lung Cancer Cells via Increasing Intracellular ROS and RNS Levels and Activating the JNK Pathway.Cell Physiol Biochem. 2019;52(4):742-757. doi: 10.33594/000000052.
• [919] TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90/uPA/MMP2 signaling pathway.BMC Cancer. 2018 Nov 26;18(1):1167. doi: 10.1186/s12885-018-5050-x.
• [920] Overexpression of TRPV3 Correlates with Tumor Progression in Non-Small Cell Lung Cancer.Int J Mol Sci. 2016 Mar 24;17(4):437. doi: 10.3390/ijms17040437.
• [921] TSG101, identified by screening a cancer cDNA library and soft agar assay, promotes cell proliferation in human lung cancer.Mol Biol Rep. 2010 Jul;37(6):2829-38. doi: 10.1007/s11033-009-9835-5. Epub 2009 Sep 29.
• [922] Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma.J Clin Endocrinol Metab. 1997 Mar;82(3):735-8. doi: 10.1210/jcem.82.3.3838.
• [923] Effects of Cigarette Smoke on TSPO-related Mitochondrial Processes.Cells. 2019 Jul 10;8(7):694. doi: 10.3390/cells8070694.
• [924] LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.Oncotarget. 2018 Jul 3;9(51):29601-29618. doi: 10.18632/oncotarget.25642. eCollection 2018 Jul 3.
• [925] HR23A-knockdown lung cancer cells exhibit epithelial-to-mesenchymal transition and gain stemness properties through increased Twist1 stability.Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118537. doi: 10.1016/j.bbamcr.2019.118537. Epub 2019 Sep 2.
• [926] Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP.Oncogene. 2019 Mar;38(11):1892-1904. doi: 10.1038/s41388-018-0534-3. Epub 2018 Nov 2.
• [927] MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2.PLoS One. 2015 Jun 24;10(6):e0129843. doi: 10.1371/journal.pone.0129843. eCollection 2015.
• [928] Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1).Biol Pharm Bull. 2019;42(11):1839-1845. doi: 10.1248/bpb.b19-00357.
• [929] A polymorphism in miR-1262 regulatory region confers the risk of lung cancer in Chinese population.Int J Cancer. 2017 Sep 1;141(5):958-966. doi: 10.1002/ijc.30788. Epub 2017 May 29.
• [930] Targeting the cellular schizophrenia. Likely employment of the antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma.Crit Rev Oncol Hematol. 2018 Aug;128:96-109. doi: 10.1016/j.critrevonc.2018.06.004. Epub 2018 Jun 11.
• [931] Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling.Biomed Pharmacother. 2019 Jun;114:108831. doi: 10.1016/j.biopha.2019.108831. Epub 2019 Apr 12.
• [932] Radiation Enhances the Epithelial- Mesenchymal Transition of A549 Cells via miR3591-5p/USP33/PPM1A.Cell Physiol Biochem. 2018;50(2):721-733. doi: 10.1159/000494238. Epub 2018 Oct 11.
• [933] USP44 regulates centrosome positioning to prevent aneuploidy and suppress tumorigenesis.J Clin Invest. 2012 Dec;122(12):4362-74. doi: 10.1172/JCI63084. Epub 2012 Nov 26.
• [934] The expression and prognostic significance of Drp1 in lung cancer: A bioinformatics analysis and immunohistochemistry.Medicine (Baltimore). 2019 Nov;98(48):e18228. doi: 10.1097/MD.0000000000018228.
• [935] Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells.Mol Ther Nucleic Acids. 2019 Sep 6;17:24-37. doi: 10.1016/j.omtn.2019.05.003. Epub 2019 May 18.
• [936] Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells.J Cell Physiol. 2012 Dec;227(12):3778-86. doi: 10.1002/jcp.24086.
• [937] Anti-lymphangiogenesis effects of a specific anti-interleukin 7 receptor antibody in lung cancer model in vivo.Mol Carcinog. 2015 Feb;54(2):148-55. doi: 10.1002/mc.22082. Epub 2013 Sep 24.
• [938] Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency.Cancer Res. 2005 Aug 1;65(15):6576-82. doi: 10.1158/0008-5472.CAN-05-1128.
• [939] Low molecular weight heparin in treating patients with lung cancer received chemotherapy: A meta-analysis.J Cancer Res Ther. 2018 Jun;14(Supplement):S437-S443. doi: 10.4103/0973-1482.176174.
• [940] Gene expression of vasoactive intestinal peptide receptors in human lung cancer.Int J Oncol. 2011 Oct;39(4):1019-24. doi: 10.3892/ijo.2011.1122. Epub 2011 Jul 13.
• [941] Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.Clin Cancer Res. 2017 Jan 15;23(2):370-378. doi: 10.1158/1078-0432.CCR-16-0150. Epub 2016 Jul 20.
• [942] FOXD3 Suppresses Tumor-Initiating Features in Lung Cancer via Transcriptional Repression of WDR5.Stem Cells. 2019 May;37(5):582-592. doi: 10.1002/stem.2984. Epub 2019 Mar 12.
• [943] Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.Clin Cancer Res. 2017 Nov 15;23(22):6993-7005. doi: 10.1158/1078-0432.CCR-17-1098. Epub 2017 Aug 18.
• [944] Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.Lung Cancer. 2019 Mar;129:92-94. doi: 10.1016/j.lungcan.2018.12.011. Epub 2018 Dec 19.
• [945] Clinical significance of aberrant Wnt7a promoter methylation in human non-small cell lung cancer in Koreans.J Korean Med Sci. 2015 Feb;30(2):155-61. doi: 10.3346/jkms.2015.30.2.155. Epub 2015 Jan 21.
• [946] XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.Nature. 2016 Oct 6;538(7623):114-117. doi: 10.1038/nature19771. Epub 2016 Sep 28.
• [947] ZWINT is the next potential target for lung cancer therapy.J Cancer Res Clin Oncol. 2019 Mar;145(3):661-673. doi: 10.1007/s00432-018-2823-1. Epub 2019 Jan 14.
• [948] Identification of differentially expressed genes and enriched pathways in lung cancer using bioinformatics analysis.Mol Med Rep. 2019 Mar;19(3):2029-2040. doi: 10.3892/mmr.2019.9878. Epub 2019 Jan 18.
• [949] Frequent down-regulation of hRAB37 in metastatic tumor by genetic and epigenetic mechanisms in lung cancer.Lung Cancer. 2009 Mar;63(3):360-7. doi: 10.1016/j.lungcan.2008.06.014. Epub 2008 Aug 8.
• [950] Serum proteome mapping of EGF transgenic mice reveal mechanistic biomarkers of lung cancer precursor lesions with clinical significance for human adenocarcinomas.Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3122-3144. doi: 10.1016/j.bbadis.2018.06.019. Epub 2018 Jun 28.
• [951] A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice.Proteomics. 2009 Feb;9(4):1044-56. doi: 10.1002/pmic.200701135.
• [952] Hyaluronic acid - dihydroartemisinin conjugate: Synthesis, characterization and in vitro evaluation in lung cancer cells.Int J Biol Macromol. 2019 Jul 15;133:495-502. doi: 10.1016/j.ijbiomac.2019.04.124. Epub 2019 Apr 17.
• [953] Correction to: CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation.Cell Death Differ. 2019 Jan;26(1):196. doi: 10.1038/s41418-018-0140-5.
• [954] The prognostic value of cyclin D1 expression in the survival of cancer patients: A meta-analysis.Gene. 2020 Feb 20;728:144283. doi: 10.1016/j.gene.2019.144283. Epub 2019 Dec 12.
• [955] Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.Cancer Res. 2018 Sep 15;78(18):5340-5348. doi: 10.1158/0008-5472.CAN-18-1119. Epub 2018 Jul 19.
• [956] Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients.Clin Transl Oncol. 2019 Nov;21(11):1538-1542. doi: 10.1007/s12094-019-02086-y. Epub 2019 Mar 22.
• [957] A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.Breast Cancer Res Treat. 2019 Apr;174(3):605-613. doi: 10.1007/s10549-018-05079-7. Epub 2019 Jan 3.
• [958] Duplicated copy of CHRNA7 increases risk and worsens prognosis of COPD and lung cancer.Eur J Hum Genet. 2015 Aug;23(8):1019-24. doi: 10.1038/ejhg.2014.229. Epub 2014 Nov 19.
• [959] A microfluidic device for studying chemotaxis mechanism of bacterial cancer targeting.Sci Rep. 2018 Apr 23;8(1):6394. doi: 10.1038/s41598-018-24748-7.
• [960] Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma.Oncol Lett. 2018 Feb;15(2):1874-1880. doi: 10.3892/ol.2017.7455. Epub 2017 Nov 21.
• [961] A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer.Oncol Lett. 2018 Oct;16(4):4114-4128. doi: 10.3892/ol.2018.9174. Epub 2018 Jul 19.
• [962] Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.PLoS One. 2010 Jul 2;5(7):e11418. doi: 10.1371/journal.pone.0011418.
• [963] Polymorphism in CYP24A1 Is Associated with Lung Cancer Risk: A Case-Control Study in Chinese Female Nonsmokers.DNA Cell Biol. 2019 Mar;38(3):243-249. doi: 10.1089/dna.2018.4510. Epub 2019 Feb 6.
• [964] Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.Cancer Res Treat. 2017 Oct;49(4):1065-1076. doi: 10.4143/crt.2016.347. Epub 2017 Jan 25.
• [965] Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer.Lung Cancer. 2007 Apr;56(1):17-23. doi: 10.1016/j.lungcan.2006.11.007. Epub 2006 Dec 18.
• [966] Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer.Onco Targets Ther. 2019 Aug 23;12:6907-6915. doi: 10.2147/OTT.S215701. eCollection 2019.
• [967] Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.Lung Cancer. 2018 Oct;124:31-39. doi: 10.1016/j.lungcan.2018.07.027. Epub 2018 Jul 21.
• [968] Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review.Front Physiol. 2019 Mar 19;10:216. doi: 10.3389/fphys.2019.00216. eCollection 2019.
• [969] Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells.J Oncol. 2019 Jan 6;2019:6164807. doi: 10.1155/2019/6164807. eCollection 2019.
• [970] Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.Cancer Lett. 2018 Jul 28;427:38-48. doi: 10.1016/j.canlet.2018.04.019. Epub 2018 Apr 19.
• [971] 8-bromo-7-methoxychrysin targets NF-B and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors.J Cancer. 2019 Aug 28;10(21):5244-5255. doi: 10.7150/jca.30143. eCollection 2019.
• [972] Long non-coding RNA FOXO1 inhibits lung cancer cell growth through down-regulating PI3K/AKT signaling pathway.Iran J Basic Med Sci. 2019 May;22(5):491-498. doi: 10.22038/ijbms.2019.31000.7480.
• [973] Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.
• [974] Association of serum follistatin levels with histological types and progression of tumor in human lung cancer.Cancer Cell Int. 2018 Oct 20;18:162. doi: 10.1186/s12935-018-0664-2. eCollection 2018.
• [975] N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies.Anticancer Res. 2019 Nov;39(11):6317-6324. doi: 10.21873/anticanres.13842.
• [976] Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells.Cancer Chemother Pharmacol. 2007 Aug;60(3):449-57. doi: 10.1007/s00280-006-0406-3. Epub 2007 Feb 16.
• [977] HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer.Oncogenesis. 2019 Aug 20;8(9):45. doi: 10.1038/s41389-019-0158-7.
• [978] Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.PLoS One. 2019 Mar 14;14(3):e0213984. doi: 10.1371/journal.pone.0213984. eCollection 2019.
• [979] Expression and the potential functions of TRIM32 in lung cancer tumorigenesis.J Cell Biochem. 2019 Apr;120(4):5232-5243. doi: 10.1002/jcb.27798. Epub 2018 Oct 30.
• [980] PCAF-mediated acetylation of Lin28B increases let-7 biogenesis in lung adenocarcinoma H1299 cells.BMC Cancer. 2018 Jan 4;18(1):27. doi: 10.1186/s12885-017-3959-0.
• [981] The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.Cancer Med. 2019 Mar;8(3):1157-1168. doi: 10.1002/cam4.1949. Epub 2019 Feb 8.
• [982] Caged-xanthone from Cratoxylum formosum ssp. pruniflorum inhibits malignant cancer phenotypes in multidrug-resistant human A549 lung cancer cells through down-regulation of NF-B.Bioorg Med Chem. 2019 Jun 15;27(12):2368-2375. doi: 10.1016/j.bmc.2018.12.042. Epub 2018 Dec 31.
• [983] A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer.Mol Ther Nucleic Acids. 2019 Dec 6;18:991-998. doi: 10.1016/j.omtn.2019.10.029. Epub 2019 Nov 2.
• [984] Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers.Int J Cancer. 2006 Feb 15;118(4):797-801. doi: 10.1002/ijc.21462.
• [985] Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38 siRNA in Lung Adenocarcinoma Cancer Cells.Anticancer Agents Med Chem. 2019;19(5):638-644. doi: 10.2174/1871520619666190301125203.
• [986] K-Ras-ERK1/2 accelerates lung cancer cell development via mediating H3(K18ac) through the MDM2-GCN5-SIRT7 axis.Pharm Biol. 2019 Dec;57(1):701-709. doi: 10.1080/13880209.2019.1672756.
• [987] Nicotine induces cell survival and chemoresistance by stimulating Mcl-1 phosphorylation and its interaction with Bak in lung cancer.J Cell Physiol. 2019 Sep;234(9):15934-15940. doi: 10.1002/jcp.28251. Epub 2019 Feb 11.
• [988] Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.Phytother Res. 2020 Feb;34(2):388-400. doi: 10.1002/ptr.6530. Epub 2019 Nov 7.
• [989] Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.Oncogene. 2019 Feb;38(9):1477-1488. doi: 10.1038/s41388-018-0522-7. Epub 2018 Oct 10.
• [990] Neuregulin1 acts as a suppressor in human lung adenocarcinoma via AKT and ERK1/2 pathway.J Thorac Dis. 2018 Jun;10(6):3166-3179. doi: 10.21037/jtd.2018.05.175.
• [991] Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.Cancers (Basel). 2019 Apr 2;11(4):462. doi: 10.3390/cancers11040462.
• [992] PCNA and GSK3 interact with each other to regulate H1299 lung adenocarcinoma cells apoptosis.Neoplasma. 2020 Jan;67(1):15-26. doi: 10.4149/neo_2019_190116N48. Epub 2019 Oct 8.
• [993] Patterns of immunotherapy use and management of toxicities in regional and tertiary settings.Intern Med J. 2019 Aug;49(8):1010-1015. doi: 10.1111/imj.14235.
• [994] Serum Paraoxonase-1-Related Variables and Lipoprotein Profile in Patients with Lung or Head and Neck Cancer: Effect of Radiotherapy.Antioxidants (Basel). 2019 Jul 10;8(7):213. doi: 10.3390/antiox8070213.
• [995] PRDX4 and Its Roles in Various Cancers.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819864313. doi: 10.1177/1533033819864313.
• [996] Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.J Cell Mol Med. 2019 Feb;23(2):1333-1342. doi: 10.1111/jcmm.14036. Epub 2018 Nov 20.
• [997] FBXL19-AS1 exerts oncogenic function by sponging miR-431-5p to regulate RAF1 expression in lung cancer.Biosci Rep. 2019 Jan 25;39(1):BSR20181804. doi: 10.1042/BSR20181804. Print 2019 Jan 31.
• [998] Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.J Pathol. 2015 Dec;237(4):520-31. doi: 10.1002/path.4597. Epub 2015 Sep 28.
• [999] Network analysis of differentially expressed smoking-associated mRNAs, lncRNAs and miRNAs reveals key regulators in smoking-associated lung cancer.Exp Ther Med. 2018 Dec;16(6):4991-5002. doi: 10.3892/etm.2018.6891. Epub 2018 Oct 23.
• [1000] Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers.Clin Transl Med. 2014 Nov 18;3:37. doi: 10.1186/s40169-014-0037-y. eCollection 2014.
• [1001] SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.Cancer Res. 2019 May 15;79(10):2761-2774. doi: 10.1158/0008-5472.CAN-18-1545. Epub 2019 Mar 15.
• [1002] SOX2 promoter hypermethylation in non-smoking Taiwanese adults residing in air pollution areas.Clin Epigenetics. 2019 Mar 12;11(1):46. doi: 10.1186/s13148-019-0647-8.
• [1003] High Mobility Group Box Protein 1 Serves as a Potential Prognostic Marker of Lung Cancer and Promotes Its Invasion and Metastasis by Matrix Metalloproteinase-2 in a Nuclear Factor-B-Dependent Manner.Biomed Res Int. 2018 Apr 19;2018:3453706. doi: 10.1155/2018/3453706. eCollection 2018.
• [1004] SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.PLoS One. 2016 Feb 16;11(2):e0148911. doi: 10.1371/journal.pone.0148911. eCollection 2016.
• [1005] A serine in exon 11 determines the full transcriptional activity of TCF-4 in lung carcinoma cells.Biochem Biophys Res Commun. 2019 Jan 15;508(3):675-681. doi: 10.1016/j.bbrc.2018.11.161. Epub 2018 Dec 5.
• [1006] Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development.Carcinogenesis. 2001 May;22(5):751-6. doi: 10.1093/carcin/22.5.751.
• [1007] Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer.Arthritis Res Ther. 2018 Aug 9;20(1):176. doi: 10.1186/s13075-018-1678-9.
• [1008] TRIM37 targets AKT in the growth of lung cancer cells.Onco Targets Ther. 2018 Nov 8;11:7935-7945. doi: 10.2147/OTT.S183303. eCollection 2018.
• [1009] GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer Sci. 2007 Oct;98(10):1625-32. doi: 10.1111/j.1349-7006.2007.00578.x. Epub 2007 Aug 16.
• [1010] Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma.Medicine (Baltimore). 2018 Jun;97(26):e11116. doi: 10.1097/MD.0000000000011116.
• [1011] Exposure to airborne PM2.5 suppresses microRNA expression and deregulates target oncogenes that cause neoplastic transformation in NIH3T3 cells.Oncotarget. 2015 Oct 6;6(30):29428-39. doi: 10.18632/oncotarget.5005.
• [1012] ABCA3 Phenotype in Non-Small Cell Lung Cancer Indicates Poor Outcome.Oncology. 2017;93(4):270-278. doi: 10.1159/000477619. Epub 2017 Jul 6.
• [1013] Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.BMC Cancer. 2019 Mar 19;19(1):246. doi: 10.1186/s12885-019-5438-2.
• [1014] ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010 Nov;101(11):2404-10.
• [1015] Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin.Int J Cancer. 2001 Nov 1;94(3):432-7. doi: 10.1002/ijc.1490.
• [1016] Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.Cancer Res. 1992 Jun 15;52(12):3506-9.
• [1017] Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN- and TRAIL and suppress the growth of H460 human lung cancer cells.Cancer Lett. 2019 Jan;440-441:202-210. doi: 10.1016/j.canlet.2018.10.017. Epub 2018 Oct 26.
• [1018] Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.Mol Carcinog. 2016 Nov;55(11):1822-1832. doi: 10.1002/mc.22430. Epub 2015 Oct 29.
• [1019] Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model.Oncotarget. 2014 Jul 15;5(13):4811-20. doi: 10.18632/oncotarget.2038.
• [1020] Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.Int J Cancer. 2009 Apr 1;124(7):1669-74. doi: 10.1002/ijc.23956.
• [1021] Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer.Int J Cancer. 1997 Apr 22;74(2):189-92. doi: 10.1002/(sici)1097-0215(19970422)74:2<189::aid-ijc9>3.0.co;2-v.
• [1022] The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets.Oncotarget. 2017 Feb 28;8(9):16036-16051. doi: 10.18632/oncotarget.13917.
• [1023] SLC39A4 expression is associated with enhanced cell migration, cisplatin resistance, and poor survival in non-small cell lung cancer.Sci Rep. 2017 Aug 3;7(1):7211. doi: 10.1038/s41598-017-07830-4.
• [1024] Functional expression of choline transporter-like protein 1 (CTL1) in small cell lung carcinoma cells: a target molecule for lung cancer therapy.Pharmacol Res. 2013 Oct;76:119-31. doi: 10.1016/j.phrs.2013.07.011. Epub 2013 Aug 13.
• [1025] Proteinase-activated receptor-2 enhances Bcl2-like protein-12 expression in lung cancer cells to suppress p53 expression.Arch Med Sci. 2019 Sep;15(5):1147-1153. doi: 10.5114/aoms.2019.86980. Epub 2019 Aug 2.
• [1026] Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer. Lung Cancer. 2013 Mar;79(3):198-204.
• [1027] TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1.Oncotarget. 2017 Jun 13;8(24):38426-38443. doi: 10.18632/oncotarget.16430.
• [1028] Associations between arsenic (+3 oxidation state) methyltransferase (AS3MT) and N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) polymorphisms, arsenic metabolism, and cancer risk in a chilean population.Environ Mol Mutagen. 2017 Jul;58(6):411-422. doi: 10.1002/em.22104. Epub 2017 Jun 22.
• [1029] Loss of asparagine synthetase suppresses the growth of human lung cancer cells by arresting cell cycle at G0/G1 phase.Cancer Gene Ther. 2016 Sep;23(9):287-94. doi: 10.1038/cgt.2016.28. Epub 2016 Jul 22.
• [1030] Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival.Cancer Res. 2019 Sep 15;79(18):4754-4766. doi: 10.1158/0008-5472.CAN-18-4080. Epub 2019 Jul 29.
• [1031] Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.BMC Cancer. 2017 Jul 5;17(1):467. doi: 10.1186/s12885-017-3452-9.
• [1032] DJ-1 as a potential biomarker for the early diagnosis in lung cancer patients.Tumour Biol. 2017 Jun;39(6):1010428317714625. doi: 10.1177/1010428317714625.
• [1033] UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis.Nature. 2019 Jul;571(7763):127-131. doi: 10.1038/s41586-019-1340-y. Epub 2019 Jun 26.
• [1034] Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.PLoS One. 2017 Feb 10;12(2):e0171539. doi: 10.1371/journal.pone.0171539. eCollection 2017.
• [1035] Coronary artery calcification in lung cancer screening.Transl Lung Cancer Res. 2018 Jun;7(3):361-367. doi: 10.21037/tlcr.2018.05.05.
• [1036] HapMap-based study: CYP2A13 may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non-smokers.Thorac Cancer. 2019 Apr;10(4):601-606. doi: 10.1111/1759-7714.12954. Epub 2019 Feb 26.
• [1037] CYP1A1 *2B and *4 polymorphisms are associated with lung cancer susceptibility in Mexican patients.Int J Biol Markers. 2008 Jan-Mar;23(1):24-30.
• [1038] Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus.Mol Carcinog. 2017 Jun;56(6):1663-1672. doi: 10.1002/mc.22622. Epub 2017 Feb 23.
• [1039] Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients.Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):71-76.
• [1040] Genetic variants of SULT1A1 and XRCC1 genes and risk of lung cancer in Bangladeshi population.Tumour Biol. 2017 Nov;39(11):1010428317729270. doi: 10.1177/1010428317729270.
• [1041] Effects of ABO and FUT2 genetic transcription absence on ABH histo-blood group antigen expression in lung cancer patients.Asian Pac J Cancer Prev. 2011;12(12):3201-6.
• [1042] Chemotherapy agents induce tartrate-resistant acid phosphatase 5a contributing to the symptom distress in lung cancer patients.Eur J Pharmacol. 2019 Mar 5;846:38-48. doi: 10.1016/j.ejphar.2019.01.011. Epub 2019 Jan 15.
• [1043] S-nitrosoglutathione reductase in human lung cancer.Am J Respir Cell Mol Biol. 2012 Jan;46(1):63-70. doi: 10.1165/rcmb.2011-0147OC.
• [1044] Prognostic and therapeutic potential of Adenylate kinase 2 in lung adenocarcinoma.Sci Rep. 2019 Nov 28;9(1):17757. doi: 10.1038/s41598-019-53594-4.
• [1045] Alcohol Consumption and Lung Cancer According to Ile349Val Polymorphism in ADH3 Gene: Beyond the Tobacco Smoking Effect.J Cancer. 2017 Jul 20;8(12):2296-2302. doi: 10.7150/jca.18853. eCollection 2017.
• [1046] AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.Theranostics. 2018 Jan 1;8(3):676-692. doi: 10.7150/thno.21463. eCollection 2018.
• [1047] LCAL1 enhances lung cancer survival via inhibiting AMPK-related antitumor functions.Mol Cell Biochem. 2019 Jul;457(1-2):11-20. doi: 10.1007/s11010-019-03507-w. Epub 2019 Feb 11.
• [1048] Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.Br J Pharmacol. 2015 Aug;172(16):4089-106. doi: 10.1111/bph.13189. Epub 2015 Jun 26.
• [1049] Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway.Mol Carcinog. 2019 Nov;58(11):2026-2039. doi: 10.1002/mc.23095. Epub 2019 Aug 9.
• [1050] Associations between abnormal vitamin D metabolism pathway function and non-small cell lung cancer.Oncol Lett. 2017 Dec;14(6):7538-7544. doi: 10.3892/ol.2017.7162. Epub 2017 Oct 10.
• [1051] Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer.Cancer Chemother Pharmacol. 2001 Jul;48(1):42-6. doi: 10.1007/s002800100291.
• [1052] Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan.Drug Metab Pharmacokinet. 2011;26(5):516-22. doi: 10.2133/dmpk.dmpk-11-rg-046. Epub 2011 Jul 26.
• [1053] Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.Cancer Discov. 2013 Aug;3(8):870-9. doi: 10.1158/2159-8290.CD-13-0015. Epub 2013 May 28.
• [1054] Prolyl hydroxylase 3 involvement in lung cancer progression under hypoxic conditions: association with hypoxia-inducible factor-1 and pyruvate kinase M2.J Thorac Dis. 2019 Sep;11(9):3941-3950. doi: 10.21037/jtd.2019.08.124.
• [1055] Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.J Pathol. 2006 Oct;210(2):192-204. doi: 10.1002/path.2039.
• [1056] Expression of alpha-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer.Cancer Res. 1996 Jan 15;56(2):325-9.
• [1057] -Glutamylcyclotransferase Knockdown Inhibits Growth of Lung Cancer Cells Through G0/G1 Phase Arrest.Cancer Biother Radiopharm. 2015 Jun;30(5):211-6. doi: 10.1089/cbr.2014.1807. Epub 2015 May 5.
• [1058] Inhibiting Glycine Decarboxylase Suppresses Pyruvate-to-Lactate Metabolism in Lung Cancer Cells.Front Oncol. 2018 Jun 1;8:196. doi: 10.3389/fonc.2018.00196. eCollection 2018.
• [1059] Phosphorylation of glutaminase by PKC is essential for its enzymatic activity and critically contributes to tumorigenesis.Cell Res. 2018 Jun;28(6):655-669. doi: 10.1038/s41422-018-0021-y. Epub 2018 Mar 7.
• [1060] Association between polymorphisms in the GSTA4 gene and risk of lung cancer: a case-control study in a Southeastern Chinese population.Mol Carcinog. 2009 Mar;48(3):253-259. doi: 10.1002/mc.20478.
• [1061] A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer.Lung Cancer. 2002 Aug;37(2):143-6. doi: 10.1016/s0169-5002(02)00078-8.
• [1062] Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):37-40. doi: 10.1016/j.prostaglandins.2011.06.005. Epub 2011 Jul 6.
• [1063] Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls.Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):133-40.
• [1064] MicroRNA-133 inhibits the growth and metastasis of the human lung cancer cells by targeting epidermal growth factor receptor.J BUON. 2019 May-Jun;24(3):929-935.
• [1065] Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe.Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):141-7. doi: 10.1158/1055-9965.EPI-07-0553.
• [1066] RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.EMBO J. 2019 Jul 1;38(13):e100532. doi: 10.15252/embj.2018100532. Epub 2019 May 27.
• [1067] High Expression of PTGR1 Promotes NSCLC Cell Growth via Positive Regulation of Cyclin-Dependent Protein Kinase Complex.Biomed Res Int. 2016;2016:5230642. doi: 10.1155/2016/5230642. Epub 2016 Jun 26.
• [1068] Discovery of EST-SSRs in lung cancer: tagged ESTs with SSRs lead to differential amino acid and protein expression patterns in cancerous tissues.PLoS One. 2011;6(11):e27118. doi: 10.1371/journal.pone.0027118. Epub 2011 Nov 4.
• [1069] Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer.Cancer Sci. 2019 Sep;110(9):2734-2747. doi: 10.1111/cas.14125. Epub 2019 Aug 23.
• [1070] UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res. 2004 Sep-Oct;24(5A):2893-6.
• [1071] UGT1A6 polymorphisms modulated lung cancer risk in a Chinese population.PLoS One. 2012;7(8):e42873. doi: 10.1371/journal.pone.0042873. Epub 2012 Aug 17.
• [1072] The association between UGT1A7 polymorphism and cancer risk: a meta-analysis.Cancer Epidemiol. 2012 Aug;36(4):e201-6. doi: 10.1016/j.canep.2012.02.004. Epub 2012 Mar 7.
• [1073] Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation.Lung Cancer (Auckl). 2018 Nov 8;9:111-116. doi: 10.2147/LCTT.S186804. eCollection 2018.
• [1074] miR-338 inhibits the metastasis of lung cancer by targeting integrin 3.Oncol Rep. 2016 Sep;36(3):1467-74. doi: 10.3892/or.2016.4928. Epub 2016 Jul 11.
• [1075] The biogenesis and biological functions of circular RNAs and their molecular diagnostic values in cancers.J Clin Lab Anal. 2020 Jan;34(1):e23049. doi: 10.1002/jcla.23049. Epub 2019 Sep 25.
• [1076] The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study.J Crohns Colitis. 2017 May 1;11(5):578-585. doi: 10.1093/ecco-jcc/jjw192.
• [1077] Acyl-CoA thioesterase 7 is involved in cell cycle progression via regulation of PKC-p53-p21 signaling pathway.Cell Death Dis. 2017 May 18;8(5):e2793. doi: 10.1038/cddis.2017.202.
• [1078] Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.PLoS One. 2016 May 12;11(5):e0155660. doi: 10.1371/journal.pone.0155660. eCollection 2016.
• [1079] Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study.Cancer Res. 2009 Aug 15;69(16):6633-41. doi: 10.1158/0008-5472.CAN-09-0680. Epub 2009 Aug 4.
• [1080] Association of polymorphisms in the telomere-related gene ACYP2 with lung cancer risk in the Chinese Han population.Oncotarget. 2016 Dec 27;7(52):87473-87478. doi: 10.18632/oncotarget.13870.
• [1081] Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis.Oncogene. 2016 Aug 18;35(33):4407-13. doi: 10.1038/onc.2015.469. Epub 2015 Dec 7.
• [1082] Targeting high transcriptional control activity of long mononucleotide A-T repeats in cancer by Argonaute 1.Gene. 2019 May 30;699:54-61. doi: 10.1016/j.gene.2019.03.010. Epub 2019 Mar 9.
• [1083] Feedback regulation of ALDOA activates the HIF-1/MMP9 axis to promote lung cancer progression.Cancer Lett. 2017 Sep 10;403:28-36. doi: 10.1016/j.canlet.2017.06.001. Epub 2017 Jun 10.
• [1084] The roles of ARHGAP10 in the proliferation, migration and invasion of lung cancer cells.Oncol Lett. 2017 Oct;14(4):4613-4618. doi: 10.3892/ol.2017.6729. Epub 2017 Aug 7.
• [1085] A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers.Clin Cancer Res. 2006 Jan 1;12(1):191-7. doi: 10.1158/1078-0432.CCR-05-1206.
• [1086] An intron SNP rs807185 in ATG4A decreases the risk of lung cancer in a southwest Chinese population.Eur J Cancer Prev. 2016 Jul;25(4):255-8. doi: 10.1097/CEJ.0000000000000174.
• [1087] The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis.Nature. 2019 Nov;575(7784):688-692. doi: 10.1038/s41586-019-1705-2. Epub 2019 Oct 21.
• [1088] Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.Cell Physiol Biochem. 2018;51(1):337-355. doi: 10.1159/000495233. Epub 2018 Nov 19.
• [1089] Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.Mol Carcinog. 2016 Oct;55(10):1477-85. doi: 10.1002/mc.22402. Epub 2015 Sep 1.
• [1090] A novel somatic FGFR3 mutation in primary lung cancer.Oncol Rep. 2014 Mar;31(3):1219-24. doi: 10.3892/or.2014.2984. Epub 2014 Jan 20.
• [1091] WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.Cell Signal. 2016 Nov;28(11):1673-82. doi: 10.1016/j.cellsig.2016.07.008. Epub 2016 Jul 21.
• [1092] Asbestos-associated genome-wide DNA methylation changes in lung cancer.Int J Cancer. 2017 Nov 15;141(10):2014-2029. doi: 10.1002/ijc.30897. Epub 2017 Aug 2.
• [1093] Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.Acta Pharmacol Sin. 2013 Apr;34(4):531-40. doi: 10.1038/aps.2012.196. Epub 2013 Mar 18.
• [1094] C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers.Clin Cancer Res. 2000 Aug;6(8):2988-93.
• [1095] Evaluation of peroxidative stress of cancer cells in vitro by real-time quantification of volatile aldehydes in culture headspace.Rapid Commun Mass Spectrom. 2017 Aug 30;31(16):1344-1352. doi: 10.1002/rcm.7911.
• [1096] Overexpression of adenylate cyclase-associated protein 1 is associated with metastasis of lung cancer.Oncol Rep. 2013 Oct;30(4):1639-44. doi: 10.3892/or.2013.2607. Epub 2013 Jul 9.
• [1097] Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells.Cell Immunol. 2015 Nov-Dec;298(1-2):18-24. doi: 10.1016/j.cellimm.2015.08.004. Epub 2015 Aug 18.
• [1098] Morin inhibited lung cancer cells viability, growth, and migration by suppressing miR-135b and inducing its target CCNG2.Tumour Biol. 2017 Oct;39(10):1010428317712443. doi: 10.1177/1010428317712443.
• [1099] Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.Oncotarget. 2017 Nov 25;8(66):110273-110288. doi: 10.18632/oncotarget.22681. eCollection 2017 Dec 15.
• [1100] Bioinformatics analysis of the prognostic value of CCT6A and associated signalling pathways in breast cancer.Mol Med Rep. 2019 May;19(5):4344-4352. doi: 10.3892/mmr.2019.10100. Epub 2019 Mar 28.
• [1101] Clinical significance of CD151 gene expression in non-small cell lung cancer.Clin Cancer Res. 2001 Dec;7(12):4109-14.
• [1102] CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.Oncotarget. 2016 Aug 9;8(33):54115-54135. doi: 10.18632/oncotarget.11132. eCollection 2017 Aug 15.
• [1103] Cancer-associated mutations in the canonical cleavage site do not influence CD99 shedding by the metalloprotease meprin but alter cell migration in vitro.Oncotarget. 2017 Jul 4;8(33):54873-54888. doi: 10.18632/oncotarget.18966. eCollection 2017 Aug 15.
• [1104] YdjC chitooligosaccharide deacetylase homolog induces keratin reorganization in lung cancer cells: involvement of interaction between YDJC and CDC16.Oncotarget. 2018 May 1;9(33):22915-22928. doi: 10.18632/oncotarget.25145. eCollection 2018 May 1.
• [1105] Study on expression of CDH4 in lung cancer.World J Surg Oncol. 2017 Jan 17;15(1):26. doi: 10.1186/s12957-016-1083-2.
• [1106] CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.Oncogene. 2017 Sep 14;36(37):5321-5330. doi: 10.1038/onc.2017.161. Epub 2017 May 22.
• [1107] Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2.J Hematol Oncol. 2015 May 29;8(1):57. doi: 10.1186/s13045-015-0153-1.
• [1108] Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases.Hum Pathol. 2019 Feb;84:221-230. doi: 10.1016/j.humpath.2018.10.009. Epub 2018 Oct 31.
• [1109] Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector Machine Algorithm.Sensors (Basel). 2017 Feb 4;17(2):287. doi: 10.3390/s17020287.
• [1110] Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma.Sci Rep. 2017 Sep 19;7(1):11893. doi: 10.1038/s41598-017-12131-x.
• [1111] A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer.Oncogene. 2017 May 25;36(21):2946-2956. doi: 10.1038/onc.2016.465. Epub 2017 Jan 16.
• [1112] Spi-B-Mediated Silencing of Claudin-2 Promotes Early Dissemination of Lung Cancer Cells from Primary Tumors.Cancer Res. 2017 Sep 15;77(18):4809-4822. doi: 10.1158/0008-5472.CAN-17-0020. Epub 2017 Jul 28.
• [1113] Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis.CNS Neurosci Ther. 2017 Dec;23(12):947-960. doi: 10.1111/cns.12764. Epub 2017 Sep 29.
• [1114] miR-26 suppresses renal cell cancer via down-regulating coronin-3.Mol Cell Biochem. 2020 Jan;463(1-2):137-146. doi: 10.1007/s11010-019-03636-2. Epub 2019 Oct 8.
• [1115] Epigenetic silencing of downstream genes mediated by tandem orientation in lung cancer.Sci Rep. 2017 Jun 20;7(1):3896. doi: 10.1038/s41598-017-04248-w.
• [1116] MiR-4458 inhibits breast cancer cell growth, migration, and invasiveness by targeting CPSF4.Biochem Cell Biol. 2019 Dec;97(6):722-730. doi: 10.1139/bcb-2019-0008. Epub 2019 Apr 10.
• [1117] Immune complexome analysis reveals the specific and frequent presence of immune complex antigens in lung cancer patients: A pilot study.Int J Cancer. 2017 Jan 15;140(2):370-380. doi: 10.1002/ijc.30455. Epub 2016 Oct 17.
• [1118] Lentivirus-mediated knockdown of CTDP1 inhibits lung cancer cell growth in vitro.J Cancer Res Clin Oncol. 2016 Apr;142(4):723-32. doi: 10.1007/s00432-015-2070-7. Epub 2015 Nov 21.
• [1119] Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer.BMC Cancer. 2010 Mar 1;10:75. doi: 10.1186/1471-2407-10-75.
• [1120] Overexpression of small GTPases directly correlates with expression of -catenin and their coexpression predicts a poor clinical outcome in nonsmall cell lung cancer.Mol Carcinog. 2013 May;52(5):338-47. doi: 10.1002/mc.21854. Epub 2011 Dec 27.
• [1121] Involvement of CXCL14 in osteolytic bone metastasis from lung cancer.Int J Oncol. 2014 Apr;44(4):1316-24. doi: 10.3892/ijo.2014.2293. Epub 2014 Feb 10.
• [1122] Telomere structure and maintenance gene variants and risk of five cancer types.Int J Cancer. 2016 Dec 15;139(12):2655-2670. doi: 10.1002/ijc.30288. Epub 2016 Sep 8.
• [1123] DDA1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle.J Cell Mol Med. 2017 Aug;21(8):1532-1544. doi: 10.1111/jcmm.13084. Epub 2017 Feb 17.
• [1124] DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle.Mol Cell Biol. 2016 Nov 14;36(23):2903-2917. doi: 10.1128/MCB.00314-16. Print 2016 Dec 1.
• [1125] Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition.BMC Cancer. 2017 Jul 17;17(1):487. doi: 10.1186/s12885-017-3472-5.
• [1126] Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer.Sci Rep. 2017 Aug 14;7(1):8072. doi: 10.1038/s41598-017-08615-5.
• [1127] Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer.Cancer Res. 2008 Feb 15;68(4):1037-45. doi: 10.1158/0008-5472.CAN-07-5782.
• [1128] Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.J Clin Invest. 2019 Jan 2;129(1):215-222. doi: 10.1172/JCI99699. Epub 2018 Nov 26.
• [1129] Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer.Oncoimmunology. 2017 Mar 31;6(5):e1310359. doi: 10.1080/2162402X.2017.1310359. eCollection 2017.
• [1130] Role of fibulin-3 in lung cancer: in vivo and in vitro analyses.Oncol Rep. 2014 Jan;31(1):79-86. doi: 10.3892/or.2013.2799. Epub 2013 Oct 18.
• [1131] Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells.FEBS Lett. 2017 Feb;591(4):636-645. doi: 10.1002/1873-3468.12566. Epub 2017 Feb 20.
• [1132] Epithelial membrane protein 2 regulates sphingosylphosphorylcholine-induced keratin 8 phosphorylation and reorganization: Changes of PP2A expression by interaction with alpha4 and caveolin-1 in lung cancer cells.Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1157-69. doi: 10.1016/j.bbamcr.2016.02.007. Epub 2016 Feb 10.
• [1133] The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis.Int J Med Sci. 2017 Jun 23;14(7):675-679. doi: 10.7150/ijms.19355. eCollection 2017.
• [1134] Diagnostic value of -enolase expression and serum -enolase autoantibody levels in lung cancer.J Bras Pneumol. 2018 Jan-Feb;44(1):18-23. doi: 10.1590/S1806-37562016000000241.
• [1135] Intersectin-1s deficiency in pulmonary pathogenesis.Respir Res. 2017 Sep 6;18(1):168. doi: 10.1186/s12931-017-0652-4.
• [1136] ERGIC3 Silencing Additively Enhances the Growth Inhibition of BFA on Lung Adenocarcinoma Cells.Curr Cancer Drug Targets. 2020;20(1):67-75. doi: 10.2174/1568009619666190917145906.
• [1137] ERP44 inhibits human lung cancer cell migration mainly via IP3R2.Aging (Albany NY). 2016 Jun;8(6):1276-86. doi: 10.18632/aging.100984.
• [1138] Identification of Serological Biomarkers for Early Diagnosis of Lung Cancer Using a Protein Array-Based Approach.Mol Cell Proteomics. 2017 Dec;16(12):2069-2078. doi: 10.1074/mcp.RA117.000212. Epub 2017 Oct 11.
• [1139] Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Staging of Patients with Non-Small Cell Lung Cancer without Mediastinal Involvement at Positron Emission Tomography-Computed Tomography.Respiration. 2017;94(3):279-284. doi: 10.1159/000477625. Epub 2017 Jul 6.
• [1140] IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5.Open Biol. 2018 Oct 10;8(10):180086. doi: 10.1098/rsob.180086.
• [1141] FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.Cancer Gene Ther. 2017 Aug;24(8):342-347. doi: 10.1038/cgt.2017.24. Epub 2017 Aug 4.
• [1142] Screening of genes related to lung cancer caused by smoking with RNA-Seq.Eur Rev Med Pharmacol Sci. 2014;18(1):117-25.
• [1143] Genetic risk analysis for an individual according to the theory of programmed onset, illustrated by lung and liver cancers.Gene. 2018 Oct 5;673:107-111. doi: 10.1016/j.gene.2018.06.044. Epub 2018 Jun 15.
• [1144] High-yield of biologically active recombinant human fibroblast growth factor-16 in E. coli and its mechanism of proliferation in NCL-H460 cells.Prep Biochem Biotechnol. 2017 Aug 9;47(7):720-729. doi: 10.1080/10826068.2017.1315599. Epub 2017 Apr 14.
• [1145] LncRNA-RMRP Acts as an Oncogene in Lung Cancer.PLoS One. 2016 Dec 1;11(12):e0164845. doi: 10.1371/journal.pone.0164845. eCollection 2016.
• [1146] Expression and prognosis analyses of forkhead box A (FOXA) family in human lung cancer.Gene. 2019 Feb 15;685:202-210. doi: 10.1016/j.gene.2018.11.022. Epub 2018 Nov 9.
• [1147] Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer.Nat Genet. 2014 Jul;46(7):736-41. doi: 10.1038/ng.3002. Epub 2014 Jun 1.
• [1148] DNA methylation of the Fthl17 5'-upstream region regulates differential Fthl17 expression in lung cancer cells and germline stem cells.PLoS One. 2017 Feb 16;12(2):e0172219. doi: 10.1371/journal.pone.0172219. eCollection 2017.
• [1149] Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis.Int J Oncol. 2016 Oct;49(4):1369-76. doi: 10.3892/ijo.2016.3638. Epub 2016 Jul 29.
• [1150] Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway.Acta Biochim Biophys Sin (Shanghai). 2017 Jul 1;49(7):581-587. doi: 10.1093/abbs/gmx046.
• [1151] FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression.Clin Cancer Res. 2018 Feb 15;24(4):916-926. doi: 10.1158/1078-0432.CCR-17-1347. Epub 2017 Dec 7.
• [1152] Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers.Clin Genet. 2020 Jan;97(1):64-72. doi: 10.1111/cge.13630. Epub 2019 Aug 28.
• [1153] Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer.Br J Cancer. 2005 Oct 17;93(8):949-52. doi: 10.1038/sj.bjc.6602790.
• [1154] Polymorphisms in GEMIN4 and AGO1 Genes Are Associated with the Risk of Lung Cancer: A Case-Control Study in Chinese Female Non-Smokers.Int J Environ Res Public Health. 2016 Sep 23;13(10):939. doi: 10.3390/ijerph13100939.
• [1155] EGF-stimulated activation of Rab35 regulates RUSC2-GIT2 complex formation to stabilize GIT2 during directional lung cancer cell migration.Cancer Lett. 2016 Aug 28;379(1):70-83. doi: 10.1016/j.canlet.2016.05.027. Epub 2016 May 26.
• [1156] Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A.Cell Prolif. 2017 Oct;50(5):e12364. doi: 10.1111/cpr.12364. Epub 2017 Jul 24.
• [1157] Carboxamide analog ITR-284 evokes apoptosis and inhibits migration ability in human lung adenocarcinoma A549 cells.Oncol Rep. 2017 Mar;37(3):1786-1792. doi: 10.3892/or.2017.5374. Epub 2017 Jan 16.
• [1158] GPR78 promotes lung cancer cell migration and metastasis by activation of Gq-Rho GTPase pathway.BMB Rep. 2016 Nov;49(11):623-628. doi: 10.5483/bmbrep.2016.49.11.133.
• [1159] Combined effects of glutathione S-transferase M1 and T1 polymorphisms on risk of lung cancer: Evidence from a meta-analysis.Oncotarget. 2017 Apr 25;8(17):28135-28143. doi: 10.18632/oncotarget.15943.
• [1160] Genetic variant in DNA repair gene GTF2H4 is associated with lung cancer risk: a large-scale analysis of six published GWAS datasets in the TRICL consortium.Carcinogenesis. 2016 Sep;37(9):888-896. doi: 10.1093/carcin/bgw070. Epub 2016 Jun 10.
• [1161] HIST1H3D: A promising therapeutic target for lung cancer.Int J Oncol. 2017 Mar;50(3):815-822. doi: 10.3892/ijo.2017.3856. Epub 2017 Jan 19.
• [1162] The deubiquitinating enzymes USP4 and USP17 target hyaluronan synthase 2 and differentially affect its function.Oncogenesis. 2017 Jun 12;6(6):e348. doi: 10.1038/oncsis.2017.45.
• [1163] HAT1 induces lung cancer cell apoptosis via up regulating Fas.Oncotarget. 2017 Sep 23;8(52):89970-89977. doi: 10.18632/oncotarget.21205. eCollection 2017 Oct 27.
• [1164] LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer.J Exp Clin Cancer Res. 2019 Jun 28;38(1):280. doi: 10.1186/s13046-019-1276-y.
• [1165] Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.Oncogene. 2015 Jan 29;34(5):578-88. doi: 10.1038/onc.2013.592. Epub 2014 Feb 10.
• [1166] Correlation between lung cancer and the HHIP polymorphisms of chronic obstructive pulmonary disease (COPD) in the Chinese Han population.Genes Immun. 2019 Apr;20(4):273-280. doi: 10.1038/s41435-018-0033-0. Epub 2018 Jun 19.
• [1167] HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.Clin Cancer Res. 2017 Feb 1;23(3):825-832. doi: 10.1158/1078-0432.CCR-15-3071. Epub 2016 Aug 23.
• [1168] Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer.Front Immunol. 2017 Sep 29;8:1215. doi: 10.3389/fimmu.2017.01215. eCollection 2017.
• [1169] PCAF-mediated acetylation of transcriptional factor HOXB9 suppresses lung adenocarcinoma progression by targeting oncogenic protein JMJD6.Nucleic Acids Res. 2016 Dec 15;44(22):10662-10675. doi: 10.1093/nar/gkw808. Epub 2016 Sep 8.
• [1170] HOXC10 Promotes the Metastasis of Human Lung Adenocarcinoma and Indicates Poor Survival Outcome.Front Physiol. 2017 Aug 2;8:557. doi: 10.3389/fphys.2017.00557. eCollection 2017.
• [1171] Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1.Neuro Oncol. 2016 Jun;18(6):819-29. doi: 10.1093/neuonc/nov281. Epub 2015 Nov 17.
• [1172] Targeted blockade of TGF- and IL-6/JAK2/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts.Sci Rep. 2017 Aug 17;7(1):8660. doi: 10.1038/s41598-017-09020-8.
• [1173] Meta-analysis of gene expression alterations and clinical significance of the HECT domain-containing ubiquitin ligase HUWE1 in cancer.Oncol Lett. 2019 Sep;18(3):2292-2303. doi: 10.3892/ol.2019.10579. Epub 2019 Jul 5.
• [1174] Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies.Lung Cancer. 2017 Nov;113:18-29. doi: 10.1016/j.lungcan.2017.08.026. Epub 2017 Sep 1.
• [1175] 4 is highly expressed in carcinogen-transformed human cells and primary human cancers.Oncogene. 2011 Jun 30;30(26):2943-53. doi: 10.1038/onc.2011.20. Epub 2011 Feb 21.
• [1176] ING5 inhibits lung cancer invasion and epithelial-mesenchymal transition by inhibiting the WNT/-catenin pathway.Thorac Cancer. 2019 Apr;10(4):848-855. doi: 10.1111/1759-7714.13013. Epub 2019 Feb 27.
• [1177] miR-937 contributes to the lung cancer cell proliferation by targeting INPP4B.Life Sci. 2016 Jun 15;155:110-5. doi: 10.1016/j.lfs.2016.05.014. Epub 2016 May 12.
• [1178] Inversin correlates with the malignant phenotype of non-small cell lung cancer and promotes the invasiveness of lung cancer cells.Tumour Biol. 2017 Jun;39(6):1010428317691177. doi: 10.1177/1010428317691177.
• [1179] Protecting PTEN in the Nucleus.Cancer Discov. 2017 Apr;7(4):OF1. doi: 10.1158/2159-8290.CD-NB2017-031. Epub 2017 Mar 3.
• [1180] Knockdown of Importin 7 Inhibits Lung Tumorigenesis in K-ras(LA1) Lung Cancer Mice.Anticancer Res. 2017 May;37(5):2381-2386. doi: 10.21873/anticanres.11576.
• [1181] Transcriptome-wide association study reveals candidate causal genes for lung cancer.Int J Cancer. 2020 Apr 1;146(7):1862-1878. doi: 10.1002/ijc.32771. Epub 2019 Dec 9.
• [1182] Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.Nat Genet. 2017 Jan;49(1):65-74. doi: 10.1038/ng.3722. Epub 2016 Nov 21.
• [1183] MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.J Biol Chem. 2017 Jan 6;292(1):82-99. doi: 10.1074/jbc.M116.750950. Epub 2016 Nov 16.
• [1184] Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.Biochem Biophys Res Commun. 2017 Sep 2;490(4):1407-1413. doi: 10.1016/j.bbrc.2017.07.048. Epub 2017 Jul 8.
• [1185] Tumour-suppression function of KLF12 through regulation of anoikis.Oncogene. 2016 Jun 23;35(25):3324-34. doi: 10.1038/onc.2015.394. Epub 2015 Oct 12.
• [1186] RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):27-38. doi: 10.1093/abbs/gmv090. Epub 2015 Sep 7.
• [1187] CYLD Promotes TNF--Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells.Mediators Inflamm. 2016;2016:1542786. doi: 10.1155/2016/1542786. Epub 2016 Sep 25.
• [1188] BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.Cancer Lett. 2017 Sep 10;403:48-58. doi: 10.1016/j.canlet.2017.05.019. Epub 2017 Jun 10.
• [1189] Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts.Oncol Lett. 2018 Apr;15(4):4676-4682. doi: 10.3892/ol.2018.7890. Epub 2018 Jan 29.
• [1190] Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD.Sci Rep. 2017 May 18;7(1):2121. doi: 10.1038/s41598-017-02405-9.
• [1191] The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness.J Cell Physiol. 2019 Aug;234(8):13220-13232. doi: 10.1002/jcp.27994. Epub 2018 Dec 19.
• [1192] Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.Cancer Res. 2004 Sep 1;64(17):6214-24. doi: 10.1158/0008-5472.CAN-04-0001.
• [1193] miR-515-5p controls cancer cell migration through MARK4 regulation.EMBO Rep. 2016 Apr;17(4):570-84. doi: 10.15252/embr.201540970. Epub 2016 Feb 10.
• [1194] Streptomyces artemisiae MCCB 248 isolated from Arctic fjord sediments has unique PKS and NRPS biosynthetic genes and produces potential new anticancer natural products.3 Biotech. 2017 May;7(1):32. doi: 10.1007/s13205-017-0610-3. Epub 2017 Apr 11.
• [1195] Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.Oncotarget. 2017 Apr 25;8(17):27966-27975. doi: 10.18632/oncotarget.15854.
• [1196] Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017.
• [1197] Loss of imprinting of PEG1/MEST in lung cancer cell lines.Oncol Rep. 2004 Dec;12(6):1273-8.
• [1198] MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.BMC Cancer. 2016 Nov 16;16(1):894. doi: 10.1186/s12885-016-2941-6.
• [1199] MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription.Oncogene. 2015 Oct 29;34(44):5570-81. doi: 10.1038/onc.2015.14. Epub 2015 Mar 9.
• [1200] Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients.Cancer Immunol Res. 2017 Sep;5(9):821-829. doi: 10.1158/2326-6066.CIR-16-0392. Epub 2017 Aug 3.
• [1201] Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-B.Oncotarget. 2016 Oct 4;7(40):66032-66050. doi: 10.18632/oncotarget.11797.
• [1202] B-Myb Is Up-Regulated and Promotes Cell Growth and Motility in Non-Small Cell Lung Cancer.Int J Mol Sci. 2017 May 27;18(6):860. doi: 10.3390/ijms18060860.
• [1203] Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC.Mol Cancer Res. 2017 Oct;15(10):1354-1365. doi: 10.1158/1541-7786.MCR-17-0191. Epub 2017 Jul 11.
• [1204] NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression.Nat Commun. 2017 Oct 13;8(1):928. doi: 10.1038/s41467-017-00988-5.
• [1205] Tumorsphere assay provides a better in vitro method for cancer stem-like cells enrichment in A549 lung adenocarcinoma cells.Tissue Cell. 2019 Oct;60:21-24. doi: 10.1016/j.tice.2019.07.003. Epub 2019 Jul 16.
• [1206] The (CCTTT)n microsatellite polymorphism in the NOS2 gene may influence lung cancer risk and long-term survival, especially in non-smokers.Tumour Biol. 2014 May;35(5):4425-34. doi: 10.1007/s13277-013-1582-5. Epub 2014 Jan 10.
• [1207] Cutaneous T-cell lymphoma-associated lung cancers show chromosomal aberrations differing from primary lung cancer.Genes Chromosomes Cancer. 2008 Feb;47(2):107-17. doi: 10.1002/gcc.20513.
• [1208] Polymorphisms in DNA repair genes in lung cancer patients living in a coal-mining region.Eur J Cancer Prev. 2019 Nov;28(6):522-528. doi: 10.1097/CEJ.0000000000000504.
• [1209] Microarray data re-annotation reveals specific lncRNAs and their potential functions in non-small cell lung cancer subtypes.Mol Med Rep. 2017 Oct;16(4):5129-5136. doi: 10.3892/mmr.2017.7244. Epub 2017 Aug 14.
• [1210] DNA damage-induced apoptosis suppressor (DDIAS), a novel target of NFATc1, is associated with cisplatin resistance in lung cancer.Biochim Biophys Acta. 2016 Jan;1863(1):40-9. doi: 10.1016/j.bbamcr.2015.10.011. Epub 2015 Oct 25.
• [1211] A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.Mol Oncol. 2016 Nov;10(9):1437-1449. doi: 10.1016/j.molonc.2016.08.001. Epub 2016 Aug 9.
• [1212] Ninjurin1 suppresses metastatic property of lung cancer cells through inhibition of interleukin 6 signaling pathway.Int J Cancer. 2016 Jul 15;139(2):383-95. doi: 10.1002/ijc.30021. Epub 2016 Feb 16.
• [1213] Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.Mol Cancer. 2017 Oct 12;16(1):158. doi: 10.1186/s12943-017-0705-9.
• [1214] Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.Nat Chem Biol. 2019 Aug;15(8):822-829. doi: 10.1038/s41589-019-0310-x. Epub 2019 Jul 8.
• [1215] OLA1 contributes to epithelial-mesenchymal transition in lung cancer by modulating the GSK3/snail/E-cadherin signaling.Oncotarget. 2016 Mar 1;7(9):10402-13. doi: 10.18632/oncotarget.7224.
• [1216] Aerosolizable gold nano-in-micro dry powder formulations for theragnosis and lung delivery.Int J Pharm. 2017 Mar 15;519(1-2):240-249. doi: 10.1016/j.ijpharm.2017.01.032. Epub 2017 Jan 19.
• [1217] Roles of partitioning-defective protein 6 (Par6) and its complexes in the proliferation, migration and invasion of cancer cells.Clin Exp Pharmacol Physiol. 2017 Sep;44(9):909-913. doi: 10.1111/1440-1681.12794.
• [1218] PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.Mol Cancer Ther. 2016 Jul;15(7):1669-81. doi: 10.1158/1535-7163.MCT-15-0182. Epub 2016 May 11.
• [1219] MicroRNA?915?p prevents the apoptosis of lung cancer cells by downregulating DRG2 and PBX2.Mol Med Rep. 2016 Jan;13(1):505-12. doi: 10.3892/mmr.2015.4565. Epub 2015 Nov 13.
• [1220] MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1.Tumour Biol. 2016 Nov;37(11):15221-15228. doi: 10.1007/s13277-016-5347-9. Epub 2016 Sep 28.
• [1221] Analysis of RTEL1 and PCDHGB6 promoter methylation in circulating-free DNA of lung cancer patients using liquid biopsy: A pilot study.Exp Lung Res. 2016 Aug;42(6):307-13. doi: 10.1080/01902148.2016.1214191. Epub 2016 Aug 2.
• [1222] LHX6, An Independent Prognostic Factor, Inhibits Lung Adenocarcinoma Progression through Transcriptional Silencing of -catenin.J Cancer. 2017 Aug 2;8(13):2561-2574. doi: 10.7150/jca.19972. eCollection 2017.
• [1223] The PDRG1 is an oncogene in lung cancer cells, promoting radioresistance via the ATM-P53 signaling pathway.Biomed Pharmacother. 2016 Oct;83:1471-1477. doi: 10.1016/j.biopha.2016.08.034. Epub 2016 Sep 7.
• [1224] Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling.Cell Death Dis. 2018 Jul 23;9(8):802. doi: 10.1038/s41419-018-0817-1.
• [1225] Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.Tumour Biol. 2014 Oct;35(10):10341-9. doi: 10.1007/s13277-014-2284-3. Epub 2014 Jul 21.
• [1226] Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression.Oncogene. 2017 Feb 16;36(7):885-898. doi: 10.1038/onc.2016.257. Epub 2016 Oct 3.
• [1227] A novel serine protease SNC19 associated with human colorectal cancer.Chin Med J (Engl). 2001 Jul;114(7):726-30.
• [1228] PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage.Cell Signal. 2013 Jan;25(1):74-84. doi: 10.1016/j.cellsig.2012.09.009. Epub 2012 Sep 11.
• [1229] PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing.Cancer Med. 2019 May;8(5):2429-2441. doi: 10.1002/cam4.2115. Epub 2019 Apr 1.
• [1230] PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer.Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5766-E5775. doi: 10.1073/pnas.1804779115. Epub 2018 Jun 4.
• [1231] Loss of polymeric immunoglobulin receptor expression is associated with lung tumourigenesis.Eur Respir J. 2012 May;39(5):1171-80. doi: 10.1183/09031936.00184410. Epub 2011 Sep 29.
• [1232] Identification and characterization of RASSF1C piRNA target genes in lung cancer cells.Oncotarget. 2017 May 23;8(21):34268-34282. doi: 10.18632/oncotarget.15965.
• [1233] Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer.Cancer Res. 2005 Aug 15;65(16):7102-10. doi: 10.1158/0008-5472.CAN-04-1877.
• [1234] PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.Am J Pathol. 2013 Nov;183(5):1634-1644. doi: 10.1016/j.ajpath.2013.07.028. Epub 2013 Sep 17.
• [1235] Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage.Clin Cancer Res. 2017 Feb 15;23(4):1104-1116. doi: 10.1158/1078-0432.CCR-16-1585. Epub 2016 Sep 2.
• [1236] Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.Cancer Sci. 2017 Mar;108(3):528-535. doi: 10.1111/cas.13142.
• [1237] S-nitrosylation of the Peroxiredoxin-2 promotes S-nitrosoglutathione-mediated lung cancer cells apoptosis via AMPK-SIRT1 pathway.Cell Death Dis. 2019 Apr 15;10(5):329. doi: 10.1038/s41419-019-1561-x.
• [1238] Anti-cancer effect of snake venom toxin through down regulation of AP-1 mediated PRDX6 expression.Oncotarget. 2015 Sep 8;6(26):22139-51. doi: 10.18632/oncotarget.4192.
• [1239] The role of Necl-5 in the invasive activity of lung adenocarcinoma.Exp Mol Pathol. 2013 Apr;94(2):330-5. doi: 10.1016/j.yexmp.2012.12.003. Epub 2012 Dec 28.
• [1240] Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion.BMC Cancer. 2017 Mar 28;17(1):224. doi: 10.1186/s12885-017-3219-3.
• [1241] Expression of Rab1A is upregulated in human lung cancer and associated with tumor size and T stage.Aging (Albany NY). 2016 Nov 29;8(11):2790-2798. doi: 10.18632/aging.101087.
• [1242] Differential expression of RAB5A in human lung adenocarcinoma cells with different metastasis potential.Clin Exp Metastasis. 1999 May;17(3):213-9. doi: 10.1023/a:1006617016451.
• [1243] Genome-wide association study of familial lung cancer.Carcinogenesis. 2018 Sep 21;39(9):1135-1140. doi: 10.1093/carcin/bgy080.
• [1244] Resveratrol induced premature senescence and inhibited epithelial-mesenchymal transition of cancer cells via induction of tumor suppressor Rad9.PLoS One. 2019 Jul 16;14(7):e0219317. doi: 10.1371/journal.pone.0219317. eCollection 2019.
• [1245] Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells.Oncotarget. 2016 Apr 5;7(14):18371-83. doi: 10.18632/oncotarget.7813.
• [1246] Genome-wide analysis of survival in early-stage non-small-cell lung cancer.J Clin Oncol. 2009 Jun 1;27(16):2660-7. doi: 10.1200/JCO.2008.18.7906. Epub 2009 May 4.
• [1247] Transforming Growth Factor--Induced RBFOX3 Inhibition Promotes Epithelial-Mesenchymal Transition of Lung Cancer Cells.Mol Cells. 2016 Aug 31;39(8):625-30. doi: 10.14348/molcells.2016.0150. Epub 2016 Jul 19.
• [1248] Functional role of RBM10 in lung adenocarcinoma proliferation.Int J Oncol. 2019 Feb;54(2):467-478. doi: 10.3892/ijo.2018.4643. Epub 2018 Nov 22.
• [1249] RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma.Oncogene. 2016 Sep 22;35(38):5000-9. doi: 10.1038/onc.2016.35. Epub 2016 Feb 29.
• [1250] A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT).Oncotarget. 2017 Jul 11;8(28):45345-45355. doi: 10.18632/oncotarget.17477.
• [1251] Trinucleotide repeat length variation in the human ribosomal protein L14 gene (RPL14): localization to 3p21.3 and loss of heterozygosity in lung and oral cancers.Mutat Res. 1998 Nov;406(1):9-23. doi: 10.1016/s1383-5726(98)00006-5.
• [1252] rpL3 promotes the apoptosis of p53 mutated lung cancer cells by down-regulating CBS and NFB upon 5-FU treatment.Sci Rep. 2016 Dec 7;6:38369. doi: 10.1038/srep38369.
• [1253] A precision-guided MWNT mediated reawakening the sunk synergy in RAS for anti-angiogenesis lung cancer therapy.Biomaterials. 2017 Sep;139:75-90. doi: 10.1016/j.biomaterials.2017.05.046. Epub 2017 May 31.
• [1254] TIF-IA: An oncogenic target of pre-ribosomal RNA synthesis.Biochim Biophys Acta. 2016 Dec;1866(2):189-196. doi: 10.1016/j.bbcan.2016.09.003. Epub 2016 Sep 15.
• [1255] Inhibition of rhotekin exhibits antitumor effects in lung cancer cells.Oncol Rep. 2016 May;35(5):2529-34. doi: 10.3892/or.2016.4634. Epub 2016 Feb 24.
• [1256] Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.J Clin Invest. 2017 Aug 1;127(8):2982-2997. doi: 10.1172/JCI89957. Epub 2017 Jul 10.
• [1257] WW45, a Gli1 binding protein, negatively regulated Hedgehog signaling in lung cancer.Oncotarget. 2016 Oct 18;7(42):68966-68975. doi: 10.18632/oncotarget.12155.
• [1258] Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis.Oncotarget. 2016 Jan 19;7(3):3297-316. doi: 10.18632/oncotarget.6489.
• [1259] ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology.PLoS One. 2016 Nov 1;11(11):e0165181. doi: 10.1371/journal.pone.0165181. eCollection 2016.
• [1260] Genetic Polymorphisms in the Apoptosis-Associated Gene CASP3 and the Risk of Lung Cancer in Chinese Population.PLoS One. 2016 Oct 10;11(10):e0164358. doi: 10.1371/journal.pone.0164358. eCollection 2016.
• [1261] Neuropilin-2 Is upregulated in lung cancer cells during TGF-1-induced epithelial-mesenchymal transition.Cancer Res. 2013 Dec 1;73(23):7111-21. doi: 10.1158/0008-5472.CAN-13-1755. Epub 2013 Oct 11.
• [1262] Methylation analysis in spontaneous sputum for lung cancer diagnosis.Lung Cancer. 2014 May;84(2):127-33. doi: 10.1016/j.lungcan.2014.01.019. Epub 2014 Jan 31.
• [1263] SWOG S1400D (NCT02965378), a Phase II Study ofthe Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated StageIV Squamous Cell Lung Cancer (Lung-MAPSubstudy).J Thorac Oncol. 2019 Oct;14(10):1847-1852. doi: 10.1016/j.jtho.2019.05.041. Epub 2019 Jun 11.
• [1264] Short stature homeobox 2 methylation as a potential noninvasive biomarker in bronchial aspirates for lung cancer diagnosis.Oncotarget. 2017 May 22;8(37):61253-61263. doi: 10.18632/oncotarget.18056. eCollection 2017 Sep 22.
• [1265] SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression.Cancer Res. 2016 Jan 15;76(2):358-69. doi: 10.1158/0008-5472.CAN-15-1879. Epub 2015 Nov 17.
• [1266] Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.Oncotarget. 2017 Jan 10;8(2):2681-2693. doi: 10.18632/oncotarget.13153.
• [1267] Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.PLoS One. 2017 Aug 14;12(8):e0181601. doi: 10.1371/journal.pone.0181601. eCollection 2017.
• [1268] A herpes simplex virus type 2-encoded microRNA promotes tumor cell metastasis by targeting suppressor of cytokine signaling 2 in lung cancer.Tumour Biol. 2017 May;39(5):1010428317701633. doi: 10.1177/1010428317701633.
• [1269] Knockdown of SOX12 expression inhibits the proliferation and metastasis of lung cancer cells.Am J Transl Res. 2017 Sep 15;9(9):4003-4014. eCollection 2017.
• [1270] SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells.Oncogene. 2019 Aug;38(34):6196-6210. doi: 10.1038/s41388-019-0865-8. Epub 2019 Jul 22.
• [1271] miR-539 inhibits prostate cancer progression by directly targeting SPAG5.J Exp Clin Cancer Res. 2016 Apr 1;35:60. doi: 10.1186/s13046-016-0337-8.
• [1272] SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma.Oncotarget. 2016 Jul 12;7(28):44417-44429. doi: 10.18632/oncotarget.10088.
• [1273] Alternative splicing in lung cancer.Biochim Biophys Acta Gene Regul Mech. 2019 Nov-Dec;1862(11-12):194388. doi: 10.1016/j.bbagrm.2019.05.006. Epub 2019 May 29.
• [1274] Antitumor activity of SR splicing-factor 5 knockdown by downregulating pyruvate kinase M2 in non-small cell lung cancer cells.J Cell Biochem. 2019 Oct;120(10):17303-17311. doi: 10.1002/jcb.28992. Epub 2019 May 20.
• [1275] Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model.Cancers (Basel). 2019 Jan 7;11(1):49. doi: 10.3390/cancers11010049.
• [1276] Identification of Methylation-Driven, Differentially Expressed STXBP6 as a Novel Biomarker in Lung Adenocarcinoma.Sci Rep. 2017 Feb 15;7:42573. doi: 10.1038/srep42573.
• [1277] TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-B pathway.Tumour Biol. 2016 Mar;37(3):3851-61. doi: 10.1007/s13277-015-3896-y. Epub 2015 Oct 17.
• [1278] Clinicopathological significance of p14(ARF) expression in lung cancer: a meta-analysis.Onco Targets Ther. 2017 May 8;10:2491-2499. doi: 10.2147/OTT.S131954. eCollection 2017.
• [1279] TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells.Biol Res. 2019 Jul 11;52(1):35. doi: 10.1186/s40659-019-0244-5.
• [1280] Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis.Biochem Pharmacol. 2019 Aug;166:23-32. doi: 10.1016/j.bcp.2019.05.005. Epub 2019 May 7.
• [1281] Prognostic value of TIM-1 expression in human non-small-cell lung cancer.J Transl Med. 2019 May 28;17(1):178. doi: 10.1186/s12967-019-1931-2.
• [1282] The association of transporter genes polymorphisms and lung cancer chemotherapy response.PLoS One. 2014 Mar 18;9(3):e91967. doi: 10.1371/journal.pone.0091967. eCollection 2014.
• [1283] TMEM45B, up-regulated in human lung cancer, enhances tumorigenicity of lung cancer cells.Tumour Biol. 2016 Sep;37(9):12181-12191. doi: 10.1007/s13277-016-5063-5. Epub 2016 May 26.
• [1284] TIPE1 function as a prognosis predictor and negative regulator of lung cancer.Oncotarget. 2017 Jul 28;8(45):78496-78506. doi: 10.18632/oncotarget.19655. eCollection 2017 Oct 3.
• [1285] Overexpression of TNKS1BP1 in lung cancers and its involvement in homologous recombination pathway of DNA double-strand breaks.Cancer Med. 2017 Feb;6(2):483-493. doi: 10.1002/cam4.995. Epub 2017 Jan 6.
• [1286] Down-regulation of tensin2 enhances tumorigenicity and is associated with a variety of cancers.Oncotarget. 2016 Jun 21;7(25):38143-38153. doi: 10.18632/oncotarget.9411.
• [1287] Expression of LUN gene that encodes a novel RING finger protein is correlated with development and progression of non-small cell lung cancer.Lung Cancer. 2004 Oct;46(1):21-8. doi: 10.1016/j.lungcan.2004.03.009.
• [1288] High expression of TRIM11 correlates with poor prognosis in patients with hepatocellular carcinoma.Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):190-196. doi: 10.1016/j.clinre.2016.09.010. Epub 2017 Jan 5.
• [1289] Tripartite motifcontaining11 regulates the proliferation and apoptosis of breast cancer cells.Oncol Rep. 2019 Apr;41(4):2567-2574. doi: 10.3892/or.2019.7015. Epub 2019 Feb 14.
• [1290] Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression.Technol Cancer Res Treat. 2016 Oct;15(5):707-15. doi: 10.1177/1533034615595903. Epub 2015 Jun 25.
• [1291] Tissue specific DNA methylation in normal human breast epithelium and in breast cancer.PLoS One. 2014 Mar 20;9(3):e91805. doi: 10.1371/journal.pone.0091805. eCollection 2014.
• [1292] Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.J Pathol. 2014 Sep;234(1):108-19. doi: 10.1002/path.4385. Epub 2014 Jul 16.
• [1293] Elevated expression of thyroid hormone receptor-interacting protein 13 drives tumorigenesis and affects clinical outcome.Biomark Med. 2017 Jan;11(1):19-31. doi: 10.2217/bmm-2016-0169. Epub 2016 Nov 9.
• [1294] Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis.Genes Chromosomes Cancer. 2010 Apr;49(4):353-67. doi: 10.1002/gcc.20747.
• [1295] MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53.Clin Cancer Res. 2017 Jul 15;23(14):3906-3917. doi: 10.1158/1078-0432.CCR-16-2530. Epub 2017 Feb 14.
• [1296] Identification of a novel transcript isoform of the TTLL12 gene in human cancers.Oncol Rep. 2016 Dec;36(6):3172-3180. doi: 10.3892/or.2016.5135. Epub 2016 Sep 28.
• [1297] AHNAK Loss in Mice Promotes Type II Pneumocyte Hyperplasia and Lung Tumor Development.Mol Cancer Res. 2018 Aug;16(8):1287-1298. doi: 10.1158/1541-7786.MCR-17-0726. Epub 2018 May 3.
• [1298] ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.Cancer Res. 2005 Dec 15;65(24):11314-25. doi: 10.1158/0008-5472.CAN-05-1507.
• [1299] Cross-cancer profiling of molecular alterations within the human autophagy interaction network.Autophagy. 2015;11(9):1668-87. doi: 10.1080/15548627.2015.1067362.
• [1300] Effect of cytokine-induced killer cells combined with dendritic cells on the survival rate and expression of 14-3-3 and p-Bad proteins in Lewis lung cancer cell lines.Oncol Lett. 2018 Aug;16(2):1815-1820. doi: 10.3892/ol.2018.8834. Epub 2018 May 30.
• [1301] Human basonuclin 2 up-regulates a cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer model.Cancer Cell Int. 2017 Feb 6;17:18. doi: 10.1186/s12935-017-0394-x. eCollection 2017.
• [1302] Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.Hum Mol Genet. 2005 Apr 15;14(8):997-1007. doi: 10.1093/hmg/ddi092. Epub 2005 Mar 3.
• [1303] Establishing a detection method for CCNY: a potentially significant clinical investigative marker in NSCLC patients.Onco Targets Ther. 2019 Jan 29;12:921-932. doi: 10.2147/OTT.S180507. eCollection 2019.
• [1304] Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis.Nat Med. 2017 Mar;23(3):291-300. doi: 10.1038/nm.4285. Epub 2017 Feb 13.
• [1305] Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice.Oncotarget. 2014 Dec 30;5(24):12835-48. doi: 10.18632/oncotarget.2547.
• [1306] The Expression Pattern of p120-Catenin is Associated With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):64-70. doi: 10.1097/PAI.0000000000000381.
• [1307] A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis.Cancer Res. 2005 Jul 1;65(13):5638-46. doi: 10.1158/0008-5472.CAN-05-0600.
• [1308] Tumor-suppressive effects of MBP-1 in non-small cell lung cancer cells.Cancer Res. 2006 Dec 15;66(24):11907-12. doi: 10.1158/0008-5472.CAN-06-2754.
• [1309] ETV4 overexpression promotes progression of non-small cell lung cancer by upregulating PXN and MMP1 transcriptionally.Mol Carcinog. 2020 Jan;59(1):73-86. doi: 10.1002/mc.23130. Epub 2019 Oct 31.
• [1310] Aberrant methylation of FBN2 in human non-small cell lung cancer.Lung Cancer. 2005 Oct;50(1):43-9. doi: 10.1016/j.lungcan.2005.04.013.
• [1311] Cigarette Smoking Condensate Disrupts Endoplasmic Reticulum-Golgi Network Homeostasis Through GOLPH3 Expression in Normal Lung Epithelial Cells.Nicotine Tob Res. 2016 Sep;18(9):1877-1885. doi: 10.1093/ntr/ntw079. Epub 2016 Mar 31.
• [1312] Triptolide inhibits Wnt signaling in NSCLC through upregulation of multiple Wnt inhibitory factors via epigenetic modifications to Histone H3.Int J Cancer. 2018 Nov 15;143(10):2470-2478. doi: 10.1002/ijc.31756. Epub 2018 Sep 19.
• [1313] A regional analysis of epidermal growth factor receptor (EGFR) mutated lung cancer for HSE South.Ir J Med Sci. 2017 Nov;186(4):855-857. doi: 10.1007/s11845-017-1579-y. Epub 2017 Feb 9.
• [1314] Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor .Int J Oncol. 2015 Jul;47(1):106-14. doi: 10.3892/ijo.2015.2988. Epub 2015 May 6.
• [1315] Polymorphisms of microRNA sequences or binding sites and lung cancer: a meta-analysis and systematic review.PLoS One. 2013 Apr 16;8(4):e61008. doi: 10.1371/journal.pone.0061008. Print 2013.
• [1316] UPregulated single-stranded DNA-binding protein 1 induces cell chemoresistance to cisplatin in lung cancer cell lines.Mol Cell Biochem. 2017 Jul;431(1-2):21-27. doi: 10.1007/s11010-017-2970-8. Epub 2017 Feb 16.
• [1317] NF-YA Overexpression in Lung Cancer: LUSC.Genes (Basel). 2019 Nov 17;10(11):937. doi: 10.3390/genes10110937.
• [1318] RASSF10 suppresses lung cancer proliferation and invasion by decreasing the level of phosphorylated LRP6.Mol Carcinog. 2019 Jul;58(7):1168-1180. doi: 10.1002/mc.23000. Epub 2019 Mar 4.
• [1319] Survival of lung cancer patients is prolonged with higher regucalcin gene expression: suppressed proliferation of lung adenocarcinoma A549 cells in vitro.Mol Cell Biochem. 2017 Jun;430(1-2):37-46. doi: 10.1007/s11010-017-2952-x. Epub 2017 Feb 8.
• [1320] TGF-Induced Lung Cancer Cell Migration Is NR4A1-Dependent.Mol Cancer Res. 2018 Dec;16(12):1991-2002. doi: 10.1158/1541-7786.MCR-18-0366. Epub 2018 Aug 2.
• [1321] Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma.PLoS One. 2013 Aug 16;8(8):e71816. doi: 10.1371/journal.pone.0071816. eCollection 2013.
• [1322] Long noncoding RNA00887 reduces the invasion and metastasis of nonsmall cell lung cancer by causing the degradation of miRNAs.Oncol Rep. 2019 Sep;42(3):1173-1182. doi: 10.3892/or.2019.7228. Epub 2019 Jul 11.
• [1323] SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via Transcriptional and Posttranslational Regulation of -Catenin in Lung Cancer.EBioMedicine. 2018 May;31:253-266. doi: 10.1016/j.ebiom.2018.04.026. Epub 2018 May 5.
• [1324] MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.Oncol Res. 2019 Aug 8;27(8):879-887. doi: 10.3727/096504018X15451308507747. Epub 2019 Apr 14.
• [1325] TIFA Promotes Cell Survival and Migration in Lung Adenocarcinoma.Cell Physiol Biochem. 2018;47(5):2097-2108. doi: 10.1159/000491478. Epub 2018 Jul 5.
• [1326] DAC can restore expression of NALP1 to suppress tumor growth in colon cancer.Cell Death Dis. 2015 Jan 22;6(1):e1602. doi: 10.1038/cddis.2014.532.
• [1327] Co-expression of RelA/p65 and ACTN4 induces apoptosis in non-small lung carcinoma cells.Cell Cycle. 2018;17(5):616-626. doi: 10.1080/15384101.2017.1417709. Epub 2018 Jan 22.
• [1328] MiR-144 inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR.Cell Physiol Biochem. 2015;35(3):997-1007. doi: 10.1159/000369755. Epub 2015 Feb 2.
• [1329] Single nucleotide polymorphisms in VTI1A gene contribute to the susceptibility of Chinese population to non-small cell lung cancer.Int J Biol Markers. 2015 Jul 22;30(3):e286-93. doi: 10.5301/jbm.5000140.
• [1330] AP-2 downregulation by cigarette smoke condensate is counteracted by p53 in human lung cancer cells.Int J Mol Med. 2014 Oct;34(4):1094-100. doi: 10.3892/ijmm.2014.1857. Epub 2014 Jul 17.
• [1331] Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations.J Thorac Imaging. 2019 May;34(3):160-169. doi: 10.1097/RTI.0000000000000379.
• [1332] Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma.Biomed Res Int. 2015;2015:358125. doi: 10.1155/2015/358125. Epub 2015 Feb 23.
• [1333] Typing tumors using pathways selected by somatic evolution.Nat Commun. 2018 Oct 8;9(1):4159. doi: 10.1038/s41467-018-06464-y.
• [1334] The association between three AXIN2 variants and cancer risk.J Cell Biochem. 2019 Sep;120(9):15561-15571. doi: 10.1002/jcb.28823. Epub 2019 Apr 30.
• [1335] Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer.Oncol Rep. 2015 Jan;33(1):283-91. doi: 10.3892/or.2014.3584. Epub 2014 Nov 3.
• [1336] Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations.Am J Hum Genet. 2015 May 7;96(5):832-40. doi: 10.1016/j.ajhg.2015.03.009. Epub 2015 Apr 30.
• [1337] Gamma Irradiation Upregulates B-cell Translocation Gene 2 to Attenuate Cell Proliferation of Lung Cancer Cells Through the JNK and NF-B Pathways.Oncol Res. 2017 Aug 7;25(7):1199-1205. doi: 10.3727/096504017X14873444858101. Epub 2017 Mar 2.
• [1338] ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma.Sci Rep. 2013;3:1305. doi: 10.1038/srep01305.
• [1339] USP24 induces IL-6 in tumor-associated microenvironment by stabilizing p300 and -TrCP and promotes cancer malignancy.Nat Commun. 2018 Sep 28;9(1):3996. doi: 10.1038/s41467-018-06178-1.
• [1340] Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation.Oncotarget. 2016 Feb 23;7(8):9513-24. doi: 10.18632/oncotarget.7069.
• [1341] Proteomic analysis of proteins related to prognosis of lung adenocarcinoma.J Proteome Res. 2014 Nov 7;13(11):4686-94. doi: 10.1021/pr4012969. Epub 2014 Jul 8.
• [1342] EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.Biochim Biophys Acta. 2015 Jul;1852(7):1540-9. doi: 10.1016/j.bbadis.2015.04.020. Epub 2015 Apr 23.
• [1343] The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas.Tumour Biol. 2015 Dec;36(12):9487-97. doi: 10.1007/s13277-015-3618-5. Epub 2015 Jul 1.
• [1344] Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.EBioMedicine. 2018 Mar;29:112-127. doi: 10.1016/j.ebiom.2018.02.001. Epub 2018 Feb 5.
• [1345] CUGBP1 promotes cell proliferation and suppresses apoptosis via down-regulating C/EBP in human non-small cell lung cancers.Med Oncol. 2015 Mar;32(3):82. doi: 10.1007/s12032-015-0544-8. Epub 2015 Feb 21.
• [1346] CEMP1 Induces Transformation in Human Gingival Fibroblasts.PLoS One. 2015 May 26;10(5):e0127286. doi: 10.1371/journal.pone.0127286. eCollection 2015.
• [1347] Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells.Mol Med Rep. 2015 Mar;11(3):2118-24. doi: 10.3892/mmr.2014.2936. Epub 2014 Nov 13.
• [1348] Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer.J Thorac Oncol. 2015 Aug;10(8):1181-8. doi: 10.1097/JTO.0000000000000592.
• [1349] Detection of sputum cofilin-1 as indicator of malignancy.Braz J Med Biol Res. 2018;51(8):e7138. doi: 10.1590/1414-431x20187138. Epub 2018 May 28.
• [1350] PKC-iPLA2-PGE2-PPAR signaling cascade mediates TNF- induced Claudin 1 expression in human lung carcinoma cells.Cell Signal. 2015 Mar;27(3):568-77. doi: 10.1016/j.cellsig.2014.12.015. Epub 2015 Jan 3.
• [1351] Proteome analysis for downstream targets of oncogenic KRAS--the potential participation of CLIC4 in carcinogenesis in the lung.PLoS One. 2014 Feb 4;9(2):e87193. doi: 10.1371/journal.pone.0087193. eCollection 2014.
• [1352] TopBP1 and Claspin contribute to the radioresistance of lung cancer brain metastases.Mol Cancer. 2014 Sep 12;13:211. doi: 10.1186/1476-4598-13-211.
• [1353] X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma cells.J Exp Clin Cancer Res. 2018 Dec 14;37(1):315. doi: 10.1186/s13046-018-1000-3.
• [1354] Alteration of DACH1 methylation patterns in lung cancer contributes to cell proliferation and migration.Biochem Cell Biol. 2018 Oct;96(5):602-609. doi: 10.1139/bcb-2017-0279. Epub 2018 Mar 28.
• [1355] CAGE Binds to Beclin1, Regulates Autophagic Flux and CAGE-Derived Peptide Confers Sensitivity to Anti-cancer Drugs in Non-small Cell Lung Cancer Cells.Front Oncol. 2018 Dec 10;8:599. doi: 10.3389/fonc.2018.00599. eCollection 2018.
• [1356] META-GSA: Combining Findings from Gene-Set Analyses across Several Genome-Wide Association Studies.PLoS One. 2015 Oct 26;10(10):e0140179. doi: 10.1371/journal.pone.0140179. eCollection 2015.
• [1357] Identification and validation of gene module associated with lung cancer through coexpression network analysis.Gene. 2015 May 25;563(1):56-62. doi: 10.1016/j.gene.2015.03.008. Epub 2015 Mar 7.
• [1358] Diacylglycerol kinase modulates oncogenic properties of lung cancer cells.Clin Transl Oncol. 2014 Jan;16(1):29-35. doi: 10.1007/s12094-013-1036-y. Epub 2013 Apr 10.
• [1359] 13q14 deletions in CLL involve cooperating tumor suppressors.Blood. 2010 May 13;115(19):3916-22. doi: 10.1182/blood-2009-10-249367. Epub 2010 Jan 13.
• [1360] Integrating expression-related SNPs into genome-wide gene- and pathway-based analyses identified novel lung cancer susceptibility genes.Int J Cancer. 2018 Apr 15;142(8):1602-1610. doi: 10.1002/ijc.31182. Epub 2017 Dec 12.
• [1361] The expression profile and prognostic significance of eukaryotic translation elongation factors in different cancers.PLoS One. 2018 Jan 17;13(1):e0191377. doi: 10.1371/journal.pone.0191377. eCollection 2018.
• [1362] Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.Lung Cancer. 2015 Nov;90(2):175-81. doi: 10.1016/j.lungcan.2015.08.019. Epub 2015 Sep 3.
• [1363] ENTPD5 induces apoptosis in lung cancer cells via regulating caspase 3 expression.PLoS One. 2015 Mar 20;10(3):e0120046. doi: 10.1371/journal.pone.0120046. eCollection 2015.
• [1364] RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer.Int J Clin Exp Pathol. 2015 Jan 1;8(1):361-7. eCollection 2015.
• [1365] XPF polymorphism toward lung cancer susceptibility and survival in patients treated with platinum-based chemotherapy.Future Oncol. 2018 May;14(11):1071-1089. doi: 10.2217/fon-2017-0569. Epub 2018 May 9.
• [1366] Adenovirus vector-mediated FAM176A overexpression induces cell death in human H1299 non-small cell lung cancer cells.BMB Rep. 2014 Feb;47(2):104-9. doi: 10.5483/bmbrep.2014.47.2.090.
• [1367] TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1.Oncogenesis. 2017 Apr 24;6(4):e323. doi: 10.1038/oncsis.2017.18.
• [1368] ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549.Tumour Biol. 2014 Feb;35(2):1377-82. doi: 10.1007/s13277-013-1188-y. Epub 2013 Sep 27.
• [1369] Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.BMC Cancer. 2015 Oct 5;15:649. doi: 10.1186/s12885-015-1649-3.
• [1370] Inhibitory mechanism of FAT4 gene expression in response to actin dynamics during Src-induced carcinogenesis.PLoS One. 2015 Feb 13;10(2):e0118336. doi: 10.1371/journal.pone.0118336. eCollection 2015.
• [1371] Inactivation of the ubiquitin-specific protease 19 deubiquitinating enzyme protects against muscle wasting.FASEB J. 2015 Sep;29(9):3889-98. doi: 10.1096/fj.15-270579. Epub 2015 Jun 5.
• [1372] FOXF1 Induces Epithelial-Mesenchymal Transition in Colorectal Cancer Metastasis by Transcriptionally Activating SNAI1.Neoplasia. 2018 Oct;20(10):996-1007. doi: 10.1016/j.neo.2018.08.004. Epub 2018 Sep 10.
• [1373] An integromic signature for lung cancer early detection.Oncotarget. 2018 May 15;9(37):24684-24692. doi: 10.18632/oncotarget.25227. eCollection 2018 May 15.
• [1374] Correlation between survivin genetic polymorphisms and lung cancer susceptibility.Int J Clin Exp Pathol. 2015 Jun 1;8(6):7426-30. eCollection 2015.
• [1375] Polymorphisms in C-reactive protein and Glypican-5 are associated with lung cancer risk and Gartrokine-1 influences Cisplatin-based chemotherapy response in a Chinese Han population.Dis Markers. 2015;2015:824304. doi: 10.1155/2015/824304. Epub 2015 Apr 27.
• [1376] Persistence of Gamma-H2AX Foci in Bronchial Cells Correlates with Susceptibility to Radiation Associated Lung Cancer in Mice.Radiat Res. 2019 Jan;191(1):67-75. doi: 10.1667/RR14979.1. Epub 2018 Nov 6.
• [1377] HBP1 promoter methylation augments the oncogenic -catenin to correlate with prognosis in NSCLC.J Cell Mol Med. 2014 Sep;18(9):1752-61. doi: 10.1111/jcmm.12318. Epub 2014 Jun 4.
• [1378] A cancer-associated mutation inactivates a region of the high-mobility group protein HMG20b essential for cytokinesis.Cell Cycle. 2014;13(16):2554-63. doi: 10.4161/15384101.2014.942204.
• [1379] Expression of HNF4G and its potential functions in lung cancer.Oncotarget. 2017 Dec 4;9(26):18018-18028. doi: 10.18632/oncotarget.22933. eCollection 2018 Apr 6.
• [1380] Transcriptional analysis of hnRNPA0, A1, A2, B1, and A3 in lung cancer cell lines in response to acidosis, hypoxia, and serum deprivation conditions.Exp Lung Res. 2014 Feb;40(1):12-21. doi: 10.3109/01902148.2013.856049. Epub 2013 Nov 18.
• [1381] Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.Immunol Lett. 2018 Aug;200:33-42. doi: 10.1016/j.imlet.2018.06.004. Epub 2018 Jun 9.
• [1382] Antagonism between HTRA3 and TGF1 Contributes to Metastasis in Non-Small Cell Lung Cancer.Cancer Res. 2019 Jun 1;79(11):2853-2864. doi: 10.1158/0008-5472.CAN-18-2507. Epub 2019 Apr 2.
• [1383] Insulin-like growth factor binding protein-4 inhibits cell growth, migration and invasion, and downregulates COX-2 expression in A549 lung cancer cells.Cell Biol Int. 2017 Apr;41(4):384-391. doi: 10.1002/cbin.10732. Epub 2017 Feb 21.
• [1384] IL-27 inhibits non-small-cell lung cancer cell metastasis by miR-935 in vitro.Onco Targets Ther. 2019 Feb 21;12:1447-1454. doi: 10.2147/OTT.S173207. eCollection 2019.
• [1385] Hepatitis B virus upregulates the expression of kinesin family member 4A.Mol Med Rep. 2015 Sep;12(3):3503-3507. doi: 10.3892/mmr.2015.3792. Epub 2015 May 15.
• [1386] IQGAP3 promotes EGFR-ERK signaling and the growth and metastasis of lung cancer cells.PLoS One. 2014 May 21;9(5):e97578. doi: 10.1371/journal.pone.0097578. eCollection 2014.
• [1387] Age-related changes in CD4+CD25+FOXP3+ regulatory T cells and their relationship with lung cancer.PLoS One. 2017 Mar 2;12(3):e0173048. doi: 10.1371/journal.pone.0173048. eCollection 2017.
• [1388] S100P interacts with integrin 7 and increases cancer cell migration and invasion in lung cancer.Oncotarget. 2015 Oct 6;6(30):29585-98. doi: 10.18632/oncotarget.4987.
• [1389] MZF-1/Elk-1/PKC is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.J Cancer. 2017 Sep 2;8(15):3028-3036. doi: 10.7150/jca.20467. eCollection 2017.
• [1390] Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells.Oncogene. 2014 Nov 20;33(47):5457-66. doi: 10.1038/onc.2013.486. Epub 2013 Nov 18.
• [1391] Kinesin KIF4A is associated with chemotherapeutic drug resistance by regulating intracellular trafficking of lung resistance-related protein.J Zhejiang Univ Sci B. 2017 Dec.;18(12):1046-1054. doi: 10.1631/jzus.B1700129.
• [1392] MicroRNA-570 promotes lung carcinoma proliferation through targeting tumor suppressor KLF9.Int J Clin Exp Pathol. 2015 Mar 1;8(3):2829-34. eCollection 2015.
• [1393] Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.Mol Cancer Ther. 2017 Jul;16(7):1355-1365. doi: 10.1158/1535-7163.MCT-16-0574. Epub 2017 Mar 23.
• [1394] Identification of a nuclear protein, LRRC42, involved in lung carcinogenesis.Int J Oncol. 2014 Jul;45(1):147-56. doi: 10.3892/ijo.2014.2418. Epub 2014 May 6.
• [1395] Pleiotropic associations of risk variants identified for other cancers with lung cancer risk: the PAGE and TRICL consortia.J Natl Cancer Inst. 2014 Apr;106(4):dju061. doi: 10.1093/jnci/dju061. Epub 2014 Mar 28.
• [1396] MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1.Nat Commun. 2013;4:1877. doi: 10.1038/ncomms2876.
• [1397] Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel.Onco Targets Ther. 2017 Jan 18;10:439-446. doi: 10.2147/OTT.S125789. eCollection 2017.
• [1398] HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis.Oncotarget. 2017 Mar 21;8(12):19342-19353. doi: 10.18632/oncotarget.14258.
• [1399] Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer.Sci Rep. 2014 Dec 18;4:7545. doi: 10.1038/srep07545.
• [1400] Germline mutations causing familial lung cancer.J Hum Genet. 2015 Oct;60(10):597-603. doi: 10.1038/jhg.2015.75. Epub 2015 Jul 16.
• [1401] A Newfound association between MDC1 functional polymorphism and lung cancer risk in Chinese.PLoS One. 2014 Sep 8;9(9):e106794. doi: 10.1371/journal.pone.0106794. eCollection 2014.
• [1402] LCMR1 interacts with DEK to suppress apoptosis in lung cancer cells.Mol Med Rep. 2017 Oct;16(4):4159-4164. doi: 10.3892/mmr.2017.7095. Epub 2017 Jul 27.
• [1403] miR?4 may be a negative regulator of menin in lung cancer.Oncol Rep. 2018 May;39(5):2342-2350. doi: 10.3892/or.2018.6327. Epub 2018 Mar 20.
• [1404] MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer.Int J Med Sci. 2019 Jan 1;16(1):68-74. doi: 10.7150/ijms.27595. eCollection 2019.
• [1405] MicroRNA-125b may function as an oncogene in lung cancer cells.Mol Med Rep. 2015 May;11(5):3880-7. doi: 10.3892/mmr.2014.3142. Epub 2014 Dec 31.
• [1406] miR-25 targets the modulator of apoptosis 1 gene in lung cancer.Carcinogenesis. 2015 Aug;36(8):925-35. doi: 10.1093/carcin/bgv068. Epub 2015 May 21.
• [1407] Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mousemodel of papillary lung adenocarcinomas.Oncotarget. 2015 Oct 13;6(31):31569-92. doi: 10.18632/oncotarget.5035.
• [1408] Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.Int J Cancer. 2018 Oct 1;143(7):1696-1705. doi: 10.1002/ijc.31542. Epub 2018 May 7.
• [1409] Early recognition of lung cancer by integrin targeted imaging in K-ras mouse model.Int J Cancer. 2015 Sep 1;137(5):1107-18. doi: 10.1002/ijc.29372. Epub 2015 Jan 14.
• [1410] S6K1 phosphorylation-dependent degradation of Mxi1 by -Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer.Theranostics. 2018 Feb 2;8(5):1286-1300. doi: 10.7150/thno.22552. eCollection 2018.
• [1411] Lentivirus-Mediated Silencing of Myosin VI Inhibits Proliferation and Cell Cycle Progression in Human Lung Cancer Cells.Chem Biol Drug Des. 2015 Oct;86(4):606-13. doi: 10.1111/cbdd.12528. Epub 2015 Feb 19.
• [1412] Characterization of germline mutations in familial lung cancer from the Chinese population.Gene. 2018 Jan 30;641:94-104. doi: 10.1016/j.gene.2017.10.020. Epub 2017 Oct 17.
• [1413] Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression.J Clin Invest. 2015 Nov 3;125(12):4407-20. doi: 10.1172/JCI81673.
• [1414] Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.Mol Med Rep. 2015 May;11(5):3523-32. doi: 10.3892/mmr.2014.3141. Epub 2014 Dec 30.
• [1415] HapMap-based study on the association between MPO and GSTP1 gene polymorphisms and lung cancer susceptibility in Chinese Han population.Acta Pharmacol Sin. 2014 May;35(5):636-44. doi: 10.1038/aps.2014.11.
• [1416] NPTX1 is a novel epigenetic regulation gene and associated with prognosis in lung cancer.Biochem Biophys Res Commun. 2015 Mar 6;458(2):381-6. doi: 10.1016/j.bbrc.2015.01.124. Epub 2015 Jan 31.
• [1417] Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma.Mol Cancer. 2007 Oct 29;6:70. doi: 10.1186/1476-4598-6-70.
• [1418] Linking functions: an additional role for an intrinsically disordered linker domain in the transcriptional coactivator CBP.Sci Rep. 2017 Jul 5;7(1):4676. doi: 10.1038/s41598-017-04611-x.
• [1419] The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells.Anticancer Agents Med Chem. 2017;17(10):1363-1373. doi: 10.2174/1871520617666170213115756.
• [1420] PEG10 plays a crucial role in human lung cancer proliferation, progression, prognosis and metastasis.Oncol Rep. 2014 Nov;32(5):2159-67. doi: 10.3892/or.2014.3469. Epub 2014 Sep 9.
• [1421] Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.World J Gastroenterol. 2014 Oct 14;20(38):13705-17. doi: 10.3748/wjg.v20.i38.13705.
• [1422] Pleiomorphic adenoma gene-like 2 expression is associated with the development of lung adenocarcinoma and emphysema.Lung Cancer. 2011 Oct;74(1):12-24. doi: 10.1016/j.lungcan.2011.02.006. Epub 2011 Mar 11.
• [1423] Phospholipase C -1 inhibits p53 expression in lung cancer.Cell Biochem Funct. 2014 Apr;32(3):294-8. doi: 10.1002/cbf.3015. Epub 2013 Dec 20.
• [1424] Role of the CKIP1 gene in proliferation and apoptosis of the human lung cancer cell line H1299.Genet Mol Res. 2015 Apr 27;14(2):4005-14. doi: 10.4238/2015.April.27.15.
• [1425] Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome.Cancer Lett. 2014 Jan 1;342(1):36-42. doi: 10.1016/j.canlet.2013.08.032. Epub 2013 Aug 24.
• [1426] Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation.Pathol Int. 2014 Sep;64(9):415-22. doi: 10.1111/pin.12198.
• [1427] Weak sharing of genetic association signals in three lung cancer subtypes: evidence at the SNP, gene, regulation, and pathway levels.Genome Med. 2018 Feb 27;10(1):16. doi: 10.1186/s13073-018-0522-9.
• [1428] Diagnostic Accuracy of Interleukin-27 in Bronchoalveolar Lavage Fluids for Pulmonary Tuberculosis.Infect Drug Resist. 2019 Dec 2;12:3755-3763. doi: 10.2147/IDR.S231215. eCollection 2019.
• [1429] RSPO fusion transcripts in colorectal cancer in Japanese population.Mol Biol Rep. 2014 Aug;41(8):5375-84. doi: 10.1007/s11033-014-3409-x. Epub 2014 May 22.
• [1430] Network analysis of DEGs and verification experiments reveal the notable roles of PTTG1 and MMP9 in lung cancer.Oncol Lett. 2018 Jan;15(1):257-263. doi: 10.3892/ol.2017.7329. Epub 2017 Nov 2.
• [1431] Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages toward tumor-suppressing phenotype.Int J Cancer. 2018 Oct 1;143(7):1753-1763. doi: 10.1002/ijc.31569. Epub 2018 Jul 3.
• [1432] Signalling with retinoids in the human lung: validation of new tools for the expression study of retinoid receptors.BMC Cancer. 2009 Dec 4;9:423. doi: 10.1186/1471-2407-9-423.
• [1433] RanGTPase: a candidate for Myc-mediated cancer progression.J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.
• [1434] Expression and DNA methylation status of the Rap2B gene in human bronchial epithelial cells treated by cigarette smoke condensate.Inhal Toxicol. 2015;27(10):502-9. doi: 10.3109/08958378.2015.1076546. Epub 2015 Aug 26.
• [1435] Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases.Clin Lung Cancer. 2014 Mar;15(2):e23-9. doi: 10.1016/j.cllc.2013.11.012. Epub 2013 Nov 20.
• [1436] Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy.Onco Targets Ther. 2017 Jan 11;10:339-345. doi: 10.2147/OTT.S125250. eCollection 2017.
• [1437] RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation.Mol Cell. 2013 Dec 12;52(5):720-33. doi: 10.1016/j.molcel.2013.11.010.
• [1438] Overexpression of the regulator of G-protein signaling5 reduces the survival rate and enhances the radiation response of human lung cancer cells.Oncol Rep. 2015 Jun;33(6):2899-907. doi: 10.3892/or.2015.3917. Epub 2015 Apr 20.
• [1439] Rnd3 in Cancer: A Review of the Evidence for Tumor Promoter or Suppressor.Mol Cancer Res. 2016 Nov;14(11):1033-1044. doi: 10.1158/1541-7786.MCR-16-0164. Epub 2016 Aug 23.
• [1440] Human Noxin is an anti-apoptotic protein in response to DNA damage of A549 non-small cell lung carcinoma.Int J Cancer. 2014 Jun 1;134(11):2595-604. doi: 10.1002/ijc.28600. Epub 2013 Nov 29.
• [1441] Effects of ribosomal protein l39-L on the drug resistance mechanisms of lung cancer A549 cells.Asian Pac J Cancer Prev. 2014;15(7):3093-7. doi: 10.7314/apjcp.2014.15.7.3093.
• [1442] Decreased expression of RPS15A suppresses proliferation of lung cancer cells.Tumour Biol. 2015 Sep;36(9):6733-40. doi: 10.1007/s13277-015-3371-9. Epub 2015 Apr 3.
• [1443] Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer.Oncogenesis. 2018 Apr 25;7(4):36. doi: 10.1038/s41389-018-0045-7.
• [1444] Lentivirus-mediated silencing of SCIN inhibits proliferation of human lung carcinoma cells.Gene. 2015 Jan 1;554(1):32-9. doi: 10.1016/j.gene.2014.10.013. Epub 2014 Oct 7.
• [1445] Differentially expressed protein-coding genes and long noncoding RNA in early-stage lung cancer.Tumour Biol. 2015 Dec;36(12):9969-78. doi: 10.1007/s13277-015-3714-6. Epub 2015 Jul 16.
• [1446] Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.Oncogene. 2014 Nov 27;33(48):5523-33. doi: 10.1038/onc.2013.498. Epub 2013 Nov 25.
• [1447] SEL1L expression in non-small cell lung cancer.Hum Pathol. 2006 May;37(5):505-12. doi: 10.1016/j.humpath.2005.12.012. Epub 2006 Mar 20.
• [1448] Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.Cancer Sci. 2019 Oct;110(10):3340-3349. doi: 10.1111/cas.14142. Epub 2019 Aug 13.
• [1449] MiR-563 restrains cell proliferation via targeting LIN28B in human lung cancer.Thorac Cancer. 2020 Jan;11(1):55-61. doi: 10.1111/1759-7714.13257. Epub 2019 Nov 25.
• [1450] Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report.Med Oncol. 2014 Apr;31(4):917. doi: 10.1007/s12032-014-0917-4. Epub 2014 Mar 16.
• [1451] An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling.PLoS One. 2015 May 11;10(5):e0124033. doi: 10.1371/journal.pone.0124033. eCollection 2015.
• [1452] Diverse Targets of -Catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse.Cancer Res. 2015 Aug 15;75(16):3398-410. doi: 10.1158/0008-5472.CAN-14-3265. Epub 2015 Jun 29.
• [1453] TC-1 (c8orf4) enhances aggressive biologic behavior in lung cancer through the Wnt/-catenin pathway.J Surg Res. 2013 Nov;185(1):255-63. doi: 10.1016/j.jss.2013.05.075. Epub 2013 Jun 11.
• [1454] Genome-Epigenome-Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells?.Cancer Res. 2019 Apr 15;79(8):1751-1752. doi: 10.1158/0008-5472.CAN-19-0645.
• [1455] Thoc1 inhibits cell growth via induction of cell cycle arrest and apoptosis in lung cancer cells.Mol Med Rep. 2014 Jun;9(6):2321-7. doi: 10.3892/mmr.2014.2088. Epub 2014 Mar 28.
• [1456] Macromolecule-Network Electrostatics Controlling Delivery of the Biotherapeutic Cell Modulator TIMP-2.Biomacromolecules. 2018 Apr 9;19(4):1285-1293. doi: 10.1021/acs.biomac.8b00107. Epub 2018 Mar 19.
• [1457] The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis.Cell Death Differ. 2020 Jun;27(6):1747-1764. doi: 10.1038/s41418-019-0458-7. Epub 2019 Nov 20.
• [1458] Tight junction protein 1 is regulated by transforming growth factor- and contributes to cell motility in NSCLC cells.BMB Rep. 2015 Feb;48(2):115-20. doi: 10.5483/bmbrep.2015.48.2.035.
• [1459] Recombinant viral capsid protein VP1 suppresses lung cancer metastasis by inhibiting COX-2/PGE2 and MIG-7.Oncotarget. 2014 Jun 15;5(11):3931-43. doi: 10.18632/oncotarget.2040.
• [1460] Tyrosylprotein sulfotransferase 1 expression is negatively correlated with cMet and lymph node metastasis in human lung cancer.Mol Med Rep. 2015 Oct;12(4):5217-22. doi: 10.3892/mmr.2015.4096. Epub 2015 Jul 20.
• [1461] Histochemical analysis of testis specific gene 13 in human normal and malignant tissues.Cell Tissue Res. 2015 Dec;362(3):653-63. doi: 10.1007/s00441-015-2227-3. Epub 2015 Jun 27.
• [1462] TSPAN2 is involved in cell invasion and motility during lung cancer progression.Cell Rep. 2014 Apr 24;7(2):527-538. doi: 10.1016/j.celrep.2014.03.027. Epub 2014 Apr 13.
• [1463] Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells.Cell Signal. 2019 Sep;61:10-19. doi: 10.1016/j.cellsig.2019.05.004. Epub 2019 May 7.
• [1464] AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer.Oncogene. 2018 Mar;37(11):1503-1518. doi: 10.1038/s41388-017-0054-6. Epub 2018 Jan 11.
• [1465] Cancer-associated loss of TARSH gene expression in human primary lung cancer.J Cancer Res Clin Oncol. 2006 Jan;132(1):28-34. doi: 10.1007/s00432-005-0032-1. Epub 2005 Oct 4.
• [1466] Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence.Cell Metab. 2017 Dec 5;26(6):842-855.e5. doi: 10.1016/j.cmet.2017.09.018. Epub 2017 Oct 19.
• [1467] Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer.PLoS One. 2013 Jul 23;8(7):e69392. doi: 10.1371/journal.pone.0069392. Print 2013.
• [1468] Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis.Cell Rep. 2016 Aug 9;16(6):1614-1628. doi: 10.1016/j.celrep.2016.07.009. Epub 2016 Jul 28.
• [1469] Differential expressions of matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs and their endogenous inhibitors among histologic subtypes of lung cancers.Anticancer Agents Med Chem. 2012 Sep;12(7):744-52. doi: 10.2174/187152012802650156.
• [1470] Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.J Cell Physiol. 2019 May;234(5):6965-6975. doi: 10.1002/jcp.27439. Epub 2018 Nov 11.
• [1471] Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer.Oncotarget. 2017 Jul 4;8(27):43978-43989. doi: 10.18632/oncotarget.16701.
• [1472] Function of low ADARB1 expression in lung adenocarcinoma.PLoS One. 2019 Sep 6;14(9):e0222298. doi: 10.1371/journal.pone.0222298. eCollection 2019.
• [1473] AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression.Oncogene. 2019 Oct;38(41):6723-6736. doi: 10.1038/s41388-019-0928-x. Epub 2019 Aug 9.
• [1474] Adenylosuccinate synthetase 1 gene is a novel target of deletion in lung adenocarcinoma.Mol Carcinog. 2009 Dec;48(12):1116-22. doi: 10.1002/mc.20563.
• [1475] Silencing of lncRNA AFAP1-AS1 Inhibits Cell Growth and Metastasis in Clear Cell Renal Cell Carcinoma.Oncol Res. 2019 Jun 21;27(6):653-661. doi: 10.3727/096504018X15420748671075. Epub 2019 Mar 4.
• [1476] HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.Nature. 2014 Jan 9;505(7482):212-7. doi: 10.1038/nature12785. Epub 2013 Dec 4.
• [1477] Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model.Mol Cells. 2006 Apr 30;21(2):213-7.
• [1478] Adenylate kinase 4 modulates oxidative stress and stabilizes HIF-1 to drive lung adenocarcinoma metastasis.J Hematol Oncol. 2019 Jan 29;12(1):12. doi: 10.1186/s13045-019-0698-5.
• [1479] Methylation of AKAP12{alpha} promoter in lung cancer.Anticancer Res. 2010 Nov;30(11):4595-600.
• [1480] Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma.Oncol Rep. 2012 Nov;28(5):1792-8. doi: 10.3892/or.2012.2002. Epub 2012 Aug 30.
• [1481] Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.Acta Pharmacol Sin. 2005 Oct;26(10):1253-8. doi: 10.1111/j.1745-7254.2005.00184.x.
• [1482] Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.Cell Cycle. 2013 Nov 1;12(21):3390-404. doi: 10.4161/cc.26417. Epub 2013 Sep 17.
• [1483] Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression.Biochem J. 2005 Nov 1;391(Pt 3):503-11. doi: 10.1042/BJ20050533.
• [1484] Chemoproteomics-Enabled Covalent Ligand Screening Reveals ALDH3A1 as a Lung Cancer Therapy Target.ACS Chem Biol. 2018 Aug 17;13(8):1970-1977. doi: 10.1021/acschembio.8b00381. Epub 2018 Jul 23.
• [1485] TP53 gene status is a critical determinant of phenotypes induced by ALKBH3 knockdown in non-small cell lung cancers.Biochem Biophys Res Commun. 2017 Jun 24;488(2):285-290. doi: 10.1016/j.bbrc.2017.05.024. Epub 2017 May 4.
• [1486] 15-Lipoxygenase-2/15(S)-hydroxyeicosatetraenoic acid regulates cell proliferation and metastasis via the STAT3 pathway in lung adenocarcinoma.Prostaglandins Other Lipid Mediat. 2018 Sep;138:31-40. doi: 10.1016/j.prostaglandins.2018.07.003. Epub 2018 Aug 12.
• [1487] Down-regulated and Commonly mutated ALPK1 in Lung and Colorectal Cancers.Sci Rep. 2016 Jun 10;6:27350. doi: 10.1038/srep27350.
• [1488] Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer. Int J Cancer. 2014 Mar 15;134(6):1311-22. doi: 10.1002/ijc.28472. Epub 2013 Nov 11.
• [1489] Autocrine motility factor receptor: a clinical review.Expert Rev Anticancer Ther. 2008 Feb;8(2):207-17. doi: 10.1586/14737140.8.2.207.
• [1490] AMMECR1 Inhibits Apoptosis and Promotes Cell-cycle Progression and Proliferation of the A549 Human Lung Cancer Cell Line.Anticancer Res. 2019 Sep;39(9):4637-4642. doi: 10.21873/anticanres.13644.
• [1491] Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers.Cancer Lett. 2001 Jan 26;162(2):201-5. doi: 10.1016/s0304-3835(00)00675-3.
• [1492] AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway.Lasers Med Sci. 2019 Apr;34(3):473-478. doi: 10.1007/s10103-018-2616-4. Epub 2018 Aug 24.
• [1493] Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility.J Clin Invest. 2013 Mar;123(3):1082-95. doi: 10.1172/JCI64044. Epub 2013 Feb 22.
• [1494] Association of MAGE A1-6 Expression with Lung Cancer Progression.J Cancer. 2017 May 12;8(8):1324-1329. doi: 10.7150/jca.18086. eCollection 2017.
• [1495] Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLC?5 lung cancer cells.Mol Med Rep. 2018 Jan;17(1):911-917. doi: 10.3892/mmr.2017.7959. Epub 2017 Nov 3.
• [1496] Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells.Cancer Sci. 2019 May;110(5):1609-1620. doi: 10.1111/cas.13998. Epub 2019 Apr 9.
• [1497] A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.Oncotarget. 2016 May 24;7(21):29927-36. doi: 10.18632/oncotarget.9179.
• [1498] MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.Cancer Gene Ther. 2012 Nov;19(11):773-8. doi: 10.1038/cgt.2012.60. Epub 2012 Sep 21.
• [1499] APOBEC3A/B deletion polymorphism and cancer risk.Carcinogenesis. 2018 Feb 9;39(2):118-124. doi: 10.1093/carcin/bgx131.
• [1500] High CEP55 expression is associated with poor prognosis in non-small-cell lung cancer.Onco Targets Ther. 2018 Aug 17;11:4979-4990. doi: 10.2147/OTT.S165750. eCollection 2018.
• [1501] The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis.Nat Commun. 2016 Sep 21;7:12918. doi: 10.1038/ncomms12918.
• [1502] APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.EBioMedicine. 2019 Jun;44:138-149. doi: 10.1016/j.ebiom.2019.05.028. Epub 2019 May 16.
• [1503] Silencing of aquaporin5 inhibits the growth of A549 lung cancer cells in vitro and in vivo.Int J Oncol. 2018 May;52(5):1643-1650. doi: 10.3892/ijo.2018.4326. Epub 2018 Mar 16.
• [1504] AQP8 inhibits colorectal cancer growth and metastasis by down-regulating PI3K/AKT signaling and PCDH7 expression.Am J Cancer Res. 2018 Feb 1;8(2):266-279. eCollection 2018.
• [1505] ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells.Oncol Rep. 2019 Apr;41(4):2281-2888. doi: 10.3892/or.2019.7031. Epub 2019 Feb 25.
• [1506] ARHGAP15 regulates lung cancer cell proliferation and metastasis via the STAT3 pathway.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5840-5850. doi: 10.26355/eurrev_201907_18326.
• [1507] The tumor suppressive roles of ARHGAP25 in lung cancer cells.Onco Targets Ther. 2019 Aug 19;12:6699-6710. doi: 10.2147/OTT.S207540. eCollection 2019.
• [1508] Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer.Oncogene. 2014 Feb 27;33(9):1181-9. doi: 10.1038/onc.2013.42. Epub 2013 Mar 11.
• [1509] A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans.Cancer. 2006 Jun 15;106(12):2716-24. doi: 10.1002/cncr.21944.
• [1510] ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.Int J Cancer. 2018 Apr 1;142(7):1379-1391. doi: 10.1002/ijc.31169. Epub 2017 Dec 4.
• [1511] Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer.Cancer. 1992 Mar 1;69(5):1130-6. doi: 10.1002/cncr.2820690512.
• [1512] Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.Int J Cancer. 2013 May 1;132(9):2217-21. doi: 10.1002/ijc.27900. Epub 2012 Nov 20.
• [1513] ARLTS1 - a novel tumor suppressor gene.Cancer Lett. 2008 Jun 8;264(1):11-20. doi: 10.1016/j.canlet.2008.02.021. Epub 2008 Mar 28.
• [1514] Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth.Mol Cancer Ther. 2019 Mar;18(3):602-612. doi: 10.1158/1535-7163.MCT-18-0824. Epub 2019 Jan 15.
• [1515] Comparative proteomics and global genome-wide expression data implicate role of ARMC8 in lung cancer.Asian Pac J Cancer Prev. 2015;16(9):3691-6. doi: 10.7314/apjcp.2015.16.9.3691.
• [1516] Alex3 suppresses non-small cell lung cancer invasion via AKT/Slug/E-cadherin pathway.Tumour Biol. 2017 Jul;39(7):1010428317701441. doi: 10.1177/1010428317701441.
• [1517] MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.Cell Death Differ. 2012 Jun;19(6):1038-48. doi: 10.1038/cdd.2011.190. Epub 2011 Dec 23.
• [1518] Role of artemin in non-small cell lung cancer.Thorac Cancer. 2018 May;9(5):555-562. doi: 10.1111/1759-7714.12615. Epub 2018 Mar 25.
• [1519] Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis.J Lipid Res. 2019 Jul;60(7):1225-1235. doi: 10.1194/jlr.M092247. Epub 2019 Apr 15.
• [1520] Deaf patient-provider communication and lung cancer screening: Health Information National Trends survey in American Sign Language (HINTS-ASL).Patient Educ Couns. 2018 Jul;101(7):1232-1239. doi: 10.1016/j.pec.2018.03.003. Epub 2018 Mar 5.
• [1521] Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-B signaling.BMC Cancer. 2014 Sep 20;14:686. doi: 10.1186/1471-2407-14-686.
• [1522] Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.J Hematol Oncol. 2013 Sep 8;6:68. doi: 10.1186/1756-8722-6-68.
• [1523] Activating transcription factor 1 promoted migration and invasion in lung cancer cells through regulating EGFR and MMP-2.Mol Carcinog. 2019 Oct;58(10):1919-1924. doi: 10.1002/mc.23086. Epub 2019 Aug 16.
• [1524] MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2.Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5554-5561. doi: 10.26355/eurrev_201809_15818.
• [1525] Role of ATG10 expression quantitative trait loci in non-small cell lung cancer survival.Int J Cancer. 2016 Oct 1;139(7):1564-73. doi: 10.1002/ijc.30205. Epub 2016 Jun 15.
• [1526] The Thr300Ala variant of ATG16L1 is associated with decreased risk of brain metastasis in patients with non-small cell lung cancer.Autophagy. 2017 Jun 3;13(6):1053-1063. doi: 10.1080/15548627.2017.1308997. Epub 2017 Apr 25.
• [1527] Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.PLoS One. 2012;7(10):e48532. doi: 10.1371/journal.pone.0048532. Epub 2012 Oct 31.
• [1528] MicroRNA-140-3p inhibits proliferation, migration and invasion of lung cancer cells by targeting ATP6AP2. Int J Clin Exp Pathol. 2015 Oct 1;8(10):12845-52. eCollection 2015.
• [1529] Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.Mol Cancer Ther. 2013 Jun;12(6):1073-84. doi: 10.1158/1535-7163.MCT-13-0065. Epub 2013 Apr 2.
• [1530] RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers.Tumour Biol. 2017 Aug;39(8):1010428317700001. doi: 10.1177/1010428317700001.
• [1531] Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology.Cancer Res. 1991 Nov 15;51(22):6142-9.
• [1532] B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells.J Clin Med. 2019 Nov 9;8(11):1928. doi: 10.3390/jcm8111928.
• [1533] Bag-1 Silence Sensitizes Non-Small Cell Lung Cancer Cells To Cisplatin Through Multiple Gene Pathways.Onco Targets Ther. 2019 Oct 31;12:8977-8989. doi: 10.2147/OTT.S218182. eCollection 2019.
• [1534] BAI1associated protein 2like 2 is a potential biomarker in lung cancer.Oncol Rep. 2019 Feb;41(2):1304-1312. doi: 10.3892/or.2018.6883. Epub 2018 Nov 26.
• [1535] Downregulation of the TGF Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGF Signaling and Invasion.Cancer Res. 2016 Jul 1;76(13):3785-801. doi: 10.1158/0008-5472.CAN-15-1326. Epub 2016 May 17.
• [1536] Decreased SARI expression predicts poor prognosis of Chinese patients with non-small cell lung cancer.Int J Clin Exp Pathol. 2013 Sep 15;6(10):2056-63. eCollection 2013.
• [1537] Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression.Tumour Biol. 2016 Nov;37(11):15157-15164. doi: 10.1007/s13277-016-5411-5. Epub 2016 Sep 27.
• [1538] Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.Cell Physiol Biochem. 2018;49(4):1615-1632. doi: 10.1159/000493497. Epub 2018 Sep 17.
• [1539] Bcl-B expression in human epithelial and nonepithelial malignancies.Clin Cancer Res. 2008 May 15;14(10):3011-21. doi: 10.1158/1078-0432.CCR-07-1955.
• [1540] BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via -catenin pathway.Life Sci. 2018 Sep 1;208:284-294. doi: 10.1016/j.lfs.2018.07.023. Epub 2018 Jul 23.
• [1541] The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells.Tumour Biol. 2013 Jun;34(3):1641-50. doi: 10.1007/s13277-013-0697-z. Epub 2013 Feb 20.
• [1542] Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.
• [1543] Characterization of an 800 kb region at 3p22-p21.3 that was homozygously deleted in a lung cancer cell line.Hum Mol Genet. 1994 Aug;3(8):1341-4. doi: 10.1093/hmg/3.8.1341.
• [1544] Upregulation of AMPK by 4-O-methylascochlorin promotes autophagy via the HIF-1 expression.J Cell Mol Med. 2018 Dec;22(12):6345-6356. doi: 10.1111/jcmm.13933. Epub 2018 Oct 19.
• [1545] Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.Clin Lung Cancer. 2013 Sep;14(5):513-20. doi: 10.1016/j.cllc.2013.04.007. Epub 2013 Jun 27.
• [1546] MicroRNA-3666 inhibits lung cancer cell proliferation, migration, and invasiveness by targeting BPTF.Biochem Cell Biol. 2019 Aug;97(4):415-422. doi: 10.1139/bcb-2018-0301. Epub 2018 Nov 27.
• [1547] Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway.J Cell Physiol. 2019 Aug;234(8):13843-13850. doi: 10.1002/jcp.28064. Epub 2019 Jan 7.
• [1548] Identification of DBCCR1 as a suppressor in the development of lung cancer that is associated with increased DNA methyltransferase 1.Oncotarget. 2017 May 16;8(20):32821-32832. doi: 10.18632/oncotarget.15826.
• [1549] Metastatic potential of lung squamous cell carcinoma associated with HSPC300 through its interaction with WAVE2.Lung Cancer. 2009 Sep;65(3):299-305. doi: 10.1016/j.lungcan.2009.06.001. Epub 2009 Jul 2.
• [1550] BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.Cancer Res. 2013 Feb 15;73(4):1308-17. doi: 10.1158/0008-5472.CAN-12-2489. Epub 2012 Dec 26.
• [1551] CD157 Confers Host Resistance to Mycobacterium tuberculosis via TLR2-CD157-PKCzeta-Induced Reactive Oxygen Species Production.mBio. 2019 Aug 27;10(4):e01949-19. doi: 10.1128/mBio.01949-19.
• [1552] Silencing of Btbd7 Inhibited Epithelial-Mesenchymal Transition and Chemoresistance in CD133(+) Lung Carcinoma A549 Cells.Oncol Res. 2017 May 24;25(5):819-829. doi: 10.3727/096504016X14772349843854. Epub 2016 Oct 26.
• [1553] The promoter region of the human BUBR1 gene and its expression analysis in lung cancer.Lung Cancer. 2002 Dec;38(3):229-34. doi: 10.1016/s0169-5002(02)00218-0.
• [1554] Overexpression of BZW1 is an independent poor prognosis marker and its down-regulation suppresses lung adenocarcinoma metastasis.Sci Rep. 2019 Oct 10;9(1):14624. doi: 10.1038/s41598-019-50874-x.
• [1555] Molecular characterization of a novel chromosomal translocation t(12;14)(q23;q11.2) in T-lymphoblastic lymphoma between the T-cell receptor delta-deleting elements (TRDREC and TRAJ61) and the hypothetical gene C12orf42.Eur J Haematol. 2010 Nov;85(5):452-6. doi: 10.1111/j.1600-0609.2010.01508.x.
• [1556] Nanoclusters prepared from ruthenium(II) and quercetin for fluorometric detection of cobalt(II), and a method for screening their anticancer drug activity.Mikrochim Acta. 2019 Jul 17;186(8):539. doi: 10.1007/s00604-019-3657-5.
• [1557] CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness.Cell. 2018 Feb 8;172(4):841-856.e16. doi: 10.1016/j.cell.2018.01.009. Epub 2018 Jan 25.
• [1558] Cables1 complex couples survival signaling to the cell death machinery.Cancer Res. 2015 Jan 1;75(1):147-158. doi: 10.1158/0008-5472.CAN-14-0036. Epub 2014 Oct 31.
• [1559] CDK-associated Cullin 1 promotes cell proliferation with activation of ERK1/2 in human lung cancer A549 cells.Biochem Biophys Res Commun. 2013 Jul 19;437(1):108-13. doi: 10.1016/j.bbrc.2013.06.048. Epub 2013 Jun 24.
• [1560] Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer.Diagn Cytopathol. 2015 Jul;43(7):527-31. doi: 10.1002/dc.23218. Epub 2014 Oct 24.
• [1561] miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer.Clin Transl Oncol. 2018 Apr;20(4):457-466. doi: 10.1007/s12094-017-1730-2. Epub 2017 Sep 4.
• [1562] Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2.Med Oncol. 2015 Mar;32(3):51. doi: 10.1007/s12032-015-0500-7. Epub 2015 Jan 31.
• [1563] Methacrylic acid/butyl acrylate onto feruloylated bagasse xylan: Graft copolymerization and biological activity.Mater Sci Eng C Mater Biol Appl. 2019 May;98:594-601. doi: 10.1016/j.msec.2018.12.103. Epub 2018 Dec 30.
• [1564] Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression.PLoS One. 2012;7(5):e36903. doi: 10.1371/journal.pone.0036903. Epub 2012 May 15.
• [1565] CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production.Int J Cancer. 2019 Oct 15;145(8):2225-2237. doi: 10.1002/ijc.32355. Epub 2019 May 6.
• [1566] Interactive potential of genetic polymorphism in Xenobiotic metabolising and DNA repair genes for predicting lung cancer predisposition and overall survival in North Indians.Mutat Res Genet Toxicol Environ Mutagen. 2018 Feb;826:15-24. doi: 10.1016/j.mrgentox.2017.12.006. Epub 2017 Dec 21.
• [1567] CASTOR1 suppresses the progression of lung adenocarcinoma and predicts poor prognosis.J Cell Biochem. 2018 Dec;119(12):10186-10194. doi: 10.1002/jcb.27360. Epub 2018 Aug 21.
• [1568] Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.Semin Oncol. 2009 Dec;36(6):572-80. doi: 10.1053/j.seminoncol.2009.10.007.
• [1569] A systematic analysis reveals gene expression alteration of serum deprivation response (SDPR) gene is significantly associated with the survival of patients with cancer.Oncol Rep. 2019 Sep;42(3):1161-1172. doi: 10.3892/or.2019.7212. Epub 2019 Jun 26.
• [1570] Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation.Oncogene. 2005 Sep 15;24(41):6249-55. doi: 10.1038/sj.onc.1208775.
• [1571] ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer.Med Oncol. 2019 Aug 2;36(9):78. doi: 10.1007/s12032-019-1301-1.
• [1572] DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.Exp Cell Res. 2019 Jan 15;374(2):304-314. doi: 10.1016/j.yexcr.2018.12.001. Epub 2018 Dec 4.
• [1573] Network biology of tumor stem-like cells identified a regulatory role of CBX5 in lung cancer.Sci Rep. 2012;2:584. doi: 10.1038/srep00584. Epub 2012 Aug 16.
• [1574] CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression.J Exp Clin Cancer Res. 2019 Mar 18;38(1):131. doi: 10.1186/s13046-019-1137-8.
• [1575] The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Mol Cancer. 2018 Feb 19;17(1):46. doi: 10.1186/s12943-018-0799-8.
• [1576] Coiled-coil domain-containing protein 8 inhibits the invasiveness and migration of non-small cell lung cancer cells.Hum Pathol. 2016 Oct;56:64-73. doi: 10.1016/j.humpath.2016.06.001. Epub 2016 Jun 21.
• [1577] CCDC85B promotes non-small cell lung cancer cell proliferation and invasion.Mol Carcinog. 2019 Jan;58(1):126-134. doi: 10.1002/mc.22914. Epub 2018 Oct 9.
• [1578] Girdin protein: A potential metastasis predictor associated with prognosis in lung cancer.Exp Ther Med. 2018 Mar;15(3):2837-2843. doi: 10.3892/etm.2018.5773. Epub 2018 Jan 19.
• [1579] The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer.Int J Biol Markers. 2019 Jun;34(2):156-162. doi: 10.1177/1724600819829758. Epub 2019 May 3.
• [1580] CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses.J Allergy Clin Immunol. 2018 Oct;142(4):1257-1271.e4. doi: 10.1016/j.jaci.2017.12.998. Epub 2018 Jan 31.
• [1581] CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.Med Oncol. 2015 Mar;32(3):66. doi: 10.1007/s12032-015-0531-0. Epub 2015 Feb 18.
• [1582] Occupational exposure to diesel engine exhaust and serum cytokine levels.Environ Mol Mutagen. 2018 Mar;59(2):144-150. doi: 10.1002/em.22142. Epub 2017 Oct 12.
• [1583] The Effect of Pyrroloquinoline Quinone on the Expression of WISP1 in Traumatic Brain Injury.Stem Cells Int. 2017;2017:4782820. doi: 10.1155/2017/4782820. Epub 2017 Aug 16.
• [1584] Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA.Cancer Sci. 2006 Oct;97(10):1082-92. doi: 10.1111/j.1349-7006.2006.00292.x.
• [1585] CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.Cancer Res. 2015 May 15;75(10):2029-38. doi: 10.1158/0008-5472.CAN-14-1494. Epub 2015 Mar 25.
• [1586] The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.Cancer Immunol Res. 2019 Nov;7(11):1775-1788. doi: 10.1158/2326-6066.CIR-19-0168. Epub 2019 Sep 4.
• [1587] Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells.Oncoimmunology. 2018 Feb 12;7(6):e1428156. doi: 10.1080/2162402X.2018.1428156. eCollection 2018.
• [1588] National practice trends for the surgical management of lung cancer in the CMS population: an atlas of care.J Thorac Dis. 2019 Mar;11(Suppl 4):S500-S508. doi: 10.21037/jtd.2019.01.05.
• [1589] Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.PLoS One. 2013 Oct 16;8(10):e76115. doi: 10.1371/journal.pone.0076115. eCollection 2013.
• [1590] Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy.Clin Sci (Lond). 2002 Mar;102(3):353-61.
• [1591] Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines.BMC Complement Altern Med. 2017 Jan 9;17(1):30. doi: 10.1186/s12906-016-1512-3.
• [1592] Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.PLoS One. 2009 Jun 9;4(6):e5611. doi: 10.1371/journal.pone.0005611.
• [1593] A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.Cancer Sci. 2011 Apr;102(4):697-705. doi: 10.1111/j.1349-7006.2011.01865.x. Epub 2011 Feb 10.
• [1594] AAV-Mediated angiotensin 1-7 overexpression inhibits tumor growth of lung cancer in vitro and in vivo.Oncotarget. 2017 Jan 3;8(1):354-363. doi: 10.18632/oncotarget.13396.
• [1595] CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer.Theranostics. 2018 Jan 1;8(3):650-662. doi: 10.7150/thno.21963. eCollection 2018.
• [1596] Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.Int J Cancer. 2003 Oct 10;106(6):913-8. doi: 10.1002/ijc.11322.
• [1597] Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.Oncogene. 2001 Nov 22;20(53):7787-96. doi: 10.1038/sj.onc.1204970.
• [1598] CGK062, a small chemical molecule, inhibits cancer upregulated gene 2induced oncogenesis through NEK2 and catenin.Int J Oncol. 2019 Apr;54(4):1295-1305. doi: 10.3892/ijo.2019.4724. Epub 2019 Feb 22.
• [1599] Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.J Clin Invest. 2016 Jan;126(1):254-65. doi: 10.1172/JCI79775. Epub 2015 Dec 7.
• [1600] CFHR1 is a potentially downregulated gene in lung adenocarcinoma.Mol Med Rep. 2019 Oct;20(4):3642-3648. doi: 10.3892/mmr.2019.10644. Epub 2019 Sep 3.
• [1601] CHTM1 regulates cancer cell sensitivity to metabolic stress via p38-AIF1 pathway.J Exp Clin Cancer Res. 2019 Jun 20;38(1):271. doi: 10.1186/s13046-019-1253-5.
• [1602] CHD5, a tumor suppressor that is epigenetically silenced in lung cancer.Lung Cancer. 2012 Jun;76(3):324-31. doi: 10.1016/j.lungcan.2011.11.019. Epub 2011 Dec 18.
• [1603] CHL1 gene polymorphisms increase lung cancer susceptibility.Oncotarget. 2018 Jan 6;9(17):13545-13550. doi: 10.18632/oncotarget.24057. eCollection 2018 Mar 2.
• [1604] CHMP4C Disruption Sensitizes the Human Lung Cancer Cells to Irradiation.Int J Mol Sci. 2015 Dec 24;17(1):18. doi: 10.3390/ijms17010018.
• [1605] Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells.Oncol Lett. 2017 Feb;13(2):715-721. doi: 10.3892/ol.2016.5466. Epub 2016 Dec 6.
• [1606] Combined effect between CHRNB3-CHRNA6 region gene variant (rs6474412) and smoking in psoriasis vulgaris severity.Gene. 2014 Jul 10;544(2):123-7. doi: 10.1016/j.gene.2014.04.070. Epub 2014 Apr 30.
• [1607] Genetic variants of CHRNA5-A3 and CHRNB3-A6 predict survival of patients with advanced non-small cell lung cancer.Oncotarget. 2016 May 3;7(18):26436-43. doi: 10.18632/oncotarget.8510.
• [1608] Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations.Clin Chem Lab Med. 2018 Jul 26;56(8):1328-1335. doi: 10.1515/cclm-2017-1157.
• [1609] Mdig, a lung cancer-associated gene, regulates cell cycle progression through p27(KIP1).Tumour Biol. 2015 Sep;36(9):6909-17. doi: 10.1007/s13277-015-3397-z. Epub 2015 Apr 9.
• [1610] Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo.Mol Cancer Res. 2011 Dec;9(12):1746-54. doi: 10.1158/1541-7786.MCR-11-0286. Epub 2011 Oct 12.
• [1611] Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes.BMC Cancer. 2018 Aug 14;18(1):818. doi: 10.1186/s12885-018-4705-y.
• [1612] 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.Biochem Pharmacol. 2017 Jul 1;135:35-49. doi: 10.1016/j.bcp.2017.03.007. Epub 2017 Mar 11.
• [1613] MicroRNA-146-5p promotes proliferation, migration and invasion in lung cancer cells by targeting claudin-12.Cancer Biomark. 2019;25(1):89-99. doi: 10.3233/CBM-182374.
• [1614] Genome-wide analysis of expression quantitative trait loci identified potential lung cancer susceptibility variants among Asian populations.Carcinogenesis. 2019 Apr 29;40(2):263-268. doi: 10.1093/carcin/bgy165.
• [1615] Claudin-3 Inhibits Lung Squamous Cell Carcinoma Cell Epithelial-mesenchymal Transition and Invasion via Suppression of the Wnt/-catenin Signaling Pathway.Int J Med Sci. 2018 Feb 5;15(4):339-351. doi: 10.7150/ijms.22927. eCollection 2018.
• [1616] The Concomitant Expression of Human Endogenous Retroviruses and Embryonic Genes in Cancer Cells under Microenvironmental Changes is a Potential Target for Antiretroviral Drugs.Cancer Microenviron. 2019 Dec;12(2-3):105-118. doi: 10.1007/s12307-019-00231-3. Epub 2019 Nov 5.
• [1617] Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.Oncoimmunology. 2018 Jan 29;7(5):e1423184. doi: 10.1080/2162402X.2017.1423184. eCollection 2018.
• [1618] Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.Clin Cancer Res. 2000 Jan;6(1):203-12.
• [1619] CNOT2 Is Critically Involved in Atorvastatin Induced Apoptotic and Autophagic Cell Death in Non-Small Cell Lung Cancers.Cancers (Basel). 2019 Sep 30;11(10):1470. doi: 10.3390/cancers11101470.
• [1620] CNOT3 contributes to cisplatin resistance in lung cancer through inhibiting RIPK3 expression.Apoptosis. 2019 Aug;24(7-8):673-685. doi: 10.1007/s10495-019-01550-y.
• [1621] TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.Int J Clin Exp Pathol. 2015 Mar 1;8(3):2690-9. eCollection 2015.
• [1622] Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers.Carcinogenesis. 2018 Mar 8;39(3):407-417. doi: 10.1093/carcin/bgx122.
• [1623] Enhancement of antiangiogenic effects of human canstatin with a hypoxia-regulated transgene vector in lung cancer model.Cancer J. 2006 Mar-Apr;12(2):136-46.
• [1624] Proteomic analysis of differentially expressed proteins in lung cancer in Wistar rats using NNK as an inducer.Chem Biol Interact. 2013 Jul 5;204(2):125-34. doi: 10.1016/j.cbi.2013.05.004. Epub 2013 May 18.
• [1625] The reciprocal relationship between coping mechanisms and lung cancer diagnosis: findings of a prospective study.Cancer Manag Res. 2018 Jan 4;10:33-40. doi: 10.2147/CMAR.S148341. eCollection 2018.
• [1626] Silencing of the COPS3 gene by siRNA reduces proliferation of lung cancer cells most likely via induction of cell cycle arrest and apoptosis.Asian Pac J Cancer Prev. 2012;13(3):1043-8. doi: 10.7314/apjcp.2012.13.3.1043.
• [1627] COX7A1 suppresses the viability of human non-small cell lung cancer cells via regulating autophagy.Cancer Med. 2019 Dec;8(18):7762-7773. doi: 10.1002/cam4.2659. Epub 2019 Oct 30.
• [1628] microRNA-214 Governs Lung Cancer Growth and Metastasis by Targeting Carboxypeptidase-D.DNA Cell Biol. 2016 Nov;35(11):715-721. doi: 10.1089/dna.2016.3398. Epub 2016 Aug 5.
• [1629] High expression of Copine1 promotes cell growth and metastasis in human lung adenocarcinoma.Int J Oncol. 2018 Dec;53(6):2369-2378. doi: 10.3892/ijo.2018.4558. Epub 2018 Sep 12.
• [1630] Quantitative proteomic analysis identifies CPNE3 as a novel metastasis-promoting gene in NSCLC.J Proteome Res. 2013 Jul 5;12(7):3423-33. doi: 10.1021/pr400273z. Epub 2013 Jun 6.
• [1631] Hypermethylation of PGCP gene is associated with human bronchial epithelial cells immortalization.Gene. 2018 Feb 5;642:505-512. doi: 10.1016/j.gene.2017.11.063. Epub 2017 Nov 28.
• [1632] Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin 1/FAK/ERK Signaling.Sci Rep. 2019 Jan 29;9(1):845. doi: 10.1038/s41598-018-37443-4.
• [1633] Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.Lung Cancer. 2019 Sep;135:130-137. doi: 10.1016/j.lungcan.2019.06.019. Epub 2019 Jun 18.
• [1634] CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.Lung Cancer. 2014 Aug;85(2):147-51. doi: 10.1016/j.lungcan.2014.05.018. Epub 2014 Jun 2.
• [1635] Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer.Oncol Lett. 2018 Feb;15(2):2661-2668. doi: 10.3892/ol.2017.7591. Epub 2017 Dec 12.
• [1636] ERCC6/CSB gene polymorphisms and lung cancer risk.Cancer Lett. 2009 Jan 8;273(1):172-6. doi: 10.1016/j.canlet.2008.08.002. Epub 2008 Sep 11.
• [1637] The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.Mol Cancer Res. 2015 Sep;13(9):1265-73. doi: 10.1158/1541-7786.MCR-15-0165. Epub 2015 Jun 17.
• [1638] Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.Carcinogenesis. 2012 Jul;33(7):1270-6. doi: 10.1093/carcin/bgs148. Epub 2012 Apr 17.
• [1639] Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer.Oncotarget. 2017 Dec 20;9(18):14084-14098. doi: 10.18632/oncotarget.23505. eCollection 2018 Mar 6.
• [1640] Expression and epigenetic regulation of cystatin B in lung cancer and colorectal cancer.Pathol Res Pract. 2017 Dec;213(12):1568-1574. doi: 10.1016/j.prp.2017.06.007. Epub 2017 Jun 6.
• [1641] Characterization of a cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer.Clin Cancer Res. 2011 Sep 15;17(18):5889-900. doi: 10.1158/1078-0432.CCR-11-0240. Epub 2011 Aug 3.
• [1642] Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer.Int J Cancer. 2009 Jun 15;124(12):2893-8. doi: 10.1002/ijc.24296.
• [1643] Identification of a new cancer/testis gene family, CT47, among expressed multicopy genes on the human X chromosome.Genes Chromosomes Cancer. 2006 Apr;45(4):392-400. doi: 10.1002/gcc.20298.
• [1644] Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1.J Immunother Cancer. 2019 Aug 28;7(1):229. doi: 10.1186/s40425-019-0678-x.
• [1645] The Alteration of CTNNBIP1 in Lung Cancer.Int J Mol Sci. 2019 Nov 13;20(22):5684. doi: 10.3390/ijms20225684.
• [1646] miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene.J Exp Clin Cancer Res. 2018 Jul 9;37(1):141. doi: 10.1186/s13046-018-0824-1.
• [1647] Dysregulation of the miR-194-CUL4B negative feedback loop drives tumorigenesis in non-small-cell lung carcinoma.Mol Oncol. 2017 Mar;11(3):305-319. doi: 10.1002/1878-0261.12038. Epub 2017 Feb 21.
• [1648] The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells.Elife. 2019 Jul 11;8:e44288. doi: 10.7554/eLife.44288.
• [1649] High CXC Chemokine Ligand 16 (CXCL16) Expression Promotes Proliferation and Metastasis of Lung Cancer via Regulating the NF-B Pathway.Med Sci Monit. 2018 Jan 21;24:405-411. doi: 10.12659/msm.906230.
• [1650] Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17.Cell Oncol (Dordr). 2020 Apr;43(2):311-320. doi: 10.1007/s13402-019-00491-7. Epub 2019 Dec 12.
• [1651] CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p.Biomed Pharmacother. 2018 Jan;97:1182-1188. doi: 10.1016/j.biopha.2017.11.004. Epub 2017 Nov 11.
• [1652] MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers.Oncogene. 2003 May 29;22(22):3506-10. doi: 10.1038/sj.onc.1206574.
• [1653] Np63 targets cytoglobin to inhibit oxidative stress-induced apoptosis in keratinocytes and lung cancer.Oncogene. 2016 Mar 24;35(12):1493-503. doi: 10.1038/onc.2015.222. Epub 2015 Jun 22.
• [1654] Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility.Cancer Med. 2019 Aug;8(10):4892-4905. doi: 10.1002/cam4.2367. Epub 2019 Jul 1.
• [1655] Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians.Pharmacogenetics. 1998 Feb;8(1):7-14. doi: 10.1097/00008571-199802000-00002.
• [1656] PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization.Oncogene. 2019 Oct;38(44):7002-7016. doi: 10.1038/s41388-019-0948-6. Epub 2019 Aug 12.
• [1657] Low Expression of ASK1-Interacting Protein-1 Is Significantly Correlated with Tumor Angiogenesis and Poor Survival in Patients with Early Stage Non-Small Cell Lung Cancer.Onco Targets Ther. 2019 Dec 10;12:10739-10747. doi: 10.2147/OTT.S222332. eCollection 2019.
• [1658] Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.PLoS One. 2014 Nov 6;9(11):e112336. doi: 10.1371/journal.pone.0112336. eCollection 2014.
• [1659] Cost-effectiveness of second-line diagnostic investigations in patients included in the DANTE trial: a randomized controlled trial of lung cancer screening with low-dose computed tomography.Nucl Med Commun. 2019 May;40(5):508-516. doi: 10.1097/MNM.0000000000000993.
• [1660] Frequent death-associated protein-kinase promoter hypermethylation in brain metastases of solid tumors.Oncol Rep. 2003 Jul-Aug;10(4):1031-3.
• [1661] Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.Drug Des Devel Ther. 2015 Mar 24;9:1785-96. doi: 10.2147/DDDT.S78012. eCollection 2015.
• [1662] Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer.Medicine (Baltimore). 2019 Aug;98(31):e16712. doi: 10.1097/MD.0000000000016712.
• [1663] Novel centrosome protein, TCC52, is a cancer-testis antigen.Cancer Sci. 2008 Nov;99(11):2274-9. doi: 10.1111/j.1349-7006.2008.00937.x. Epub 2008 Oct 14.
• [1664] Polymorphism of rs9387478 correlates with overall survival in female nonsmoking patients with lung cancer.Int J Biol Markers. 2016 May 28;31(2):e144-52. doi: 10.5301/jbm.5000180.
• [1665] Potential association of DCBLD2 polymorphisms with fall rates of FEV(1) by aspirin provocation in Korean asthmatics.J Korean Med Sci. 2012 Apr;27(4):343-9. doi: 10.3346/jkms.2012.27.4.343. Epub 2012 Mar 21.
• [1666] New therapeutic perspectives in CCDC6 deficient lung cancer cells.Int J Cancer. 2015 May 1;136(9):2146-57. doi: 10.1002/ijc.29263. Epub 2014 Oct 24.
• [1667] Polymorphisms in DNA damage binding protein 2 (DDB2) and susceptibility of primary lung cancer in the Chinese: a case-control study.Carcinogenesis. 2006 Jul;27(7):1475-80. doi: 10.1093/carcin/bgi350. Epub 2006 Mar 7.
• [1668] DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells.Oncogene. 2018 Mar;37(9):1251-1262. doi: 10.1038/s41388-017-0025-y. Epub 2017 Dec 15.
• [1669] miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP).Cancer Lett. 2018 Aug 1;428:55-68. doi: 10.1016/j.canlet.2018.04.028. Epub 2018 Apr 24.
• [1670] Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer.Mol Carcinog. 2018 Mar;57(3):305-318. doi: 10.1002/mc.22756. Epub 2017 Nov 14.
• [1671] RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.Oncogene. 2016 May 19;35(20):2574-83. doi: 10.1038/onc.2015.336. Epub 2015 Sep 14.
• [1672] SAGE mRNA expression in advanced-stage lung cancers.Eur J Surg Oncol. 2003 Dec;29(10):900-3. doi: 10.1016/j.ejso.2003.06.001.
• [1673] EGFR and Ras regulate DDX59 during lung cancer development.Gene. 2018 Feb 5;642:95-102. doi: 10.1016/j.gene.2017.11.029. Epub 2017 Nov 10.
• [1674] Dysregulated Redox Regulation Contributes to Nuclear EGFR Localization and Pathogenicity in Lung Cancer.Sci Rep. 2019 Mar 19;9(1):4844. doi: 10.1038/s41598-019-41395-8.
• [1675] Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D.Lung Cancer. 2013 Feb;79(2):104-10. doi: 10.1016/j.lungcan.2012.10.012. Epub 2012 Nov 20.
• [1676] Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.Am J Pathol. 2013 Mar;182(3):954-64. doi: 10.1016/j.ajpath.2012.11.019. Epub 2013 Jan 7.
• [1677] The subpopulation of CD44-positive cells promoted tumorigenicity and metastatic ability in lung adenocarcinoma.J Chin Med Assoc. 2019 Mar;82(3):196-201. doi: 10.1097/JCMA.0000000000000056.
• [1678] Genetic transfer of PNAS-4 induces apoptosis and enhances sensitivity to gemcitabine in lung cancer.Cell Biol Int. 2009 Mar;33(3):276-82. doi: 10.1016/j.cellbi.2008.11.014. Epub 2008 Dec 11.
• [1679] RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin.Am J Transl Res. 2017 Feb 15;9(2):674-682. eCollection 2017.
• [1680] Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro.Mol Biol Rep. 2013 Mar;40(3):2671-8. doi: 10.1007/s11033-012-2353-x. Epub 2012 Dec 18.
• [1681] KIAA1735 gene on human chromosome 11q23.1 encodes a novel protein with myosine-tail homologous domain and C-terminal DIX domain.Int J Oncol. 2003 Jul;23(1):145-50.
• [1682] Multiscale in situ analysis of the role of dyskerin in lung cancer cells.Integr Biol (Camb). 2013 Feb;5(2):402-13. doi: 10.1039/c2ib20219k.
• [1683] Genetic Variants in the Wingless Antagonist Genes (sFRP, DKK, and Axin2) Predict the Overall Survival and Prognosis of North Indian Lung Cancer Patients Treated with Platinum-Based Doublet Chemotherapy.Cancer Biother Radiopharm. 2018 Dec;33(10):466-477. doi: 10.1089/cbr.2018.2491. Epub 2018 Oct 20.
• [1684] Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.Cancer Res. 2012 Nov 15;72(22):5900-11. doi: 10.1158/0008-5472.CAN-12-2368. Epub 2012 Sep 25.
• [1685] Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A. 1999 Nov23;96(24):13989-94.
• [1686] MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells.Cancer Res. 2006 Aug 15;66(16):7939-47. doi: 10.1158/0008-5472.CAN-06-1888.
• [1687] Role of DMP1 and its future in lung cancer diagnostics.Expert Rev Mol Diagn. 2008 Jul;8(4):435-47. doi: 10.1586/14737159.8.4.435.
• [1688] HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.Oncogene. 2016 Oct 27;35(43):5674-5685. doi: 10.1038/onc.2016.106. Epub 2016 Apr 11.
• [1689] Cladribine enhances apoptotic cell death in lung carcinoma cells over-expressing DNase .Biol Pharm Bull. 2011;34(7):1001-4. doi: 10.1248/bpb.34.1001.
• [1690] TdIF1: a putative oncogene in NSCLC tumor progression.Signal Transduct Target Ther. 2018 Oct 19;3:28. doi: 10.1038/s41392-018-0030-9. eCollection 2018.
• [1691] Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.Int J Oncol. 2006 Feb;28(2):321-8.
• [1692] Identification of DOK genes as lung tumor suppressors.Nat Genet. 2010 Mar;42(3):216-23. doi: 10.1038/ng.527. Epub 2010 Feb 7.
• [1693] DOK7V1 influences the malignant phenotype of lung cancer cells through PI3K/AKT/mTOR and FAK/paxillin signaling pathways.Int J Oncol. 2019 Jan;54(1):381-389. doi: 10.3892/ijo.2018.4624. Epub 2018 Nov 5.
• [1694] Inhibition of cell-adhesion protein DPYSL3 promotes metastasis of lung cancer.Respir Res. 2018 Mar 7;19(1):41. doi: 10.1186/s12931-018-0740-0.
• [1695] NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.J Thorac Oncol. 2012 May;7(5):779-89. doi: 10.1097/JTO.0b013e31824c92b4.
• [1696] High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer.Oncotarget. 2015 Sep 15;6(27):23399-416. doi: 10.18632/oncotarget.4351.
• [1697] The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer.Carcinogenesis. 2012 Dec;33(12):2326-33. doi: 10.1093/carcin/bgs273. Epub 2012 Aug 31.
• [1698] SOX30 is a key regulator of desmosomal gene suppressing tumor growth and metastasis in lung adenocarcinoma.J Exp Clin Cancer Res. 2018 May 31;37(1):111. doi: 10.1186/s13046-018-0778-3.
• [1699] Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.Clin Cancer Res. 2004 Dec 15;10(24):8501-11. doi: 10.1158/1078-0432.CCR-04-1072.
• [1700] Genetic Variant of Notch Regulator DTX1 Predicts Survival After Lung Cancer Surgery.Ann Surg Oncol. 2019 Oct;26(11):3756-3764. doi: 10.1245/s10434-019-07614-2. Epub 2019 Jul 16.
• [1701] The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms.BMC Cancer. 2016 Feb 1;16:49. doi: 10.1186/s12885-016-2087-6.
• [1702] Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.J Cancer Res Ther. 2018;14(Supplement):S72-S78. doi: 10.4103/0973-1482.172108.
• [1703] Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin.Int J Mol Sci. 2014 Jun 13;15(6):10635-51. doi: 10.3390/ijms150610635.
• [1704] Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells.Lung Cancer. 1996 Nov;15(3):341-54. doi: 10.1016/0169-5002(95)00597-8.
• [1705] Metformin induces cell cycle arrest at the G1 phase through E2F8 suppression in lung cancer cells.Oncotarget. 2017 Oct 6;8(60):101509-101519. doi: 10.18632/oncotarget.21552. eCollection 2017 Nov 24.
• [1706] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [1707] Diagnostic and prognostic significance of receptor-binding cancer antigen expressed on SiSo cells in lung-cancer-associated pleural effusion.Clin Respir J. 2018 Jan;12(1):279-284. doi: 10.1111/crj.12527. Epub 2016 Jul 21.
• [1708] Association of 12 polymorphic variants conferring genetic risk to lung cancer in Indian population: An extensive meta-analysis.Environ Mol Mutagen. 2017 Dec;58(9):688-700. doi: 10.1002/em.22149. Epub 2017 Oct 27.
• [1709] Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage.PLoS One. 2013;8(3):e60065. doi: 10.1371/journal.pone.0060065. Epub 2013 Mar 22.
• [1710] Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.Int J Nanomedicine. 2013;8:4481-94. doi: 10.2147/IJN.S41782. Epub 2013 Nov 21.
• [1711] Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers.Clin Chem. 2004 Mar;50(3):490-9. doi: 10.1373/clinchem.2003.026849. Epub 2004 Jan 15.
• [1712] NF-B-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.Cell Death Dis. 2018 Apr 1;9(4):418. doi: 10.1038/s41419-018-0447-7.
• [1713] Needle-based confocal laser endomicroscopy for real-time diagnosingand staging of lung cancer.Eur Respir J. 2019 Jun 20;53(6):1801520. doi: 10.1183/13993003.01520-2018. Print 2019 Jun.
• [1714] Circular RNA screening from EIF3a in lung cancer.Cancer Med. 2019 Aug;8(9):4159-4168. doi: 10.1002/cam4.2338. Epub 2019 Jun 13.
• [1715] Decreased eIF3e Expression Can Mediate Epithelial-to-Mesenchymal Transition through Activation of the TGF Signaling Pathway.Mol Cancer Res. 2015 Oct;13(10):1421-30. doi: 10.1158/1541-7786.MCR-14-0645. Epub 2015 Jun 8.
• [1716] Association between eIF3 polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.Br J Clin Pharmacol. 2013 Feb;75(2):516-23. doi: 10.1111/j.1365-2125.2012.04379.x.
• [1717] Targeting EIF4F complex in non-small cell lung cancer cells.Oncotarget. 2017 Jun 8;8(33):55731-55735. doi: 10.18632/oncotarget.18413. eCollection 2017 Aug 15.
• [1718] Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.Eur J Cancer. 2018 Sep;101:165-180. doi: 10.1016/j.ejca.2018.07.001. Epub 2018 Aug 1.
• [1719] Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma.Nat Commun. 2019 Nov 28;10(1):5438. doi: 10.1038/s41467-019-13295-y.
• [1720] Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer.Front Oncol. 2019 May 7;9:363. doi: 10.3389/fonc.2019.00363. eCollection 2019.
• [1721] Correction: LCE: an open web portal to explore gene expression and clinical associations in lung cancer.Oncogene. 2020 Jan;39(3):718-719. doi: 10.1038/s41388-019-1000-6.
• [1722] EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer.Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):199-211. doi: 10.1016/j.bbcan.2017.04.004. Epub 2017 Apr 10.
• [1723] Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.Exp Mol Pathol. 2013 Dec;95(3):313-8. doi: 10.1016/j.yexmp.2013.07.001. Epub 2013 Aug 3.
• [1724] EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene. 2010 Nov 4;29(44):5969-75. doi: 10.1038/onc.2010.330. Epub 2010 Aug 9.
• [1725] Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers.Mol Cells. 2019 Nov 30;42(11):804-809. doi: 10.14348/molcells.2019.0099.
• [1726] Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma.Int J Oncol. 2019 May;54(5):1747-1758. doi: 10.3892/ijo.2019.4732. Epub 2019 Feb 27.
• [1727] Enhanced recovery after surgery and video-assisted thoracic surgery lobectomy: the Italian VATS Group surgical protocol.J Thorac Dis. 2018 Mar;10(Suppl 4):S564-S570. doi: 10.21037/jtd.2018.01.157.
• [1728] Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population.Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1336-40. doi: 10.1158/1055-9965.EPI-06-0194.
• [1729] Novel metastasis-related gene CIM functions in the regulation of multiple cellular stress-response pathways.Cancer Res. 2010 Dec 1;70(23):9949-58. doi: 10.1158/0008-5472.CAN-10-1055. Epub 2010 Nov 30.
• [1730] Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization.Artif Cells Nanomed Biotechnol. 2017 Aug;45(5):1023-1028. doi: 10.1080/21691401.2016.1200058. Epub 2016 Jun 25.
• [1731] Human endogenous retrovirus env genes: Potential blood biomarkers in lung cancer.Microb Pathog. 2018 Feb;115:189-193. doi: 10.1016/j.micpath.2017.12.040. Epub 2017 Dec 20.
• [1732] Circular RNA circNOL10 Inhibits Lung Cancer Development by Promoting SCLM1-Mediated Transcriptional Regulation of the Humanin Polypeptide Family.Adv Sci (Weinh). 2018 Nov 16;6(2):1800654. doi: 10.1002/advs.201800654. eCollection 2019 Jan 23.
• [1733] Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.Lung Cancer (Auckl). 2019 Sep 9;10:87-94. doi: 10.2147/LCTT.S190786. eCollection 2019.
• [1734] A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer.Cancer Res. 1999 Jan 1;59(1):35-43.
• [1735] The exonuclease 1 Glu589Lys gene polymorphism and cancer susceptibility: evidence based on a meta-analysis.Asian Pac J Cancer Prev. 2014;15(6):2571-6. doi: 10.7314/apjcp.2014.15.6.2571.
• [1736] Sec3 knockdown inhibits TGF- induced epithelial-mesenchymal transition through the down-regulation of Akt phosphorylation in A549 cells.Biochem Biophys Res Commun. 2019 Nov 5;519(2):253-260. doi: 10.1016/j.bbrc.2019.08.145. Epub 2019 Sep 5.
• [1737] miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer.Cell Prolif. 2018 Feb;51(1):e12406. doi: 10.1111/cpr.12406. Epub 2017 Nov 12.
• [1738] Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1.Oncol Rep. 2009 Nov;22(5):1069-75.
• [1739] FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma.Onco Targets Ther. 2019 Apr 17;12:2829-2842. doi: 10.2147/OTT.S190934. eCollection 2019.
• [1740] FAM13A as a Novel Hypoxia-Induced Gene in Non-Small Cell Lung Cancer.J Cancer. 2017 Oct 23;8(19):3933-3938. doi: 10.7150/jca.20342. eCollection 2017.
• [1741] FAM98A promotes proliferation of non-small cell lung cancer cells via the P38-ATF2 signaling pathway.Cancer Manag Res. 2018 Jul 27;10:2269-2278. doi: 10.2147/CMAR.S163323. eCollection 2018.
• [1742] The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer.Mol Biol Rep. 2019 Aug;46(4):4001-4008. doi: 10.1007/s11033-019-04846-z. Epub 2019 May 8.
• [1743] Establishment and characterization of primary lung cancer cell lines from Chinese population.Acta Pharmacol Sin. 2011 Mar;32(3):385-92. doi: 10.1038/aps.2010.214.
• [1744] FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells.Respir Res. 2018 Oct 25;19(1):206. doi: 10.1186/s12931-018-0910-0.
• [1745] FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.Cell Death Dis. 2019 Jun 19;10(7):486. doi: 10.1038/s41419-019-1732-9.
• [1746] Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.J Immunol. 2019 Aug 15;203(4):1012-1020. doi: 10.4049/jimmunol.1801557. Epub 2019 Jul 15.
• [1747] FBXW2 suppresses migration and invasion of lung cancer cells via promoting -catenin ubiquitylation and degradation.Nat Commun. 2019 Mar 27;10(1):1382. doi: 10.1038/s41467-019-09289-5.
• [1748] Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis.J Natl Cancer Inst. 2011 Sep 7;103(17):1323-37. doi: 10.1093/jnci/djr290. Epub 2011 Aug 10.
• [1749] Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction.Cancer Prev Res (Phila). 2011 Apr;4(4):552-61. doi: 10.1158/1940-6207.CAPR-10-0183. Epub 2011 Mar 16.
• [1750] Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.Cancer Res. 2005 Feb 15;65(4):1207-12. doi: 10.1158/0008-5472.CAN-04-3461.
• [1751] Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.Cancer Gene Ther. 2002 Aug;9(8):633-40. doi: 10.1038/sj.cgt.7700478.
• [1752] Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2, and their genetic interaction is associated with lung cancer.FASEB J. 2015 May;29(5):1986-98. doi: 10.1096/fj.14-264580. Epub 2015 Feb 9.
• [1753] Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.Int J Clin Exp Pathol. 2015 Jan 1;8(1):601-7. eCollection 2015.
• [1754] Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer diagnosis.Cancer Res. 2009 Nov 15;69(22):8629-35. doi: 10.1158/0008-5472.CAN-09-1568. Epub 2009 Nov 3.
• [1755] FOXD1 and Gal-3 Form a Positive Regulatory Loop to Regulate Lung Cancer Aggressiveness.Cancers (Basel). 2019 Nov 28;11(12):1897. doi: 10.3390/cancers11121897.
• [1756] Profiling analysis of FOX gene family members identified FOXE1 as potential regulator of NSCLC development.Cell Mol Biol (Noisy-le-grand). 2016 Sep 30;62(11):57-62.
• [1757] Circular RNA circMAN2B2 facilitates lung cancer cell proliferation and invasion via miR-1275/FOXK1 axis.Biochem Biophys Res Commun. 2018 Apr 15;498(4):1009-1015. doi: 10.1016/j.bbrc.2018.03.105. Epub 2018 Mar 16.
• [1758] Expression of Frat1 correlates with expression of -catenin and is associated with a poor clinical outcome in human SCC and AC.Tumour Biol. 2012 Oct;33(5):1437-44. doi: 10.1007/s13277-012-0394-3. Epub 2012 Apr 17.
• [1759] FRK plays an oncogenic role in non-small cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.Int J Cancer. 2020 Jan 1;146(1):208-222. doi: 10.1002/ijc.32530. Epub 2019 Jul 26.
• [1760] FERM-containing protein FRMD5 is a p120-catenin interacting protein that regulates tumor progression.FEBS Lett. 2012 Sep 21;586(19):3044-50. doi: 10.1016/j.febslet.2012.07.019. Epub 2012 Jul 27.
• [1761] FRMPD1 activates the Hippo pathway via interaction with WWC3 to suppress the proliferation and invasiveness of lung cancer cells.Cancer Manag Res. 2019 Apr 18;11:3395-3410. doi: 10.2147/CMAR.S194512. eCollection 2019.
• [1762] miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.J Cell Mol Med. 2018 Jul;22(7):3526-3536. doi: 10.1111/jcmm.13629. Epub 2018 Apr 17.
• [1763] Elevated fibrous sheath interacting protein 1 levels are associated with poor prognosis in non-small cell lung cancer patients.Oncotarget. 2017 Feb 14;8(7):12186-12193. doi: 10.18632/oncotarget.14575.
• [1764] An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.Cancer Immunol Res. 2019 Aug;7(8):1267-1279. doi: 10.1158/2326-6066.CIR-18-0874. Epub 2019 Jun 11.
• [1765] Clinical significance and biological function of fucosyltransferase 2 in lung adenocarcinoma.Oncotarget. 2017 Oct 19;8(57):97246-97259. doi: 10.18632/oncotarget.21896. eCollection 2017 Nov 14.
• [1766] Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis.Am J Pathol. 2009 Dec;175(6):2646-56. doi: 10.2353/ajpath.2009.080571. Epub 2009 Nov 5.
• [1767] FXYD5 (dysadherin) may mediate metastatic progression through regulation of the -Na(+)-K(+)-ATPase subunit in the 4T1 mouse breast cancer model.Am J Physiol Cell Physiol. 2017 Jul 1;313(1):C108-C117. doi: 10.1152/ajpcell.00206.2016. Epub 2017 May 17.
• [1768] miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1.Biomed Pharmacother. 2016 Dec;84:123-129. doi: 10.1016/j.biopha.2016.09.027. Epub 2016 Sep 16.
• [1769] Frizzled-8 as a putative therapeutic target in human lung cancer.Biochem Biophys Res Commun. 2012 Jan 6;417(1):62-6. doi: 10.1016/j.bbrc.2011.11.055. Epub 2011 Nov 25.
• [1770] Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches.Int J Cancer. 2010 Apr 15;126(8):1895-1902. doi: 10.1002/ijc.24947.
• [1771] Polymorphisms of rs1347093 and rs1397529 are associated with lung cancer risk in northeast Chinese population.Oncotarget. 2017 Oct 24;8(55):94862-94871. doi: 10.18632/oncotarget.22030. eCollection 2017 Nov 7.
• [1772] Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2/STAT6 pathway.FASEB J. 2012 Nov;26(11):4603-13. doi: 10.1096/fj.12-211755. Epub 2012 Aug 2.
• [1773] Apoptosis of human lung cancer cells by curcumin mediated through up-regulation of "growth arrest and DNA damage inducible genes 45 and 153".Biol Pharm Bull. 2010;33(8):1291-9. doi: 10.1248/bpb.33.1291.
• [1774] Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis. Toxicol Lett. 2019 May 1;305:40-50.
• [1775] A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.J Exp Med. 1995 Sep 1;182(3):689-98. doi: 10.1084/jem.182.3.689.
• [1776] GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.J Thorac Oncol. 2014 Jun;9(6):784-93. doi: 10.1097/JTO.0000000000000165.
• [1777] Radiation-induced lung adenocarcinoma is associated with increased frequency of genes inactivated by promoter hypermethylation.Radiat Res. 2007 Oct;168(4):409-14. doi: 10.1667/RR0825.1.
• [1778] In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.Nat Commun. 2018 Jul 16;9(1):2732. doi: 10.1038/s41467-018-04572-3.
• [1779] Clinicopathological significance of core 2 beta1,6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization.Cancer Res. 2001 Mar 1;61(5):2226-31.
• [1780] The mechanism of miR-16-5p protection on LPS-induced A549 cell injury by targeting CXCR3.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1200-1206. doi: 10.1080/21691401.2019.1593998.
• [1781] A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study.BMC Cancer. 2008 Feb 20;8:54. doi: 10.1186/1471-2407-8-54.
• [1782] Bioinformatics analysis of Rab GDP dissociation inhibitor beta and its expression in non-small cell lung cancer.Diagn Pathol. 2014 Nov 4;9:201. doi: 10.1186/s13000-014-0201-0.
• [1783] Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells.Cancer Res. 2004 Oct 1;64(19):6874-82. doi: 10.1158/0008-5472.CAN-04-0633.
• [1784] Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2226-2231. doi: 10.1073/pnas.1818865116. Epub 2019 Jan 18.
• [1785] Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors.Int J Mol Med. 2002 May;9(5):509-13.
• [1786] Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.J Exp Clin Cancer Res. 2019 Feb 21;38(1):96. doi: 10.1186/s13046-019-1057-7.
• [1787] D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo.Br J Cancer. 2011 Jun 28;105(1):74-82. doi: 10.1038/bjc.2011.170. Epub 2011 Jun 7.
• [1788] Preferential overexpression of glutaredoxin3 in human colon and lung carcinoma.Cancer Epidemiol. 2009 Oct;33(3-4):281-7. doi: 10.1016/j.canep.2009.08.006. Epub 2009 Sep 30.
• [1789] Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin.Oncogene. 1996 Mar 21;12(6):1289-97.
• [1790] Cloning of the nucleostemin gene and its function in transforming human embryonic bone marrow mesenchymal stem cells into F6 tumor cells.Int J Mol Med. 2005 Aug;16(2):205-13.
• [1791] GOLGA2/GM130, cis-Golgi matrix protein, is a novel target of anticancer gene therapy.Mol Ther. 2012 Nov;20(11):2052-63. doi: 10.1038/mt.2012.125. Epub 2012 Jun 26.
• [1792] Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).Target Oncol. 2019 Oct;14(5):577-590. doi: 10.1007/s11523-019-00667-z.
• [1793] Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.
• [1794] Glypican-5 suppresses Epithelial-Mesenchymal Transition of the lung adenocarcinoma by competitively binding to Wnt3a.Oncotarget. 2016 Nov 29;7(48):79736-79746. doi: 10.18632/oncotarget.12945.
• [1795] MiR-921 directly downregulates GPx3 in A549 lung cancer cells.Gene. 2019 Jun 5;700:163-167. doi: 10.1016/j.gene.2019.02.086. Epub 2019 Mar 19.
• [1796] Development of transcriptomic biomarker signature in human saliva to detect lung cancer.Cell Mol Life Sci. 2012 Oct;69(19):3341-3350. doi: 10.1007/s00018-012-1027-0. Epub 2012 Jun 12.
• [1797] Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation.Apoptosis. 2019 Apr;24(3-4):312-325. doi: 10.1007/s10495-019-01515-1.
• [1798] Pore-forming spider venom peptides show cytotoxicity to hyperpolarized cancer cells expressing K+ channels: A lentiviral vector approach.PLoS One. 2019 Apr 12;14(4):e0215391. doi: 10.1371/journal.pone.0215391. eCollection 2019.
• [1799] Chromosome 4q31 locus in COPD is also associated with lung cancer.Eur Respir J. 2010 Dec;36(6):1375-82. doi: 10.1183/09031936.00033310.
• [1800] Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.Cancer Biol Ther. 2009 Aug;8(16):1540-9. doi: 10.4161/cbt.8.16.8950. Epub 2009 Aug 8.
• [1801] Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis.J Clin Invest. 2013 Mar;123(3):1241-61. doi: 10.1172/JCI61271. Epub 2013 Feb 15.
• [1802] Thromboxane A2 receptor promotes tumor growth through an autoregulatory feedback pathway.J Mol Cell Biol. 2013 Dec;5(6):380-90. doi: 10.1093/jmcb/mjt038. Epub 2013 Oct 9.
• [1803] Evaluating the association of polymorphisms in the HAP1 gene with lung cancer risk: a meta-analysis.Tumour Biol. 2014 Nov;35(11):10825-31. doi: 10.1007/s13277-014-2236-y. Epub 2014 Aug 1.
• [1804] Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.Clin Cancer Res. 2009 Apr 15;15(8):2602-11. doi: 10.1158/1078-0432.CCR-08-2755. Epub 2009 Apr 7.
• [1805] Depletion of hepatoma-derived growth factor-related protein-3 induces apoptotic sensitization of radioresistant A549 cells via reactive oxygen species-dependent p53 activation.Biochem Biophys Res Commun. 2013 Sep 27;439(3):333-9. doi: 10.1016/j.bbrc.2013.08.086. Epub 2013 Sep 6.
• [1806] The Emerging Roles of the HERC Ubiquitin Ligases in Cancer.Curr Pharm Des. 2018;24(15):1676-1681. doi: 10.2174/1381612824666180528081024.
• [1807] Identification of HERC5 and its potential role in NSCLC progression.Int J Cancer. 2015 May 15;136(10):2264-72. doi: 10.1002/ijc.29298. Epub 2014 Nov 9.
• [1808] Hes3 Enhances the Malignant Phenotype of Lung Cancer through Upregulating Cyclin D1, Cyclin D3 and MMP7 Expression.Int J Med Sci. 2019 Mar 9;16(3):470-476. doi: 10.7150/ijms.28139. eCollection 2019.
• [1809] Loss of hypermethylated in cancer 1 (HIC1) promotes lung cancer progression.Cell Signal. 2019 Jan;53:162-169. doi: 10.1016/j.cellsig.2018.10.006. Epub 2018 Oct 10.
• [1810] Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer.Cancer Lett. 2009 Jun 18;278(2):183-191. doi: 10.1016/j.canlet.2009.01.012. Epub 2009 Feb 8.
• [1811] Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).BMC Cancer. 2018 Apr 16;18(1):429. doi: 10.1186/s12885-018-4215-y.
• [1812] A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation.Transl Oncol. 2017 Oct;10(5):818-827. doi: 10.1016/j.tranon.2017.07.008. Epub 2017 Aug 29.
• [1813] Knockdown of HMGN5 expression by RNA interference induces cell cycle arrest in human lung cancer cells.Asian Pac J Cancer Prev. 2012;13(7):3223-8. doi: 10.7314/apjcp.2012.13.7.3223.
• [1814] Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-1-mediated epithelial to mesenchymal transition in lung cancer cells.BMC Cancer. 2019 Sep 6;19(1):894. doi: 10.1186/s12885-019-6119-x.
• [1815] The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.Onco Targets Ther. 2019 Jul 22;12:5897-5906. doi: 10.2147/OTT.S210223. eCollection 2019.
• [1816] HOPX is methylated and exerts tumour-suppressive function through Ras-induced senescence in human lung cancer.J Pathol. 2015 Feb;235(3):397-407. doi: 10.1002/path.4469. Epub 2014 Dec 18.
• [1817] Association of polymorphisms at HORMAD2 and prognosis in advanced non-small-cell lung cancer patients.Cancer Epidemiol. 2014 Aug;38(4):414-8. doi: 10.1016/j.canep.2014.03.013. Epub 2014 May 3.
• [1818] Long Non-Coding RNA HOXA Transcript Antisense RNA Myeloid-Specific 1-HOXA1 Axis Downregulates the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in Lung Cancer.Front Immunol. 2018 Mar 12;9:473. doi: 10.3389/fimmu.2018.00473. eCollection 2018.
• [1819] HOXA4, down-regulated in lung cancer, inhibits the growth, motility and invasion of lung cancer cells.Cell Death Dis. 2018 May 1;9(5):465. doi: 10.1038/s41419-018-0497-x.
• [1820] Recombinant cell-permeable HOXA9 protein inhibits NSCLC cell migration and invasion.Cell Oncol (Dordr). 2019 Jun;42(3):275-285. doi: 10.1007/s13402-019-00424-4. Epub 2019 Jan 29.
• [1821] HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype.Oncogene. 2018 Jun;37(26):3575-3588. doi: 10.1038/s41388-018-0229-9. Epub 2018 Mar 26.
• [1822] Homeobox C8 is a transcriptional repressor of E-cadherin gene expression in non-small cell lung cancer.Int J Biochem Cell Biol. 2019 Sep;114:105557. doi: 10.1016/j.biocel.2019.06.005. Epub 2019 Jun 13.
• [1823] Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations.Dis Markers. 2019 Mar 3;2019:8170759. doi: 10.1155/2019/8170759. eCollection 2019.
• [1824] Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis.PLoS One. 2013 Nov 12;8(11):e79634. doi: 10.1371/journal.pone.0079634. eCollection 2013.
• [1825] Isolation and characterization of novel human short-chain dehydrogenase/reductase SCDR10B which is highly expressed in the brain and acts as hydroxysteroid dehydrogenase.Acta Biochim Pol. 2009;56(2):279-89. Epub 2009 May 12.
• [1826] The relationship between three heat shock protein 70 gene polymorphisms and susceptibility to lung cancer.Clin Chem Lab Med. 2010 Nov;48(11):1657-63. doi: 10.1515/CCLM.2010.304. Epub 2010 Aug 13.
• [1827] JAG1 Is Associated with Poor Survival through Inducing Metastasis in Lung Cancer.PLoS One. 2016 Mar 1;11(3):e0150355. doi: 10.1371/journal.pone.0150355. eCollection 2016.
• [1828] Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):482-7. doi: 10.1158/1078-0432.CCR-06-1593.
• [1829] ICAM3 mediates inflammatory signaling to promote cancer cell stemness.Cancer Lett. 2018 May 28;422:29-43. doi: 10.1016/j.canlet.2018.02.034. Epub 2018 Mar 2.
• [1830] Inhibitor of DNA-Binding Protein 4 Suppresses Cancer Metastasis through the Regulation of Epithelial Mesenchymal Transition in Lung Adenocarcinoma.Cancers (Basel). 2019 Dec 14;11(12):2021. doi: 10.3390/cancers11122021.
• [1831] Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients.Onco Targets Ther. 2019 Oct 3;12:8139-8149. doi: 10.2147/OTT.S220698. eCollection 2019.
• [1832] Inhibiting of Proliferation, Migration, and Invasion in Lung Cancer Induced by Silencing Interferon-Induced Transmembrane Protein 1 (IFITM1).Biomed Res Int. 2019 May 8;2019:9085435. doi: 10.1155/2019/9085435. eCollection 2019.
• [1833] RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer.J Exp Clin Cancer Res. 2019 Nov 27;38(1):478. doi: 10.1186/s13046-019-1479-2.
• [1834] Serous IFNA3 predicts unfavorable prognosis in lung cancer via abnormal activation of AKT signaling.IUBMB Life. 2019 Nov;71(11):1806-1814. doi: 10.1002/iub.2152. Epub 2019 Aug 16.
• [1835] Integrative genomic analyses on IL28RA, the common receptor of interferon-lambda1, -lambda2 and -lambda3.Int J Mol Med. 2010 May;25(5):807-12.
• [1836] The human homolog of the rodent immediate early response genes, PC4 and TIS7, resides in the lung cancer tumor suppressor gene region on chromosome 3p21.Hum Genet. 1997 Mar;99(3):334-41. doi: 10.1007/s004390050368.
• [1837] IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner.Nucleic Acids Res. 2019 Jan 10;47(1):375-390. doi: 10.1093/nar/gky1012.
• [1838] Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell lung cancer.Tumour Biol. 2017 Apr;39(4):1010428317695928. doi: 10.1177/1010428317695928.
• [1839] Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments.Int J Oncol. 2020 Jan;56(1):193-205. doi: 10.3892/ijo.2019.4926. Epub 2019 Nov 28.
• [1840] Ectopic Ikaros expression positively correlates with lung cancer progression.Anat Rec (Hoboken). 2013 Jun;296(6):907-13. doi: 10.1002/ar.22700. Epub 2013 Apr 12.
• [1841] Comprehensive genomic and prognostic analysis of the IL?7 family genes in lung cancer.Mol Med Rep. 2019 Jun;19(6):4906-4918. doi: 10.3892/mmr.2019.10164. Epub 2019 Apr 15.
• [1842] A positive feedback loop of IL-17B-IL-17RB activates ERK/-catenin to promote lung cancer metastasis.Cancer Lett. 2018 May 28;422:44-55. doi: 10.1016/j.canlet.2018.02.037. Epub 2018 Feb 26.
• [1843] Reduced interleukin-38 in non-small cell lung cancer is associated with tumour progression.Open Biol. 2018 Oct 31;8(10):180132. doi: 10.1098/rsob.180132.
• [1844] High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers.Sci Rep. 2018 Jan 11;8(1):418. doi: 10.1038/s41598-017-18796-8.
• [1845] Interaction between epidermal growth factor receptor and interleukin-6 receptor in NSCLC progression.J Cell Biochem. 2019 Jan;120(1):872-881. doi: 10.1002/jcb.27448. Epub 2018 Aug 21.
• [1846] EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.Lung Cancer. 2018 Feb;116:80-89. doi: 10.1016/j.lungcan.2017.12.017. Epub 2017 Dec 29.
• [1847] C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn.Tumour Biol. 2015 Aug;36(8):5979-85. doi: 10.1007/s13277-015-3274-9. Epub 2015 Mar 4.
• [1848] Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):434-42. doi: 10.1158/1078-0432.CCR-06-1297.
• [1849] Genetic alterations of tumor suppressor ING1 in human non-small cell lung cancer.Oncol Rep. 2011 Apr;25(4):1073-81. doi: 10.3892/or.2011.1172. Epub 2011 Jan 31.
• [1850] Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.Oncol Rep. 2006 Mar;15(3):545-9.
• [1851] MicroRNA?14 upregulates HIF? and VEGF by targeting ING4 in lung cancer cells.Mol Med Rep. 2019 Jun;19(6):4935-4945. doi: 10.3892/mmr.2019.10170. Epub 2019 Apr 16.
• [1852] INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer.Oncogene. 2017 Mar;36(10):1430-1439. doi: 10.1038/onc.2016.311. Epub 2016 Sep 19.
• [1853] Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.J Natl Cancer Inst. 2019 Jul 1;111(7):664-674. doi: 10.1093/jnci/djy166.
• [1854] Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.Cell Signal. 2018 Jun;46:83-91. doi: 10.1016/j.cellsig.2018.02.014. Epub 2018 Mar 1.
• [1855] Gender differences and lung cancer risk in occupational chefs: analyzing more than 350,000 chefs in Taiwan, 1984-2011.Int Arch Occup Environ Health. 2019 Jan;92(1):101-109. doi: 10.1007/s00420-018-1358-8. Epub 2018 Sep 18.
• [1856] Wnt3 knockdown sensitizes human non-small cell type lung cancer (NSCLC) cells to cisplatin via regulating the cell proliferation and apoptosis.Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1323-1332. doi: 10.26355/eurrev_201803_14474.
• [1857] Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens.BMC Mol Biol. 2008 Nov 17;9:103. doi: 10.1186/1471-2199-9-103.
• [1858] MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer.Cell Death Dis. 2017 May 4;8(5):e2764. doi: 10.1038/cddis.2017.145.
• [1859] A comprehensive lipid binding and activity validation of a cancer-specific peptide-peptoid hybrid PPS1.Biochem Biophys Res Commun. 2017 Apr 29;486(2):545-550. doi: 10.1016/j.bbrc.2017.03.083. Epub 2017 Mar 18.
• [1860] Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses.PLoS One. 2011;6(12):e28683. doi: 10.1371/journal.pone.0028683. Epub 2011 Dec 14.
• [1861] Regulation of OLC1 protein expression by the anaphase-promoting complex.Oncol Lett. 2019 Mar;17(3):2639-2646. doi: 10.3892/ol.2019.9881. Epub 2019 Jan 2.
• [1862] Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.Int J Mol Med. 2013 Jan;31(1):33-42. doi: 10.3892/ijmm.2012.1171. Epub 2012 Nov 1.
• [1863] Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer.Oncogene. 1994 Feb;9(2):611-9.
• [1864] Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway.Carcinogenesis. 2013 Nov;34(11):2600-9. doi: 10.1093/carcin/bgt281. Epub 2013 Aug 16.
• [1865] Elevated integrin 64 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer.Hum Pathol. 2016 Aug;54:174-83. doi: 10.1016/j.humpath.2016.04.003. Epub 2016 Apr 20.
• [1866] Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis.BMC Cancer. 2008 Jan 28;8:25. doi: 10.1186/1471-2407-8-25.
• [1867] Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.Epigenetics. 2015;10(10):903-12. doi: 10.1080/15592294.2015.1078049. Epub 2015 Aug 7.
• [1868] Effect of the actin- and calcium-regulating activities of ITPKB on the metastatic potential of lung cancer cells.Biochem J. 2018 Jun 26;475(12):2057-2071. doi: 10.1042/BCJ20180238.
• [1869] A simple robust method of synthesis of copper-silver core-shell nano-particle: evaluation of its structural and chemical properties with anticancer potency.Nanotechnology. 2018 Aug 10;29(32):325102. doi: 10.1088/1361-6528/aac372. Epub 2018 May 9.
• [1870] Hydrophobic oxime ethers: a versatile class of pDNA and siRNA transfection lipids.ChemMedChem. 2011 Nov 4;6(11):2063-9. doi: 10.1002/cmdc.201100259. Epub 2011 Aug 31.
• [1871] Ultrasensitive Detection of Circulating Tumor DNA of Lung Cancer via an Enzymatically Amplified SERS-Based Frequency Shift Assay.ACS Appl Mater Interfaces. 2019 May 22;11(20):18145-18152. doi: 10.1021/acsami.9b02953. Epub 2019 May 10.
• [1872] Selective Surface Enhanced Raman Scattering for Quantitative Detection of Lung Cancer Biomarkers in Superparticle@MOF Structure.Adv Mater. 2018 Feb;30(5). doi: 10.1002/adma.201702275. Epub 2017 Dec 11.
• [1873] Copy number variations of chromosome 17p13.1 might be linked to high risk of lung cancer in heavy smokers.Mol Biol Rep. 2011 Nov;38(8):5211-7. doi: 10.1007/s11033-010-0672-3. Epub 2011 Jan 4.
• [1874] The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.Anticancer Res. 2016 Sep;36(9):4841-6. doi: 10.21873/anticanres.11046.
• [1875] K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification.Clin Chem. 2000 Dec;46(12):1929-38.
• [1876] Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing.Lung Cancer. 2018 Apr;118:27-29. doi: 10.1016/j.lungcan.2017.08.019. Epub 2017 Sep 4.
• [1877] Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.Int J Cancer. 2012 Apr 15;130(8):1844-54. doi: 10.1002/ijc.26189. Epub 2011 Aug 5.
• [1878] Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.Cancer Gene Ther. 2012 Nov;19(11):767-72. doi: 10.1038/cgt.2012.57. Epub 2012 Sep 7.
• [1879] An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma.Oncogene. 2017 Jan 5;36(1):110-121. doi: 10.1038/onc.2016.181. Epub 2016 May 23.
• [1880] KIF3A binds to -arrestin for suppressing Wnt/-catenin signalling independently of primary cilia in lung cancer.Sci Rep. 2016 Sep 6;6:32770. doi: 10.1038/srep32770.
• [1881] Overexpression of Klotho Inhibits HELF Fibroblasts SASP-related Protumoral Effects on Non-small Cell Lung Cancer Cells.J Cancer. 2018 Mar 14;9(7):1248-1258. doi: 10.7150/jca.23967. eCollection 2018.
• [1882] Kinesin light chain-4 depletion induces apoptosis of radioresistant cancer cells by mitochondrial dysfunction via calcium ion influx.Cell Death Dis. 2018 May 1;9(5):496. doi: 10.1038/s41419-018-0549-2.
• [1883] Radiotherapy in combination with hyperthermia suppresses lung cancer progression via increased NR4A3 and KLF11 expression.Int J Radiat Biol. 2019 Dec;95(12):1696-1707. doi: 10.1080/09553002.2019.1665213. Epub 2019 Sep 17.
• [1884] Krppel-like factor 17 inhibits urokinase plasminogen activator gene expression to suppress cell invasion through the Src/p38/ MAPK signaling pathway in human lung adenocarcionma.Oncotarget. 2017 Jun 13;8(24):38743-38754. doi: 10.18632/oncotarget.17020.
• [1885] Smurf1 ubiquitin ligase targets Kruppel-like factor KLF2 for ubiquitination and degradation in human lung cancer H1299 cells.Biochem Biophys Res Commun. 2011 Apr 1;407(1):254-9. doi: 10.1016/j.bbrc.2011.03.016. Epub 2011 Mar 5.
• [1886] MiR-326/Sp1/KLF3: A novel regulatory axis in lung cancer progression.Cell Prolif. 2019 Mar;52(2):e12551. doi: 10.1111/cpr.12551. Epub 2018 Nov 28.
• [1887] Krppel-like factor 5 promotes lung tumorigenesis through upregulation of Sox4.Cell Physiol Biochem. 2014;33(1):1-10. doi: 10.1159/000356645. Epub 2014 Jan 2.
• [1888] Krppel like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1.Cancer Biol Ther. 2019;20(5):680-691. doi: 10.1080/15384047.2018.1550570. Epub 2018 Dec 27.
• [1889] KLF8 overexpression promotes the growth of human lung cancer cells by promoting the expression of JMJD2A.Cancer Cell Int. 2019 Oct 7;19:258. doi: 10.1186/s12935-019-0970-3. eCollection 2019.
• [1890] Decreased kallikrein 11 messenger RNA expression in lung cancer.Clin Lung Cancer. 2006 Jul;8(1):45-8. doi: 10.3816/CLC.2006.n.032.
• [1891] CASC15 contributes to proliferation and invasion through regulating miR-766-5p/ KLK12 axis in lung cancer.Cell Cycle. 2019 Sep;18(18):2323-2331. doi: 10.1080/15384101.2019.1646562. Epub 2019 Aug 5.
• [1892] Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation.Biochem Biophys Res Commun. 2011 Jun 10;409(3):442-7. doi: 10.1016/j.bbrc.2011.05.022. Epub 2011 May 8.
• [1893] Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers.Br J Cancer. 2002 Jun 5;86(11):1757-62. doi: 10.1038/sj.bjc.6600328.
• [1894] Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression.J Transl Med. 2013 Sep 26;11:232. doi: 10.1186/1479-5876-11-232.
• [1895] YY1-mediated overexpression of long noncoding RNA MCM3AP-AS1 accelerates angiogenesis and progression in lung cancer by targeting miR-340-5p/KPNA4 axis.J Cell Biochem. 2020 Mar;121(3):2258-2267. doi: 10.1002/jcb.29448. Epub 2019 Nov 6.
• [1896] Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation.Oncogene. 2019 Sep;38(36):6354-6369. doi: 10.1038/s41388-019-0889-0. Epub 2019 Jul 18.
• [1897] Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer.J Cancer Res Clin Oncol. 2016 Dec;142(12):2479-2487. doi: 10.1007/s00432-016-2253-x. Epub 2016 Sep 6.
• [1898] Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP.Molecules. 2018 Nov 20;23(11):3030. doi: 10.3390/molecules23113030.
• [1899] Implication of leucyl-tRNA synthetase 1 (LARS1) over-expression in growth and migration of lung cancer cells detected by siRNA targeted knock-down analysis.Exp Mol Med. 2008 Apr 30;40(2):229-36. doi: 10.3858/emm.2008.40.2.229.
• [1900] TNFAIP8 regulates Hippo pathway through interacting with LATS1 to promote cell proliferation and invasion in lung cancer.Mol Carcinog. 2018 Feb;57(2):159-166. doi: 10.1002/mc.22740. Epub 2017 Dec 5.
• [1901] Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.Clin Cancer Res. 2013 Feb 15;19(4):773-84. doi: 10.1158/1078-0432.CCR-12-2638. Epub 2012 Dec 6.
• [1902] Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer.Cancers (Basel). 2019 Jan 9;11(1):63. doi: 10.3390/cancers11010063.
• [1903] Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin.Mol Cancer Ther. 2012 Nov;11(11):2362-72. doi: 10.1158/1535-7163.MCT-12-0107. Epub 2012 Aug 29.
• [1904] Suppression of lung tumorigenesis by leucine zipper/EF hand-containing transmembrane-1.PLoS One. 2010 Sep 2;5(9):e12535. doi: 10.1371/journal.pone.0012535.
• [1905] Two messenger RNAs and five isoforms for Po66-CBP, a galectin-8 homolog in a human lung carcinoma cell line.Gene. 2001 Aug 22;274(1-2):253-62. doi: 10.1016/s0378-1119(01)00598-4.
• [1906] Leucine-rich glioma inactivated 3: Integrative analyses reveal its potential prognostic role in cancer.Mol Med Rep. 2018 Mar;17(3):3993-4002. doi: 10.3892/mmr.2017.8279. Epub 2017 Dec 14.
• [1907] Novel spliced form of a lens protein as a novel lung cancer antigen, Lengsin splicing variant 4.Cancer Sci. 2009 Aug;100(8):1485-93. doi: 10.1111/j.1349-7006.2009.01187.x. Epub 2009 May 19.
• [1908] LIMCH1 suppress the growth of lung cancer by interacting with HUWE1 to sustain p53 stability.Gene. 2019 Sep 5;712:143963. doi: 10.1016/j.gene.2019.143963. Epub 2019 Jul 5.
• [1909] LIMD1 phosphorylation in mitosis is required for mitotic progression and its tumor-suppressing activity.FEBS J. 2019 Mar;286(5):963-974. doi: 10.1111/febs.14743. Epub 2019 Jan 16.
• [1910] Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET.J Exp Med. 2019 Jun 3;216(6):1377-1395. doi: 10.1084/jem.20181394. Epub 2019 Apr 23.
• [1911] Haplotype sharing suggests that a genomic segment containing six genes accounts for the pulmonary adenoma susceptibility 1 (Pas1) locus activity in mice.Oncogene. 2004 May 27;23(25):4495-504. doi: 10.1038/sj.onc.1207584.
• [1912] LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.Lung Cancer. 2018 Nov;125:174-184. doi: 10.1016/j.lungcan.2018.09.017. Epub 2018 Sep 24.
• [1913] Downregulation of lysyl oxidase-like 4 LOXL4 by miR-135a-5p promotes lung cancer progression in vitro and in vivo.J Cell Physiol. 2019 Aug;234(10):18679-18687. doi: 10.1002/jcp.28508. Epub 2019 Apr 16.
• [1914] Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci.Carcinogenesis. 2016 Jan;37(1):96-105. doi: 10.1093/carcin/bgv165. Epub 2015 Nov 20.
• [1915] Lipin-1 determines lung cancer cell survival and chemotherapy sensitivity by regulation of endoplasmic reticulum homeostasis and autophagy.Cancer Med. 2018 Jun;7(6):2541-2554. doi: 10.1002/cam4.1483. Epub 2018 Apr 16.
• [1916] Single nucleotide polymorphism in the 3' untranslated region of LPP is a risk factor for lung cancer: a case-control study.BMC Cancer. 2019 Jan 8;19(1):35. doi: 10.1186/s12885-018-5241-5.
• [1917] Stromal LRP1 in lung adenocarcinoma predicts clinical outcome.Clin Cancer Res. 2011 Apr 15;17(8):2426-33. doi: 10.1158/1078-0432.CCR-10-2385. Epub 2011 Feb 15.
• [1918] Downregulation of lumican accelerates lung cancer cell invasion through p120 catenin.Cell Death Dis. 2018 Apr 1;9(4):414. doi: 10.1038/s41419-017-0212-3.
• [1919] Water-soluble variant of human Lynx1 induces cell cycle arrest and apoptosis in lung cancer cells via modulation of 7 nicotinic acetylcholine receptors.PLoS One. 2019 May 31;14(5):e0217339. doi: 10.1371/journal.pone.0217339. eCollection 2019.
• [1920] Exposure to asbestos and the risk of colorectal cancer mortality: a systematic review and meta-analysis.Occup Environ Med. 2019 Nov;76(11):861-871. doi: 10.1136/oemed-2019-105735. Epub 2019 Oct 8.
• [1921] Leucine zipper tumor suppressor 2 inhibits cell proliferation and regulates Lef/Tcf-dependent transcription through Akt/GSK3 signaling pathway in lung cancer.J Histochem Cytochem. 2013 Sep;61(9):659-70. doi: 10.1369/0022155413495875. Epub 2013 Jun 12.
• [1922] Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.Acta Biochim Biophys Sin (Shanghai). 2018 Aug 1;50(8):748-756. doi: 10.1093/abbs/gmy074.
• [1923] Histone macroH2A isoforms predict the risk of lung cancer recurrence.Oncogene. 2009 Sep 24;28(38):3423-8. doi: 10.1038/onc.2009.26. Epub 2009 Aug 3.
• [1924] Mitotic Arrest-Deficient Protein 2B Overexpressed in Lung Cancer Promotes Proliferation, EMT, and Metastasis.Oncol Res. 2019 Aug 8;27(8):859-869. doi: 10.3727/096504017X15049209129277. Epub 2017 Sep 11.
• [1925] Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer.PLoS One. 2010 Aug 3;5(8):e11934. doi: 10.1371/journal.pone.0011934.
• [1926] Silencing of NRAGE induces autophagy via AMPK/Ulk1/Atg13 signaling pathway in NSCLC cells.Tumour Biol. 2017 Jun;39(6):1010428317709676. doi: 10.1177/1010428317709676.
• [1927] Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2013 Dec;386(12):1047-59. doi: 10.1007/s00210-013-0905-9. Epub 2013 Aug 3.
• [1928] Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.Biochem Pharmacol. 2013 Feb 15;85(4):583-94. doi: 10.1016/j.bcp.2012.12.001. Epub 2012 Dec 7.
• [1929] Purification and characterization of a highly specific polyclonal antibody against human extracellular signal-regulated kinase 8 and its detection in lung cancer.PLoS One. 2017 Sep 13;12(9):e0184755. doi: 10.1371/journal.pone.0184755. eCollection 2017.
• [1930] Urine Proteome Profiling Predicts Lung Cancer from Control Cases and Other Tumors.EBioMedicine. 2018 Apr;30:120-128. doi: 10.1016/j.ebiom.2018.03.009. Epub 2018 Mar 17.
• [1931] Knockdown of end-binding protein 1 induces apoptosis in radioresistant A549 lung cancer cells via p38 kinase-dependent COX-2 upregulation.Oncol Rep. 2018 Apr;39(4):1565-1572. doi: 10.3892/or.2018.6278. Epub 2018 Feb 22.
• [1932] MARCH8 is associated with poor prognosis in non-small cell lung cancers patients.Oncotarget. 2017 Nov 21;8(64):108238-108248. doi: 10.18632/oncotarget.22602. eCollection 2017 Dec 8.
• [1933] Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers.Carcinogenesis. 2014 Jun;35(6):1248-57. doi: 10.1093/carcin/bgt494. Epub 2014 Jan 7.
• [1934] Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients.Int J Cancer. 1999 May 5;81(3):325-9. doi: 10.1002/(sici)1097-0215(19990505)81:3<325::aid-ijc2>3.0.co;2-s.
• [1935] A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer.J Cancer Res Clin Oncol. 2019 Nov;145(11):2713-2723. doi: 10.1007/s00432-019-03032-9. Epub 2019 Sep 24.
• [1936] Significance of Erythropoietin Receptor Antagonist EMP9 in Cancers.Vitam Horm. 2017;105:297-310. doi: 10.1016/bs.vh.2017.03.001. Epub 2017 Apr 18.
• [1937] Methyl-CpG binding domain 1 gene polymorphisms and lung cancer risk in a Chinese population.Biomarkers. 2008 Sep;13(6):607-17. doi: 10.1080/13547500802168031.
• [1938] Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.Clin Epigenetics. 2018 Apr 2;10:41. doi: 10.1186/s13148-018-0474-3. eCollection 2018.
• [1939] Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.Mol Carcinog. 2012 Jul;51(7):546-52. doi: 10.1002/mc.20819. Epub 2011 Jul 7.
• [1940] Minichromosome maintenance protein 10 as a marker for proliferation and prognosis in lung cancer.Int J Oncol. 2019 Dec;55(6):1349-1360. doi: 10.3892/ijo.2019.4899. Epub 2019 Oct 14.
• [1941] Minichromosome maintenance protein 2 correlates with the malignant status and regulates proliferation and cell cycle in lung squamous cell carcinoma.Onco Targets Ther. 2018 Aug 20;11:5025-5034. doi: 10.2147/OTT.S169002. eCollection 2018.
• [1942] MCMs expression in lung cancer: implication of prognostic significance.J Cancer. 2017 Oct 9;8(18):3641-3647. doi: 10.7150/jca.20777. eCollection 2017.
• [1943] Analysis of 20 genes at chromosome band 12q13: RACGAP1 and MCRS1 overexpression in nonsmall-cell lung cancer.Genes Chromosomes Cancer. 2013 Mar;52(3):305-15. doi: 10.1002/gcc.22030. Epub 2012 Dec 8.
• [1944] Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.Oncotarget. 2016 Apr 26;7(17):23043-23055. doi: 10.18632/oncotarget.8469.
• [1945] Selective requirement for Mediator MED23 in Ras-active lung cancer.Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):E2813-22. doi: 10.1073/pnas.1204311109. Epub 2012 Sep 17.
• [1946] Absent expression of miR-30a promotes the growth of lung cancer cells by targeting MEF2D.Oncol Lett. 2018 Jul;16(1):1173-1179. doi: 10.3892/ol.2018.8719. Epub 2018 May 16.
• [1947] Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells.Immunol Lett. 2014 Mar-Apr;158(1-2):175-82. doi: 10.1016/j.imlet.2014.01.004. Epub 2014 Jan 16.
• [1948] Prognostic significance of MEOX2 in gliomas.Mod Pathol. 2019 Jun;32(6):774-786. doi: 10.1038/s41379-018-0192-6. Epub 2019 Jan 18.
• [1949] Aberrant expression of embryonic mesendoderm factor MESP1 promotes tumorigenesis.EBioMedicine. 2019 Dec;50:55-66. doi: 10.1016/j.ebiom.2019.11.012. Epub 2019 Nov 21.
• [1950] miR-600 inhibits lung cancer via downregulating the expression of METTL3.Cancer Manag Res. 2019 Feb 1;11:1177-1187. doi: 10.2147/CMAR.S181058. eCollection 2019.
• [1951] A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2A.Mol Cancer. 2011 Jul 7;10:81. doi: 10.1186/1476-4598-10-81.
• [1952] Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.
• [1953] Rational combinations of indirubin and arylidene derivatives exhibit synergism in human non-small cell lung carcinoma cells.J Food Biochem. 2019 Jul;43(7):e12861. doi: 10.1111/jfbc.12861. Epub 2019 Apr 24.
• [1954] Aquaporin 1 promotes the proliferation and migration of lung cancer cell invitro.Oncol Rep. 2015 Sep;34(3):1440-8. doi: 10.3892/or.2015.4107. Epub 2015 Jul 3.
• [1955] MLKL-PITP signaling-mediated necroptosis contributes to cisplatin-triggered cell death in lung cancer A549 cells.Cancer Lett. 2018 Feb 1;414:136-146. doi: 10.1016/j.canlet.2017.10.047.
• [1956] Monocyte to macrophage differentiation-associated (MMD) targeted by miR-140-5p regulates tumor growth in non-small cell lung cancer.Biochem Biophys Res Commun. 2014 Jul 18;450(1):844-50. doi: 10.1016/j.bbrc.2014.06.075. Epub 2014 Jun 24.
• [1957] Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer.Am J Respir Crit Care Med. 2014 Oct 1;190(7):780-90. doi: 10.1164/rccm.201310-1903OC.
• [1958] Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells.Oncol Rep. 2018 Apr;39(4):1765-1774. doi: 10.3892/or.2018.6258. Epub 2018 Feb 12.
• [1959] Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.Proteomics Clin Appl. 2018 Nov;12(6):e1800015. doi: 10.1002/prca.201800015. Epub 2018 Jul 5.
• [1960] Molecular analysis of a Myc antagonist, ROX/Mnt, at 17p13.3 in human lung cancers.Jpn J Cancer Res. 1998 Apr;89(4):347-51. doi: 10.1111/j.1349-7006.1998.tb00569.x.
• [1961] MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation.Oncogene. 2017 Jul 20;36(29):4201-4211. doi: 10.1038/onc.2017.58. Epub 2017 Mar 27.
• [1962] RAGE may act as a tumour suppressor to regulate lung cancer development.Gene. 2018 Apr 20;651:86-93. doi: 10.1016/j.gene.2018.02.009. Epub 2018 Feb 5.
• [1963] Biomarkers in non-small cell lung cancer prevention.Eur J Cancer Prev. 2004 Oct;13(5):425-36. doi: 10.1097/00008469-200410000-00011.
• [1964] Enzymatic MPG DNA repair assays for two different oxidative DNA lesions reveal associations with increased lung cancer risk.Carcinogenesis. 2014 Dec;35(12):2763-70. doi: 10.1093/carcin/bgu214. Epub 2014 Oct 29.
• [1965] Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.Oncogene. 2008 Jul 10;27(30):4137-49. doi: 10.1038/onc.2008.60. Epub 2008 Mar 17.
• [1966] HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer.Cancer Lett. 2019 Mar 1;444:94-104. doi: 10.1016/j.canlet.2018.12.006. Epub 2018 Dec 21.
• [1967] Expression and clinical contribution of MRGD mRNA in non-small cell lung cancers.J BUON. 2015 Jul-Aug;20(4):1101-6.
• [1968] Screening of key genes and prediction of therapeutic agents in Arsenic-induced lung carcinoma.Cancer Biomark. 2019;25(4):351-360. doi: 10.3233/CBM-182333.
• [1969] Immature Colon Carcinoma Transcript-1 (ICT1) Expression Correlates with Unfavorable Prognosis and Survival in Patients with Colorectal Cancer.Ann Surg Oncol. 2016 Nov;23(12):3924-3933. doi: 10.1245/s10434-016-5305-1. Epub 2016 Jul 13.
• [1970] Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery.J Exp Clin Cancer Res. 2019 Feb 8;38(1):62. doi: 10.1186/s13046-019-1027-0.
• [1971] Systematic analysis of mRNA expression profiles in NSCLC cell lines to screen metastasis-related genes.Mol Med Rep. 2016 Dec;14(6):5093-5103. doi: 10.3892/mmr.2016.5911. Epub 2016 Nov 1.
• [1972] Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China.Cancer Manag Res. 2019 Jun 28;11:5785-5797. doi: 10.2147/CMAR.S186217. eCollection 2019.
• [1973] Methylenetetrahydrofolate Dehydrogenase 1 Silencing Expedites the Apoptosis of Non-Small Cell Lung Cancer Cells via Modulating DNA Methylation.Med Sci Monit. 2018 Oct 21;24:7499-7507. doi: 10.12659/MSM.910265.
• [1974] Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer.Protein Cell. 2017 Jun;8(6):455-466. doi: 10.1007/s13238-017-0393-7. Epub 2017 Mar 31.
• [1975] Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press.Tumour Biol. 2014 Apr;35(4):3941-2. doi: 10.1007/s13277-013-1390-y. Epub 2013 Nov 17.
• [1976] Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers.Cancer Biomark. 2015;15(5):645-51. doi: 10.3233/CBM-150504.
• [1977] Integrative system genetic analysis reveals mRNA-lncRNA network associated with mouse spontaneous lung cancer susceptibility.Oncotarget. 2019 Jan 8;10(3):339-351. doi: 10.18632/oncotarget.26554. eCollection 2019 Jan 8.
• [1978] Correlation of expression of human arrest-defective-1 (hARD1) protein with breast cancer.Cancer Invest. 2009 Dec;27(10):978-83. doi: 10.3109/07357900902769723.
• [1979] Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells.Am J Pathol. 2010 Jul;177(1):70-83. doi: 10.2353/ajpath.2010.091164. Epub 2010 May 20.
• [1980] Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer.Tumour Biol. 2015 May;36(5):3693-701. doi: 10.1007/s13277-014-3008-4. Epub 2015 Mar 1.
• [1981] Nanos genes and their role in development and beyond.Cell Mol Life Sci. 2018 Jun;75(11):1929-1946. doi: 10.1007/s00018-018-2766-3. Epub 2018 Feb 3.
• [1982] NCBP1 promotes the development of lung adenocarcinoma through up-regulation of CUL4B.J Cell Mol Med. 2019 Oct;23(10):6965-6977. doi: 10.1111/jcmm.14581. Epub 2019 Aug 26.
• [1983] Nuclear hormone receptor coregulator: role in hormone action, metabolism, growth, and development.Endocr Rev. 2005 Jun;26(4):583-97. doi: 10.1210/er.2004-0012. Epub 2004 Nov 23.
• [1984] Mitochondrial NDUFA4L2 protein promotes the vitality of lung cancer cells by repressing oxidative stress.Thorac Cancer. 2019 Apr;10(4):676-685. doi: 10.1111/1759-7714.12984. Epub 2019 Feb 2.
• [1985] The opposite prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncojanus role of mitochondrial complex I.Sci Rep. 2016 Aug 12;6:31357. doi: 10.1038/srep31357.
• [1986] miR-93 promotes TGF--induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells.Tumour Biol. 2016 Apr;37(4):5645-51. doi: 10.1007/s13277-015-4328-8. Epub 2015 Nov 18.
• [1987] NEIL2 protects against oxidative DNA damage induced by sidestream smoke in human cells.PLoS One. 2014 Mar 3;9(3):e90261. doi: 10.1371/journal.pone.0090261. eCollection 2014.
• [1988] NEK4 kinase regulates EMT to promote lung cancer metastasis.J Cell Mol Med. 2018 Dec;22(12):5877-5887. doi: 10.1111/jcmm.13857. Epub 2018 Sep 24.
• [1989] Drosophila caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells.Oncogene. 2005 Dec 15;24(56):8229-39. doi: 10.1038/sj.onc.1208962.
• [1990] Somatic mutations of the HER2 in metastatic breast cancer.Tumour Biol. 2014 Dec;35(12):11851-4. doi: 10.1007/s13277-014-2414-y. Epub 2014 Oct 19.
• [1991] Copy number variation, increased gene expression, and molecular mechanisms of neurofascin in lung cancer.Mol Carcinog. 2017 Sep;56(9):2076-2085. doi: 10.1002/mc.22664. Epub 2017 May 2.
• [1992] High expression of NFAT2 contributes to carboplatin resistance in lung cancer.Exp Mol Pathol. 2019 Oct;110:104290. doi: 10.1016/j.yexmp.2019.104290. Epub 2019 Jul 27.
• [1993] Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling.Oncogene. 2020 Jan;39(2):385-398. doi: 10.1038/s41388-019-0994-0. Epub 2019 Sep 2.
• [1994] Haplotype-tagging single nucleotide polymorphisms in the GSTP1 gene promoter and susceptibility to lung cancer.Cancer Detect Prev. 2009;32(5-6):403-15. doi: 10.1016/j.cdp.2009.02.004. Epub 2009 Mar 17.
• [1995] Evaluating the effect of nicotinic cholinergic receptor genes on the risk of nonsyndromic cleft lip with or without cleft palate.Oral Dis. 2018 Sep;24(6):1068-1072. doi: 10.1111/odi.12879. Epub 2018 Jun 8.
• [1996] FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding.EBioMedicine. 2019 Jul;45:25-38. doi: 10.1016/j.ebiom.2019.06.022. Epub 2019 Jun 28.
• [1997] Silencing NID2 by DNA Hypermethylation Promotes Lung Cancer.Pathol Oncol Res. 2020 Apr;26(2):801-811. doi: 10.1007/s12253-019-00609-0. Epub 2019 Mar 2.
• [1998] Profiling Lung Cancer Patients Using Electronic Health Records.J Med Syst. 2018 May 31;42(7):126. doi: 10.1007/s10916-018-0975-9.
• [1999] Inhibition of NIPBL enhances the chemosensitivity of non-small-cell lung cancer cells via the DNA damage response and autophagy pathway.Onco Targets Ther. 2018 Apr 5;11:1941-1948. doi: 10.2147/OTT.S158655. eCollection 2018.
• [2000] Nitrilase 1 modulates lung tumor progression in vitro and in vivo.Oncotarget. 2016 Apr 19;7(16):21381-92. doi: 10.18632/oncotarget.7820.
• [2001] Down-regulation of NKD1 increases the invasive potential of non-small-cell lung cancer and correlates with a poor prognosis.BMC Cancer. 2011 May 20;11:186. doi: 10.1186/1471-2407-11-186.
• [2002] Both gene amplification and allelic loss occur at 14q13.3 in lung cancer.Clin Cancer Res. 2011 Feb 15;17(4):690-9. doi: 10.1158/1078-0432.CCR-10-1892. Epub 2010 Dec 10.
• [2003] Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis.Curr Cancer Drug Targets. 2019;19(8):674-680. doi: 10.2174/1568009618666181119150521.
• [2004] Is NLRP3 or NLRP6 inflammasome activation associated with inflammation-related lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide?.Ecotoxicol Environ Saf. 2019 Dec 15;185:109687. doi: 10.1016/j.ecoenv.2019.109687. Epub 2019 Sep 24.
• [2005] Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.Eur J Pharmacol. 2010 Jul 10;637(1-3):38-45. doi: 10.1016/j.ejphar.2010.03.057. Epub 2010 Apr 11.
• [2006] Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells.J Biol Chem. 1991 Oct 5;266(28):18771-9.
• [2007] CARMA3 Represses Metastasis Suppressor NME2 to Promote Lung Cancer Stemness and Metastasis.Am J Respir Crit Care Med. 2015 Jul 1;192(1):64-75. doi: 10.1164/rccm.201411-1957OC.
• [2008] The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer.Cancer Res. 2006 Oct 1;66(19):9408-19. doi: 10.1158/0008-5472.CAN-06-1349.
• [2009] Association between CLOCK, PER3 and CCRN4L with nonsmall cell lung cancer in Brazilian patients.Mol Med Rep. 2014 Jul;10(1):435-40. doi: 10.3892/mmr.2014.2224. Epub 2014 May 8.
• [2010] Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.J Biol Chem. 2011 Oct 28;286(43):37335-46. doi: 10.1074/jbc.M111.256156. Epub 2011 Sep 1.
• [2011] Cerium oxide and barium sulfate nanoparticle inhalation affects gene expression in alveolar epithelial cells type II.J Nanobiotechnology. 2018 Feb 20;16(1):16. doi: 10.1186/s12951-018-0343-4.
• [2012] The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma.Nat Commun. 2019 Jul 16;10(1):3108. doi: 10.1038/s41467-019-10902-w.
• [2013] Overexpression of COUPTFII suppresses proliferation and metastasis of human gastric cancer cells.Mol Med Rep. 2018 Feb;17(2):2393-2401. doi: 10.3892/mmr.2017.8164. Epub 2017 Nov 27.
• [2014] NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.Sci Rep. 2016 Sep 8;6:32952. doi: 10.1038/srep32952.
• [2015] Comprehensive assessment of P21 polymorphisms and lung cancer risk.J Hum Genet. 2008;53(1):87-95. doi: 10.1007/s10038-007-0222-6. Epub 2007 Nov 28.
• [2016] DNA Base-Excision Repair Genes OGG1 and NTH1 in Brazilian Lung Cancer Patients.Mol Diagn Ther. 2015 Dec;19(6):389-95. doi: 10.1007/s40291-015-0164-1.
• [2017] Select human cancer mutants of NRMT1 alter its catalytic activity and decrease N-terminal trimethylation.Protein Sci. 2017 Aug;26(8):1639-1652. doi: 10.1002/pro.3202. Epub 2017 Jun 11.
• [2018] Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody.Cancer Lett. 2019 Mar 1;444:147-161. doi: 10.1016/j.canlet.2018.12.007. Epub 2018 Dec 21.
• [2019] Nesfatin-1 in advanced lung cancer patients with weight loss.Regul Pept. 2013 Feb 10;181:1-3. doi: 10.1016/j.regpep.2012.11.005. Epub 2012 Dec 23.
• [2020] CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7. doi: 10.1073/pnas.131590998.
• [2021] MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?.BMC Cancer. 2018 Apr 16;18(1):423. doi: 10.1186/s12885-018-4332-7.
• [2022] Critical function for nuclear envelope protein TMEM209 in human pulmonary carcinogenesis.Cancer Res. 2012 Aug 15;72(16):4110-8. doi: 10.1158/0008-5472.CAN-12-0159. Epub 2012 Jun 19.
• [2023] NUP58 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the GSK-3/Snail signaling pathway.Am J Transl Res. 2019 Jan 15;11(1):393-405. eCollection 2019.
• [2024] Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer.PLoS One. 2012;7(8):e42086. doi: 10.1371/journal.pone.0042086. Epub 2012 Aug 2.
• [2025] Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro.J Med Genet. 2005 Jul;42(7):558-64. doi: 10.1136/jmg.2004.029686.
• [2026] Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract (acRoots).Cell Biol Toxicol. 2018 Jun;34(3):207-218. doi: 10.1007/s10565-018-9422-4. Epub 2018 Mar 5.
• [2027] Downregulation of occludin affects the proliferation, apoptosis and metastatic properties of human lung carcinoma.Oncol Rep. 2018 Jul;40(1):454-462. doi: 10.3892/or.2018.6408. Epub 2018 May 2.
• [2028] Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis.Cancer Sci. 2012 Mar;103(3):577-86. doi: 10.1111/j.1349-7006.2011.02167.x. Epub 2012 Jan 9.
• [2029] Hepatocyte nuclear factor 6 suppresses the migration and invasive growth of lung cancer cells through p53 and the inhibition of epithelial-mesenchymal transition.J Biol Chem. 2013 Oct 25;288(43):31206-16. doi: 10.1074/jbc.M113.480285. Epub 2013 Sep 10.
• [2030] Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation.J Clin Med. 2019 Sep 3;8(9):1380. doi: 10.3390/jcm8091380.
• [2031] Glycosylated Alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker.Int J Biochem Cell Biol. 2016 Jan;70:68-75. doi: 10.1016/j.biocel.2015.11.006. Epub 2015 Nov 10.
• [2032] Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and -catenin.Cancer Sci. 2018 Jun;109(6):1799-1810. doi: 10.1111/cas.13614. Epub 2018 May 23.
• [2033] The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis.Nat Commun. 2019 Jul 2;10(1):2914. doi: 10.1038/s41467-019-10824-7.
• [2034] Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma.Front Oncol. 2019 Sep 11;9:862. doi: 10.3389/fonc.2019.00862. eCollection 2019.
• [2035] OVCA2 is downregulated and degraded during retinoid-induced apoptosis.Int J Cancer. 2002 May 10;99(2):185-92. doi: 10.1002/ijc.10334.
• [2036] Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy.J Control Release. 2018 Sep 10;285:230-243. doi: 10.1016/j.jconrel.2018.07.014. Epub 2018 Jul 25.
• [2037] Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.Exp Cell Res. 2018 Feb 1;363(1):121-128. doi: 10.1016/j.yexcr.2017.12.020. Epub 2017 Dec 23.
• [2038] Differential Expression of TOM34, AL1A1, PADI2 and KLRBA in NNK Induced Lung Cancer in Wistar Rats and their Implications.Curr Cancer Drug Targets. 2019;19(11):919-929. doi: 10.2174/1871525717666190717162646.
• [2039] Anticancer Activity and Cisplatin Binding Ability of Bis-Quinoline and Bis-Isoquinoline Derived [Pd(2)L(4)](4+) Metallosupramolecular Cages.Front Chem. 2018 Nov 22;6:563. doi: 10.3389/fchem.2018.00563. eCollection 2018.
• [2040] Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.Cancer Genet. 2017 Apr;212-213:13-18. doi: 10.1016/j.cancergen.2017.03.007. Epub 2017 Mar 24.
• [2041] Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12426-31. doi: 10.1073/pnas.1305207110. Epub 2013 Jul 8.
• [2042] Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo.PLoS One. 2012;7(11):e48799. doi: 10.1371/journal.pone.0048799. Epub 2012 Nov 9.
• [2043] Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor -mediated mechanisms.Oncol Rep. 2013 May;29(5):1873-80. doi: 10.3892/or.2013.2336. Epub 2013 Mar 6.
• [2044] An In-Vitro Study for Early Detection and to Distinguish Breast and Lung Malignancies Using the Pcb Technology Based Nanodosimeter.Sci Rep. 2019 Jan 23;9(1):380. doi: 10.1038/s41598-018-36805-2.
• [2045] Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.Cancer Biomark. 2012-2013;12(1):11-9. doi: 10.3233/CBM-2012-00280.
• [2046] Modulation of Mutant Kras(G12D) -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function.Mol Cancer Res. 2019 Feb;17(2):594-603. doi: 10.1158/1541-7786.MCR-18-0739. Epub 2018 Nov 8.
• [2047] The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells.Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6225-6230. doi: 10.1073/pnas.1719871115. Epub 2018 May 29.
• [2048] Cancers Due to Excess Weight, Low Physical Activity, and Unhealthy Diet.Dtsch Arztebl Int. 2018 Sep 3;115(35-36):578-585. doi: 10.3238/arztebl.2018.0578.
• [2049] Expression of programmed cell death 5 protein inhibits progression of lung carcinoma in vitro and in vivo via the mitochondrial apoptotic pathway.Mol Med Rep. 2014 Oct;10(4):2059-64. doi: 10.3892/mmr.2014.2454. Epub 2014 Aug 5.
• [2050] Contribution of programmed cell death 6 genetic variations, gender, and smoking status to lung cancer.Onco Targets Ther. 2019 Aug 9;12:6237-6244. doi: 10.2147/OTT.S205544. eCollection 2019.
• [2051] CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.Lung Cancer. 2017 May;107:14-21. doi: 10.1016/j.lungcan.2016.05.026. Epub 2016 Jun 1.
• [2052] HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin- Resistance in Lung Adenocarcinoma Cells.Anticancer Agents Med Chem. 2018;18(14):2062-2067. doi: 10.2174/1871520619666181203110835.
• [2053] Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance.Nat Commun. 2019 Nov 22;10(1):5324. doi: 10.1038/s41467-019-13331-x.
• [2054] Podoplanin expression in cancer-associated fibroblasts predicts unfavourable prognosis in patients with pathological stage IA lung adenocarcinoma.Histopathology. 2018 Feb;72(3):490-499. doi: 10.1111/his.13390. Epub 2017 Nov 27.
• [2055] Sp1 Mediates the Constitutive Expression and Repression of the PDSS2 Gene in Lung Cancer Cells.Genes (Basel). 2019 Nov 27;10(12):977. doi: 10.3390/genes10120977.
• [2056] EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.Oncol Lett. 2018 May;15(5):6655-6665. doi: 10.3892/ol.2018.8129. Epub 2018 Feb 27.
• [2057] Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.J Natl Cancer Inst. 2017 Jun 1;109(6):djw297. doi: 10.1093/jnci/djw297.
• [2058] Pellino-1 promotes lung carcinogenesis via the stabilization of Slug and Snail through K63-mediated polyubiquitination.Cell Death Differ. 2017 Mar;24(3):469-480. doi: 10.1038/cdd.2016.143. Epub 2016 Dec 23.
• [2059] The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.Cancer Res Treat. 2019 Apr;51(2):706-717. doi: 10.4143/crt.2018.316. Epub 2018 Aug 23.
• [2060] PERP gene therapy attenuates lung cancer xenograft via inducing apoptosis and suppressing VEGF.Cancer Biol Ther. 2011 Dec 15;12(12):1114-9. doi: 10.4161/cbt.12.12.18435. Epub 2011 Dec 15.
• [2061] MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines.Oncol Rep. 2017 May;37(5):3146-3154. doi: 10.3892/or.2017.5566. Epub 2017 Apr 11.
• [2062] Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene.Br J Cancer. 2010 Jan 19;102(2):428-35. doi: 10.1038/sj.bjc.6605450.
• [2063] Identification of suitable reference genes for gene expression studies using quantitative polymerase chain reaction in lung cancer in vitro.Mol Med Rep. 2015 May;11(5):3767-73. doi: 10.3892/mmr.2015.3159. Epub 2015 Jan 8.
• [2064] Serial analysis of gene expression in non-small cell lung cancer.Cancer Res. 1998 Dec 15;58(24):5690-4.
• [2065] A novel PHD-finger protein 14/KIF4A complex overexpressed in lung cancer is involved in cell mitosis regulation and tumorigenesis.Oncotarget. 2017 Mar 21;8(12):19684-19698. doi: 10.18632/oncotarget.14962.
• [2066] PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt.Cell. 2009 Feb 6;136(3):535-50. doi: 10.1016/j.cell.2008.12.002.
• [2067] USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells.J Cancer Res Clin Oncol. 2012 Jul;138(7):1231-8. doi: 10.1007/s00432-012-1193-3. Epub 2012 Mar 20.
• [2068] Knockdown of 14-kDa phosphohistidine phosphatase expression suppresses lung cancer cell growth in vivo possibly through inhibition of NF-B signaling pathway.Neoplasma. 2016;63(4):540-7. doi: 10.4149/neo_2016_407.
• [2069] PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.Int J Cancer. 2014 Mar 1;134(5):1045-54. doi: 10.1002/ijc.28448. Epub 2013 Sep 23.
• [2070] Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis.J Exp Clin Cancer Res. 2019 Jan 6;38(1):5. doi: 10.1186/s13046-018-0996-8.
• [2071] Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer.Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15043-8. doi: 10.1073/pnas.1307107110. Epub 2013 Aug 26.
• [2072] MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway.Mol Biol Cell. 2013 Jan;24(1):42-55. doi: 10.1091/mbc.E12-07-0519. Epub 2012 Nov 7.
• [2073] PINK1 Expression Is Associated with Poor Prognosis in Lung Adenocarcinoma.Tohoku J Exp Med. 2018 Jun;245(2):115-121. doi: 10.1620/tjem.245.115.
• [2074] Decreased PITX1 homeobox gene expression in human lung cancer.Lung Cancer. 2007 Mar;55(3):287-94. doi: 10.1016/j.lungcan.2006.11.001. Epub 2006 Dec 8.
• [2075] Plakophilin 1 is methylated and has a tumor suppressive activity in human lung cancer.Exp Mol Pathol. 2019 Jun;108:73-79. doi: 10.1016/j.yexmp.2019.04.001. Epub 2019 Apr 1.
• [2076] Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development.Oncogene. 2014 Oct 30;33(44):5193-200. doi: 10.1038/onc.2014.128. Epub 2014 May 26.
• [2077] Ameliorating effect of lipo-ATRA treatment on the expression of TIG3 and its suppressing effect on PPAR gene expression in lung cancer animal model.Mol Cell Biochem. 2019 Oct;460(1-2):105-112. doi: 10.1007/s11010-019-03574-z. Epub 2019 Jul 12.
• [2078] Genomic structure of the human PLCD1 (phospholipase C delta 1) locus on 3p22-->p21.3.Cytogenet Cell Genet. 1997;78(1):58-60. doi: 10.1159/000134629.
• [2079] Unbiased peptoid combinatorial cell screen identifies plectin protein as a potential biomarker for lung cancer stem cells.Sci Rep. 2019 Oct 18;9(1):14954. doi: 10.1038/s41598-019-51004-3.
• [2080] AKT1EK Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer.PLoS One. 2016 Feb 9;11(2):e0147334. doi: 10.1371/journal.pone.0147334. eCollection 2016.
• [2081] Intron/exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines.Genes Chromosomes Cancer. 2001 Dec;32(4):384-9. doi: 10.1002/gcc.1204.
• [2082] PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway.Cell Death Dis. 2019 Feb 15;10(3):156. doi: 10.1038/s41419-019-1405-8.
• [2083] TMEPAI inhibits TGF- signaling by promoting lysosome degradation of TGF- receptor and contributes to lung cancer development.Cell Signal. 2014 Sep;26(9):2030-9. doi: 10.1016/j.cellsig.2014.06.001. Epub 2014 Jun 13.
• [2084] EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway.Cancer Res. 2019 May 1;79(9):2257-2270. doi: 10.1158/0008-5472.CAN-18-3238. Epub 2019 Mar 12.
• [2085] Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.BMC Genomics. 2016 Dec 22;17(Suppl 13):1029. doi: 10.1186/s12864-016-3322-x.
• [2086] Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.Sci Rep. 2019 Oct 31;9(1):15767. doi: 10.1038/s41598-019-52414-z.
• [2087] siRNA of DNA polymerase iota inhibits the migration and invasion in the lung cancer cell A549.Acta Biochim Biophys Sin (Shanghai). 2018 Sep 1;50(9):929-933. doi: 10.1093/abbs/gmy089.
• [2088] POLQ Overexpression Is Associated with an Increased Somatic Mutation Load and PLK4 Overexpression in Lung Adenocarcinoma.Cancers (Basel). 2019 May 24;11(5):722. doi: 10.3390/cancers11050722.
• [2089] Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p, and 4q.Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):434-442. doi: 10.1158/1055-9965.EPI-19-0887. Epub 2019 Dec 11.
• [2090] RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer.Cancer Med. 2012 Aug;1(1):68-75. doi: 10.1002/cam4.13. Epub 2012 Jul 12.
• [2091] CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer.Cancer Med. 2018 Feb;7(2):325-335. doi: 10.1002/cam4.1292. Epub 2018 Jan 22.
• [2092] Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.Cancer Prev Res (Phila). 2018 Mar;11(3):143-156. doi: 10.1158/1940-6207.CAPR-17-0264. Epub 2017 Dec 15.
• [2093] Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.Ann Oncol. 2017 Jul 1;28(7):1625-1630. doi: 10.1093/annonc/mdx161.
• [2094] Absence of PPP2R1B gene alterations in primary ovarian cancers.Oncogene. 1999 Nov 4;18(46):6367-9. doi: 10.1038/sj.onc.1203070.
• [2095] Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population.Nat Genet. 2012 Jul 15;44(8):895-9. doi: 10.1038/ng.2351.
• [2096] Clonal divergence in lung cancer development is associated with allelic loss on chromosome 4.Genes Chromosomes Cancer. 2007 Sep;46(9):852-60. doi: 10.1002/gcc.20472.
• [2097] A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A.Oncogene. 2010 Jul 8;29(27):3933-41. doi: 10.1038/onc.2010.161. Epub 2010 May 17.
• [2098] Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese.PLoS One. 2013 Oct 29;8(10):e77285. doi: 10.1371/journal.pone.0077285. eCollection 2013.
• [2099] p53 and lung cancer.Pathol Biol (Paris). 1997 Dec;45(10):852-63.
• [2100] Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer.Oncogene. 2005 Sep 1;24(38):5821-6. doi: 10.1038/sj.onc.1208880.
• [2101] Potential Oncogenic Role of the Papillary Renal Cell Carcinoma Gene in Non-Small Cell Lung Cancers.Yonsei Med J. 2019 Apr;60(4):326-335. doi: 10.3349/ymj.2019.60.4.326.
• [2102] High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker in resected non-small cell lung cancer.Med Oncol. 2013;30(3):605. doi: 10.1007/s12032-013-0605-9. Epub 2013 May 21.
• [2103] PRDM16 functions as a suppressor of lung adenocarcinoma metastasis.J Exp Clin Cancer Res. 2019 Jan 25;38(1):35. doi: 10.1186/s13046-019-1042-1.
• [2104] Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer.Carcinogenesis. 2007 Sep;28(9):1971-7. doi: 10.1093/carcin/bgm156. Epub 2007 Aug 11.
• [2105] Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma.Tumour Biol. 2014 May;35(5):4509-16. doi: 10.1007/s13277-013-1593-2. Epub 2014 Jan 7.
• [2106] Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer.Ann Agric Environ Med. 2019 Sep 19;26(3):415-419. doi: 10.26444/aaem/105899. Epub 2019 Apr 1.
• [2107] Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression.Int J Mol Sci. 2019 Sep 7;20(18):4407. doi: 10.3390/ijms20184407.
• [2108] Changes in gene expression in lungs of mice exposed to traffic-related air pollution.Mol Cell Probes. 2018 Jun;39:33-40. doi: 10.1016/j.mcp.2018.03.005. Epub 2018 Apr 3.
• [2109] MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.Int J Cancer. 2010 Jul 15;127(2):313-20. doi: 10.1002/ijc.25049.
• [2110] Ouabain impairs cancer metabolism and activates AMPK-Src signaling pathway in human cancer cell lines.Acta Pharmacol Sin. 2020 Jan;41(1):110-118. doi: 10.1038/s41401-019-0290-0. Epub 2019 Sep 12.
• [2111] Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.Acta Pharmacol Sin. 2020 Jan;41(1):93-100. doi: 10.1038/s41401-019-0260-6. Epub 2019 Jul 8.
• [2112] PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages.Mol Cancer Res. 2020 Jan;18(1):166-178. doi: 10.1158/1541-7786.MCR-19-0204. Epub 2019 Oct 16.
• [2113] Inhibition of cellular growth and migration by suppression of endothelial protein C receptor (EPCR) in lung carcinoma cells.Oncol Res. 2012;20(5-6):231-40. doi: 10.3727/096504013x13589503482932.
• [2114] PRR11 and SKA2 gene pair is overexpressed and regulated by p53 in breast cancer.BMB Rep. 2019 Feb;52(2):157-162. doi: 10.5483/BMBRep.2019.52.2.207.
• [2115] PRR14 overexpression promotes cell growth, epithelial to mesenchymal transition and metastasis of colon cancer via the AKT pathway.PLoS One. 2019 Oct 9;14(10):e0218839. doi: 10.1371/journal.pone.0218839. eCollection 2019.
• [2116] Proscillaridin A Promotes Oxidative Stress and ER Stress, Inhibits STAT3 Activation, and Induces Apoptosis in A549 Lung Adenocarcinoma Cells.Oxid Med Cell Longev. 2018 Jan 11;2018:3853409. doi: 10.1155/2018/3853409. eCollection 2018.
• [2117] Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.Cancer Sci. 2017 Apr;108(4):732-743. doi: 10.1111/cas.13185. Epub 2017 Apr 25.
• [2118] Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.Mol Carcinog. 2011 Apr;50(4):301-9. doi: 10.1002/mc.20632.
• [2119] PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells.Regul Pept. 2002 Nov 15;109(1-3):135-40. doi: 10.1016/s0167-0115(02)00196-9.
• [2120] Phosphoserine Phosphatase Promotes Lung Cancer Progression through the Dephosphorylation of IRS-1 and a Noncanonical L-Serine-Independent Pathway.Mol Cells. 2019 Aug 31;42(8):604-616. doi: 10.14348/molcells.2019.0160.
• [2121] CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth.Br J Cancer. 2011 Feb 1;104(3):496-504. doi: 10.1038/sj.bjc.6606033. Epub 2011 Jan 4.
• [2122] Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A.Med Sci Monit. 2019 Jan 29;25:836-846. doi: 10.12659/MSM.912059.
• [2123] SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance.EBioMedicine. 2018 Dec;38:113-126. doi: 10.1016/j.ebiom.2018.11.007. Epub 2018 Nov 11.
• [2124] A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.Genes Chromosomes Cancer. 2010 Apr;49(4):342-52. doi: 10.1002/gcc.20746.
• [2125] Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.Oncol Rep. 2015 Sep;34(3):1137-45. doi: 10.3892/or.2015.4082. Epub 2015 Jun 25.
• [2126] Mutational analysis of PTPRT phosphatase domains in common human cancers.APMIS. 2007 Jan;115(1):47-51. doi: 10.1111/j.1600-0463.2007.apm_554.x.
• [2127] Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer.Oncol Lett. 2018 Jan;15(1):731-740. doi: 10.3892/ol.2017.7400. Epub 2017 Nov 14.
• [2128] Quaking-5 suppresses aggressiveness of lung cancer cells through inhibiting -catenin signaling pathway.Oncotarget. 2017 Jul 7;8(47):82174-82184. doi: 10.18632/oncotarget.19066. eCollection 2017 Oct 10.
• [2129] Hypermethylation of the GATA genes in lung cancer.Clin Cancer Res. 2004 Dec 1;10(23):7917-24. doi: 10.1158/1078-0432.CCR-04-1140.
• [2130] Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer.Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):571-5. doi: 10.1158/1055-9965.EPI-04-0472.
• [2131] Sublocalization of Rab23, a mediator of Sonic hedgehog signaling pathway, in hepatocellular carcinoma cell lines.Mol Med Rep. 2012 Dec;6(6):1276-80. doi: 10.3892/mmr.2012.1094. Epub 2012 Sep 20.
• [2132] Suppression of Tobacco Carcinogen-Induced Lung Tumorigenesis by Aerosol-Delivered Glycerol Propoxylate Triacrylate-Spermine Copolymer/Short Hairpin Rab25 RNA Complexes in Female A/J Mice.J Aerosol Med Pulm Drug Deliv. 2017 Apr;30(2):81-90. doi: 10.1089/jamp.2016.1301. Epub 2016 Oct 28.
• [2133] Targeted Delivery of Rab26 siRNA with Precisely Tailored DNA Prism for Lung Cancer Therapy.Chembiochem. 2019 May 2;20(9):1139-1144. doi: 10.1002/cbic.201800761. Epub 2019 Feb 27.
• [2134] Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment.Nanomedicine. 2018 Feb;14(2):373-384. doi: 10.1016/j.nano.2017.11.010. Epub 2017 Nov 16.
• [2135] RAC2 promotes abnormal proliferation of quiescent cells by enhanced JUNB expression via the MAL-SRF pathway.Cell Cycle. 2018;17(9):1115-1123. doi: 10.1080/15384101.2018.1480217. Epub 2018 Jul 9.
• [2136] Interruption of lung cancer cell migration and proliferation by fungal immunomodulatory protein FIP-fve from Flammulina velutipes.J Agric Food Chem. 2013 Dec 11;61(49):12044-52. doi: 10.1021/jf4030272. Epub 2013 Nov 22.
• [2137] Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues.Cancer Res. 2001 Oct 15;61(20):7417-21.
• [2138] Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China.Int J Cancer. 2005 Sep 20;116(5):768-73. doi: 10.1002/ijc.21117.
• [2139] RalGPS2 Is Essential for Survival and Cell Cycle Progression of Lung Cancer Cells Independently of Its Established Substrates Ral GTPases.PLoS One. 2016 May 5;11(5):e0154840. doi: 10.1371/journal.pone.0154840. eCollection 2016.
• [2140] miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.PLoS One. 2012;7(6):e39167. doi: 10.1371/journal.pone.0039167. Epub 2012 Jun 18.
• [2141] Frequent somatic demethylation of RAPGEF1/C3G intronic sequences in gastrointestinal and gynecological cancer.Int J Oncol. 2011 Jun;38(6):1575-7. doi: 10.3892/ijo.2011.972. Epub 2011 Mar 11.
• [2142] Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1.
• [2143] RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer.Mol Cancer Res. 2013 Aug;11(8):937-51. doi: 10.1158/1541-7786.MCR-12-0685-T. Epub 2013 May 16.
• [2144] RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer.Mod Pathol. 2013 Aug;26(8):1111-22. doi: 10.1038/modpathol.2013.32. Epub 2013 Mar 29.
• [2145] RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion.Tumour Biol. 2016 Apr;37(4):4865-71. doi: 10.1007/s13277-015-4343-9. Epub 2015 Nov 2.
• [2146] Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma.Lung Cancer. 2011 Jan;71(1):19-27. doi: 10.1016/j.lungcan.2010.04.006.
• [2147] The coiled-coil domain of oncogene RASSF 7 inhibits hippo signaling and promotes non-small cell lung cancer.Oncotarget. 2017 Aug 12;8(45):78734-78748. doi: 10.18632/oncotarget.20223. eCollection 2017 Oct 3.
• [2148] Identification of RASSF8 as a candidate lung tumor suppressor gene.Oncogene. 2006 Jun 29;25(28):3934-8. doi: 10.1038/sj.onc.1209422. Epub 2006 Feb 6.
• [2149] Association of genetic variants in the retinoblastoma binding protein 6 gene with the risk of glioma: a case-control study in a Chinese Han population.J Neurosurg. 2014 Nov;121(5):1209-18. doi: 10.3171/2014.6.JNS132240. Epub 2014 Aug 15.
• [2150] Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer.BMC Genomics. 2010 Nov 30;11:676. doi: 10.1186/1471-2164-11-676.
• [2151] Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer.Clin Cancer Res. 1997 Oct;3(10):1691-7.
• [2152] Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.J Cancer Res Clin Oncol. 2019 Apr;145(4):873-879. doi: 10.1007/s00432-019-02850-1. Epub 2019 Feb 13.
• [2153] Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.Tumour Biol. 2017 Oct;39(10):1010428317711662. doi: 10.1177/1010428317711662.
• [2154] RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.BMC Cancer. 2018 Jan 10;18(1):67. doi: 10.1186/s12885-017-3908-y.
• [2155] RCCD1 depletion attenuates TGF--induced EMT and cell migration bystabilizing cytoskeletal microtubules in NSCLC cells.Cancer Lett. 2017 Aug 1;400:18-29. doi: 10.1016/j.canlet.2017.04.021. Epub 2017 Apr 26.
• [2156] E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells. Genes Cancer. 2016 Nov;7(11-12):383-393. doi: 10.18632/genesandcancer.123.
• [2157] RAD52 motifcontaining protein1 promotes nonsmall cell lung cancer cell proliferation and survival via cell cycle regulation.Oncol Rep. 2018 Aug;40(2):833-840. doi: 10.3892/or.2018.6459. Epub 2018 May 23.
• [2158] Effects of RECQ1 helicase silencing on non-small cell lung cancer cells.Biomed Pharmacother. 2016 Oct;83:1227-1232. doi: 10.1016/j.biopha.2016.07.053. Epub 2016 Aug 23.
• [2159] Variants in DNA double-strand break repair and DNA damage-response genes and susceptibility to lung and head and neck cancers.Int J Cancer. 2008 Jul 15;123(2):457-463. doi: 10.1002/ijc.23524.
• [2160] The transcription factor REST is lost in aggressive breast cancer.PLoS Genet. 2010 Jun 10;6(6):e1000979. doi: 10.1371/journal.pgen.1000979.
• [2161] Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma.Oncol Rep. 2018 Dec;40(6):3392-3404. doi: 10.3892/or.2018.6736. Epub 2018 Sep 26.
• [2162] MAG-2 promotes invasion, mobility and adherence capability of lung cancer cells by MMP-2, CD44 and intracellular calcium in vitro.Oncol Rep. 2009 Mar;21(3):697-706.
• [2163] Effects of polymorphisms in translesion DNA synthesis genes on lung cancer risk and prognosis in Chinese men.Cancer Epidemiol. 2013 Dec;37(6):917-22. doi: 10.1016/j.canep.2013.08.003. Epub 2013 Sep 5.
• [2164] Absence of REV3L promotes p53-regulated cancer cell metabolism in cisplatin-treated lung carcinoma cells.Biochem Biophys Res Commun. 2018 Jan 29;496(1):199-204. doi: 10.1016/j.bbrc.2018.01.026. Epub 2018 Jan 4.
• [2165] Knockdown of response gene to complement 32 (RGC32) induces apoptosis and inhibits cell growth, migration, and invasion in human lung cancer cells.Mol Cell Biochem. 2014 Sep;394(1-2):109-18. doi: 10.1007/s11010-014-2086-3. Epub 2014 May 16.
• [2166] Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development.Oncotarget. 2019 Mar 5;10(19):1760-1774. doi: 10.18632/oncotarget.26678. eCollection 2019 Mar 5.
• [2167] Diagnosing the RGS11 Lung Cancer Biomarker: The Integration of Competitive Immunoassay and Isothermal Nucleic Acid Exponential Amplification Reaction.Anal Chem. 2019 Mar 5;91(5):3327-3335. doi: 10.1021/acs.analchem.8b04374. Epub 2019 Feb 15.
• [2168] MiRNA-199 inhibits malignant progression of lung cancer through mediating RGS17.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3390-3400. doi: 10.26355/eurrev_201904_17703.
• [2169] The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells.Oncogene. 2008 Nov 20;27(54):6856-65. doi: 10.1038/onc.2008.317. Epub 2008 Sep 1.
• [2170] The RHOV gene is overexpressed in human non-small cell lung cancer.Cancer Genet. 2013 Nov;206(11):393-7. doi: 10.1016/j.cancergen.2013.10.006. Epub 2013 Nov 5.
• [2171] Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning.Int J Oncol. 2012 Jan;40(1):93-8. doi: 10.3892/ijo.2011.1173. Epub 2011 Aug 19.
• [2172] Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.Pathol Oncol Res. 2014 Jul;20(3):549-56. doi: 10.1007/s12253-013-9727-9. Epub 2014 Jan 11.
• [2173] The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior.EBioMedicine. 2017 Jun;20:79-97. doi: 10.1016/j.ebiom.2017.04.015. Epub 2017 Apr 12.
• [2174] Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer.Mol Cancer Ther. 2007 Feb;6(2):542-51. doi: 10.1158/1535-7163.MCT-06-0659.
• [2175] Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer.Lung Cancer. 2010 Aug;69(2):232-8. doi: 10.1016/j.lungcan.2009.10.010. Epub 2009 Nov 14.
• [2176] Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.J Biol Chem. 2003 Jun 27;278(26):23630-8. doi: 10.1074/jbc.M300997200. Epub 2003 Apr 24.
• [2177] Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein.Cell Growth Differ. 2000 Apr;11(4):185-90.
• [2178] Overexpression of RNF146 in non-small cell lung cancer enhances proliferation and invasion of tumors through the Wnt/-catenin signaling pathway.PLoS One. 2014 Jan 14;9(1):e85377. doi: 10.1371/journal.pone.0085377. eCollection 2014.
• [2179] Ring finger protein 38 promote non-small cell lung cancer progression by endowing cell EMT phenotype.J Cancer. 2018 Feb 12;9(5):841-850. doi: 10.7150/jca.23138. eCollection 2018.
• [2180] Association of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection.Ann Thorac Cardiovasc Surg. 2018 Feb 20;24(1):13-18. doi: 10.5761/atcs.oa.17-00127. Epub 2017 Nov 10.
• [2181] Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study.Onco Targets Ther. 2019 Oct 9;12:8263-8273. doi: 10.2147/OTT.S217514. eCollection 2019.
• [2182] The changing face of cancer treatments.BMJ Case Rep. 2018 Sep 1;2018:bcr2018224784. doi: 10.1136/bcr-2018-224784.
• [2183] Down-regulation of ribosomal protein L22 in non-small cell lung cancer.Med Oncol. 2013;30(3):646. doi: 10.1007/s12032-013-0646-0. Epub 2013 Jun 25.
• [2184] Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors.BMC Cancer. 2004 Aug 4;4:43. doi: 10.1186/1471-2407-4-43.
• [2185] A novel platform to enable inhaled naked RNAi medicine for lung cancer.Sci Rep. 2013 Nov 25;3:3325. doi: 10.1038/srep03325.
• [2186] SOX9 dependent FOXA1 expression promotes tumorigenesis in lung carcinoma.Biochem Biophys Res Commun. 2019 Aug 13;516(1):236-244. doi: 10.1016/j.bbrc.2019.05.169. Epub 2019 Jun 17.
• [2187] HPV 16 E6/E7 up-regulate the expression of both HIF-1 and GLUT1 by inhibition of RRAD and activation of NF-B in lung cancer cells.J Cancer. 2019 Nov 17;10(27):6903-6909. doi: 10.7150/jca.37070. eCollection 2019.
• [2188] Identification of a novel nucleus protein involved in the regulation of urokinase in 95D cells.Acta Biochim Biophys Sin (Shanghai). 2005 May;37(5):303-9. doi: 10.1111/j.1745-7270.2005.00041.x.
• [2189] RUFY3 Predicts Poor Prognosis and Promotes Metastasis through Epithelial-mesenchymal Transition in Lung Adenocarcinoma.J Cancer. 2019 Oct 17;10(25):6278-6285. doi: 10.7150/jca.35072. eCollection 2019.
• [2190] RUVBL1, a novel C-RAF-binding protein, activates the RAF/MEK/ERK pathway to promote lung cancer tumorigenesis.Biochem Biophys Res Commun. 2018 Apr 15;498(4):932-939. doi: 10.1016/j.bbrc.2018.03.084. Epub 2018 Mar 15.
• [2191] RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial-Mesenchymal Transition.Transl Oncol. 2017 Apr;10(2):280-287. doi: 10.1016/j.tranon.2017.01.004. Epub 2017 Feb 28.
• [2192] Selective expression of S100A11 in lung cancer and its role in regulating proliferation of adenocarcinomas cells.Mol Cell Biochem. 2012 Jan;359(1-2):323-32. doi: 10.1007/s11010-011-1026-8. Epub 2011 Aug 23.
• [2193] S100A13 is a new angiogenic marker in human melanoma.Mod Pathol. 2010 Jun;23(6):804-13. doi: 10.1038/modpathol.2010.54. Epub 2010 Mar 5.
• [2194] Expression and clinicopathological significance of S100 calcium binding protein A2 in lung cancer patients of Chinese Han ethnicity.Clin Chim Acta. 2017 Jan;464:118-122. doi: 10.1016/j.cca.2016.11.027. Epub 2016 Nov 19.
• [2195] S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells.Oncotarget. 2017 Apr 11;8(15):24804-24814. doi: 10.18632/oncotarget.15063.
• [2196] Graphene Oxide-Facilitated Comprehensive Analysis of Cellular Nucleic Acid Binding Proteins for Lung Cancer.ACS Appl Mater Interfaces. 2018 May 30;10(21):17756-17770. doi: 10.1021/acsami.8b05428. Epub 2018 May 15.
• [2197] Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer.Genes Chromosomes Cancer. 2008 Sep;47(9):810-8. doi: 10.1002/gcc.20582.
• [2198] Effects of SASH1 on lung cancer cell proliferation, apoptosis, and invasion in vitro.Tumour Biol. 2012 Oct;33(5):1393-401. doi: 10.1007/s13277-012-0387-2. Epub 2012 Apr 10.
• [2199] Role of miR-31 and SATB2 in arsenic-induced malignant BEAS-2B cell transformation.Mol Carcinog. 2018 Aug;57(8):968-977. doi: 10.1002/mc.22817. Epub 2018 Apr 17.
• [2200] Dose-dependent activation of putative oncogene SBSN by BORIS.PLoS One. 2012;7(7):e40389. doi: 10.1371/journal.pone.0040389. Epub 2012 Jul 5.
• [2201] Scavenger Receptor A1 Prevents Metastasis of Non-Small Cell Lung Cancer via Suppression of Macrophage Serum Amyloid A1.Cancer Res. 2017 Apr 1;77(7):1586-1598. doi: 10.1158/0008-5472.CAN-16-1569. Epub 2017 Feb 15.
• [2202] Alterations in SCAI Expression during Cell Plasticity, Fibrosis and Cancer.Pathol Oncol Res. 2018 Jul;24(3):641-651. doi: 10.1007/s12253-017-0293-4. Epub 2017 Aug 16.
• [2203] Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.BMC Cancer. 2010 Feb 12;10:41. doi: 10.1186/1471-2407-10-41.
• [2204] Differential expression of the gene encoding the novel pituitary polypeptide 7B2 in human lung cancer cells.Cancer Res. 1989 Aug 1;49(15):4154-8.
• [2205] The Epithelial Sodium Channel (ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.Transl Oncol. 2018 Apr;11(2):292-299. doi: 10.1016/j.tranon.2018.01.004. Epub 2018 Feb 2.
• [2206] The SNAIL family member SCRATCH1 is not expressed in human tumors.Oncol Rep. 2010 Feb;23(2):523-9.
• [2207] Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue.Mod Pathol. 2008 Apr;21(4):387-95. doi: 10.1038/modpathol.3801005. Epub 2008 Jan 25.
• [2208] SDH5 Depletion Enhances Radiosensitivity by Regulating p53: A New Method for Noninvasive Prediction of Radiotherapy Response.Theranostics. 2019 Aug 14;9(22):6380-6395. doi: 10.7150/thno.34443. eCollection 2019.
• [2209] Molecular characterization of defective antigen processing in human prostate cancer.J Natl Cancer Inst. 1995 Feb 15;87(4):280-5. doi: 10.1093/jnci/87.4.280.
• [2210] Tumor Suppressor Activity of Selenbp1, a Direct Nkx2-1 Target, in Lung Adenocarcinoma.Mol Cancer Res. 2018 Nov;16(11):1737-1749. doi: 10.1158/1541-7786.MCR-18-0392. Epub 2018 Jul 12.
• [2211] Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism.Eur J Nutr. 2008 Feb;47(1):47-54. doi: 10.1007/s00394-008-0696-9. Epub 2008 Jan 31.
• [2212] Hypoxia and hypoxia-inducible factor 1 repress SEMA4B expression to promote non-small cell lung cancer invasion.Tumour Biol. 2014 May;35(5):4949-55. doi: 10.1007/s13277-014-1651-4. Epub 2014 Jan 29.
• [2213] The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type.Tumour Biol. 2017 Jun;39(6):1010428317703819. doi: 10.1177/1010428317703819.
• [2214] Genetic network and gene set enrichment analysis to identify biomarkers related to cigarette smoking and lung cancer.Cancer Treat Rev. 2013 Feb;39(1):77-88. doi: 10.1016/j.ctrv.2012.06.001. Epub 2012 Jul 11.
• [2215] Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin.BMC Cancer. 2010 May 31;10:245. doi: 10.1186/1471-2407-10-245.
• [2216] Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.Carcinogenesis. 2017 Feb 1;38(2):184-195. doi: 10.1093/carcin/bgw124.
• [2217] Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.Respir Res. 2019 Oct 17;20(1):222. doi: 10.1186/s12931-019-1192-x.
• [2218] SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence.Cancer Res. 2019 Sep 15;79(18):4729-4743. doi: 10.1158/0008-5472.CAN-19-1084. Epub 2019 Jul 15.
• [2219] H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.Cancer Res. 2014 Dec 15;74(24):7333-43. doi: 10.1158/0008-5472.CAN-13-3572. Epub 2014 Dec 4.
• [2220] Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: the Liverpool Lung Project.Cancer Prev Res (Phila). 2010 May;3(5):664-9. doi: 10.1158/1940-6207.CAPR-09-0141. Epub 2010 Apr 27.
• [2221] Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer.Cancer Sci. 2006 Aug;97(8):737-45. doi: 10.1111/j.1349-7006.2006.00258.x.
• [2222] Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma.Am J Pathol. 2012 Apr;180(4):1653-62. doi: 10.1016/j.ajpath.2011.12.014. Epub 2012 Feb 4.
• [2223] Secreted frizzled-related protein 1 (SFRP1) gene methylation changes in the human lung adenocarcinoma cells treated with L-securinine.J Asian Nat Prod Res. 2018 Feb;20(2):163-171. doi: 10.1080/10286020.2017.1329828. Epub 2017 May 26.
• [2224] Epigallocatechin-3-gallate (EGCG) inhibits aggregation of pulmonary fibrosis associated mutant surfactant protein A2 via a proteasomal degradation pathway.Int J Biochem Cell Biol. 2019 Nov;116:105612. doi: 10.1016/j.biocel.2019.105612. Epub 2019 Sep 20.
• [2225] MiR-629-3p-induced downregulation of SFTPC promotes cell proliferation and predicts poor survival in lung adenocarcinoma.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3286-3296. doi: 10.1080/21691401.2019.1648283.
• [2226] New perspective on SH2B1: An accelerator of cancer progression.Biomed Pharmacother. 2020 Jan;121:109651. doi: 10.1016/j.biopha.2019.109651. Epub 2019 Nov 15.
• [2227] Imputation-based association analyses identify new lung cancer susceptibility variants in CDK6 and SH3RF1 and their interactions with smoking in Chinese populations.Carcinogenesis. 2013 Sep;34(9):2010-6. doi: 10.1093/carcin/bgt145. Epub 2013 May 3.
• [2228] Shank-associated RH domain-interacting protein expression is upregulated in entodermal and mesodermal cancer or downregulated in ectodermal malignancy.Oncol Lett. 2018 Dec;16(6):7180-7188. doi: 10.3892/ol.2018.9514. Epub 2018 Sep 27.
• [2229] DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers.Oncogene. 2008 Jul 31;27(33):4615-24. doi: 10.1038/onc.2008.98. Epub 2008 Apr 7.
• [2230] The Shisa3 knockout mouse exhibits normal bone phenotype.J Bone Miner Metab. 2019 Nov;37(6):967-975. doi: 10.1007/s00774-019-01014-y. Epub 2019 Jun 20.
• [2231] SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production.J Exp Clin Cancer Res. 2019 Feb 12;38(1):70. doi: 10.1186/s13046-019-1067-5.
• [2232] Variants in folate pathway genes as modulators of genetic instability and lung cancer risk.Genes Chromosomes Cancer. 2011 Jan;50(1):1-12. doi: 10.1002/gcc.20826.
• [2233] The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways.Cell Rep. 2019 Mar 12;26(11):3037-3050.e4. doi: 10.1016/j.celrep.2019.02.052.
• [2234] The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.PLoS One. 2015 Nov 18;10(11):e0143376. doi: 10.1371/journal.pone.0143376. eCollection 2015.
• [2235] FAM60A, increased by Helicobacter pylori, promotes proliferation and suppresses apoptosis of gastric cancer cells by targeting the PI3K/AKT pathway.Biochem Biophys Res Commun. 2020 Jan 22;521(4):1003-1009. doi: 10.1016/j.bbrc.2019.11.029. Epub 2019 Nov 12.
• [2236] Sipa1 promoter polymorphism predicts risk and metastasis of lung cancer in Chinese.Mol Carcinog. 2013 Nov;52 Suppl 1:E110-7. doi: 10.1002/mc.22039. Epub 2013 May 9.
• [2237] SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway.Oncogene. 2017 May 11;36(19):2724-2736. doi: 10.1038/onc.2016.425. Epub 2016 Dec 12.
• [2238] MiR-150-5p regulates melanoma proliferation, invasion and metastasis via SIX1-mediated Warburg Effect.Biochem Biophys Res Commun. 2019 Jul 12;515(1):85-91. doi: 10.1016/j.bbrc.2019.05.111. Epub 2019 May 23.
• [2239] Six2 promotes non-small cell lung cancer cell stemness via transcriptionally and epigenetically regulating E-cadherin.Cell Prolif. 2019 Jul;52(4):e12617. doi: 10.1111/cpr.12617. Epub 2019 Apr 22.
• [2240] A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.Oncotarget. 2015 Sep 22;6(28):24895-903. doi: 10.18632/oncotarget.4366.
• [2241] Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity.Oncogene. 2015 Apr 9;34(15):1979-90. doi: 10.1038/onc.2014.123. Epub 2014 May 26.
• [2242] SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3/-catenin pathway.Cell Signal. 2019 Jul;59:1-12. doi: 10.1016/j.cellsig.2019.03.004. Epub 2019 Mar 4.
• [2243] Effects of Slit3 silencing on the invasive ability of lung carcinoma A549 cells.Oncol Rep. 2015 Aug;34(2):952-60. doi: 10.3892/or.2015.4031. Epub 2015 Jun 5.
• [2244] SMAGP, a new small trans-membrane glycoprotein altered in cancer.Oncogene. 2004 Apr 22;23(19):3395-403. doi: 10.1038/sj.onc.1207469.
• [2245] Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.Nat Med. 2018 Oct;24(10):1627. doi: 10.1038/s41591-018-0173-9.
• [2246] MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.J Biol Chem. 2016 Jan 22;291(4):1877-1889. doi: 10.1074/jbc.M115.667568. Epub 2015 Nov 5.
• [2247] SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.Cell Res. 2015 Apr;25(4):445-58. doi: 10.1038/cr.2015.16. Epub 2015 Feb 6.
• [2248] Downregulating PRL-3 inhibit migration and invasion of lung cancer cell via RhoA and mDia1.Tumori. 2012 May-Jun;98(3):370-6. doi: 10.1177/030089161209800315.
• [2249] Evaluation of the diagnostic efficacy of (18) F-Fluorine-2-Deoxy-D-Glucose PET/CT for lung cancer and pulmonary tuberculosis in a Tuberculosis-endemic Country.Cancer Med. 2020 Feb;9(3):931-942. doi: 10.1002/cam4.2770. Epub 2019 Dec 13.
• [2250] Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKI.Oncogene. 2017 Oct 12;36(41):5668-5680. doi: 10.1038/onc.2017.166. Epub 2017 Jun 5.
• [2251] MiR-195 and miR-497 suppress tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF- receptor I ubiquitination.Mol Oncol. 2019 Dec;13(12):2663-2678. doi: 10.1002/1878-0261.12581. Epub 2019 Nov 8.
• [2252] High expression of SNIP1 correlates with poor prognosis in non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.Lung Cancer. 2013 Oct;82(1):24-30. doi: 10.1016/j.lungcan.2013.07.015. Epub 2013 Aug 9.
• [2253] Brucea javanica oil emulsion alleviates cachexia induced by Lewis lung cancer cells in mice.J Drug Target. 2018 Mar;26(3):222-230. doi: 10.1080/1061186X.2017.1354003. Epub 2017 Jul 18.
• [2254] Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.Int J Oncol. 2012 Oct;41(4):1520-30. doi: 10.3892/ijo.2012.1578. Epub 2012 Jul 31.
• [2255] Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.Cancer Sci. 2013 May;104(5):573-83. doi: 10.1111/cas.12117. Epub 2013 Mar 8.
• [2256] Amplification, up-regulation and over-expression of C3G (CRK SH3 domain-binding guanine nucleotide-releasing factor) in non-small cell lung cancers.J Hum Genet. 2004;49(6):290-295. doi: 10.1007/s10038-004-0148-1. Epub 2004 May 8.
• [2257] Epigenetic inactivation of SOX1 promotes cell migration in lung cancer.Tumour Biol. 2015 Jun;36(6):4603-10. doi: 10.1007/s13277-015-3107-x. Epub 2015 Jan 23.
• [2258] SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer.Discov Med. 2012 Jul;14(74):33-40.
• [2259] Influence of miR-7a and miR-24-3p on the SOX18 transcript in lung adenocarcinoma.Oncol Rep. 2018 Jan;39(1):201-208. doi: 10.3892/or.2017.6077. Epub 2017 Nov 6.
• [2260] Down-regulated SOX4 expression suppresses cell proliferation, metastasis and induces apoptosis in Xuanwei female lung cancer patients.J Cell Biochem. 2015 Jun;116(6):1007-18. doi: 10.1002/jcb.25055.
• [2261] SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21(CIPI) , cyclin D1 and -catenin.FEBS Open Bio. 2020 Jan;10(1):135-146. doi: 10.1002/2211-5463.12762. Epub 2019 Dec 12.
• [2262] The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer.Mol Cell Biol. 2020 Jan 3;40(2):e00307-19. doi: 10.1128/MCB.00307-19. Print 2020 Jan 3.
• [2263] Small regulatory polypeptide of amino acid response negatively relates to poor prognosis and controls hepatocellular carcinoma progression via regulating microRNA-5581-3p/human cardiolipin synthase 1.J Cell Physiol. 2019 Aug;234(10):17589-17599. doi: 10.1002/jcp.28383. Epub 2019 Mar 1.
• [2264] The expression of DAMP proteins HSP70 and cancer-testis antigen SPAG9 in peripheral blood of patients with HCC and lung cancer.Cell Stress Chaperones. 2017 Mar;22(2):237-244. doi: 10.1007/s12192-016-0758-5. Epub 2016 Dec 27.
• [2265] A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer.Oncotarget. 2017 Jul 4;8(39):65469-65480. doi: 10.18632/oncotarget.18971. eCollection 2017 Sep 12.
• [2266] Spindle pole body component 25 homolog expressed by ECM stiffening is required for lung cancer cell proliferation.Biochem Biophys Res Commun. 2018 Jun 12;500(4):937-943. doi: 10.1016/j.bbrc.2018.04.205. Epub 2018 May 2.
• [2267] ECRG2 regulates ECM degradation and uPAR/FPRL1 pathway contributing cell invasion/migration.Cancer Lett. 2010 Apr 1;290(1):87-95. doi: 10.1016/j.canlet.2009.09.001. Epub 2009 Sep 30.
• [2268] Critical role of Spns2, a sphingosine-1-phosphate transporter, in lung cancer cell survival and migration.PLoS One. 2014 Oct 20;9(10):e110119. doi: 10.1371/journal.pone.0110119. eCollection 2014.
• [2269] SPOP regulates the DNA damage response and lung adenocarcinoma cell response to radiation.Am J Cancer Res. 2019 Jul 1;9(7):1469-1483. eCollection 2019.
• [2270] Sprouty 2 gene in mouse lung tumorigenesis.Chest. 2004 May;125(5 Suppl):111S. doi: 10.1378/chest.125.5_suppl.111s.
• [2271] A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer.Sci Rep. 2019 May 20;9(1):7618. doi: 10.1038/s41598-019-43100-1.
• [2272] SRSF7 knockdown promotes apoptosis of colon and lung cancer cells.Oncol Lett. 2018 Apr;15(4):5545-5552. doi: 10.3892/ol.2018.8072. Epub 2018 Feb 16.
• [2273] Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9.Cancer Lett. 2000 Mar 31;150(2):155-64. doi: 10.1016/s0304-3835(99)00385-7.
• [2274] The E3 Ligase CHIP Mediates p21 Degradation to Maintain Radioresistance.Mol Cancer Res. 2017 Jun;15(6):651-659. doi: 10.1158/1541-7786.MCR-16-0466. Epub 2017 Feb 23.
• [2275] Influences of two significant variants located in the ST6GAL1 3'-untranslated region on lung carcinoma susceptibility in the Chinese Han population.Eur J Cancer Prev. 2020 Jan;29(1):60-64. doi: 10.1097/CEJ.0000000000000512.
• [2276] Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers.Oncogene. 2006 Nov 2;25(52):6924-35. doi: 10.1038/sj.onc.1209683. Epub 2006 Jul 24.
• [2277] Mutational and expressional analyses of STAG2 gene in solid cancers.Neoplasma. 2012;59(5):524-9. doi: 10.4149/neo_2012_067.
• [2278] Forensic evaluation of STR typing reliability in lung cancer.Leg Med (Tokyo). 2018 Jan;30:38-41. doi: 10.1016/j.legalmed.2017.11.004. Epub 2017 Nov 11.
• [2279] Elevated expression of STIM1 is involved in lung tumorigenesis.Oncotarget. 2016 Dec 27;7(52):86584-86593. doi: 10.18632/oncotarget.13359.
• [2280] Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel.DNA Repair (Amst). 2014 Jan;13:1-9. doi: 10.1016/j.dnarep.2013.09.001. Epub 2013 Dec 16.
• [2281] Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPK signaling in STK11 mutant lung cancer.Autophagy. 2020 Apr;16(4):659-671. doi: 10.1080/15548627.2019.1634945. Epub 2019 Jun 28.
• [2282] A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer.Clin Cancer Res. 2009 Dec 1;15(23):7309-15. doi: 10.1158/1078-0432.CCR-09-1572. Epub 2009 Nov 17.
• [2283] Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.Oncogene. 2019 Jun;38(26):5191-5210. doi: 10.1038/s41388-019-0786-6. Epub 2019 Mar 27.
• [2284] HSULF-1 inhibits ERK and AKT signaling and decreases cell viability in vitro in human lung epithelial cells.Respir Res. 2012 Aug 8;13(1):69. doi: 10.1186/1465-9921-13-69.
• [2285] SUMO1 promotes the proliferation and invasion of non-small cell lung cancer cells by regulating NF-B.Thorac Cancer. 2019 Jan;10(1):33-40. doi: 10.1111/1759-7714.12895. Epub 2018 Nov 4.
• [2286] SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer.Tumour Biol. 2016 Jul;37(7):9919-30. doi: 10.1007/s13277-015-4734-y. Epub 2016 Jan 27.
• [2287] The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.J Cancer. 2019 Jan 1;10(3):721-729. doi: 10.7150/jca.28254. eCollection 2019.
• [2288] Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis.J Transl Med. 2017 Jun 17;15(1):138. doi: 10.1186/s12967-017-1241-5.
• [2289] Synergistic Anticancer Effect of a Combination of Paclitaxel and 5-Demethylnobiletin Against Lung Cancer Cell Line In Vitro and In Vivo.Appl Biochem Biotechnol. 2019 Apr;187(4):1328-1343. doi: 10.1007/s12010-018-2869-1. Epub 2018 Sep 19.
• [2290] Synaptotagmin-7, a binding protein of P53, inhibits the senescence and promotes the tumorigenicity of lung cancer cells.Biosci Rep. 2019 Feb 8;39(2):BSR20181298. doi: 10.1042/BSR20181298. Print 2019 Feb 28.
• [2291] Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay.Mol Cell. 2019 Sep 5;75(5):967-981.e9. doi: 10.1016/j.molcel.2019.06.001. Epub 2019 Jul 9.
• [2292] TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis.Nat Cell Biol. 2019 Dec;21(12):1604-1614. doi: 10.1038/s41556-019-0429-8. Epub 2019 Dec 2.
• [2293] TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer.Cell Death Differ. 2019 Jul;26(7):1235-1250. doi: 10.1038/s41418-018-0202-8. Epub 2018 Sep 25.
• [2294] Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer.J Cell Commun Signal. 2018 Jun;12(2):423-432. doi: 10.1007/s12079-017-0418-2. Epub 2017 Oct 30.
• [2295] Vitamin B12 and its binding proteins in patients with non-small cell lung cancer referred to fast-track diagnostic work-up for lung cancer.Scand J Clin Lab Invest. 2020 Feb;80(1):14-19. doi: 10.1080/00365513.2019.1692232. Epub 2019 Nov 18.
• [2296] Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma.Cancers (Basel). 2019 Jun 3;11(6):768. doi: 10.3390/cancers11060768.
• [2297] Testin is a tumor suppressor in non-small cell lung cancer.Oncol Rep. 2017 Feb;37(2):1027-1035. doi: 10.3892/or.2016.5316. Epub 2016 Dec 14.
• [2298] Tescalcin/c-Src/IGF1R-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1.Sci Rep. 2018 Jul 16;8(1):10711. doi: 10.1038/s41598-018-29142-x.
• [2299] Expression of tesmin (MTL5) in nonsmall cell lung cancer: A preliminary study.Oncol Rep. 2019 Jul;42(1):253-262. doi: 10.3892/or.2019.7145. Epub 2019 May 2.
• [2300] Expression and methylation of mitochondrial transcription factor a in chronic obstructive pulmonary disease patients with lung cancer.PLoS One. 2013 Dec 18;8(12):e82739. doi: 10.1371/journal.pone.0082739. eCollection 2013.
• [2301] TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling.Mol Cancer. 2014 Apr 26;13:89. doi: 10.1186/1476-4598-13-89.
• [2302] A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.BMC Genomics. 2013;14 Suppl 6(Suppl 6):S5. doi: 10.1186/1471-2164-14-S6-S5. Epub 2013 Oct 25.
• [2303] Possible Molecular Mechanisms for the Roles of MicroRNA-21 Played in Lung Cancer.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819875130. doi: 10.1177/1533033819875130.
• [2304] Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer.Oncol Rep. 2012 Apr;27(4):1277-83. doi: 10.3892/or.2012.1627. Epub 2012 Jan 11.
• [2305] Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.Cancer Sci. 2015 Jan;106(1):34-42. doi: 10.1111/cas.12569. Epub 2014 Dec 8.
• [2306] Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3.IUBMB Life. 2018 Jun;70(6):536-546. doi: 10.1002/iub.1752. Epub 2018 Apr 29.
• [2307] Carboxyl-terminal modulator protein induces apoptosis by regulating mitochondrial function in lung cancer cells.Int J Oncol. 2012 May;40(5):1515-24. doi: 10.3892/ijo.2011.1319. Epub 2011 Dec 23.
• [2308] Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.Sci Rep. 2017 Jul 25;7(1):6478. doi: 10.1038/s41598-017-06922-5.
• [2309] The Fibroblast TIAM2 Promotes Lung Cancer Cell Invasion and Metastasis.J Cancer. 2019 Apr 21;10(8):1879-1889. doi: 10.7150/jca.30477. eCollection 2019.
• [2310] Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer.Mol Cancer. 2018 May 12;17(1):88. doi: 10.1186/s12943-018-0839-4.
• [2311] TIM-4 promotes the growth of non-small-cell lung cancer in a RGD motif-dependent manner.Br J Cancer. 2015 Nov 17;113(10):1484-92. doi: 10.1038/bjc.2015.323. Epub 2015 Oct 29.
• [2312] Silencing of CT120 by antisense oligonucleotides could inhibit the lung cancer cells growth.Ir J Med Sci. 2010 Jun;179(2):217-23. doi: 10.1007/s11845-009-0418-1. Epub 2009 Dec 20.
• [2313] Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis.Respir Res. 2019 May 29;20(1):106. doi: 10.1186/s12931-019-1071-5.
• [2314] Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer.Mol Cells. 2012 Aug;34(2):171-6. doi: 10.1007/s10059-012-0083-5. Epub 2012 Jul 18.
• [2315] Association of lung adenocarcinoma clinical stage with gene expression pattern in noninvolved lung tissue.Int J Cancer. 2012 Sep 1;131(5):E643-8. doi: 10.1002/ijc.27426. Epub 2012 Feb 28.
• [2316] TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins.Nat Commun. 2018 Jul 16;9(1):2731. doi: 10.1038/s41467-018-05013-x.
• [2317] TMEM17 depresses invasion and metastasis in lung cancer cells via ERK signaling pathway.Oncotarget. 2017 Aug 7;8(41):70685-70694. doi: 10.18632/oncotarget.19977. eCollection 2017 Sep 19.
• [2318] TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer.Mol Carcinog. 2019 Apr;58(4):474-487. doi: 10.1002/mc.22942. Epub 2018 Dec 11.
• [2319] The Expression of TMEM74 in Liver Cancer and Lung Cancer Correlating With Survival Outcomes.Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):618-625. doi: 10.1097/PAI.0000000000000659.
• [2320] Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers.Clin Cancer Res. 2012 Jul 1;18(13):3658-67. doi: 10.1158/1078-0432.CCR-11-2857. Epub 2012 May 9.
• [2321] Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.Cancer Lett. 2019 Jul 1;453:21-33. doi: 10.1016/j.canlet.2019.03.013. Epub 2019 Mar 21.
• [2322] TIPE2 Induced the Proliferation, Survival, and Migration of Lung Cancer Cells Through Modulation of Akt/mTOR/NF-B Signaling Cascade.Biomolecules. 2019 Dec 6;9(12):836. doi: 10.3390/biom9120836.
• [2323] TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.BMC Cancer. 2018 Mar 6;18(1):260. doi: 10.1186/s12885-018-4177-0.
• [2324] The inherited variations of a p53-responsive enhancer in 13q12.12 confer lung cancer risk by attenuating TNFRSF19 expression.Genome Biol. 2019 May 24;20(1):103. doi: 10.1186/s13059-019-1696-1.
• [2325] Association of a novel functional promoter variant (rs2075533 C>T) in the apoptosis gene TNFSF8 with risk of lung cancer--a finding from Texas lung cancer genome-wide association study.Carcinogenesis. 2011 Apr;32(4):507-15. doi: 10.1093/carcin/bgr014. Epub 2011 Feb 2.
• [2326] CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-.Thorac Cancer. 2019 Dec;10(12):2225-2235. doi: 10.1111/1759-7714.13207. Epub 2019 Oct 17.
• [2327] Overexpression of high mobility group protein B1 correlates with the proliferation and metastasis of lung adenocarcinoma cells.Mol Med Rep. 2013 May;7(5):1678-82. doi: 10.3892/mmr.2013.1362. Epub 2013 Mar 6.
• [2328] Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor.Cancer Res. 2003 Aug 15;63(16):5095-104.
• [2329] TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinoma.Oncol Lett. 2019 Oct;18(4):4144-4152. doi: 10.3892/ol.2019.10748. Epub 2019 Aug 16.
• [2330] Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer.J Exp Clin Cancer Res. 2009 Feb 19;28(1):22. doi: 10.1186/1756-9966-28-22.
• [2331] Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-B Signaling Pathway in Vitro and in Vivo.Cell Physiol Biochem. 2018;46(3):999-1008. doi: 10.1159/000488831. Epub 2018 Apr 13.
• [2332] Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer.Br J Cancer. 2019 Aug;121(5):405-416. doi: 10.1038/s41416-019-0531-5. Epub 2019 Jul 30.
• [2333] TRK inhibitors in TRK fusion-positive cancers.Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30. doi: 10.1093/annonc/mdz282.
• [2334] TPM4 promotes cell migration by modulating F-actin formation in lung cancer.Onco Targets Ther. 2019 May 31;12:4055-4063. doi: 10.2147/OTT.S198542. eCollection 2019.
• [2335] TRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis.Cancer Res. 2018 Jul 15;78(14):3982-3994. doi: 10.1158/0008-5472.CAN-18-0429. Epub 2018 May 10.
• [2336] TRAF4 promotes lung cancer aggressiveness by modulating tumor microenvironment in normal fibroblasts.Sci Rep. 2017 Aug 21;7(1):8923. doi: 10.1038/s41598-017-09447-z.
• [2337] TRAP1 regulates autophagy in lung cancer cells.Eur J Clin Invest. 2018 Apr;48(4). doi: 10.1111/eci.12900. Epub 2018 Feb 23.
• [2338] Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer.Oncogene. 2003 Mar 27;22(12):1892-905. doi: 10.1038/sj.onc.1206304.
• [2339] An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.J Mol Med (Berl). 2006 Mar;84(3):215-25. doi: 10.1007/s00109-005-0009-1. Epub 2005 Dec 31.
• [2340] A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling.Cell Death Dis. 2018 May 1;9(5):443. doi: 10.1038/s41419-018-0467-3.
• [2341] TRIB3 promotes lung cancer progression by activating -catenin signaling.Eur J Pharmacol. 2019 Nov 15;863:172697. doi: 10.1016/j.ejphar.2019.172697. Epub 2019 Sep 25.
• [2342] Tripartite motif-containing 15 overexpression in non-small cell lung cancer is associated with poor patient prognoses.J Cancer. 2019 Jan 29;10(4):843-852. doi: 10.7150/jca.27856. eCollection 2019.
• [2343] SSA/RO52gene and expressed sequence tags in an 85 kb region of chromosome segment 11p15.5.Int J Cancer. 2000 Jul 1;87(1):61-7. doi: 10.1002/1097-0215(20000701)87:1<61::aid-ijc9>3.0.co;2-r.
• [2344] TRIM45 Suppresses the Development of Non-small Cell Lung Cancer.Curr Mol Med. 2020;20(4):299-306. doi: 10.2174/1566524019666191017143833.
• [2345] TRIM52 regulates the proliferation and invasiveness of lung cancer cells via the Wnt/catenin pathway.Oncol Rep. 2019 Jun;41(6):3325-3334. doi: 10.3892/or.2019.7110. Epub 2019 Apr 11.
• [2346] TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma.Oncol Rep. 2018 Jul;40(1):206-216. doi: 10.3892/or.2018.6426. Epub 2018 May 8.
• [2347] Combinatory inhibition of TRIM65 and MDM2 in lung cancer cells.Biochem Biophys Res Commun. 2018 Nov 30;506(3):698-702. doi: 10.1016/j.bbrc.2018.10.130. Epub 2018 Oct 27.
• [2348] The human tRNA-modifying protein, TRIT1, forms amyloid fibers in vitro.Gene. 2017 May 15;612:19-24. doi: 10.1016/j.gene.2016.10.041. Epub 2016 Oct 29.
• [2349] Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer.Eur J Cancer. 2007 Mar;43(4):782-90. doi: 10.1016/j.ejca.2006.09.029. Epub 2007 Jan 24.
• [2350] Trophinin-associated protein expression is an independent prognostic biomarker in lung adenocarcinoma.J Thorac Dis. 2019 May;11(5):2043-2050. doi: 10.21037/jtd.2019.04.86.
• [2351] Trps1 is associated with the multidrug resistance of lung cancer cell by regulating MGMT gene expression.Cancer Med. 2018 May;7(5):1921-1932. doi: 10.1002/cam4.1421. Epub 2018 Mar 30.
• [2352] Bone Marrow and Tumor Radiomics at (18)F-FDG PET/CT: Impact on Outcome Prediction in Non-Small Cell Lung Cancer.Radiology. 2019 Nov;293(2):451-459. doi: 10.1148/radiol.2019190357. Epub 2019 Sep 17.
• [2353] Overexpression of TSPAN8 Promotes Tumor Cell Viability and Proliferation in Nonsmall Cell Lung Cancer.Cancer Biother Radiopharm. 2016 Dec;31(10):353-359. doi: 10.1089/cbr.2016.2108.
• [2354] Differentially expressed nucleolar TGF-beta1 target (DENTT) shows tissue-specific nuclear and cytoplasmic localization and increases TGF-beta1-responsive transcription in primates.Biochim Biophys Acta. 2005 May 1;1728(3):163-80. doi: 10.1016/j.bbaexp.2005.02.010. Epub 2005 Mar 22.
• [2355] Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort.BMJ Open. 2019 Jan 17;9(1):e024719. doi: 10.1136/bmjopen-2018-024719.
• [2356] AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival.PLoS One. 2019 Feb 7;14(2):e0211745. doi: 10.1371/journal.pone.0211745. eCollection 2019.
• [2357] Overexpression of APC11 predicts worse survival in lung adenocarcinoma.Onco Targets Ther. 2018 Oct 17;11:7125-7132. doi: 10.2147/OTT.S177252. eCollection 2018.
• [2358] Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.Sci Rep. 2018 Oct 5;8(1):14896. doi: 10.1038/s41598-018-33190-8.
• [2359] ANKRD18A as a novel epigenetic regulation gene in lung cancer.Biochem Biophys Res Commun. 2012 Dec 14;429(3-4):180-5. doi: 10.1016/j.bbrc.2012.10.116. Epub 2012 Nov 3.
• [2360] Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes.BMC Med Genomics. 2018 Apr 20;11(Suppl 2):29. doi: 10.1186/s12920-018-0352-z.
• [2361] DNA methylation and associated gene expression in blood prior to lung cancer diagnosis in the Norwegian Women and Cancer cohort.Sci Rep. 2018 Nov 13;8(1):16714. doi: 10.1038/s41598-018-34334-6.
• [2362] GLTSCR1, ATM, PPP1R13L and CD3EAP Genetic Variants and Lung Cancer Risk in a Chinese Population.Curr Med Sci. 2018 Aug;38(4):734-740. doi: 10.1007/s11596-018-1938-6. Epub 2018 Aug 20.
• [2363] CDP138 silencing inhibits TGF-/Smad signaling to impair radioresistance and metastasis via GDF15 in lung cancer.Cell Death Dis. 2017 Sep 7;8(9):e3036. doi: 10.1038/cddis.2017.434.
• [2364] Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers.Int J Cancer. 2003 Nov 10;107(3):341-5. doi: 10.1002/ijc.11393.
• [2365] miR-23b suppresses lung carcinoma cell proliferation through CCNG1.Oncol Lett. 2018 Oct;16(4):4317-4324. doi: 10.3892/ol.2018.9181. Epub 2018 Jul 20.
• [2366] CDH13 promoter methylation regulates cisplatin resistance of non-small cell lung cancer cells.Oncol Lett. 2018 Nov;16(5):5715-5722. doi: 10.3892/ol.2018.9325. Epub 2018 Aug 20.
• [2367] Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker.PLoS One. 2018 Nov 19;13(11):e0207483. doi: 10.1371/journal.pone.0207483. eCollection 2018.
• [2368] Centromere protein U expression promotes non-small-cell lung cancer cell proliferation through FOXM1 and predicts poor survival.Cancer Manag Res. 2018 Dec 14;10:6971-6984. doi: 10.2147/CMAR.S182852. eCollection 2018.
• [2369] Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.Respir Med. 2015 Jan;109(1):131-6. doi: 10.1016/j.rmed.2014.11.004. Epub 2014 Nov 21.
• [2370] Decreased Lung Tumor Development in SwAPP Mice through the Downregulation of CHI3L1 and STAT 3 Activity via the Upregulation of miRNA342-3p.Mol Ther Nucleic Acids. 2019 Jun 7;16:63-72. doi: 10.1016/j.omtn.2019.02.007. Epub 2019 Feb 20.
• [2371] The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity invitro and invivo.J Cell Mol Med. 2019 Jan;23(1):143-154. doi: 10.1111/jcmm.13899. Epub 2018 Oct 24.
• [2372] Comorbidity Assessment in the National Cancer Database for Patients With Surgically Resected Breast, Colorectal, or Lung Cancer (AFT-01, -02, -03).J Oncol Pract. 2018 Oct;14(10):e631-e643. doi: 10.1200/JOP.18.00175. Epub 2018 Sep 12.
• [2373] Long non-coding RNA CRYBG3 regulates glycolysis of lung cancer cells by interacting with lactate dehydrogenase A.J Cancer. 2018 Jun 23;9(14):2580-2588. doi: 10.7150/jca.24896. eCollection 2018.
• [2374] Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.Oncol Lett. 2018 Oct;16(4):4707-4712. doi: 10.3892/ol.2018.9182. Epub 2018 Jul 20.
• [2375] Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy.Cancer Res. 2007 Jul 1;67(13):6293-303. doi: 10.1158/0008-5472.CAN-06-3884.
• [2376] Downregulation of TM7SF4 inhibits cell proliferation and metastasis of A549 cells through regulating the PI3K/AKT/mTOR signaling pathway.Mol Med Rep. 2017 Nov;16(5):6122-6127. doi: 10.3892/mmr.2017.7324. Epub 2017 Aug 22.
• [2377] DDX49 is a novel biomarker and therapeutic target for lung cancer metastases.J Cell Mol Med. 2020 Jan;24(1):1141-1145. doi: 10.1111/jcmm.14734. Epub 2019 Nov 20.
• [2378] Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells.Clin Lung Cancer. 2008 Nov;9(6):367-74. doi: 10.3816/CLC.2008.n.053.
• [2379] RNA sequencing identifies novel markers of non-small cell lung cancer.Lung Cancer. 2014 Jun;84(3):229-35. doi: 10.1016/j.lungcan.2014.03.018. Epub 2014 Mar 26.
• [2380] Distribution of serum neuron-specific enolase and the establishment of a population reference interval in healthy adults.J Clin Lab Anal. 2019 Jun;33(5):e22863. doi: 10.1002/jcla.22863. Epub 2019 Feb 19.
• [2381] Pivotal roles of protein 4.1B/DAL?, a FERMdomain containing protein, in tumor progression (Review).Int J Oncol. 2019 Nov;55(5):979-987. doi: 10.3892/ijo.2019.4877. Epub 2019 Sep 13.
• [2382] Effect of separase depletion on ionizing radiation-induced cell cycle checkpoints and survival in human lung cancer cell lines.Cell Prolif. 2008 Aug;41(4):660-70. doi: 10.1111/j.1365-2184.2008.00540.x. Epub 2008 Jun 19.
• [2383] Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand?.World J Urol. 2000 Apr;18(2):121-4. doi: 10.1007/s003450050183.
• [2384] Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms.Lung Cancer. 2018 May;119:25-35. doi: 10.1016/j.lungcan.2018.02.015. Epub 2018 Mar 2.
• [2385] Adjudin synergizes with paclitaxel and inhibits cell growth and metastasis by regulating the sirtuin 3-Forkhead box O3a axis in human small-cell lung cancer.Thorac Cancer. 2019 Apr;10(4):642-658. doi: 10.1111/1759-7714.12976. Epub 2019 Feb 18.
• [2386] FRMD3, a novel putative tumour suppressor in NSCLC.Oncogene. 2007 Jun 28;26(30):4464-8. doi: 10.1038/sj.onc.1210225. Epub 2007 Jan 29.
• [2387] Follistatin-like Protein 1 Inhibits Lung Cancer Metastasis by Preventing Proteolytic Activation of Osteopontin.Cancer Res. 2019 Dec 15;79(24):6113-6125. doi: 10.1158/0008-5472.CAN-19-0842. Epub 2019 Oct 25.
• [2388] Early detection of lung cancer by using an autoantibody panel in Chinese population.Oncoimmunology. 2017 Oct 16;7(2):e1384108. doi: 10.1080/2162402X.2017.1384108. eCollection 2018.
• [2389] Induction of Human-Lung-Cancer-A549-Cell Apoptosis by 4-Hydroperoxy-2-decenoic Acid Ethyl Ester through Intracellular ROS Accumulation and the Induction of Proapoptotic CHOP Expression.J Agric Food Chem. 2018 Oct 17;66(41):10741-10747. doi: 10.1021/acs.jafc.8b04424. Epub 2018 Oct 8.
• [2390] HPIP silencing inhibits TGF-1-induced EMT in lung cancer cells.Int J Mol Med. 2017 Feb;39(2):479-483. doi: 10.3892/ijmm.2017.2851. Epub 2017 Jan 5.
• [2391] Deregulated ALG-2/HEBP2 axis alters microtubule dynamics and mitotic spindle behavior to stimulate cancer development.J Cell Physiol. 2017 Nov;232(11):3067-3076. doi: 10.1002/jcp.25754. Epub 2017 Mar 1.
• [2392] Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.Cancer Res. 2007 Sep 1;67(17):8051-7. doi: 10.1158/0008-5472.CAN-07-1022.
• [2393] Circular RNA HIPK3 exerts oncogenic properties through suppression of miR-124 in lung cancer.Biochem Biophys Res Commun. 2018 Nov 30;506(3):455-462. doi: 10.1016/j.bbrc.2018.10.087. Epub 2018 Oct 20.
• [2394] Lung cancer susceptibility genetic variants modulate HOXB2 expression in the lung.Int J Dev Biol. 2018;62(11-12):857-864. doi: 10.1387/ijdb.180210yb.
• [2395] Clinical translation of [(18)F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer.Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2285-2299. doi: 10.1007/s00259-018-4098-9. Epub 2018 Sep 27.
• [2396] KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.Oncogene. 2017 Nov 2;36(44):6177-6189. doi: 10.1038/onc.2017.287. Epub 2017 Sep 4.
• [2397] Increased KIF15 Expression Predicts a Poor Prognosis in Patients with Lung Adenocarcinoma.Cell Physiol Biochem. 2018;51(1):1-10. doi: 10.1159/000495155. Epub 2018 Nov 15.
• [2398] Correction to: KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.Mol Cancer. 2019 Nov 19;18(1):164. doi: 10.1186/s12943-019-1093-0.
• [2399] Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer.Lung Cancer. 2018 Dec;126:55-63. doi: 10.1016/j.lungcan.2018.07.005. Epub 2018 Jul 5.
• [2400] Identification of a Novel Tumor-Binding Peptide for Lung Cancer Through in-vitro Panning.Iran J Pharm Res. 2018 Winter;17(1):396-407.
• [2401] Lipase member H is a novel secreted protein selectively upregulated in human lung adenocarcinomas and bronchioloalveolar carcinomas.Biochem Biophys Res Commun. 2014 Jan 24;443(4):1141-7. doi: 10.1016/j.bbrc.2013.12.106. Epub 2013 Dec 28.
• [2402] Tumor suppressive functions of LZTFL1 in hepatocellular carcinoma.Onco Targets Ther. 2019 Jul 10;12:5537-5544. doi: 10.2147/OTT.S196925. eCollection 2019.
• [2403] Overexpression of MCPH1 inhibits the migration and invasion of lung cancer cells.Onco Targets Ther. 2018 May 25;11:3111-3117. doi: 10.2147/OTT.S156102. eCollection 2018.
• [2404] Human MOB1 expression in non-small-cell lung cancer.Clin Lung Cancer. 2007 Jan;8(4):273-6. doi: 10.3816/CLC.2007.n.006.
• [2405] MORC2 Enhances Tumor Growth by Promoting Angiogenesis and Tumor-Associated Macrophage Recruitment via Wnt/-Catenin in Lung Cancer.Cell Physiol Biochem. 2018;51(4):1679-1694. doi: 10.1159/000495673. Epub 2018 Nov 30.
• [2406] Prognostic significance of folate metabolism polymorphisms for lung cancer.Br J Cancer. 2007 Jul 16;97(2):247-52. doi: 10.1038/sj.bjc.6603830. Epub 2007 May 29.
• [2407] Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility.Clin Transl Oncol. 2014 Jan;16(1):107-12. doi: 10.1007/s12094-013-1080-7. Epub 2013 Jul 30.
• [2408] Suppression of cleavage factor Im 25 promotes the proliferation of lung cancer cells through alternative polyadenylation.Biochem Biophys Res Commun. 2018 Sep 5;503(2):856-862. doi: 10.1016/j.bbrc.2018.06.087. Epub 2018 Jun 23.
• [2409] Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC.Oncol Rep. 2009 Nov;22(5):1057-61. doi: 10.3892/or_00000536.
• [2410] Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.Cancer Res. 2006 May 1;66(9):4617-26. doi: 10.1158/0008-5472.CAN-05-4437.
• [2411] Hexavalent chromium induces malignant transformation of human lung bronchial epithelial cells via ROS-dependent activation of miR-21-PDCD4 signaling.Oncotarget. 2016 Aug 9;7(32):51193-51210. doi: 10.18632/oncotarget.9967.
• [2412] Chemical identification of a sulfated glucan from Antrodia cinnamomea and its anti-cancer functions via inhibition of EGFR and mTOR activity.Carbohydr Polym. 2018 Dec 15;202:536-544. doi: 10.1016/j.carbpol.2018.09.009. Epub 2018 Sep 6.
• [2413] PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.Oncotarget. 2015 Apr 9;9(38):24914-24926. doi: 10.18632/oncotarget.3674. eCollection 2018 May 18.
• [2414] The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth.Cell Death Dis. 2018 May 22;9(6):603. doi: 10.1038/s41419-018-0580-3.
• [2415] Association between polymorphisms in COMT, PLCH1, and CYP17A1, and non-small-cell lung cancer risk in Chinese nonsmokers.Clin Lung Cancer. 2013 Jan;14(1):45-9. doi: 10.1016/j.cllc.2012.04.004. Epub 2012 Jun 1.
• [2416] The Prognostic and Clinicopathologic Characteristics of OCT4 and Lung Cancer: A Meta-Analysis.Curr Mol Med. 2019;19(1):54-75. doi: 10.2174/1566524019666190308163315.
• [2417] Methylation status of the PPP1R13L promoter region among lung cancer patients and healthy controls. Analytical cross-sectional study.Sao Paulo Med J. 2019 Aug 29;137(3):255-261. doi: 10.1590/1516-3180.2018.0358230419.
• [2418] Downregulation of PRDM1 promotes cellular invasion and lung cancer metastasis.Tumour Biol. 2017 Apr;39(4):1010428317695929. doi: 10.1177/1010428317695929.
• [2419] Long Noncoding RNA PRRG4-4 Promotes Viability, Cell Cycle, Migration, and Invasion in Lung Cancer Cells.DNA Cell Biol. 2018 Dec;37(12):953-966. doi: 10.1089/dna.2018.4220. Epub 2018 Oct 26.
• [2420] Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer.Cancer Res. 2006 Jun 15;66(12):6210-8. doi: 10.1158/0008-5472.CAN-05-4447.
• [2421] Quiescin Sulfhydryl Oxidase 1 (QSOX1) Secreted by Lung Cancer Cells Promotes Cancer Metastasis.Int J Mol Sci. 2018 Oct 17;19(10):3213. doi: 10.3390/ijms19103213.
• [2422] Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.Oncol Rep. 2006 May;15(5):1281-5.
• [2423] Role of RNA-binding protein 5 in the diagnosis and chemotherapeutic response of lung cancer.Oncol Lett. 2019 Feb;17(2):2013-2019. doi: 10.3892/ol.2018.9818. Epub 2018 Dec 10.
• [2424] Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis.Oncol Lett. 2018 Oct;16(4):4201-4210. doi: 10.3892/ol.2018.9221. Epub 2018 Jul 26.
• [2425] Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice.Int Immunopharmacol. 2018 Feb;55:306-311. doi: 10.1016/j.intimp.2017.12.029. Epub 2018 Jan 5.
• [2426] Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma.Cancer Sci. 2010 Jan;101(1):46-53. doi: 10.1111/j.1349-7006.2009.01351.x. Epub 2009 Sep 9.
• [2427] Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma.Oncotarget. 2017 Jul 11;8(28):45710-45724. doi: 10.18632/oncotarget.17391.
• [2428] Plasma selenoprotein P concentration and lung cancer risk: results from a case-control study nested within the Shanghai Men's Health Study.Carcinogenesis. 2018 Dec 13;39(11):1352-1358. doi: 10.1093/carcin/bgy103.
• [2429] SERINC2-knockdown inhibits proliferation, migration and invasion in lung adenocarcinoma.Oncol Lett. 2018 Nov;16(5):5916-5922. doi: 10.3892/ol.2018.9403. Epub 2018 Sep 5.
• [2430] Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis.Sci Rep. 2017 Sep 4;7(1):10407. doi: 10.1038/s41598-017-10891-0.
• [2431] Hydrogen gas inhibits lung cancer progression through targeting SMC3.Biomed Pharmacother. 2018 Aug;104:788-797. doi: 10.1016/j.biopha.2018.05.055. Epub 2018 May 29.
• [2432] SMYD5 Controls Heterochromatin and Chromosome Integrity during Embryonic Stem Cell Differentiation.Cancer Res. 2017 Dec 1;77(23):6729-6745. doi: 10.1158/0008-5472.CAN-17-0828. Epub 2017 Sep 26.
• [2433] Snail1-dependent cancer-associated fibroblasts induce epithelial-mesenchymal transition in lung cancer cells via exosomes.QJM. 2019 Aug 1;112(8):581-590. doi: 10.1093/qjmed/hcz093.
• [2434] Spermassociated antigen 4 (SPAG4) as a new cancer marker interacts with Nesprin3 to regulate cell migration in lung carcinoma.Oncol Rep. 2018 Aug;40(2):783-792. doi: 10.3892/or.2018.6473. Epub 2018 Jun 4.
• [2435] Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes.Front Oncol. 2018 Oct 30;8:482. doi: 10.3389/fonc.2018.00482. eCollection 2018.
• [2436] A genetic variant in the APE1/Ref-1 gene promoter -141T/G may modulate risk of glioblastoma in a Chinese Han population.BMC Cancer. 2011 Mar 23;11:104. doi: 10.1186/1471-2407-11-104.
• [2437] VAMP8, a vesicle-SNARE required for RAB37-mediated exocytosis, possesses a tumor metastasis suppressor function.Cancer Lett. 2018 Nov 28;437:79-88. doi: 10.1016/j.canlet.2018.08.023. Epub 2018 Aug 27.
• [2438] Antibacterial and anticancer potential of marine endophytic actinomycetes Streptomyces coeruleorubidus GRG 4 (KY457708) compound against colistin resistant uropathogens and A549 lung cancer cells.Microb Pathog. 2018 Dec;125:325-335. doi: 10.1016/j.micpath.2018.09.025. Epub 2018 Sep 19.
• [2439] Transmembrane Protease TMPRSS11B Promotes Lung Cancer Growth by Enhancing Lactate Export and Glycolytic Metabolism.Cell Rep. 2018 Nov 20;25(8):2223-2233.e6. doi: 10.1016/j.celrep.2018.10.100.
• [2440] LncRNA LCPAT1 Mediates Smoking/ Particulate Matter 2.5-Induced Cell Autophagy and Epithelial-Mesenchymal Transition in Lung Cancer Cells via RCC2.Cell Physiol Biochem. 2018;47(3):1244-1258. doi: 10.1159/000490220. Epub 2018 Jun 15.
• [2441] TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway.Oncotarget. 2016 May 24;7(21):30479-91. doi: 10.18632/oncotarget.8586.
• [2442] Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer.Pathol Res Pract. 2018 Aug;214(8):1130-1135. doi: 10.1016/j.prp.2018.06.008. Epub 2018 Jun 18.